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There is little understanding of, or information about, CAM products, their use, or multifarious issues 
surrounding them in New Zealand.  It is therefore unsurprising that NZ has lacked effective CAM 
product regulation for decades.  Following a review of surrounding legislation, and a preliminary 
investigation into CAM product prevalence and perceptions, this research proposes new legislation 
for the regulation of CAM products, which takes a forward-looking, evidence-based approach to 
succeed where numerous other proposals have failed. 
CAM products are effective unregulated in New Zealand, with the Dietary Supplements Regulations 
1985 being sorely outdated, and every new proposal for the past three decades failing to come to 
fruition.  As a result, general legislation like the Fair Trading Act 1986 is used to handle misleading or 
deceptive conduct in relation to CAM products, although its regulation of these products is inherently 
limited. 
The two pieces of quantitative research in this thesis consider the habits and perceptions of New 
Zealanders around CAM products; first studying students, and second broadening the scope to collect 
data from a representative sample of New Zealanders.  With 80% of New Zealanders having used CAM 
products, and a significant number being misled by the labelling and packaging on these products, 
new regulations around CAM products must address these issues to protect consumers. 
This thesis proposes a new piece of legislation for the risk-based regulation of CAM products in NZ.  
Through adaptation of regulatory models and provisions utilised in other legislation, this proposed 
CAM Products Bill establishes an effective risk-based approach, which categorises CAM products into 
three tiers, plus a black-list for prohibited ingredients or products.  This is a pre-approval scheme that 
links the evidence, safety, and research on the CAM product, to the fee structure, indirectly 
encouraging industry research and development into safe, quality and effective CAM products.  
Additionally, this Bill proposes a sound administrative structure and effective enforcement measures 
which have a history of use with CAM products. 
Ultimately, this proposed legislation will fill the void which currently exists around CAM product 
regulation in NZ, particularly following the withdrawal by the new Labour Government of the Natural 
Health and Supplementary Products Bill in November 2017.  It also addresses systemic problems of an 
information deficit by incentivising research into CAM products, and regulating in a manner that 
promotes scientific evidence, safety, efficacy, honest information for consumers, and high-quality 
CAM products through soft-touch risk-based CAM product legislation.  
xi 
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By definition … alternative medicine … 
has either not been proved to work 
or been proved not to work. 
Do you know what they call alternative medicine that’s been proved to work? 
Medicine.1 
Why does the regulation of complementary and alternative medicine (CAM) products matter? 
CAM product regulation is not perceived to be a problem by the general public, and therein lies the 
issue.  Typical comments might be: ‘CAM products are something someone else takes, but not me.  I 
just take my Vitamin C tablets when I feel a cold coming on, my iron pills when I am feeling a bit tired, 
and occasionally some arnica cream on a bruise, because my grandmother swore by it.  Even if these 
are CAM products, they have to be regulated somehow, and the worst that could happen is they do 
nothing, right?’ 
During this research, innumerable conversations like this indicated two things.  There exists a 
pervasive Antipodean (if not more widespread), laissez-faire attitude towards CAM products, that they 
are regulated somehow, because that is just the way things are: foods are regulated, medicines are 
regulated, so CAM products must be too.  Secondly, public belief in their effect ranges from the naïve 
‘they might do something, but at least they will not harm me’, to the actively illogical ‘it is a remedy 
derived from plants that this particular culture has being using for hundreds of years, therefore it is 
natural, and must be safe’. 
1.1 Complementary and Alternative Medicine 
The truth about regulation of CAM products in NZ is somewhat more limited than the public might 
think.  The New Zealand (NZ) regulations, the Dietary Supplements Regulations (DSRs) 1985, predate 
even the term ‘complementary and alternative medicine’, and given the Regulations’ age and limited 
scope, they are all but redundant.  Consequently, CAM products proliferate relatively unchecked 
throughout the NZ market, generating huge profits in a $1.4 billion industry,2 and frequently making 
illegal therapeutic claims (TCs) about everything from relieving headaches, to treating cancer. 3  
                                                          
1 Tim Minchin “Tim Minchin's Storm the Animated Movie” (Film, 7 April 2011) YouTube <www.youtube.com>. 
2 Natural Products New Zealand “Report: Natural Products Industry a Signficant Contributor to NZ's Economy” 
(press release, 19 February 2015), at 1. 
3 Ministry of Health Regulatory Impact Statement: The Development of a Natural Health Products Bill (June 2011 




Unfortunately, the idea that these products or this industry is regulated is a fallacy, with almost 20 
years of proposals for a new CAM product regulatory system, but nothing to show for it.  Furthermore, 
there is next to no impartial scientific information on the safety, or quality of CAM products in NZ, let 
alone their efficacy, and the little international evidence which exists suggests that product 
contamination, and the use of fillers or unlisted ingredients may be relatively common.4   
New Zealanders have perhaps the highest affinity for CAM products in the ‘western world’, but are 
put at greater risk by the lack of regulation, and dearth of information surrounding CAM products in 
NZ.  This thesis delves into the problems that have stymied new regulations, as well as scratching the 
surface of the information deficit, in order to put forward an informed, effective proposal for the 
regulation of CAM products in NZ. 
1.2 Definitions 
This section defines three key terms upon which this thesis is built.  For the most part, important terms 
are defined within the thesis as they arise.  However, it is necessary to consider what ‘complementary 
and alternative medicine products’ are, as well as detailing the scope of ‘dietary supplements’, and 
‘traditional medicine’, to lay the foundations for this thesis. 
Before defining these two terms, the term ‘natural’ must be debunked and its misappropriation in the 
medium of alternative healthcare highlighted.  Except where unavoidable from its use in legislation 
like the Natural Health and Supplementary Products Bill 20115  (NHSPB) or in reference to other 
sources, the term ‘natural’ will not be employed in this thesis when considering CAM products, as it 
engenders what has been referred to as the ‘naturalistic fallacy’.6  That is the idea that because a 
product is ‘natural’ it is ipso facto safe.  Aside from that being patently incorrect, it also belies the fact 
that not all CAM products are ‘natural’ within the ordinary meaning of the word – namely that they 
are not “existing in or caused by nature”.7 
                                                          
4 Steven G Newmaster and others “DNA barcoding detects contamination and substitution in North American 
herbal products” (2013) 11 BMC Medicine 222. 
5 Natural Health and Supplementary Products Bill 2011 (324-2). 
6 Professor Sir Peter Gluckman “Submission to the Health Committee on the Natural Health Products Bill 2011” 
(February 2012) at 1. 




1.2.1 Complementary & Alternative Medicine Products 
“A clear, objective and neutral … definition of [complementary and alternative medicine] is the first 
requirement for any reasoned debate and discourse…”, 8  however it remains one of the major 
problems of this area due to disagreement on the appropriateness of the term ‘complementary and 
alternative medicine’, let alone defining what the term incorporates. 
For the purposes of this thesis, it is simplest to first cover what CAM does not include, before delving 
into a definition and details of what it does include.  This thesis is concerned with the regulation of 
CAM products, not CAM modalities or practices.  The regulation of CAM modalities and the 
practitioners involved in those practices requires a different approach to the regulation of CAM 
products, and for that reason, neither this definition, nor this thesis includes discussion of CAM 
practices; except where absolutely necessary for the bigger picture.  The second exclusion is that CAM 
products do not include medicines.  Throughout this thesis, the term ‘medicine’ in isolation refers to 
conventional medicine, or evidence-based medicine; again terms which have broadly unsatisfactory 
definitions,9 but nevertheless are generally comprehended as being distinct to CAM products insofar 
as ‘western countries’ are concerned.  As shall be seen, despite excluding ‘medicine’ from the 
definition of CAM products, there remains an unavoidable overlap in practice; one which is especially 
pronounced in the present NZ regulatory scheme.10 
There are multiple different approaches to defining ‘complementary and alternative medicine’.11  The 
World Health Organization defines ‘complementary’ and ‘alternative’ medicine as two separate terms 
“…used inter-changeably with traditional medicine in some countries.  They refer to a broad set of 
health care practices that are not part of the country’s own tradition and are not integrated in to the 
                                                          
8  Terry S. H. Kaan “Traditional, complementary, and alternative medicine” in Yann Joly and Bartha Maria 
Knoppers (eds) Routledge Handbook of Medical Law and Ethics (Routledge, Oxford, 2015) 419, at 419. 
9 Despite the term ‘evidence-based medicine’ being relatively common-place, it is estimated that approximately 
20% of conventional medicine is actually scientifically proven; R. Imrie and D.W. Ramey “The evidence for 
evidence-based medicine” (2000) 8(2) Complementary Therapies in Medicine 123.  Similarly, CAM is now widely 
taught in American medical schools and a number of modalities and products are part of mainstream medical 
tradition in some European countries; Katherine R Ellena “The uncritical enthusiasts versus the uninformed 
sceptics: Regulation of complementary and alternative medicines” (2005) 13(1) JLM 106, at 107. 
10 See Chapter 3. 
11 For example, the House of Lords Select Committee inquiry into CAM opted not to present a definition, due to 
a lack of agreement for a single definition, and instead they presented a list of therapies; House of Lords, Science 
and Technology Committee Sixth Report: Complementary and Alternative Medicine (online ed, 21 November 
2000), Kaan, above n 8, at 421.  Another common approach has been defining CAM by what it is not, namely 




dominant health care system.” 12   While this definition is all-encompassing, it lacks clarity and 
applicability due to its focus on practices, its breadth and consequent abstraction. 
The United States of America (USA) National Center for Complementary and Integrative Health also 
defines ‘complementary’ and ‘alternative’ medicine separately: “If a non-mainstream practice is used 
together with conventional medicine, it’s considered ‘complementary’. If a non-mainstream practice 
is used in place of conventional medicine, it’s considered ‘alternative’.”13  Although these definitions 
are objectively correct, they fail to provide a useable definition for ‘CAM’ in the context of the host of 
heterogeneous products that the term encompasses in this thesis. 
Some commentators argue that CAM is largely a social construct, which must take account of the 
situation in different contexts.14  In the context of this thesis, the following definition is posited, which 
incorporates some elements from the many commentators, while attempting to maintain sufficient 
flexibility for a broad study into the regulation of CAM products. 
CAM products are not usually conventional medicines or foods, but are commonly (although not 
exclusively) biologically based products,15  which may have some effect in treating, preventing or 
diagnosing illness, disease or symptoms, or promoting health and wellbeing;16 whether that effect is 
real, or merely a manifestation of the placebo effect.  These products often lack scientific evidence as 
to one or more of their safety, quality or efficacy.17  They may be categorised as CAM products by: 
user-identification as a CAM product,18 their inability or lack of desire to meet the scientific and legal 
requirements for recognition and regulation as a medicine, or third party identification as CAM 
products due to their failure to meet common standards or usual definitions of foods, conventional 
medicines, or any other broad category of product for direct human use.   
                                                          
12 World Health Organization General Guidelines on Methodologies on Research and Evaluation of Traditional 
Medicine (WHO, online ed, Geneva, 2000). 
13  National Center for Complementary and Integrative Health “Complementary, Alternative, or Integrative 
Health: What's In a Name?” (June 2016) <https://nccih.nih.gov/health/integrative-health>. 
14 Kaan, above n 8, at 420, when discussing the ideas of Mertz on a definition; see M. Mertz “Complementary 
and alternative medicine: the challenges of ethical justification.  A philosophical analysis and evaluation of 
ethical reasons for the offer, use and promotion of complementary and alternative medicine” (2007) 10(3) 
Medicine, Health Care and Philosophy 329. 
15 Lucinda E. Jesson and Stacey A. Tovino Complementary and Alternative Medicine and the Law (Carolina 
Academic Press, North Carolina, 2010), at 6-10. 
16 Ministerial Advisory Committee on Complementary and Alternative Health Complementary and Alternative 
Health Care in New Zealand: Advice to the Minister of Health (Wellington, June 2004), at 1. 
17 Ellena, above n 9, at 106-107. 




As an aside, it is important to note that the frequent use of the term ‘quality’ throughout this thesis is 
not synonymous with ‘efficacy’, but rather is used in reference to CAM (or other) products which are 
well-made, do not contain unlisted ingredients, fillers, or foreign constituents, but do contain the 
listed ingredients on the label, in the amounts stated thereon. 
This entire thesis could be spent arguing the nuances of that definition of CAM products, and while 
there are undoubtedly flaws therein, it serves the purpose of facilitating discussion around their 
regulation, with a broad and reasonably flexible definition. 
1.2.2 Dietary supplements 
In 1985, when the DSRs were first published, the CAM product industry was generally limited to 
products classified as ‘dietary supplements’.  As the Regulations define them, these are amino acids, 
edible substances, herbs, minerals, synthetic nutrients or vitamins which are intended to supplement 
a person’s diet.19  The reason for the identification and definition of DSs in this section is that at the 
time of writing, these are the primary type of CAM product regulated in NZ under the DSRs, and thus 
they arise frequently throughout this thesis. 
1.2.3 Traditional medicine 
Generally, traditional medicine (TM) products are considered within the scope of CAM products 
throughout this thesis, except where explicitly noted.  Nevertheless, it is worth briefly outlining two 
prevalent forms of TM in NZ to appreciate the nuances of the largest, discrete field under the 
overarching umbrella of ‘CAM products’.20 
Rongoā or ‘Rongoā Māori’ is Māori Traditional Medicine.  It is an holistic form of healthcare and 
comprises three primary elements: rakau rongoā, akin to herbal medicine, mirimiri, or massage, and 
karakia, which is prayer.21  Additionally, the mana22 or standing of the tohunga (usually the expert 
healer or priest) comprises a vital part of the healing process.23  The herbal treatments involve both 
                                                          
19 Dietary Supplements Regulations 1985, reg2A. 
20 The other major forms of TM in NZ are Traditional Chinese Medicine, and Ayurvedic medicine, although in the 
interests of brevity, these are not substantially considered within this thesis. 
21 Ministry of Health “Rongoā Māori: Traditional Māori healing” (18 December 2015) <www.health.govt.nz/>. 
22 The concept of ‘mana’ is widespread throughout Polynesian cultures, and while lacking a concrete definition, 
is generally considered to encompass the prestige, honour, aura and identity of both a society and a people.  It 
can be both a positive and negative element, but is inextricably interwoven with an individual, tribe and society’s 
sense of identity and consequent behaviour.  See Chris Winitana “The Meaning of Mana” New Zealand 
Geographic (online ed, New Zealand, January-March 1990) for more on Mana. 




internal and external application of native plants for treatment of a variety of ailments, from 
respiratory and digestive problems, to broken bones and dermatological conditions.24 
While homeopathy does not have the same history of traditional use as other TM, it nevertheless has 
an important standing as a TM in Europe and abroad.25  Developed in the late 18th century by Samuel 
Hahnemann,26 homeopathy is premised on two principles; similia similibus curentur or the law of 
similars which claims that like cures like,27 and the idea of ‘potentisation’, that the more dilute a 
homeopathic solution is made through dilution and constant shaking, the stronger the homeopathic 
remedy becomes.28  The ‘like cures like’ principle rationalises that the cause of a problem can also be 
the cure for that problem, where the substance is diluted and shaken multiple times.29  This theory of 
‘potentisation’ defies established laws of pharmacology, biochemistry, chemistry and physics.   
1.3 The Problems with NZ’s CAM Product Regulations 
There are a host of minor issues surrounding CAM regulation in NZ currently, however, for the 
purposes of this thesis, these can be grouped into two major heads: the failure of current and 
proposed legislation to effectively regulate CAM products, and the widespread information deficit 
about the size and scope of the CAM product market in NZ. 
The DSRs are over 30 years old, and critiques acknowledge they are at best ineffective,30 and at worst, 
they amount to deregulation.31  In the past 20 years, there have been a number of proposals for new 
CAM product regulation, but nothing has come to fruition.  Nearly all these approaches have 
attempted to regulate with insufficient information of the market they aim to govern, ultimately 
prioritising stakeholder satisfaction over sound evidence-based measures around the safety, efficacy 
and quality of CAM products.  As a result, this problem continues to grow, with the only means of 
                                                          
24 At 1. 
25 This can be seen in the UK, with allowance for therapeutic claims on homeopathic products providing they are 
used within the established homeopathic tradition; Medicines and Healthcare Products Regulatory Agency 
“Register a homeopathic medicine or remedy” (27 January 2017) <www.gov.uk>. 
26 Edzard Ernst, Max H. Pittler and Barbara Wider (eds) The Desktop Guide to Complementary and Alternative 
Medicine: An evidence-based approach (2nd ed, Elsevier, Exeter, 2006), at 326. 
27 Michael Weir Law and Ethics in Complementary Medicine: A handbook for practitioners in Australia and New 
Zealand (5th ed, Allen & Unwin, Sydney, 2016), at 222. 
28 Ernst, Pittler and Wider, above n 26, at 326. 
29 At 326. 
30 Ministry of Health, above n 3, at 2-6. 
31  Barbara von Tigerstrom “Globalisation, harmonisation and the regulation of therapeutic products: the 
Australian New Zealand Therapeutic Products Authority in global context” (2007) 13 Canterbury Law Review 




enforcement around CAM products being the use of alternative legislation like the Medicines Act 1981 
(MA) or Fair Trading Act 1986 (FTA), which act as a stop-gap. 
The lack of information on NZ’s CAM product market is inseparable from the first issue.  While many 
of the proposed measures have highlighted the need for more information on; the CAM market, usage 
of CAM products, perceptions around CAM products, and the safety, efficacy, and quality of CAM 
products, no major work has been done in this area.  As such, proposals like the NHSPB are destined 
to fail before they are even enacted, due to this information deficit which will cause regulators to 
wander blind into a huge market, plagued with issues no proposal has foreseen. 
1.4 The Aim of this Thesis 
There are three aims to this research.  The first is to analyse specific and more general legislation, and 
its role in regulating CAM products.  The second aim is gain a more detailed knowledge of the scale 
and scope of the issues with CAM products, through empirical data which will begin to address the 
information deficit.  Finally, on the basis of the research and findings in this thesis, the third aim will 
be to design and propose a new piece of legislation to provide the best solution for the regulation of 
CAM products in NZ. 
The first and second aims will be achieved through three stages.  To begin, this research will review 
surrounding legislation, with an especial focus on risk-based legislation as a potential model for future 
CAM product regulation.  This leads into the second stage, which comprises an in-depth study of the 
flaws with the current CAM product regulations, and reasons for failure of the various proposals.  With 
a sound appreciation for this background, the third stage analyses whether alternative legislation is 
effective as a means of enforcement, in addition to delving deeper into the scale of the problems in a 
quantitative capacity.  Through the coalescence of the review, research, and studies, the third aim will 
be met in the ultimate proposal of a new Bill for CAM product regulation. 
1.5 The Scope & Limitations of this Research 
Any research which aims to not only design new legislation, but also proposes addressing a large 
information deficit, must limit its scope at some point.  While tomes could be written on this subject, 
there are three key areas which this research intentionally put aside in the interests of greater depth 
on the issues raised herein. 
A conversation on CAM product regulation in NZ is complemented by a discussion and comparison of 
other major international actors, and their systems for CAM product regulation, but such a discussion 




This thesis is focused on the issue of consumer protection legislation and the way it interacts with 
CAM products, but there is a similar topic to be addressed in the way intellectual property and CAM 
products intersect, especially insofar as traditional medicine, traditional knowledge, and patent law is 
concerned. 
Finally, the legislation proposed is a draft Bill.  It was neither the intention, nor the desire of this 
research, to put forward wording of every clause of the Bill, but rather to propose key provisions which 
contain a sound strategy for the regulation of CAM products, and address the problems raised 
throughout this thesis. 
1.6 An Overview of this Thesis 
The stages discussed at 1.4 to achieving the aims of this research give an indication of the structure of 
this thesis.  There are four parts to this thesis, with each chapter building upon the information and 
research of those that precede it. 
Part I discusses specific legislation; namely the Food Act (FA) of 1981 and 2014, the MA, the DSRs, and 
the NHSPB.  This review of surrounding legislation enables a study of risk-based legislation in Chapters 
2 and 3, before considering CAM product regulations and proposals, and the problems surrounding 
them in Chapters 4 and 5.  This Part finishes with a case study in Chapter 6 of a controversial CAM 
product, Miracle Mineral Solution, and attempts to apply the legislation to this issue. 
Part II takes a broader perspective.  Initially, it considers the FTA and the Consumer Guarantees Act 
1993 (CGA) as they may apply to CAM products, and uses the case study from Chapter 6 to 
demonstrate the ability of alternative legislation to address such matters.  It turns from this general 
legislation to the issue of the Treaty of Waitangi and the Wai 262 Report in Chapter 8, to briefly discuss 
their role within CAM product regulation. 
Part III introduces the substantial empirical research conducted in the course of this thesis.  Chapter 9 
details the Pilot Study and its findings on CAM product usage and misleading packaging and labelling.  
This is built upon by the Representative Study in Chapter 10, which provides the best indication of 
CAM product usage in the general NZ population in more than 20 years, as well as studying the impact 
of packaging more specifically on consumer perceptions of CAM products.  This is followed by Chapter 
11, which returns to the FTA to determine whether this alternative legislation can also adequately 
handle a novel issue like misleading and deceptive packaging. 
Finally, this thesis culminates with Part IV.  Chapter 12 corrals the strategies, solutions, and practical 




regulation of CAM products in NZ.  This Bill aims to provide a new hope and future for CAM product 
regulation, bringing it out of the metaphorical wilderness of 30 years of effective deregulation. 
1.7 Appendices 
There are five appendices to this thesis.  Appendices 1 and 3 contain Human Ethics Committee 
Approval for the two surveys which were conducted, while  appendices 2 and 4 contain those two 
surveys: ‘Public Perceptions on Dietary Supplements: A Pilot Study’, and ‘Packaging of Complementary 
and Alternative Medicines in New Zealand: A Representative Survey’.  Appendix 5 contains the 
complete draft of the Complementary and Alternative Medicinal Products Bill, to facilitate ease of 




Part I: Specific Legislation 
2 Food 
2.1 Introduction 
As a nation which derives over 10% of its gross domestic product from its internal food sector,32 
employs 20% of the work force in the food sector,33 and exports in excess of $20 billion of food related 
products per annum,34 food safety and the thorough regulation of NZ’s food industry is crucial. 
To appreciate the position of NZ food regulation in the 21st Century, it is vital to understand the history 
of food legislation in NZ.  Of particular importance is the FA 1981, which provided an invaluable 
regulatory foundation for the ensuing three decades, and supported the development of legislation, 
like the DSRs, which regulate products on the outskirts of food legislation. 
Upon this background, as well as substantial scientific research, the rigorous new FA 2014 was 
developed, which employs a risk-based approach bringing NZ’s food legislation in line with the best in 
the world; a crucial improvement for a country so dependent on its food export industry.  This ensured 
NZ could uphold its obligations to key trading partners, and maintain relevance within the structure 
of the Australia New Zealand Food Standards Code 2002 (ANZFSC). 
2.2 A History of Food Legislation 
Food regulation in NZ began in the early days of the colony, with the enactment of the Adulteration 
of Food Act 1866, followed by the more comprehensive Sale of Food and Drugs Act of 1907.  This was 
eventually replaced by the Food and Drug Act 1969, which was separated into two pieces of legislation 
in 1981: the FA35 and the MA.36  These Acts show the changing priorities of the times, with the 1866 
and 1907 Acts focusing on the purity of foods or ramifications for a lack thereof, while the 1969 and 
                                                          
32 (22 July 2010) 665 NZPD 12615. 
33 (13 May 2014) 698 NZPD 17755. 
34 Statistics New Zealand “Infoshare: Exports Summary Data Key Statistics Table 7.04 - Value of principal exports 
(Annual)” (24 August 2016) <http://www.stats.govt.nz/infoshare/>. 
35 Food Act 1981. 




1981 Acts display a paradigm shift towards increasingly rigorous consumer protection through 
regulation of sale, advertisements,37 hygiene,38 and food safety and standards.39 
Introduced into Parliament at the same time as the Medicines Bill,40 the Food Bill of 198041 was 
relatively uncontroversial.  The new Food Bill sought to control the entire process of food regulation, 
from preparation, storage, packaging and sale, through to import, export, labelling and marketing of 
food products.42   
One issue received significant discussion in the passage of the 1980 Food Bill.  The Minister of Health, 
Hon George Gair MP, commented that the Bill intentionally allowed for cross-over of DSs, slimming 
foods, or other special purpose foods, between food and medicine regulations on the grounds that, 
“[o]ne man’s food may conceivably be another man’s medicine.”43  The particular classification of 
these products would ultimately rest on their presentation to the public and the manufacturer’s 
claims.44  While the Labour Opposition attempted to illustrate the incongruity of regulating vitamin 
and mineral products with either the food or medicines’ legislation,45 Mr Gair contended that the 
categorisation of such products obviously rested on the quantity of vitamin or mineral present in the 
product, easily determining whether a product was a food or a medicine in its present form.46  Despite 
Labour’s concerns, this issue was relegated to discussion under the second reading of the Medicines 
Bill, and the Food Bill otherwise enjoyed bi-partisan support, receiving Royal Assent late in 1981. 
In 2010, the new Food Bill was finally brought before the House, having begun its slow journey in 2003 
when a review of food safety legislation was conducted, followed by the drafting of a new bill.47  This 
tome aimed to replace the FA 1981, as well as repeal or amend associated legislation and regulations, 
including the Food Hygiene Regulations 1974, the DSRs, the Agricultural Compounds and Veterinary 
                                                          
37 Food and Drug Act 1969, ss3 and 6-11. 
38 Food Act 1981, Part 1A. 
39 At Part 2A. 
40 Medicines Bill 1980 (157-1). 
41 Food Bill 1980 (158-1). 
42 (12 December 1980) 436 NZPD 5919; The Act was in essence the first piece of legislation to endeavour to 
encompass all food activities, alongside similarly outdated regulations like the Food Hygiene Regulations 1974. 
43 (26 August 1981) 440 NZPD 2982; in specific reference to the non-exclusive definition of both food and drug 
in the 1969 Act, and the same between food, medicine and related product in the Food and Medicine Bills. 
44 At 2982. 
45 At 2983. 
46 At 2984. 
47 (13 May 2014) 698 NZPD 17750.  The domestic food review took approximately 3 years, following which the 
new Food Bill began to be drafted.  With a change of government in 2008, the introduction of the Bill was 
somewhat delayed, with a number of Ministries being reorganised, including the Food Safety Authority; (22 July 




Medicines Act 1997, the Animal Products Act 1999, and the Wine Act 2003.  In addition to updating 
penalties and enforcement measures to bring them into line with similar legislation and be 
commensurate with the offence,48 the Bill introduced to NZ a novel method of regulating food safety; 
a risk based approach.49 
Delayed slightly by the scare of botulism contamination of NZ whey protein in 2013,50 this Food Bill 
also moved through Parliament with widespread support, except on two issues: apparently unchecked 
regulatory power, and country of origin labelling.  The initial iteration of the Food Bill took a strong 
regulatory approach, inciting fear that over regulation would adversely affect small businesses and 
uniquely NZ fixtures like the Saturday morning fundraising sausage sizzle.51  However, fears were 
allayed following the Bill’s return from the Select Committee, with the requirement that the regulation 
of such activities be reasonable and proportionate to their risk.52  The second issue dividing the House 
was that of compulsory country of origin labelling on food.  There was no country of origin labelling 
provision in the Bill, which reflected NZ’s stance in the ANZFSC where an exemption had been sought 
to similar provisions.53  However, there was significant opposition support for the inclusion of country 
of origin labelling, with the impetus behind it being that it demonstrated to both NZ and global 
consumers where food was sourced NZ, and also followed international trends in identifying food 
sourced in part or in full from other countries.  While this matter was discussed in the Select 
Committee, as well as proposed by two supplementary order papers,54 these were narrowly defeated 
by National’s majority, primarily due to the commercial implications of such labelling.  Nevertheless, 
a new proposal for country of origin labelling was introduced into Parliament by the Green party in 
2016,55 which will require country of origin labelling on most single component foods.56 
                                                          
48 (22 July 2010) 665 NZPD 12616. 
49 See 2.4 and 3.5. 
50 Miriam Dean, Anne Astin and Tony Nowell The WPC80 Incident: Causes and Responses (Department of Internal 
Affairs, 24 November 2014), at 5; In mid-2013, a batch of Fonterra milk powder was found to be contaminated 
with a strain of Clostridium bacteria, part of the family of bacteria which produce botulinum toxin which is 
potentially fatal to adults, and even more highly toxic in infants.  As a result, global recalls of the product, and 
all products of which it was an ingredient were orchestrated, causing a significant fallout for Fonterra and New 
Zealand.  As it eventuated, the bacteria was not the botulinum producing strain, and no adverse effects were 
reported. 
51 (22 July 2010) 665 NZPD 12626-12627; Labour MPs, namely Dr Ashraf Choudhary MP, Hon Damien O’Connor 
MP, and David Shearer MP. 
52 (13 May 2014) 698 NZPD 17756. 
53 (13 May 2014) 698 NZPD 17752-17753. 
54 Supplementary Order Paper 2014 (440) Food Bill 2010 (160-3); Supplementary Order Paper 2014 (449) Food 
Bill 2014 (160-3). 
55 Consumers' Right to Know (Country of Origin of Food) Bill 2016 (231-1). 
56 At s4; “single component foods means food or food products, whether packaged or unpackaged, that contain 




This aside, the Food Bill had multi-partisan support, passing into law on the 6 June 2014, with a 
staggered process of commencement, beginning in earnest on 1 March 2016.57 
2.3 Definitions within the Food Act 2014 
There are two major changes insofar as the core definitions within the FA are concerned from its 
earlier 1980s iteration. 
Foremost is the expansive new definition given to ‘food’ in the new Act.58  The 1981 Act merely stated 
in s2 that “food means anything that is used or represented for use as food or drink for human 
beings…”,59  and then went on to list three specific categories which came under that umbrella: 
ingredients or nutrients, anything mixed with food or drink, and chewing gum.  The 2014 Act 
incorporated these three categories, and extended the definition to include seeds, plants, plant 
material, and live animals, where any of those items are intended for human consumption, allowing 
the Governor-General to declare additional items as foods where necessary.60   Furthermore, s9 
explicitly excludes a number of items from being foods,61 including “…any substances used only as 
medicines (within the meaning of the Medicines Act 1981)…”.62  The changes in the new Act also 
extend to ingredients, which are not required to comply on their own with the requirements of the 
Act,63 so long as the food in its final form does meet the Act’s requirements.64   
This new ‘meaning of food’ in s9 gives wide scope to food within the Act, largely relying on the 
exclusions in subs(c), and legislation like the MA or Misuse of Drugs Act 1975 (MoDA) to limit what 
can be classified as a food.65  There is little in the Hansard or associated materials to explain this 
expanded definition, but for NZ First MP Richard Prosser’s speech on the Bill during the Committee 
Stage, where he emphasised the logical nature of the s9 definition, importantly noting “…it is the letter 
of the law that determines the relative foodness or non-foodness [sic] of any particular substance.”66 
                                                          
or its substitutes, salt, or other ingredients used in preserving, colouring or flavouring.”  At the time of writing, 
the Bill had near unanimous support in Parliament, and was before the Primary Product Select Committee. 
57 Food Act 2014, s2. 
58 At s9. 
59 Food Act 1981, s2, ‘food’. 
60 At ss9(1)(b)(i)-(iii) and (viii). 
61 At s9(1)(c). 
62 At s9(1)(c)(iii). 
63 At s9(2). 
64 At s9(4). 
65 See 3.3.1. 




The Act also expands the concept of safety,67 ensuring that food will not cause illness or injury.  
However, it elaborates further than the previous Act, including the requirement that the food must 
be fit for purpose (that is the food must be correctly labelled, in good condition, and not harmed, 
damaged, or perished in any way).68  Pertinently, the Act then employs these ideals in s14, in addition 
to the same statement in the purpose section,69 requiring any person “…who trades in food [to] ensure 
that it is safe and suitable.”  Given the juvenility of the Act, these principles are currently untested, 
but it is likely that they will inform regulatory and judicial decision making, akin to ‘purpose’ sections. 
2.4 A Risk-based Approach to Food Regulation 
Where the 1981 food legislation required management of hazards to reduce risk, the new FA 
assimilates this with a plethora of other factors to take a more integrative, risk-based approach to 
food safety.70   Hazard-based approaches generally view any deleterious component or potential 
consequence arising from the food as a rationale for regulation,71 consequently creating the system 
in NZ which focused to a greater degree on microbiological hazard in the form of the control of food 
premises, rather than the food itself.72  In addition, the somewhat ad-hoc development of the 1981 
legislation and surrounding regulations resulted in varying levels of enforcement across local councils, 
rendering the system neither uniform, nor egalitarian.73 
In contrast to a hazard-based approach, a risk-analysis within the context of food safety usually 
involves identification of a particular foodborne hazard, and then consideration of the exposure 
level.74 
𝑅𝑖𝑠𝑘 = 𝐻𝑎𝑧𝑎𝑟𝑑 × 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 
Equation 2.1: Risk Equation75 
                                                          
67 Food Act 2014, s12(2). 
68 At s12(3)-(5). 
69 At s4(f). 
70 (22 July 2010) 665 NZPD 12615. 
71 Eirini Tsigarida “Risk-based Approaches to Food Safety (Abstract)” (11 May 2016) International Association for 
Food Protection's European Symposium on Food Safety 
<https://iafp.confex.com/iafp/euro16/webprogram/Paper12746.html>. 
72 (13 May 2014) 698 NZPD 17750. 
73 (27 May 2014) 699 NZPD 18341; (14 May 2014) 698 NZPD 17845 and 17868.  One particular foible of the 1981 
Act was that regional authorities had discretion in their interpretation of the legislation and regulations, resulting 
in a confusing and changeable system with regards to both food standards and fees between different areas. 
74 Tsigarida, above n 71. 




This approach subsequently enables regulation commensurate with the exposure to the hazard, which 
determines the risk.  In practice, a risk-based approach involves three stages; hazard determination, 
risk management and risk communication.76 
Over the past couple of decades, a number of countries, including the World Health Organisation, 
have been researching the potential for the development of risk-based regulatory systems, which can 
take account of both microbial and chemical hazards in food and their effects across a population.77  
As a part of the review into food safety in NZ, similar research was carried out from the early 2000s, 
exploring the best method for ranking risks of food.78  Amongst matters like strategic planning and the 
efficient allocation of regulatory resources, a core tenet of risk assessment in food safety involves a 
risk-ranking system.79  On the basis of a number of discussion and review documents,80 a single metric 
for risk assessment was eventually settled on for NZ, which could apply uniformly to microbiological 
and chemical hazards.81  This metric is Disability Adjusted Life Years (DALY), which was chosen in favour 
of the similar, but less informative Quality Adjusted Life Years.82 
𝐷𝐴𝐿𝑌 = 𝑌𝐿𝐿 + 𝑌𝐿𝐷 
Equation 2.2: Disability Adjusted Life Years83 
Where:  DALY = Disability Adjusted Life Years 
 YLL = Years of Life Lost due to mortality 
 YLD = Years of Life lived with a Disability 
                                                          
76 Tsigarida, above n 71. 
77 Robert B. Wallace and Maria Oria (eds) Enhancing Food Safety: The Role of the Food and Drug Administration 
(The National Academies Press, Washington D.C., 2010); Arie H. Havelaar and others “WHO Initiative to Estimate 
the Global Burden of Foodborne Diseases” (2013) 381(Supplement 2) The Lancet S59; Julia Black “Risk Based 
Regulation” (OECD, 1 December 2008); Frédéric Forge Food Safety: An overview of Canada's approach (Science 
and Technology Division, online, Government of Canada Publications, 16 October 2002). 
78 Peter Cressey and Rob Lake Ranking Food Safety Risks: A Discussion Document (Institute of Environmental 
Science & Research Limited, June 2003); Peter Cressey and Rob Lake Ranking Food Safety Risks: A Prototype 
Methodology (Institute of Environmental Science & Research Limited, October 2004); Minister for Food Safety 
Regulatory Impact Statement: Food Bill (New Zealand Food Safety Authority, 2 October 2009). 
79 Wallace and Oria, above n 77, at 79. 
80 Cressey and Lake, above n 78. 
81  Rob Lake Risk Ranking: Development of a Single Metric for Risk Ranking by the NZFSA (Institute of 
Environmental Science & Research, December 2006); Ministry for Primary Industries “Risk ranking”  
<http://foodsafety.govt.nz/>. 
82 The distinction between the two is that DALY is a negative consideration, looking at the loss stemming from a 
loss of quality of life, whereas Quality Adjusted Life Years (QALY) is more of a positive consideration, looking at 
the additional quality of life derived from treatment for example; Lake, above n 81.  An equivalent formula for 
QALY to that seen for DALY at Equation 2.2 would look something like: QALY = YLS × U, where YLS = Year or life 
lived in a state, and U = Utility value of that particular state or situation. 
83 Robin J. Lake and others “Risk Ranking for Foodborne Microbial Hazards in New Zealand: Burden of Disease 




This formula takes account of the years of life lost due to mortality (YLL), and the years of life lived 
with a disability (YLD), which is weighted for the severity of the disability.84  This metric will commonly 
be informed by the cost of the illness, which considers the monetary impact for the affected 
individual.85  Through analysis of the statistical data on the effects of many pathogens, it is then 
possible to extrapolate a ranking in order to assess their relative risk.  Nevertheless, such a system so 
inherently linked to numerical values suffers from the lack of reliable longitudinal data showing 
additive effects of chemicals in food products.86  Summarily, risk is managed by minimising exposure 
to hazards. 
With the strong foundation provided by an extensive, and generally workable, risk assessment 
method, it was possible to build the new FA measures to manage these risks.  Under the FA, there are 
three broad classes for food sectors87 based on risk.88  The highest risk food sectors89 are outlined in 
Schedule 1 of the Act, and are required to have food control plans in place which heavily regulate their 
operation.90  In contrast, the lowest risk food sectors91 as classified in Schedule 3 are not required to 
have any food control plan in place, nor operate under part of the national programme for food safety, 
due to the fact they pose negligible risk to public health.92  The middle risk category93 is subdivided 
into three further risk levels.  These risk levels correspond to the particular national programme under 
which the food sectors must operate, dependent on the degree of risk they present.94  As the name 
suggests, national programmes are generic systems which seek to control, mitigate and manage the 
risks presented by the particular food sectors which fall within each programmes’ ambit.95  This is a 
lower regulatory burden upon food sectors than the requirement to create a food control plan which 
                                                          
84 At 743. 
85 At 744. 
86 Lake, above n 81, at 1. 
87 Food Act 2014, s8 ‘food sector’; “food sector means a group of 2 or more food businesses”. 
88 At s20(2)(a). 
89  For example, retail food manufacturers like bakeries, dairy product manufacturers and meat product 
manufacturers; at Schedule 1, Part 3. 
90 At s21(3)(a). 
91 For example, once a year food trading, direct to consumer horticultural producers; at Schedule 3, Part 3. 
92 At s21(3)(c). 
93 For example, manufacturers of food additives, vitamins, minerals or other nutrients to be added to food; at 
National Programme Level 3, Schedule 2, Part 3.  Manufacturers of confectionary or processors of nuts or seeds; 
at National Programme Level 2, Schedule 2, Part 4.  Extractors and packers of honey; at National Programme 
Level 1, Schedule 2, Part 5. 
94 At s20(2)(c) and s21(3)(b). 





must be targeted to the individual food business.96  At the time of writing, there have been no cases 
surrounding the national programmes or classification of food sectors. 
Risk communication is perhaps the least studied component of food safety risk-based programmes, 
but remains vital for educating consumers about the processes in place, and minimising exposure 
through targeted information.  While the Ministry of Primary Industries claims that communication 
occurs throughout the whole risk-based programme,97 the reality is somewhat more limited, whereby 
warnings after the fact are one of the more common methods of risk communication, alongside 
limited guidelines on domestic food preparation and the components of food.98  It is well recognised 
across the literature that risk communication is a commonly deficient, but vitally important, part of 
any risk management process, to ensure consumer involvement and participation in the minimisation 
and control of risks.99 
2.5 The Relationship between the Food Act 2014 and other Legislation, Codes and Regulations 
Where the 1981 FA blurred the lines between foods and medicines; an issue exemplified in the 
confusing and unworkable DSRs,100  the new FA looks to foster increasing clarity between foods, 
medicines, DSs and other CAM products, an issue which will be expanded upon in subsequent 
chapters.101  In order to carry out its purpose and aims of ensuring safe and suitable food, the FA must 
co-exist with a series of other legislation and regulations.  These range from legislation and treaties 
concerning the relationship of the NZ food system with Australia’s,102 through to the relationship with 
more general Acts and regulations that govern the daily operation of the food and beverage sector in 
NZ. 
2.5.1 The Australia New Zealand Food Standards Code 2002 
The journey to a joint food standards agreement with Australia began in 1983, with the Closer 
Economic Relations Trade Agreement. 103   This led to the creation of the Trans-Tasman Mutual 
                                                          
96 Food Act 2014, s36. 
97 Hilary Eade “Food Safety in New Zealand” (University of Otago Public Health Summer School, February 2015) 
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98  Ministry for Primary Industries “Food safety for consumers”  <https://www.mpi.govt.nz/>; Ministry for 
Primary Industries “What's in our food?”  <https://www.mpi.govt.nz/>. 
99 Gerd Gigerenzer Reckoning with Risk (Penguin Books, London, 2003), at Chs.1-2; Paul Slovic The Perception of 
Risk (Earthscan Publications Ltd., London, 2000), at Chs.9 and 13. 
100 See 4.4. 
101 See 3.4 and 4.4. 
102 See 2.5.1. 
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Recognition Agreement (TTMRA),104 and the Food Standards Treaty,105 from which both the ANZFSC 
and the agency in charge of the Code, Food Standards Australia New Zealand (FSANZ), originated.  
The TTMRA, through the empowering NZ Act,106 applies to most goods and services between NZ and 
Australia, and to achieve its goals, the Act requires that all other legislation be read subject to the 
TTMRA.107  The effect of this is that all food, except for a small number of high-risk foods,108 is subject 
to the TTMRA.109  The fact that the FA makes no reference to the TTMRA is irrelevant in light of its 
place as overarching legislation.110  The presence of the ANZFSC means that the only effect of the 
TTMRA is upon the import and sale of Australian food-stuffs. 
While theoretically a bilateral agency, FSANZ operates on the basis of the Australian Food Standards 
Australia New Zealand Act 1991.111  The primary duty of FSANZ is the administration of the ANZFSC, 
which extends to drafting new food standards, and generally ensuring a safe, co-ordinated system of 
food safety between Australia and NZ.112  FSANZ authority does not extend to enforcement of the 
Code, which remains the responsibility of the Ministry for Primary Industries113 and local government 
in NZ.114  The focus of the ANZFSC is setting standards for food contents, ensuring food safety, and 
putting in place labelling requirements for food.115  Chapter One of the ANZFSC considers generally 
the food standards and labelling requirements, which apply to all foods, while Chapter Two looks at 
the food standards applicable to particular items. 116   The remainder of the ANZFSC, comprising 
Chapters Three and Four does not apply to NZ.117  Additionally, it is important to note that the ANZFSC 
                                                          
104 The Trans-Tasman Mutual Recognition Agreement which was brought into force in NZ through the Trans-
Tasman Mutual Recognition Act 1997, and aims to encourage an integrated trans-Tasman economy and foster 
closer economic ties and co-operation; Trans-Tasman Mutual Recognition Agreement 1998. 
105 Agreement between the Government of New Zealand and the Government of Australia establishing a System 
for the Development of Joint Food Standards [1996] NZTS 9 (1 January 1996). 
106 Trans-Tasman Mutual Recognition Act 1997. 
107 At s5. 
108 High-risk foods exempt from the TTMRA include beef, fish, dried coconut, peanuts, pistachios and seaweed; 
John Holah and Huub Lelieveld Hygienic Design of Food Factories (1st ed. ed, Woodhead Publishing, United 
Kingdom, 2011), at 128. 
109  Ministry for Primary Industries “Trans-Tasman Mutual Recognition Agreement (TTMRA)” (2016) 
<http://www.foodsafety.govt.nz/>. 
110 At 1. 
111 Food Standards Australia New Zealand Act 1991 (Cth). 
112  Food Standards Australia New Zealand “What we do and don't do” (August 2012) 
<http://www.foodstandards.gov.au/>. 
113 Formerly Ministry of Agriculture and Fisheries (MAF). 
114  Food Standards Australia New Zealand “Food Standards Australia New Zealand” (2015) 
<http://www.foodstandards.gov.au/>. 
115 New Zealand (Australia New Zealand Food Standards Code) Food Standards 2002. 
116  Food Standards Australia New Zealand “Food Standards Code” (1 March 2016) 
<http://www.foodstandards.gov.au/>. 




does not regulate or provide standards for DSs or any therapeutic goods.118  The FA gives effect to the 
NZ’s obligations under the ANZFSC in ss397-402 FA. 119 
2.5.2 The Dietary Supplements Regulations 1985 
A discussion of the legislation and regulations surrounding the FA in both its 1981 and 2014 iterations 
would be incomplete without at least noting the DSRs.  As previously discussed, significant room was 
left in the 1981 FA for the Minister to make regulations; and one key area where this power was 
brought to bear was the DSRs, which came into force in 1987.120  The DSRs govern the sale, export, 
and labelling of DSs, as well as listing some of the ingredients permitted in DSs.  Despite a number of 
moves to repeal or substantially update this system, the DSRs remained in force for the duration of 
the 1981 FA’s existence.  Given the legislative delay and troubles encountered by the NHSPB,121 the 
regulations were carried over into the 2014 FA, and remain in force at the time of writing.122  A full 
discussion of the DSRs is in Chapter 4. 
2.6 Advertising and Labelling 
The FA does little to control or stipulate the content of food advertisements.123  Section 238 FA sets 
out the variety of offences around advertising relating to food or food-related accessories, which can 
be largely grouped into three categories; advertisements which breach the requirements of the FA, 
advertisements which are misleading or deceptive, or advertisements which omit to include 
information required by the FA.124 
There are two industry codes which set out guidelines for the advertising of food.  Foremost is the 
Code for Advertising Food,125 which concerns advertisements for food and beverages directed at 
people 14 years and older.  The principle of this Code is that advertising should be conducted in a 
‘socially responsible’ manner which ‘does not mislead or deceive the consumer’.126  Additionally, the 
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119 Food Act 2014, s396. 
120 Dietary Supplements Regulations 1985, s1(3). 
121 Natural Health and Supplementary Products Bill 2011 (324-2). 
122 Food Act 2014, s413(3). 
123 Compare to the stringent criteria for advertising medicines; see 3.3.4. 
124 Food Act 2014 s238(2) 
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Children’s Code for Advertising Food has a similar purpose, but recognises the susceptibility and 
receptivity of children under the age of 14 to advertising, and formulates the code accordingly.127 
There are additional regulations regarding the advertising of supplemented foods, especially insofar 
as health claims may be made for such products, but this will be discussed when considering DSs, given 
the relationship of these products, at Chapter 4.  Likewise, the FTA and CGA have roles in ensuring the 
advertising and statements on the packaging of food and beverages are not misleading or deceiving 
the consumer by falsely representing the food to be something it is not.  These Acts will be discussed 
further in Chapter 7 in the context of CAM products. 
2.7 Conclusion 
Substantial work was done to create the 2014 FA and bring the legislation into the 21st Century with a 
well-researched scientific approach, which built upon the foundations of the 1981 Act, but 
substantially improved food regulation through the adoption of a risk-based approach.  This brings the 
FA into line with legislation like the MA, which was one of the earliest instances of a risk-based strategy 
for regulation of products in NZ. 
Through this risk-based approach, in addition to a detailed and well considered stance on what 
amounts to ‘food’ within the Act, the FA sets the benchmark for future NZ legislation regulating food, 
medicines, therapeutic goods and CAM products, independently, and in conjunction with 
international agreements and trade-relationships. 
  
                                                          





Herbal medicine is an area where we find some of the best evidence in all of alternative 
medicine.  Some herbal extracts contain pharmacologically active compounds that obviously 
can have health effects – both positive and negative.  This means that some herbal supplements 
are effective but the question is, which?  In the absence of regulatory oversight to enforce 
standards for purity, concentration and dosage limits, herbal medicines may very definitely 
cause harm.128 
3.1 Introduction 
The MA 1981 adopts a sound, risk-based approach to the regulation of medicines, which has remained 
relatively unchanged for more than 35 years.  When enacted, this was a novel form of regulation, 
however, through clear and effective regulations, and the governance and implementation by 
competent and clearly-defined regulatory bodies, the MA has remained relevant into the 21st Century.  
Nevertheless, with new legislation around food and food sectors, and imminent legislation 
surrounding CAM products, there is a view towards an updated approach to medicines’ regulation in 
the Therapeutic Products Bill. 
This Chapter considers key definitions in the MA, especially where they impact upon the regulation or 
enforcement actions against CAM products, like the notorious ‘therapeutic purpose’.  It also builds 
upon two issues introduced in Chapter 2; the relationship between medicines and foods, and the 
concept of risk in legislation, concluding by reviewing how the MA interacts with other legislation.  
Before delving into the effects and nuances of the MA with a view to CAM products, it is first necessary 
to appreciate the impetus for the development of the MA. 
3.2 Medicines’ Legislation 
The 1960s saw one of the greatest medical tragedies of the 20th Century when an unknown side effect 
of thalidomide for pregnant women became apparent.  Intended as a sedative for insomnia and 
anxiety, thalidomide was commonly prescribed for the off-label use of alleviation of morning sickness 
during pregnancy.  Thalidomide was used for a number of years before it was identified as a 
teratogen, 129  affecting approximately 24,000 babies and resulting in 123,000 still-births or 
miscarriages.130  A consequence of this tragedy was an increased movement worldwide, including in 
                                                          
128  Edzard Ernst A Scientist in Wonderland: A Memoir of Searching for Truth and Finding Trouble (Imprint 
Academic, United Kingdom, 2015), Addendum. 
129 A teratogen is; “an agent or factor which causes malformation of an embryo” Oxford Dictionaries, 2017, 
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NZ, to introduce more thorough, safety conscious medicines’ legislation.131  In conjunction with this, 
more extensive toxicity testing was implemented for new medicines to avoid missing key markers like 
that of the animal embryo resorptions which occurred for thalidomide during testing, masking its 
toxicity.132 
Prior to 1980, NZ’s medicine regulatory environment was controlled by a number of pieces of 
legislation; the Food and Drug Act 1969, the Restricted Drugs Act 1960, the MoDA, and the Poisons 
Act 1960.  In December 1980, the Minister of Health introduced the Medicines Bill into Parliament to 
consolidate the control of medicinal products into a single Act, and to cohere with the Food Bill of 
1980.133  The Medicines Bill passed into law late in 1981.  A few years later, the extensive Medicines 
Regulations 1984 came into force, providing much of the practicalities to the MA 1981 and enabling 
its commencement on 1 August 1984.134  In a testament to the MA, it lasted with remarkably few 
amendments or calls for repeal into the 21st Century.   
In the late 1990s, there began an almost 20-year conversation with Australia on creating a joint 
regulatory scheme; the Australia New Zealand Therapeutic Products Agency (ANZTPA).  As a part of 
this plan, NZ’s medicine legislation would require amendment, becoming more akin to Australia’s 
Therapeutic Goods Administration (TGA), but with a bilateral regulator.  However, the combination of 
a lack of public enthusiasm, and varying levels of commitment from successive governments saw this 
scheme fatally falter in November 2014.135 
At this time, the Minister of Health, Hon Dr Jonathan Coleman announced that work would begin on 
a comprehensive new regulatory scheme including medicines, medical devices and cell and tissue 
treatments to replace the MA.136  With an all-encompassing approach, this Therapeutic Products Bill 
aimed to establish a strong regulatory stance that maintains relevance through empowering a new 
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132 Steve K. Teo and others “Effects of thalidomide on reproductive function and early embryonic development 
in male and female New Zealand white rabbits” 2004 71(1) Birth defects research. Part B. Developmental and 
reproductive toxicology 1, at 15; no teratogenic effects were seen in the animals used for toxicity testing, as it 
later turned out, due to resorption of effected embryos.  Consequently, the first sign of the teratogenic effects 
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133 (12 December 1980) 436 NZPD 5918. 
134 Medicines Act Commencement Order 1984. 
135 Ministry of Health Therapeutic Products Regulation Paper 1: Context and Overview (November 2015) at 3; 
see further discussion at 5.3.1. 




government department with extensive regulatory and decision making powers to control medicines 
and other aforementioned therapeutic products.137  In this way, the Therapeutic Products Bill would 
complement the new FA, to bring the legislative triumvirate of food, medicine and CAM products into 
the 21st Century.  At the time of writing, an exposure draft of the Bill allowing for public and 
stakeholder consultation was due for release at the end of 2017.138 
3.2.1 Medicines Act 1981 & Medicines Regulations 1984 
While the Medicines Bill was primarily intended to consolidate the earlier legislation, it also introduced 
a couple of important changes, for example including natural remedies in its purview, and increasing 
the authority of the responsible minister by extending their ability to make regulations.  As a result of 
these new provisions, the progress of the Bill through Parliament in 1980 was a somewhat rocky 
journey. 
As stated in the Parliamentary debate on the Bill, “There is a movement towards natural remedies… 
[and] alternative health care is attracting a growing number of followers”.139  The Labour opposition 
cast the issue as being about freedom of choice, and the ability to choose one’s health remedies with 
seemingly little restriction.140  The provisions in the Medicines Bill in relation to natural remedies were 
significantly reworked at the committee stages, eventually compromising by reducing any restrictions 
on natural remedies and classifying them as foods within the FA, so long as they did not make any 
TCs.141  Nevertheless, ‘Herbal Remedy’ is still defined in the Act as a medicine,142 although this appears 
to have had little effect since the Bill’s passing. 
The Act also allowed for the drafting of extensive regulations, and the Medicines Regulations 1984 
(MRs)143 were empowered by the Governor-General under s105 MA in 1984.  In concert with s3(3) 
MA, reg3 MRs introduces the permissive ‘white list’144 approach for categorising medicines into either 
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prescription medicines,145 restricted medicines,146 or pharmacy-only medicines,147 with the latter two 
being accompanied by dose restrictions.  Despite the MRs not controlling general sale medicines, they 
provide an otherwise thorough basis for the administrative operation of the MA; simultaneously 
heralding an uncommon vesting of power in subordinate legislation.148 
3.2.2 Regulatory bodies under the Medicines Act 1981 
There are three primary bodies which were created under the MA.  These exist in a pseudo-
hierarchical structure, whereby the NZ Medicines and Medical Devices Safety Authority (Medsafe), 
sits at the head, followed by the Pharmaceutical Management Agency (PHARMAC).  Finally, Medicines 
Control as a part of the Ministry of Health (MoH) is at the bottom of the ladder. 
Medsafe is a business unit of the MoH, whose responsibility is generally to administer the MA and 
MRs.149   Medsafe operates on a platform of dual accountability, where it is naturally responsible to 
the MoH, but additionally is responsible to the pharmaceutical industry, which partially funds Medsafe 
through fees paid for its services and related activities.150  One of the most important responsibilities 
of Medsafe is the assessment of new medicines through a multi-faceted process, which determines 
whether they may be marketed in NZ.151 More generally, Medsafe regulates any product covered by 
the MA through granting approval where they meet the requisite standards, and continuing post-
market monitoring if the products gain marketing approval.152   
A key element of the regulatory process which remains outside Medsafe’s purview is that of funding 
medicines.  Determining which medicines to fund and distributing this funding is the responsibility of 
PHARMAC.  PHARMAC is a government agency which receives its funding from both national and local 
government through the District Health Boards.153  The rationale behind the concept of a nationally 
funded pharmaceutical program is in keeping with NZ’s approach to public healthcare, with PHARMAC 
existing to increase NZ’s purchasing power with regards to pharmaceuticals by tendering for 
medicines to reduce costs.154  This role of funding pharmaceuticals extends to contract negotiation 
and funding of medical devices in hospitals, as well as campaigns for responsible use of medicines and 
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administration of the Pharmaceutical Schedule, which contains information on all the medicines and 
therapeutic products which district health boards fund.155 
Finally, Medicines Control operates within the MoH as a regulatory team; that is, as an enforcement 
taskforce for the control of medicines and drugs within NZ.156  While Medicines Control also facilitates 
the administration of the MA and MRs, the fact that they primarily monitor compliance with the 
legislation, enforcing decisions made by Medsafe, and issuing licences, except for those which permit 
manufacture and packaging of medicines (something within Medsafe’s purview) is evidence to the 
fact that they are merely an enforcement subsidiary, rather than a corollary to Medsafe.157 
3.2.3 The emerging need for new regulation 
Increasingly, the MA, and its associated regulations are in need of reform due to their age and reactive, 
rather than proactive approach to regulation of medicines, medical devices and related products.  
Furthermore, the enforcement provisions within the Act158 are uncertain, and insufficient to act as a 
suitable deterrent.159  This results in enforcement actions being taken under alternative legislation like 
the FA 160  and the FTA 161  instead, where enforcement is straight-forward and yields penalties 
commensurate with the offence.162  The need for a modern, functional medicines legislation, which 
addresses such issues and allows thorough control of therapeutic products within NZ has been driving 
the desire for a new form of regulation over the past decade. 
3.2.4 Therapeutic Products Bill 
Rising from the ruins of the ANZTPA, the development of a Therapeutic Products Bill was first voiced 
at the end of 2014.163  A year later, the Minister of Health produced two papers on the context and 
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overview,164 and proposals165 for the Bill, accompanied by a Regulatory Impact Statement from the 
MoH.166  Six months later, the Minister released another paper recounting further policy approvals167 
for the new Bill, alongside a second Regulatory Impact Statement.168  These papers envisaged an 
exposure draft169 facilitating stakeholder consultation to be released during 2016,170 followed by the 
Bill being introduced to Parliament late in 2016,171 with a view to the quick passage of this Bill to law 
in 2017.172  However, at the time of writing, the release of the exposure draft had been delayed until 
the end of 2017 “…due to the number and complexity of the issues to be worked through.”173 
The papers on the new Bill identify several key areas where changes from the current MA and MRs 
will arise.  The new Bill will take a much more general focus on therapeutic products, including, but 
not limited to, medicines, blood and blood products, medical devices, cell and tissue therapies, and 
hybrids of these categories. 174   Through generalised and flexible primary legislation, the Bill will 
endeavour to future-proof itself to incorporate any unforeseen new therapeutic products, 175 
operating largely through subordinate legislation and the regulatory departments which the totality 
of the legislation will empower.176  Given the breadth of regulation proposed by the papers, there may 
be significantly greater interface between the Therapeutic Products Bill, and other legislation 
including;177 the Hazardous Substances and New Organisms Act 1996, the FA 2014, the Psychoactive 
Substances Act 2013, the MoDA, the Human Tissue Act 2008, the Health Practitioners Competence 
Assurance Act 2003, and the NZ Public Health and Disability Act 2000.  Were this increased interface 
to occur, it would likely be a result of legislation which is more flexible and designed to allow recent 
developments and research in matters surrounding medicines, medical devices, human tissue and 
other therapeutic products to affect how they are controlled between the various acts. 
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3.3 Definitions and the Impact of the Medicines Act 1981 
3.3.1 The definition of medicines 
There are two main requirements within the MA for a substance to be classified as a medicine.  The 
particular substance must be primarily for use in humans for a therapeutic purpose,178 and should 
achieve this therapeutic purpose, or be likely to do so “…by pharmacological, immunological or 
metabolic means.”179  The concept of therapeutic purpose in the MA is discussed below in detail at 
3.3.2.  Section 3(1) MA goes on to exclude items like medical devices180 and food181 from the purview 
of the definition of ‘medicine’, leaving a fairly narrow type of product which meets this classification. 
The Act then further defines particular types of medicines, which may be grouped into two broad 
categories: new medicines and approved medicines. 
As the term suggests, a new medicine is one which has either not been generally available in NZ in the 
last five years,182 or is a product which seeks to alter its previously approved classification or chemical 
composition.183  An assessment of new medicines considers the safety, efficacy, and quality standards 
associated with the application for approval of the new or changed medicine, and this information is 
used to inform the Minister of Health on whether the medicine has a suitable risk-benefit basis for 
approval.184  In carrying out this process, Medsafe evaluates the data and information provided by the 
sponsor185 against the international standards of similar drug regulatory agencies like the USA Food 
and Drug Administration, the European Medicines Agency, Health Canada, and the International 
Council for Harmonisation.186  While the data requirements for each new medicine application will 
differ slightly, this information must demonstrate key safety, quality, and good manufacturing 
practices (GMP).187  Such evidence will commonly take the form of detailed chemical analyses of active 
and non-active ingredients, the chemical and mechanical process for producing the medicine, 
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information on the quality tests and controls in place, and the results from extensive animal and 
human clinical studies.188 
Within the group of approved medicines, there are four classes into which medicines may be further 
categorised: prescription medicines, restricted medicines, pharmacy-only medicines and general sale 
medicines.  This categorisation is instigated by the sponsor, who notes in their new drug application 
where they envisage their drug being classified.  While in principle higher risk drugs will require 
substantially more information for the new drug application, most sponsors in practice include all this 
information regardless of the classification they are seeking.  The final decision on classification of the 
new medicine is made by the regulator, although it is usually the same as that identified by the 
sponsor.  After approval has been granted and the medicine has been marketed for a period of time, 
the sponsor may make a changed medicine application to apply for a lower classification if post-
marketing monitoring demonstrates low risks.  Occasionally, further research will uncover additional 
risks from a product which has received approval to be marketed over-the-counter, and in these cases, 
the regulator or drug company may reclassify the drug in a higher risk category189 or remove it from 
the market altogether.190  Except for general sale medicines, each medicine which receives approval 
is then listed in Schedule 1 of the MRs, or on the Medsafe Classification Database 191  under its 
appropriate category.  The only mention of general sale medicines in the MA is to note the ability of 
the Director-General to publish a list of these medicines which do not come within the other three 
categories. 192   Instead, the full record of general sale medicines is available on the Medsafe 
Classification Database,193 generally accompanied by dose conditions, as are restricted medicines194 
and pharmacy only medicines.195 
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3.3.2 Therapeutic purpose 
One of the key measures in place to distinguish foods and associated products from therapeutic 
products is that medicines,196 medical devices197 and related products198 have a therapeutic purpose 
and consequently, may make TCs.199  Section 4 MA defines therapeutic purpose in broad terms, 
meaning any preventative, diagnostic, or curative measure for a malady, injury,200 pregnancy201 or 
conception, 202  as well as any modification of a physiological process, 203  or part of the human 
anatomy. 204   Therapeutic claims exclusively describe the treatment of a medical condition (the 
therapeutic purpose) for which the medicine was granted approval.205  Due to the MA’s monopoly on 
TCs, any other product making such a claim is holding itself out as a medicine or related product when 
this is not the case, thus breaching s20(2) MA as well as engaging in misleading or deceptive conduct 
or representations contrary to the FTA. 
3.3.3 Related products 
‘Related products’ is a broad term used in the MA to encompass any cosmetic, dentifrice, or food 
which makes a TC.206  In the event one of those three products makes a TC and becomes a related 
product, certain sections of the MA apply to the products in the same way those sections apply to 
medicines.207  Consequently, s20 prohibits the sale, distribution, or advertisement of related products 
where they do not have approval from the Minister.  These provisions around related products arise 
fairly regularly in relation to CAM products as seen throughout this thesis, as this is one of the avenues 
for prosecuting a company who makes TCs on their CAM products.208 
3.3.4 Medicine marketing and advertising 
A benefit of obtaining approval as a medicine is the ability to market the product with TCs.  This 
informs the consumer exactly what the product will do, and theoretically differentiates medicines 
from arguably less effective, less regulated CAM products.  Aside from the benefits to the supplier, 
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there is a public benefit in being able to select medicines best suited to the affliction.  As such, the 
MRs requires all medicines except for prescription medicines to display a statement of purpose on 
their label indicating the medicine’s intended use.209  A medicine’s intended use is that use for which 
the medicine received marketing approval. 
Similarly, advertisements for all medicines must contain a statement of the therapeutic purpose for 
which the medicine received consent. 210   However, this regulation must be read in light of the 
restrictions on advertisements in the MA.211  Section 58(1)(a) and (b) prevent advertisements that 
claim treatment or cure of conditions specified in Parts 1 and 2 of Schedule 1 MA.  The purpose of 
such a restriction would appear to be consumer protection, given the general lack of a remedy for 
most of the scheduled conditions.  Further credence is added to this view by s58(3), which goes on to 
note that truth is a good defence to a breach of subs(a) and (b).  Thus, verifiable treatment or cure of 
the scheduled conditions will obviate any prosecution under this section. 
In addition to the restrictions on advertising imposed by the legislation, there are a range of guidelines 
and services governing the advertising of therapeutic purpose.  The advertising industry recognises 
the social responsibility which comes with the benefits of making TCs, and therefore has developed 
extensive guidelines212  and vetting for TCs.213   While essentially a collation of material from the 
relevant legislation, the Advertising Standards Authority Code condenses and simplifies this to set out 
the responsibilities of advertisers, and the manner in which advertisements should be executed.214  
Along similar lines, the Association of New Zealand Advertisers has developed a thorough set of 
guidelines and checklists regarding medicines advertising,215 as well as a pre-vetting service216 which 
endeavours to aid advertisers in complying with therapeutic advertising regulations, as well as 
preventing TCs for unauthorised products; a pervasive issue with regards to CAM products, which will 
be considered further at Chapter 4.  Additionally, the FTA and CGA both contain checks on misleading 
or deceptive advertising practices, or remedies where the goods do not match their description in an 
advertisement.  This legislation and its value in handling false representations especially is discussed 
in more detail in relation to CAM products at Chapter 7. 
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3.4 The relationship between medicine and food 
The relationship between medicine and food regulation is a complex one.  While both pieces of 
primary legislation are intended to operate independently with little overlap, the relationship which 
exists in practise is one which resides in the grey areas between the definitions proffered in the 
legislation. 
3.4.1 ‘Food’ in the Medicines Act 1981 
In addition to defining a medicine in s3, the MA provides a list of items which do not qualify as 
medicines for the purposes of the Act.  Included in this list, is “any food within the meaning of s2 of 
the Food Act 1981…”217  Aside from the fact that this has not been updated to refer to the new FA in 
the 7 March 2017 MA reprint, the effect of this section still elicits a blanket ban on foods and 
ingredients218 from being a medicine.  It is important to note two factors which permeate this issue.  
While little commentary or case law is available on the interpretation of s3 MA, it is likely that the aim 
of the section is to define a medicine as something intended primarily for a therapeutic purpose in 
humans, 219  which seeks to avoid absurdity through the exclusion of some other substances. 220  
Furthermore, as evidenced by the lack of update to bring the MA in line with current associated 
legislation, it is likely that the MA is now in a period of decline as new legislation is drafted to overhaul 
the medicines regulatory system, and therefore in effect, a strict interpretation of the definition in s3 
is redundant.221 
3.4.2 ‘Medicine’ in the Food Act 2014 
The FA specifies what does and does not amount to a food in s9; importantly, whether it is “…capable 
of being used, or represented as being for use, for human consumption…”.222  However its exclusion 
of medicines is much more nuanced than its counterpart in the MA, with s9(1)(c)(iii) FA excluding “any 
substances used only as medicines (within the meaning of the Medicines Act 1981)…” from being a 
food.223  A substance like paracetamol, for example, does have exclusive usage as a medicine, and 
therefore could not be classified as a food.  The effect of the word ‘only’ is potentially problematic, 
for even upon a strict interpretation of this subsection, it would appear to allow for substances which 
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have multiple uses to be defined as a food or ingredient as well as being a medicine, given such a 
medicine would not fall within this subsection’s concept of exclusive usage.224 
3.4.3 The food and medicine relationship in practice 
While the FA allows some crossover between foods and medicines, on a strict constructionist 
interpretation of MA, no medicine could meet the definition of food, and by extension, no herbal 
remedy (being a medicine within the definition in the MA) could be a food.225  Given a herbal remedy 
may comprise any plant which has been dried, crushed, or had a similar process applied, no plant 
which is used as a herbal remedy could be an ingredient, and consequently a food.226  The absurdity 
of this situation shows that in practice, such an interpretation is not employed, nor is likely to be 
enforced, but rather there is a certain interrelationship between these substances.  Figure 3.1 depicts 
the relationship which exists in practice between foods and medicines: 
As can be seen from this Venn diagram, while most foods and medicines are independent of each 
other, there are some compounds like iron, which are both a food and a medicine, depending on the 
intent behind their presentation and usage.  In the case of iron, it is a medicine when sold in capsules 
or tablet form, but a part of food when added to iron-fortified cereals.  While iron is strictly a 
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Figure 3.1: Venn diagram showing the relationship between Food & Medicine 
Where: F = Food, M = Medicine 
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constituent of food, it is important to bear in mind that the FA includes “any ingredient or other 
constituent of any food or drink…” as being a food for the purposes of the Act.227 
This Venn diagram (Figure 3.2) holds true when a third category of ‘herbal remedies’ are added.  While 
the MA includes herbal remedies as medicines, this is not applicable in every instance, as shown, 
where some herbs or herbal remedies are not used as medicines.  Cardamom compounds are one 
example of something which transects the artificial legislative boundaries between foods, medicines 
and herbs, by fulfilling each category in certain instances.  When Cardamom is used as a spice, it is an 
ingredient and thus a food.  However, when it is part of an herbal remedy for IBS, it falls within the 
realm of herbal medicine, and if it were to state a therapeutic purpose on the packaging, it would be 
a medicine as well.  This begins to demonstrate the complexity inherent in devising legislation for 
compounds which share many similarities, but also present a plethora of individual risks.  The 
complexity surrounding foods, medicines and herbal remedies will be revisited in more detail below 
when the category of DSs are added to the picture.228 
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Figure 3.2: Venn diagram showing the relationship between Food, Medicine & Herbal Remedies 




3.5 The concept of risk 
In a similar manner to the new FA, 229  risk is an indispensable element in the toxicological 
underpinnings of medicine regulation in the MA.  While the level of risk from medicines is generally 
much higher than that from foods, this may be appropriate given the greater benefit: a great benefit 
allows an acceptable risk.  This brings into question how the legal and scientific conceptions of risk co-
exist from practice through to legislation and litigation. 
The schools of science and law have developed concepts of risk that on first appearances, seem 
entirely distinct.  However, a detailed analysis shows that they may not in fact be unique concepts, 
instead sharing a somewhat symbiotic relationship.230  This section considers these two approaches 
to the definition of risk, and then juxtaposes them through the example of new medicine applications, 
where the two fields intersect.   
3.5.1 A scientific concept of risk 
Risk is defined in the Oxford Dictionaries as “A situation involving exposure to danger”. 231   This 
corresponds with the commonly accepted toxicological conception of risk; that the hazard 
(synonymous with danger), multiplied by the exposure is equal to the risk, as seen in Equation 2.1. 
Although some scientific sources will substitute dose and time for exposure (Equation 3.1), this is 
effectively the same formula, given that exposure takes both these factors into account, 232 but also 
provides a more general scope beyond merely chemicals.233 
𝑅𝑖𝑠𝑘 = 𝐻𝑎𝑧𝑎𝑟𝑑 ×  𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 
𝑊ℎ𝑒𝑟𝑒: 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 = 𝐷𝑜𝑠𝑒 × 𝑇𝑖𝑚𝑒 
Equation 3.1: Variant Toxicological Risk Equation234 
While Equation 2.1 can be quantified,235 it generally operates as an empirical formula, rather than a 
numerical one, as the calculus of the hazard and exposure do not usually generate single integers.  
Equation 2.1 will be considered the first of two phases in the consideration of scientific risk. 
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Considering the ‘hazard’ from a toxicological perspective will involve looking at the intrinsic toxicity of 
the substance.  In a new medicine, for example, this will take the form of studies on how the medicine 
is metabolised, the structural similarities to other known molecules and their consequent effects, and 
acute and chronic toxicity testing.236  Formerly, acute toxicity testing was measured as the LD50 of a 
substance; that is the lethal dose for fifty percent of the population (studied in rats or similar 
mammals).237  However, with a move to more ethical forms of clinical testing, the toxicity is now 
primarily measured as the ‘no observable adverse effect level’ (NOAEL); this being the highest dose 
where no effect is seen from the substance in test subjects.238  On the basis of this testing, it is then 
possible to forecast the chronic toxicity by dividing the NOAEL by one hundred, to obtain the 
acceptable daily intake for the particular substance, which is comparable to extensive reference 
standards, enabling a determination of the long-term effects of the compound.239 
The ‘exposure’ is a simplified measurement which is informed by the toxicity testing.  For example, in 
a medicine, the exposure takes the form of the dose which will be given to a patient over a specified 
period.240 
The multiplication of the hazard and the exposure generate the risk, which is further analysed in Phase 
Two of a scientific risk assessment.  Phase Two is much more theoretical and policy orientated than 
Phase One, as it involves weighing the risk alongside the benefit to determine whether the particular 
activity or substance is safe or worth pursuing in the context of its benefit.  This is the idea of 
acceptable risk. 
Returning to the illustration of thalidomide; if a pregnant woman was internalising a toxicological risk 
analysis to determine what medicine to take for morning sickness, the hazard posed by thalidomide,241 
coupled with the very low exposure required for toxicity242 would result in an exceptionally high risk 
from the medicine.  A Phase Two analysis would likely demonstrate high risk, while the benefit 
(considering the plethora of other safer medicines now available) is correspondingly low.  As such, the 
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woman would almost certainly decide against thalidomide based on this risk analysis, as the risk is 
unacceptable compared to the benefit. 
Conversely, thalidomide can be analysed from the opposite perspective.  Consider a male who has a 
form of leprosy – a type II reaction called erythema nodosum leprosum.  Through its inhibition of 
tumour necrosis factor, thalidomide has been shown to be an effective treatment for this disease.243  
While this man is not part of the typical risk group for thalidomide to cause birth defects, there are 
other hazards inherent in the consumption of the drug, including the risk of genetic damage being 
transferred to a female partner via semen.244  Nevertheless, these are largely controllable, and the 
dosage or exposure is commensurate with these hazards as evidenced by the extensive research into 
thalidomide over the past fifty years.  There is certainly a risk to this man from taking thalidomide, but 
the Phase Two analysis shows this risk to be controllable, lessening its probability, which when coupled 
with the benefits from treatment of this condition, may prove a worthwhile risk due to the benefit in 
this instance.245 
3.5.2 A legal concept of risk 
Risk assessment from a legal perspective is a broad subject area, ranging from risk in employment 
situations, to risk inherent in the insurance practice and the risk of reoffending in criminal proceedings.  
Each area of law and every organisation within that area has their own unique risk assessment 
procedures and practices, however in this instance, the primary tenets of general legal risk assessment 
are sought, to provide a comparison to the scientific perspective previously considered. 
While some psychologists argue that there is no adequate answer to the question in risk management 
of ‘how safe is safe enough?’,246 this potentially comes from too narrow a conception of risk based on 
the desire for a numerical calculus.  Such an approach fails to take account of the fact that “…only in 
very special and crucial cases [can] anything like a mathematical (exhaustive and quantitative) study 
… be made.”247  Instead, legal risk assessment operates in a more theoretical capacity to judge and 
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weigh the various elements to ascertain the particular risk.  Knightian theory248 draws a stark contrast 
between scientific and economic risk assessment (the latter being akin to legal risk assessment), when 
the present reality is that the two are merely points on the same spectrum.249  This spectrum ranges 
from pure numerical probabilities, through the empirical scientific risk assessment espoused above, 
to a more theoretical legal perspective, and finally the completely intuitive or inference-based 
Knightian perspective, which does not allow reasoned knowledge to inform the assessment.250 
Within the concept of this spectrum, there are three theories to legal risk which merit discussion: a 
numerical theory, a philosophical theory, and a theory which balances the two. 
Within some risk management contexts, legal risk is condensed to a mere numerical formula (Equation 
3.2).  While this has the benefit of allowing straightforward assessment for financial events, it does 
not allow scope for determination of risk in less quantifiable events. 
𝑅𝑖𝑠𝑘 = 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) × 𝐿𝑜𝑠𝑠 𝑜𝑓 𝑎 𝐺𝑖𝑣𝑒𝑛 𝐸𝑣𝑒𝑛𝑡 (𝐿𝐺𝐸) 
Equation 3.2: Numerical Risk Equation251 
When the aforementioned thalidomide example is considered in light of this equation, it is apparent 
that financial or insurance calculi like the loss of life or impacted quality of life arising from thalidomide 
consumption are well suited to this equation, as the risk of these events can be readily calculated.  
However, risks arising from human error rely on less definitive variables, and are thus not so readily 
measurable. 
The opposite approach is to take a highly theoretical perspective on risk which precludes simple 
assessment, given the integral role which uncertainty plays in this equation (Equation 3.3).  While 
uncertainty features in any risk calculus, the aim of the whole process is to determine an accurate 
assessment of the risk, based on historical outcomes or a similar means, as seen by the weighing of 
the probability in phase two of the toxicological risk assessment. 
𝑅𝑖𝑠𝑘 = 𝑇ℎ𝑒 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑦 𝑜𝑛 𝑜𝑏𝑗𝑒𝑐𝑡𝑖𝑣𝑒𝑠 
Equation 3.3: Theoretical Risk Equation252 
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In direct contrast to the prior adaptation of the thalidomide example, this risk equation allows no 
certainty or quantification within the risk analysis, which has the general effect of leaving one deeply 
uncertain about the risks they are engaging in by taking thalidomide.  The incompatibility of this 
equation with the example shows the need for a risk equation to have some form of quantifiability – 
even in a legal context. 
The third approach to legal risk is somewhat of a hybrid between Equation 3.2 and Equation 3.3, which 
allows the influence of quantitative certainty through the probability, while bestowing the formula 
with a discretionary element necessary for theoretical analysis (Equation 3.4). 
𝑅𝑖𝑠𝑘 = 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 ×  𝐿𝑒𝑔𝑎𝑙 𝐶𝑜𝑛𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠 
Equation 3.4: A Balanced Legal Risk Equation253 
While legal consequences commonly take the form of loss, there is much more room within Equation 
3.4 for the consequences to in fact be either neutral or positive outcomes compared with Equation 
3.2, which purely casts this as loss.  Furthermore, the term ‘legal consequences’ does not imbue the 
formula with the same preference for financial calculus as does Equation 3.2, but by adding in the 
statistical ‘probability’ qualifier, there is still more practical functionality than occurs in Equation 3.3. 
Much like the toxicological approach to risk, the legal approach at Equation 3.4 still requires a second 
phase analysis, where the risk is weighed against the benefit to determine whether the activity is 
worthwhile.  The key difference between this and the toxicological risk calculus is that the risk in the 
legal Phase Two is already informed by the probability.  The reason for accounting for the probability 
in the first phase in the legal risk assessment is that the chance of an event occurring is to law what 
the exposure is to science.  The probability in law and the exposure in science are the key determinants 
on whether the consequence or hazard will occur. 
If Equation 3.4 is applied to the same example of thalidomide, it will be seen that an identical outcome 
is reached to that in the toxicological risk assessment, despite the differences between Phase One and 
Two and the respective terminology.  The reason for this is that in effect, the term ‘legal consequence’ 
is the hazard inherent in a legal situation.  Therefore, despite appearing quite unique and arising at 
different locations on the spectrum, both these equations operate in substantially similar ways, to 
control markedly different subject areas. 
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Returning momentarily to the FA, the phraseology ‘unfit for human consumption’ arises in the 1981 
Act,254 and a similar principle can be seen through s12 FA.  This provides an apt example of the similar 
legal and scientific approaches to the risk equations, as the commentary on the FA notes in light of a 
couple of cases:255 “There is no need to prove that the food would be injurious to health if it were 
eaten; it is a matter of degree in every case”.256  To paraphrase, regardless of the hazard posed by the 
food, the question of ‘fitness for human consumption’ or the lack thereof comes down to the amount 
required to have deleterious effects; that is to say the exposure. 
3.5.3 The relationship of toxicological and legal risk for new medicines 
While scientific risk and legal risk are similar, they differ in the types of risk, or issues to which they 
apply.  A new medicine application is one example of this, where there are a plethora of risks on both 
sides which must be calculated prior to a determination on whether the new medicine will be 
approved; that is whether it is safe. 
On the one hand, scientific risk looks at issues like the toxicity, as discussed at 3.5.1, as well as risks 
from interaction with other substances, environmental hazard, the effects on pregnant women, and 
many other potential toxicological risks from the new medicine.  On the other hand, legal risks are 
commonly considered by the sponsor prior to filing the application to determine whether it is worth 
pursuing the new medicine application.  Some examples of these will be the risk of infringing an 
existing patent, or patent application for the substance seeking approval, or the risk that the new 
medicine application is denied.   
There are a couple of combinative risks where the legal and scientific fields merge.  For example, the 
risk that a subject is injured from taking a medicine first requires a consideration of the hazards and 
exposure from a toxicological perspective to determine if or when this could happen, and to put dose 
restrictions in place accordingly; a practice known as risk minimisation.  However, even once this 
analysis and subsequent phase two toxicological analysis has been conducted, there remains a 
possibility of adverse effects in untested populations.  Such an incident occurred in the case of the 
anti-arthritic nonsteroidal anti-inflammatory drug (NSAID) Opren, which was removed from the 
market in 1982 due to many adverse effects and 61 reported deaths, primarily of elderly patients.257  
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Consequently, the legal risk for possible eventualities must also be weighed at the time of making the 
application.  This risk calculus may be made by looking at the legal consequences of such an event; 
likely to be damages, litigation, or the rescinding of regulatory approval.  These consequences will 
then be balanced against the probability of the event occurring, which will have been derived from 
the toxicological risk assessment. This demonstrates how the two forms of risk assessment both 
usually co-exist harmoniously, but can complement each other where necessary. 
3.6 Relationship of the Medicines Act 1981 with other legislation 
The MA does not act in isolation as a code, but rather draws upon a variety of other legislation to carry 
out its functions.  The interplay between the MA and other legislation can fundamentally alter the 
interpretation or enforcement of the MA, and is therefore worth mentioning. 
3.6.1 The Medicines Act 1981 & the Misuse of Drugs Act 1975 
The MoDA is built upon a similar risk-based approach to the MA, however it classifies the three classes 
of drugs on a risk-based system, which relates to the harm posed by the drug to both the individual or 
to society by its misuse.258  This is a somewhat more holistic approach to considering risk as opposed 
to a primarily empirical system as employed in the FA. 
While the police play an important role in the administration of the MoDA, Medicines Control as 
discussed above259 also handles the compliance with the legislation, especially insofar as the MoDA 
relates to medicines.  While the MoDA does not define ‘medicine’, the MA does pay homage to the 
earlier Act by noting that ‘controlled drug’ has the same meaning as in the MoDA.260  The MA goes on 
to acknowledge the close relationship between the two pieces of legislation in s109.  This section’s 
importance cannot be overlooked, as it provides for the close interworking between the two Acts, 
noting that they must both operate in concert,261 although where a person bears a licence to deal with 
drugs under the MoDA, they are also permitted to deal with medicines under the MA;262 a gesture to 
the more stringent regulations in place for handling drugs under the MoDA. 
While the MA is generally a permissive statute which provides safeguards to ensure that medicines 
are not abused where there are substantial risks associated with their use, the MoDA is in contrast, a 
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prohibitive statute, which prevents people dealing with,263 or otherwise possessing or using controlled 
drugs.264  However, the lines between the two Acts can be blurry, in that many of the substances 
classified in any of the three MoDA classes may in fact also come under Schedule 1 MRs.265  While 
there is little written on this subject, it appears that the rationale is that in some instances, these 
substances operate as medicines, and thus have the evidential backing necessary to be at home in 
Schedule 1 MRs, but at the same time, they pose a substantial risk to individuals and society where 
not managed correctly, making them equally at home in the MoDA.  This is another example of the 
fluidity which exists in the classification of products across the spectrum, from food, all the way 
through to Class A controlled drugs.266  
3.6.2 The Medicines Act 1981 & the Trans-Tasman Mutual Recognition Act 1997 
It is important to briefly note the TTMRA’s relationship with the MA given the different way the TTMRA 
interacts with the FA.  The MA is one of the Acts listed in Schedule 2 TTMRA, as being permanently 
exempt from the scope of the TTMRA such that it cannot affect the operation of the Act.267  The 
applicable part of Schedule 2 clarifies this exemption: “Misuse of Drugs Act 1975, Medicines Act 1981 
and Dietary Supplements Regulations 1985, to the extent that they or any of them deal with any 
requirement described in s10(2) applicable to therapeutic goods”.  Section 10 generally outlines the 
mutual recognition principle in relation to goods, with ss(2) specifically outlining the requirements to 
which goods may be subject; notably requirements like that of the goods satisfying standards with 
regards to their composition and quality,268 a pertinent provision insofar as the MA is concerned. 
Consequently, medicines under the MA are exempt from the requirements of the TTMRA and 
therefore theoretically cannot be imported and sold like any other good from Australia without 
ensuring compliance with NZ’s regulatory framework. 
3.6.3 The Medicines Act 1981 & the Health Practitioners Competence Assurance Act 2003 
Practitioners’ authority to prescribe medicines provides a valuable contrast to later discussions on the 
current and proposed dispersal of CAM products.269 
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Section 2 MA lists a nurse practitioner, an optometrist, a medical practitioner, a dentist, a registered 
midwife, and a designated prescriber as ‘authorised prescribers’ under the MA who may distribute 
prescription medicines.  These authorised prescribers, except for a designated prescriber, are 
empowered by professional boards or councils, whose authority is bestowed by the Health 
Practitioners Competence Assurance Act 2003.270  Many of these authorised prescribers have limits to 
their power to prescribe, which are regulated by their professional body, usually requiring 
prescriptions to be within the scope of their practise.271   
The category of ‘designated prescriber’ is a catch-all term which enables the MRs to specify further 
health professionals who may prescribe medicines. 272   The MRs employ this power, allowing 
veterinarians to distribute a prescription medicine for the treatment of animals,273 but currently not 
specifying any further class of health professionals who are authorised to dispense prescription 
medicines.  Whether the practical operation of the term ‘designated prescriber’ allows any practising 
member of a professional body under the 2003 Act to dispense prescription medicines remains 
unclear. 
3.7 Conclusion 
The risk-based approach in the MA was one of the earliest appearances of a well-structured, evidence 
based approach to the regulation of a particular category of products.  While it has done an admirable 
job of maintaining its relevance due to sufficient flexibility throughout the legislation and the 
regulations, it is beginning to show its age, with difficulty keeping up with newer legislation, and the 
definitional problems exemplified in the legislative incongruity between food and medicine.  While 
the Therapeutic Products Bill is set to bring medicines’ regulation into the 21st Century, its enactment 
may still be some time away. 
The risk-based approach in the MA provides a platform to consider risk management and the way 
scientific risk assessment is conducted in the context of goods with potentially high benefit, but 
correspondingly high risk.  At the same time, legal risk arises in terms of secondary consequences from 
the risk of medicines, facilitating discussion on a variety of methods for analysing and quantifying both 
legal and scientific risk; methods which ultimately share much in common, despite the distinct 
operation of these two forms of risk assessment.  Beginning with food regulation, and then medicine 
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regulation, risk is an increasingly important part of this discussion, as the perspective now turns to 





4 Complementary & Alternative Medicine Products 
What we needed were facts, not opinions.  Alternativists usually disagreed with this view, 
pointing out that conventional medicine, and pharmaceuticals in particular, were burdened 
with much greater risks than alternative treatments.  I argued that, while this may well be so, 
the worth of any intervention must be seen in the context of a balance between its risks and its 
demonstrable benefits.  If the benefits are uncertain, then even relatively small risks will weigh 
heavily and tilt the risk-benefit balance into the negative.274 
4.1 Introduction 
In Chapter 2, food products were generally seen as low risk, with high benefit.  In Chapter 3, medicines’ 
risk profiles showed a relatively higher risk, but with correspondingly high benefit; justifying much 
more rigorous risk-based regulation of medicines.  This Chapter turns to CAM products, and while the 
risk is usually considered to be low to moderate, in reality, the risk of most CAM products is simply 
not known.  In contrast to medicines, CAM products have a relatively low benefit, but without an 
appreciation of the risk of these products, regulation of CAM products poses a real challenge. 
Chapter 4 looks at the current NZ regulations for dietary supplements – the DSRs and the mechanisms 
by which they seek to control these products.  This is followed by a broader look at CAM products and 
a continuation of Chapter 3’s classification discussion, with the additional category of DSs.  Finally, the 
Chapter turns to consider three examples which illustrate some of the problems associated with the 
DSRs since their inception more than 30 years ago. 
4.2 The Dietary Supplements Regulations 1985 
The DSRs are a product of their time.  They were created to provide a ‘catch-all’ for products which 
are neither foods nor medicines; regulating products which provide nutritional supplementation and 
alleged health benefits, but do not meet the standards for medicines.275  Utilising the extensive range 
of law making powers endowed by the 1981 FA,276 the Executive created the DSRs, which remain in 
force more than thirty years later.277  Neither clarifying the distinction between foods and medicines, 
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nor establishing a regulatory system requiring adherence, the DSRs have generally been marginalised 
by both industry and government.278 
4.2.1 The definition of a ‘dietary supplement’ in the Dietary Supplements Regulations 
The nascent inklings of the DSRs naturally arose during the second reading of the Food Bill.279  It was 
stated here that: 280 
How various dietary supplements offering vitamins and minerals or the so-called slimming 
foods or other special-purpose foods are regarded under the law will in many instances depend 
on how they are presented to the public.  One man’s food may conceivably be another man’s 
medicine. 
This theme of the presentation of DSs is interesting for the fact that it appears multiple times in the 
Hansard on the Food Bill,281 and yet this theme is not present when defining DSs in the DSRs.282 
Regulation 2A DSRs defines a DS as a liquid, powder, tablet, or lozenge283 intended to be taken orally284 
which comprises an amino acid, edible substance, herb, mineral, synthetic nutrient, or vitamin285 
either alone or in a mixture,286 the intention of which is to supplement those components which may 
be normally derived from food.287  However the reality is that this definition does little to clarify any 
distinction between a DS, food or medicine, with these characteristics in reg2A applicable to all three 
classes.288 
Regulation 3 DSRs specifies the maximum levels of nine vitamins and minerals permitted in DSs, 
however in so doing, it further muddies the waters.  All of these specified products are already 
included in the MRs289 or General-Sale Medicine Classification list290 with identical maximum dose 
levels to those in reg3 DSRs.  Consequently, all these products are general sale medicines and DSs 
based on their maximum daily dose.  Evidently, the DSRs were never intended to classify DSs in the 
absence of other legislation given the overlap in both directions, and thus they will be added to the 
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bigger picture to determine their place in the matrix between foods, herbal remedies and 
medicines.291 
4.2.2 Labelling requirements 
Regulations 4-11 DSRs detail the specific requirements associated with the labelling and material 
attached to the packet of a DS.  While the majority of these are mundane regulations relating to the 
labelling, two have wide-reaching implications in the marketing of DSs.  For example, while not as 
omnipresent as it should be, consumers are accustomed to seeing the term ‘dietary supplement’ on 
the products which they buy, as required by reg5(1)(e) DSRs.292 
Regulation 10 prohibits any false or misleading statement on or with a DS, especially one which makes 
claims to the nature, suitability, or effects of the DS or its ingredients.293  While well intentioned, this 
is a toothless provision, as it is not included in the list of provisions for which a breach amounts to an 
offence under the regulations.294  Consequently, action must be taken under the FTA if someone seeks 
to allege misleading or deceptive statements on a DS.295 
Regulation 11 prohibits TCs on DSs.  This regulation goes on to specify what amounts to a TC for the 
purposes of this regulation, giving the phrase a similar, although slightly more limited, definition to 
that of ‘therapeutic purpose’ at s4 MA.296  As with reg10, this section is not within the scope of the 
offences in the DSRs.  Rather it appears that if such a claim is made, then action should be taken under 
the MA on the basis that such a product is holding itself out to be a medicine or related product by 
making a TC; a position initially espoused during the second reading of the FA: “…if any special claims 
are made for products containing vitamins or minerals they may be regarded as medicines…”.297 
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Due to the difficulty and multi-legislative approach required to enforce these provisions, they are 
widely flouted in the industry.  A MoH Regulatory Impact Statement for the NHSPB noted that over 
half of the 12,000 online products reviewed displayed TCs in breach of the legislation.298 
4.2.3 A black-list or white list approach? 
The DSRs employ neither a black-list nor white-list approach in their regulation of DSs.  A black-list is 
usually a list of products prohibited from being part of the larger group – namely DSs in this case.  
Conversely, a white-list is commonly an exclusive list of the products which are permitted to be used 
as ingredients or products as part of the larger group.    
Part 2 DSRs specifies nine different types of products which may be present in DSs, but it is not an 
exclusive list.  The definition of DSs at reg2A describes a broader category of products than Part 2, and 
while this Part does limit some products like vitamins299 and minerals300 to an exclusive list, on the 
whole, the DSRs do not employ a white-list approach. 
Neither do these regulations employ a black-list approach, for while the levels of some constituents 
are specified,301 there is no outright ban on products or ingredients in the DSRs, and consequently, no 
black-list. 
4.2.4 Penalties under the Dietary Supplements Regulations 
Regulation 21(1) DSRs specifies the regulations where a breach or failure to comply, amounts to an 
offence.  This does not include breaches of regs6-12, which regulate the labelling, consumer 
information, misleading statements, and TCs on DSs; with no penalties for infringing these regulations.  
In the event of an offence, reg21(2) goes on to detail the penalty of a fine not exceeding $500, and 
where the offence is a continuing one, a fine not exceeding $50 per day the offence continues.  Even 
if that figure were adjusted for inflation, the maximum fine in 2016 would be $1,398.23: barely more 
than a slap on the wrist in 1985, let alone 2016 when the prices of these goods are considered.302  
There is significant fluctuation in DS pricing depending on variables like brand, ingredients and the 
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claims the product makes, commonly ranging from $12 to $80 for a product,303 although it is not 
uncommon for some products to exceed $100 depending on the amount supplied.304 
As a result of this nominal penalty, almost all of the few prosecutions which are taken around DSs seek 
to utilise other legislation.  Commerce Commission v Mega Vitamin Laboratories (NZ) Ltd305 was one 
of the earliest cases to take this approach.  The case dealt with the amount of vitamins in the 
defendant’s products, which had undergone degradation during the manufacturing process and 
consequently were significantly lower306 than the amounts claimed on the label, despite still being 
within their ‘use by’ period.  It was held that the defendant had made false or misleading 
representations as to the composition of his goods under s13 FTA.  Similarly in Commerce Commission 
v Zenith Corporation Ltd307 the defendants were prosecuted under s13 FTA for the false or misleading 
representations made on the weight loss product they sold, despite the fact that they advertised it as 
a weight loss product “…in contravention of the Food Act 1981, the Medicines Act 1981 and … the 
Dietary Supplements Regulations 1984.”308  Ministry of Health v Pacific Pharmaceuticals Ltd309 took a 
slightly different approach, where the green-lipped mussel extract they sold was labelled as a DS, but 
displayed a number of TCs on their website.  In this instance, the respondent was prosecuted under 
s20(2) MA for selling a new medicine without approval from the Minister. 
4.2.5 The present day Dietary Supplements Regulations 
Many of the problems outlined above are the result of the DSRs receiving only two amendments since 
their inception.310   This appears to be the results of the move over that period towards a joint 
Australia-NZ regulatory scheme, and when that failed, the move towards the NHSPB.  The one update 
which did occur in 2010 addressed two issues; updating the meaning of DS to conform with the 
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separation of supplemented foods into the New Zealand Food (Supplemented Food) Standard 2010, 
and amending regulation 3(1) with respect to Folic Acid.311 
Perhaps the greatest concern with the DSRs is not what is there, but rather what is not.  The 
regulations do not regulate all the products they define as DSs, and some of the most important 
regulations have no mechanism for enforcement.312  Furthermore, some aspects are missing entirely, 
like standards for GMP, and policies surrounding recall of unsafe products.  Not only are the current 
DSRs insufficient, they have promulgated a ‘wild-west’ culture of CAM products, which is now 
increasingly difficult to reign in, as was seen in the progress of the NHSPB.313 
4.3 Other products 
There are two further situations where CAM or related products may not be covered in the preceding 
discussion.  That is the dispensing of CAM products by practitioners, and the increasing incidence of 
supplemented food and where it fits in relation to CAM products. 
4.3.1 CAM products dispensed by practitioners 
There are several pieces of legislation or guidelines in addition to the MA, FA, DSRs, FTA and CGA 
which govern medical and CAM practitioners.  This includes the Health and Disability Commissioner 
Act 1994, the Health Practitioners Competence Assurance Act 2003, the Code of Health and Disability 
Services314 and the Tianga ā-Rongoā toolkits.315  There are also a number of professional national or 
international organisations which providers of CAM modalities may belong to, however these are 
generally unregulated in NZ. 
On the present issue, the most important legislation is again the MA, where at s32 it provides an 
exemption for natural therapists to manufacture or supply patients with a general sale medicine or 
DS.316  In theory, this exemption only applies to patients who seek a consultation, and does not allow 
the therapist to advertise or state products as having a therapeutic purpose, but there is little 
oversight of Natural Therapists operating under this exemption.317  
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The one NZ case which dealt with practitioners focused on misleading and deceptive conduct under 
the FTA when they had falsely advertised their qualifications and the efficacy of their products.318  The 
issue in Godwin was not the dispensing of CAM products by practitioners, which they were entitled to 
do, but rather the broader issue of misleading and deceptive conduct, which is considered in the 
context of this case at 7.5.3. 
4.3.2 Supplemented foods and nutraceuticals 
Supplemented foods and nutraceuticals are two further categories of products which could very 
loosely be considered CAM products, although due to their presentation, they fit more naturally with 
food.319  Nevertheless, they still warrant a brief discussion on their definition and regulation. 
Supplemented foods are fairly straightforward insofar as regulations are concerned.  The New Zealand 
(Supplemented Food) Standard 2016 was enacted under the FA 1981, and remains in force under the 
2014 iteration, defining ‘supplemented foods’ as “…a product that is represented as a food that has a 
substance or substances added to it, or that has been modified in some way, to perform a physiological 
role beyond the provisions of a simple nutritive requirement.”320  Alongside this definition, clause 1.3 
excludes dietary supplements, medicines and a number of other products from being supplemented 
foods.321  The standard was intended to be an interim measure until there are supplemented food 
standards under the ANZFSC.322  As noted earlier, supplemented foods were previously regulated 
under the DSRs, although this changed in 2010 on the basis that the requirement for modification 
made them distinct from foods.323  Much like the DSRs, the Standard provides basic requirements for 
supplemented foods, like the requirement that they display the phrase ‘supplemented food’ on the 
label,324 and proceeds to list a small number of restrictions, prohibitions and levels of supplements 
which may be added to supplemented foods.325 
Nutraceuticals are slightly different in their nature.  Perhaps the simplest definition of nutraceuticals 
is a food product which has natural medicinal, or antibacterial properties without the need for 
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substantial modification.  Generally nutraceuticals are considered to encompass products like 
propolis, deer velvet and green-lipped mussels.326  A paper produced for government in 2011 on 
nutraceuticals and functional foods took an in-depth look at the global market and NZ’s place within 
it. 327   Therein, the difficulty with a single definition of nutraceuticals is discussed, although the 
following definition is offered: “Natural product extracts sold in dosage form (capsules, tablets, 
powders, etc.)”.328  Importantly, there is no specific legislation for nutraceuticals, although from that 
definition, it can be seen that the DSRs apply to nutraceuticals.  There is little mention of the DSRs in 
the report, however, one of the key observations which came from discussions with industry in the 
preparation of the paper highlighted the importance of new legislation – specifically the early iteration 
of the NHSPB.  Many of the stakeholders supported the Bill, in establishing a credible and world-
standard legislative scheme which would promote NZ products to the world and ensure that outside 
countries could not ride on the coat-tails of NZ’s brand in marketing their products.329  It is likely that 
the NHSPB would have encompassed nutraceuticals in a much more organic manner than the DSRs, 
primarily as a result of such products being fairly novel, at least in the context of regulations from 
1985.  This will be discussed a little more in Chapter 5 when the NHSPB is considered in detail. 
4.4 When a CAM product is not a CAM product: The classification debacle 
As discussed at the outset, the term ‘CAM’ struggles to encompass the plethora of products, not to 
mention modalities within this form of medicine.  This issue is further exacerbated when the 
legislation cannot determine what a CAM product is, or where one particular CAM sub-group stops 
and another starts. 
4.4.1 Four types of products & their origins 
Broadly speaking, there are four primary types of CAM products in NZ in a regulatory sense. 
Herbal remedies are the first CAM sub-group.  They are defined in s2 MA as previously discussed,330 
as well as being loosely referenced in reg2A DSRs.  While they are defined as a medicine in s2 MA, it 
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seems only logical from the inclusion of ‘herbs’ in the DSRs that they may also be a DS depending on 
the whim of the sponsor. 
Unsurprisingly, DSs are the second type of CAM product.  Certainly the most generic of all four 
products, DSs can be anything from daily multivitamins, to muscle-building creatine capsules.  The 
DSRs define DSs at reg2A, but being exceedingly general and rarely enforced, this does little to 
delineate between DSs and other CAM products. 
Homeopathic remedies are an integral part of any categorisation of CAM products, and yet they barely 
feature in NZ’s DSRs or related legislation.  The only specific mention of homeopathic remedies is in 
reg15(1)(d) MRs where it exempts the containers of homeopathic remedies from adherence to the 
labelling requirements for medicines331 or related products.332  On a broad interpretation of reg2A 
DSRs they may be included within ‘edible substances’,333 however there is no authority on this issue.334  
As such, homeopathic products are effectively unregulated in the current NZ CAM product 
environment. 
Traditional medicines are the fourth CAM product sub-group.  While strictly, traditional medicines 
may be considered under pre-existing legislation and regulations given the majority of them comprise 
herbs or other edible substances, this does not do justice to the additional factors associated with 
traditional medicines, like the processes and historical importance of these products.  In essence, 
traditional medicines are currently unregulated in NZ. 
While there are some products which defy classification into these heads, like the aforementioned 
nutraceuticals,335 or probiotics, the purpose of this grouping is to allow discussion of these products 
in the current legislative environment.  As discussed from the beginning, the term ‘CAM products’ 
ideally avoids many of the problems associated with most classifications of such products into divisible 
subgroups. 
4.4.2 The impact of therapeutic claims on products’ classification 
Generally the presence of a TC, especially a high-level claim dealing with something like cancer, will 
be sufficient to bring the product making that claim within the purview of the MA as either a new 
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medicine which is being sold without consent,336 or as a related product; namely a food, cosmetic or 
dentifrice which claims to be effective for a therapeutic purpose.337  Either way, the TC is likely to 
result in penalties for that product given it held itself out to be a medicine. 
The leading case supporting this application of the legislation was the High Court (HC) decision in 
Ministry of Health v Pacific Pharmaceuticals Ltd.338  In this case capsules of purified green-lipped 
mussel extract were distributed to a range of pharmacies in NZ.  Their packaging clearly stated ‘dietary 
supplement’ in line with the regulations, and contained no TC.  However, the associated website which 
was referenced on the label made both low and high-level TCs; regarding joint inflammation and 
asthma, and cancer respectively.339  On the grounds that reg11 DSRs directly references the MA,340 
the fact that there is no penalty in the DSRs for a breach of reg11, and the general theme of the MA 
that TCs are restricted to medicines; the District Court (DC)341 and HC in Pacific Pharmaceuticals held 
that the MA implicitly requires a product with a TC to be a medicine under s20 (or a related product, 
to which s20 applies “…with all necessary modifications…”).342  This stance is also adopted by some 
commentators, 343  and has been corroborated in the only other case around this issue.  While 
distinguishing Pacific Pharmaceuticals on the basis of a substantially different fact pattern, the case of 
Zheng v Ministry of Health344  supported the broad applicability of s20 MA “…to deal with cases 
covering a very wide range of circumstances.”345 
While penalising DSs for making TCs under the MA (as either an unregistered new medicine or related 
product) is uncontroversial and comes well within the interpretation of the relevant sections, it is 
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important to note the historic case of Diet Tea Company Ltd v Attorney-General,346 which interpreted 
the MA in a more rigid manner.  This case concerned a tea which made TCs regarding its facilitation of 
weight loss.  There was no question that this was a TC, but instead, Henry J focused on whether tea 
was a food under s94(1) MA.  Ultimately, he held that as the MA did not define ‘food’ and was a 
distinct, albeit companion piece of legislation to the FA, that tea could not come within the ordinary 
meaning of food.347   
However, on the basis of the more recent case of Pacific Pharmaceuticals and the cases and 
commentary in support of its stance, it is likely that the Courts have moved on from such a rigid 
interpretation as in Diet Tea, and are willing to allow a certain fluidity in their identification of food, 
medicines and CAM products; especially where a TC facilitates this classification. 
4.4.3 Food, medicine & CAM products 
Having touched on the complexity of the definition of CAM products in isolation, it is worth taking a 
step back to consider how CAM products, and more specifically those that are currently regulated, fit 
in to the food and medicine regulatory schemes discussed above.   Two diagrammatic aids will be used 
to illustrate the mêlée. 
A legislative flow-chart 
It is first important to appreciate the inter-relatedness of food, 
medicines, herbal remedies, and DSs from a legislative 
standpoint.  Foods are generally governed by the FA, which 
empowers the DSRs.  As such, DSs can be considered a subset of 
foods (Figure 4.1).  Similarly, medicines are governed by the MA, 
which includes herbal remedies (Figure 4.2).   However, foods and 
medicines are united by two primary links.  Firstly, herbal 
remedies can also be DSs and thus foods, and secondly, DSs can 
also be medicines either as herbs, or by way of TCs (Figure 4.3).  Therefore, the attempt at an 
impenetrable barrier between foods and medicines espoused by the MA348 does not exist in practice, 
for while an argument may be made for products not co-existing as both medicines and foods 
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simultaneously, there is no doubt that the same product could be a medicine or a food, depending on 
its presentation and marketing.  
A return to the Venn diagrams 
In the previous chapter at 3.4.3, the following Venn diagram was used to depict the overlap between 
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Figure 4.4: Venn diagram showing the relationship between Food, Medicine & Herbal Remedies 











Figure 4.3: Legislative relationship of Food, Medicine, Herbal Remedies and Dietary Supplements 




Through the logic of Figure 4.3, it now becomes clear that merely adding DSs to the Venn diagrams 
employed at 3.4.3, does not adequately depict the legislative relationship of these four products 
(Figure 4.5).  There are multiple reasons for this, but two which cripple this style of Venn.  The spaces 
in the ‘herbal remedy’ and ‘DS’ circles which presume these two can exist without being either 
medicine or a food is false; as shown by Figure 4.3.  Secondly, even if that were not an insurmountable 
issue, this style of Venn diagram does not allow for two overlaps: that between herbal remedies and 
DSs, and that between foods and medicines.  While it is possible to construct an adaptation of a Venn 
diagram which accounts for all possible permutations (Figure 4.6), this starkly illustrates the 
impossibility of this diagrammatic representation of the legislative relationship, through the exact 
links it sought to make: that between food and medicines, which are unquestionably mutually 
exclusive by way of s3(1)(c)(ii) MA.  While in theory, it is possible to create Venn diagrams which come 
close to representing the current legislative relationship between these four products (Figure 4.7), 
they are all premised on the basis that at some level in the subsets of ‘DSs’ and ‘herbal remedies’, 
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Figure 4.5: Venn diagram of Food, Medicine, Herbal Remedies and Dietary Supplements 








there is cross-over between medicines and foods, which is not supposed to be the case.  As seen in 
Figure 4.7, any depiction which comes close is practically unworkable. 
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Figure 4.6: Adapted Venn diagram for Food, Medicine, Herbal Remedies and Dietary Supplements 
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Figure 4.7: A close graphical representation of the classification relationship 




There are two possible work-arounds for this conundrum.  The first approach, and that likely to be 
taken by the courts, were this ever to be an issue, would be to assess each case on its own merits, 
devoid of context or other examples which highlight the impossible relationship between these 
related products.  For example, Manuka honey is commonly cited as having medicinal properties, 
being accepted in an obiter statement in the CA that it does have health benefits as a wound 
dressing.349  Similarly, it was observed in the debate on the NHSPB that honey is a therapeutic product, 
a food, and a supplementary product.350  If the question of honey being a medicine came before the 
courts, it is almost certain that they would deem it a related product under s94(1) MA, thus avoiding 
any conflict between the FA and MA.  Honey is a straightforward example, however the problems are 
immediately apparent if a CAM product like silver, or garlic came before the courts, due to their 
crossover between medicines and DSs, or foods and herbal remedies respectively.  Silver is a general 
sale, or pharmacy only medicine depending on the concentration, but is also commonly present as 
‘colloidal silver’ in a number of CAM products, while garlic powder is frequently added to capsules or 
other CAM products, as well as being a common ingredient in food.  To avoid a conflict between the 
legislation, a court is likely to adopt any one of a number of canons of statutory interpretation, ranging 
from the rule generalia specialibus non derogant, meaning that general provisions do not take 
precedence over specific ones, to leges posteriors priores contrarias abrogant, where later legislation 
takes precedence over earlier legislation.  The court’s approach will turn on the facts of the case, but 
the important point is that the court will do all in its power to avoid deeming the legislation incorrect 
or contradictory. 
However, from an academic perspective, the legislative issues between the classifications of these 
four products arise due to the incongruous provisions in different statutes.  Occam’s razor dictates 
that the simplest explanation should prevail, and in this instance, that explanation is that the conflict 
between CAM products, foods and medicines under the current legislation is a result of piecemeal 
legislative development, coupled with radical changes in the nature and diversity of CAM products 
over the past three decades, rendering the legislation contradictory and unworkable. 
4.5 The problems inherent in the DSRs 
At the beginning of this chapter, the nature of the DSRs were considered, somewhat devoid of context.  
Section 4.4 then turned to look towards one of the problems with the DSRs in light of associated 
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legislation and the definitions therein.  This section continues that theme, but turns more directly to 
the question of why there is a need to change the existing CAM product regulations.  Alternatively, 
the question may be posed as: ‘What are the problems which make the DSRs untenable for the future 
regulation of CAM products?’   
While there are countless issues which could be considered, three pertinent NZ examples will be 
employed to demonstrate a variety of harms, or problems which exist under the current regulations. 
4.5.1 The Pan Pharmaceuticals recall 
In 2003, one of the biggest crises around CAM products in Australia and NZ came to the fore.  Nearly 
1600 products produced by Australian company Pan Pharmaceuticals were recalled as a result of 
serious adverse reactions to the Pan product ‘Travacalm’, for preventing motion sickness, with 19 
people requiring hospitalisation due to life threatening reactions.351  This occurred due to a huge 
variation in the quantity of active ingredient present in the product,352 ranging from 0-700% of the 
advertised amount.353  Upon further audit, it became apparent that this issue of “manipulation”, 
“fabrication”, and “substitution” 354  was somewhat endemic throughout the manufacturing and 
testing of Pan Pharmaceuticals products, resulting in the recall and license suspension by Australia’s 
medicine and CAM product regulatory body, the TGA.355 
Naturally, this recall was of grave concern to food safety and medicine authorities in NZ.  This was 
further exacerbated by the fact that Pan manufactured a number of products for other companies 
which were popular in NZ, including Red Seal, Nutralife and Thompson Nutrition.356  While the issue 
of unsafe and substandard products is exceedingly concerning, and shall be discussed further below,357 
the uniquely NZ problem in the context of the Pan Pharmaceuticals case was the difficulty with which 
the recall was executed.358 
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Two elements do warrant noting.  Firstly, while many detractors of the joint-agency vitriolically 
condemned the TGA for failing to pick up on the Pan Pharmaceuticals’ issues sooner,359 the fact the 
issues were identified at all is testament to the post-marketing surveillance, adverse event reporting 
and the rigorous powers of the TGA to audit and control therapeutic goods in Australia.  Such a wide-
scale operation against a manufacturer who, at the time, produced about 70% of Australia’s CAM 
products could simply not occur under the DSRs in NZ.360   
The second, and more pertinent issue for NZ is the execution of the recall of Pan products.  On 30 April 
2003, the Health and Food Safety Minister, Annette King made a statement acknowledging the 
Australian recall, highlighting the problem with a similar response in NZ.361  This is the fact that there 
is no register of CAM products in NZ, making a widespread recall of goods produced by one 
manufacturer quite difficult.362  Of the 219 products initially recalled, only three were medicines in NZ, 
with the remaining 216 products classified as foods.363   Consequently, these products had to be 
recalled under s40 FA 1981 on the basis that the ‘food’ was unsound, or unfit for human 
consumption.364  Due to the lack of a register, recalling the vast majority of these products came down 
to an ad-hoc process, which required retailers, importers and other stockists of any of the products 
highlighted in the recall to destroy or return these products.  There was considerable confusion around 
the recall in NZ, with the process taking many days, and several different recall documents before all 
the information was available, due to an array of problems ranging from different names of the 
Australian equivalent products, to the sheer volume of products to be recalled – 642 DSs in NZ.365   
The failings of the DSRs in managing any kind of recall are epitomised by the NZFSA director of policy 
and regulatory standards who at the time noted: “We just don’t have a handle on the scope of the 
New Zealand industry.”366  The inability to recall CAM products under the DSRs, and the lack of any 
kind of database of either CAM products, or the manufacturers, suppliers and importers of CAM 
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products in NZ amounts to a major problem in terms of ensuring product safety and consumer 
protection.  
4.5.2 Contaminants, fillers, and the corresponding false labelling of CAM products 
In 2013, researchers in Canada published an article recounting the results of a study which used DNA 
barcoding to determine the purity, or lack thereof, in North American herbal products.367   They 
isolated the DNA of 44 products available in Canada or the USA from 12 different suppliers, and 
compared this to a standard reference material herbal barcode library to ascertain whether the 
product was authentic, or if there was substitution, contamination or a filler material present in the 
herbal product.368  While the study acknowledged the possibility of error in using only three or four 
herbal product samples from a small selection of companies, their results showed that the products 
from only two of the 12 companies were authentic with no substitution, contaminants or fillers.369  
These results are more stark when it is seen that only 48% of the products were able to be 
authenticated, 59% of the products displayed evidence of substitution with species not on the label, 
and 33% of the authenticated products showed the presence of contaminants and fillers,370 as seen in 
Figure 4.8. 371 
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These results are highly concerning on a number of levels.  The risks posed by imbibing a product 
which is of a different species and not present on the label, or more alarmingly, a product which is 
contaminated or consists of filler materials, could pose a risk of either acute toxicity, or serious allergic 
reaction.  Furthermore, from a legal and regulatory perspective, there is a major problem when 
products are marketed as something they are not, or when the label does not correspond to what is 
inside the container.372 
Although this study is somewhat geographically removed from NZ, it would be naïve to dismiss the 
gravity of its results on this basis, given that the regulations in the USA are akin to NZ’s DSRs, and 
Canada’s regulations are more comprehensive.373  Proponents of lower regulation, or a self-regulating 
industry for CAM products take pleasure in citing a lack of evidence of harms, which they claim justifies 
a very low risk profile for CAM products.374  However this ignores the wealth of information and 
evidence indicating a dangerously cavalier attitude which pervades CAM product manufacturing with 
respect to the purity, authenticity, safety and GMP, as seen in both the Pan Pharmaceuticals case375 
and in the Newmaster research.376 
One further example demonstrates the severity of this issue in NZ.  In 2015 the NZ Herald began an 
investigation into workout supplements which came under the DSRs.  Commissioning testing by the 
Crown Research Institute ESR, the Herald found the banned stimulant DMBA377 in sports supplements 
available in NZ.378  This went hand-in-hand with evidence of the death of a NZ airman in 2009 from a 
supplement containing DMMA,379 a close analogue of DMBA.380  An Official Information Act381 request 
in the investigation also revealed two NZers who had contracted acute non-viral hepatitis from a 
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different supplement.382  More than six-months later, another restricted drug, Picamilon, a precursor 
to the date rape drug GHB, was found in a number of supplements.383 
While the CAM product industry may try to distance itself from workout supplements and the litany 
of toxic and illicit drugs found therein, two facts are unavoidable.  The workout supplement industry 
currently exists largely under the ambit of the DSRs, and therefore there is no reason to presume CAM 
products are not subject to the same problems.  Secondly, the attempts of the industry to claim that 
no evidence of harm is good evidence, is an illogical and dangerous stance, when the little scientific 
evidence which does exist around such products, prompts serious questions about the nature and 
safety of the CAM product industry as it currently exists. 
4.5.3 Medicine & CAM product adverse interactions 
The final issue to be considered here when looking at the effectiveness of the DSRs is the matter of 
adverse reactions resulting from a combination of medicines, or medical procedures with the 
consumption of CAM products.  This is a well-documented area of research, so little time will be spent 
dwelling on it. 
Nevertheless, it is important to acknowledge the multifarious harms which come from a lack of 
regulation of CAM products, and ensuing reactions with medicines.  One of these is the lack of 
information around the actual constituents of CAM products on the market, as previously discussed,384 
and the havoc which these unknown ingredients may reap on the body, either alone, or in combination 
with medicines.  This is a particularly difficult situation, given the dearth of information which both 
consumers, and healthcare professionals may have as to the cause of the adverse effects. 
Even in the event that the CAM product which a patient has consumed is exactly what is labelled on 
the bottle, medical experts frequently struggle with the interactions due to an unwillingness on the 
patient’s behalf to disclose the CAM product, or products which they are taking.385  While this is a 
problem in prescribing medication to patients due to interactions which may otherwise be avoided, it 
is an even greater risk in surgery, when the earlier consumption of CAM products can result in any 
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number of problematic occurrences; from interference with blood clotting, 386  to rejection of 
transplants,387 and heightened effects of sedatives or anaesthetics.388   
The effects seen in these products are both good and bad news for the CAM product industry.  
Extensive research in the past decade has looked into the therapeutic effects of St John’s Wort, with 
the results showing that it has a serious effect on the Cytochrome P450 proteins; more specifically 
that it speeds up the activity of one specific enzyme involved in the metabolism of more than 50% of 
medicines.389  The results of this are numerous, and include lower drug levels and consequently lower 
effect, hypertension, arrhythmia, thromboembolism and serotonin syndrome.390  While the herbal 
remedy is clearly having a therapeutic effect, the evidence begs the question of whether it should 
instead be regulated as a medicine, given there is no provision within the DSRs to handle the vast array 
of complexities associated with St John’s wort and medicine interactions, let alone the host of other 
products which may cause similar adverse interactions.  As an aside, St John’s wort provides a neat 
illustration of the fact that coining a remedy or medicine “natural” in no way means that it is safe.391 
While on its own, these interactions are not reason enough to prohibit allowing people to make some 
choices for their own health and wellbeing, there is a definite need to recognise the risks involved 
when people self-treat with CAM products in conjunction with medicines, without involving a medical 
professional in that decision-making process.  Currently, there is no requirement for DSRs to include 
a statement on the label to ‘consult your healthcare professional in the event of side-effects, or if 
symptoms persist’.  Coupled with the fact that there is an increasing amount of stigma around CAM 
products due to their relative lack of regulation, it is unsurprising that patients withhold information 
from their doctors on the cocktail of CAM products they may be taking, in turn increasing their risk of 
adverse reactions.   
                                                          
386 Feverfew, ginger, cranberry, St John’s Wort, ginseng, garlic, glucosamine, chondroitin and flavocoxid are all 
documented as affecting blood clotting or interacting with anti-clotting pharmaceutical products like Warfarin.  
See American Academy of Orthopaedic Surgeons “Herbal supplements may cause dangerous drug interactions 
in orthopaedic surgery patients, study suggests” ScienceDaily (online ed, 11 October 2011). 
387 Garlic and St John’s Wort show evidence of interacting with immunosuppressant drugs, which can lead to 
transplant rejection; at 1. 
388 Valerian and motherwort cause exaggerated effects from sedatives, intensifying anaesthetics and potentially 
resulting in a coma; at 1.  Ara Tachjian, Viqar Maria and Arshad Jahangir “Use of Herbal Products and Potential 
Interactions in Patients with Cardiovascular Diseases” (2010) 55(6) J Am Coll Cardiol. 515. 
389 St John’s wort “…induces the hepatic cytochrome P450 system, particularly CYP3A4, an enzyme involved in 
oxidative metabolism of more than 50% of all prescription medications.” at 517. 
390 Tachjian, Maria and Jahangir, above n 517-518. 





Despite the ramifications of section 4.5, it is important to bear two points in mind.  Firstly, while the 
risks and harms considered above are a very real problem, purely on the basis of the free-market’s 
self-regulation it is likely that the majority of CAM products pose little risk.  Nevertheless, it is vital to 
recall the fact that given the dubious benefits surrounding the majority of CAM products, even a little 
risk could be unacceptable when the benefit is so minimal, and new regulation should propose 
strategies for ascertaining and managing this risk in a proactive manner.   
This brings the discussion full circle, illustrating the second point, the overarching problem which 
section 4.5 sought to illustrate; namely that these issues exist due to the “…permissive laissez-faire 
[DSRs] which in practice amounts to deregulation.”392  The combination of the outdated DSRs with the 
problems highlighted at 4.5, and the confusion around classification of DSs at 4.4 demonstrate why 
almost all stakeholders agree that new regulation for CAM products is long overdue.  Nevertheless, 
the question remains, whether the most recent proposed mechanism for addressing this problem, in 
the form of the NHSPB, would adequately rectify the situation. 
  
                                                          




5 The Natural Health and Supplementary Products Bill 
Even if one particular alternative therapy was entirely devoid of risk … we still have to consider 
its indirect risks, by far the most important of which is the possibility that a patient will avoid an 
effective mainstream treatment in favour of an ineffective alternative option.393 
5.1 Introduction 
This Chapter turns to the history of CAM product regulation since the DSRs; most notably the 
numerous proposals for regulating CAM products in NZ.  The Chapter focuses on the most recent 
proposal; the NHSPB and its legislative history, and the nature and details of the Bill. 
The NHSPB was withdrawn from Parliament on 8 November 2017, but posed the best attempt at CAM 
product regulation in NZ to date, despite its numerous flaws.  It also made the most progress of any 
proposal so far, passing its second reading in Parliament. 
5.2 Issues in CAM Product Regulation 
Before delving into the practical details, a brief discussion on three key principles of CAM product 
regulation is warranted.  This provides some prescience to the ensuing analysis by first addressing a 
couple of the matters which permeate the history of CAM product regulation in NZ. 
The first issue is that of risk in relation to CAM products, which informs the second issue of government 
paternalism over CAM products.  Finally, the principled argument that proponents of CAM products 
frequently raise of the ‘right to choose’ is considered alongside issues of autonomy and self-
determination in healthcare decision, as well as the possibility of a limited ‘right to choose’. 
5.2.1 Risk 
There is no need to extensively reiterate the risk-benefit discussions of an earlier chapter,394 but it is 
important to note this metric for determining the level of ‘acceptable risk’.  When the risk is high, the 
benefit must be similarly large to offset the risk and thus make it acceptable.  When the risk is low, 
however, the benefit does not need to be equally low in order for the risk to be acceptable.  The 
problem with applying risk-benefit analyses to CAM products is that the benefit is often very low, but 
the risk uncertain, which poses a uniquely difficult situation.  If the benefit of CAM products is low, to 
very low, then the risk must be infinitesimal in order for it to be acceptable.  In an ideal world the 
solution to this problem would be to determine the hazard of each product, allowing a proper risk 
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assessment to take place, however on the basis of practicalities alone this would take years and would 
be unlikely to have stakeholder support.   
The MoH recently identified an Australian report from 2005 which recorded about 400 adverse events 
each year, and 62 deaths in the previous ten years from CAM products.395  However, these figures are 
widely considered an under-estimate,396 and the market has grown exponentially in the past decade, 
and presumably so too have the hazards, leaving the risk of these products inherently uncertain. 
5.2.2 Paternalism 
As the risk of CAM products is unknown, the question of the appropriate level of regulation for CAM 
products becomes increasingly complex.  Regulation inherently involves restrictions on the freedoms 
of individuals, but modern society recognises that a restriction of liberty can be justifiable if it prevents 
harm to self or others.397  The harms from CAM products and a rigorous adherence to them are 
multifaceted, often going beyond the harms directly caused by the products themselves, to indirect 
harms including; harm from giving CAM products to young children or the elderly, reliance on CAM 
instead of competent medical care, and adverse reactions between CAM and medicines. 
Any action which causes harm to another, like parents medicating children with CAM products which 
at best may not work, and at worst may cause worsening or additional problems, can be a serious 
matter which permits a relatively high level of paternalism.  Conversely, at such a time when either 
the benefits of CAM products can be demonstrated to be as good as, or better than evidence-based 
medicine, or a lower degree of hazard is established, then a correspondingly lower degree of 
paternalism should apply.  
5.2.3 Right to choose 
The issue of paternalism struggles with the idea that individuals have a ‘right to choose’ their own 
healthcare.398  The ‘right to choose’ and healthcare have long been in conflict; for example, with the 
                                                          
395 Ministry of Health, above n 3, at 4. 
396 At 4. 
397 While Mill’s harm principle dictates that power can only be exercised over people in order to prevent them 
harming others, a more restrictive approach is generally applied in practice, whereby people are restricted from 
causing harm to themselves through regulation from the requirement to wear seatbelts, through to the ability 
under common law to restrain a person in a medical setting if the pose a harm to either themselves or others. 
398 Airedale NHS Trust v Bland [1993] AC 789 (HL) is one of the leading cases on autonomy in a healthcare setting; 
“The first point to make is that it is unlawful so as to constitute both a tort and the crime of battery, to administer 
medical treatment to an adult, who is conscious and of sound mind, without his consent… Such a person is 





‘woman’s right to choose’ in abortion cases, and the desire of anti-vaccination campaigners to have a 
‘right to choose’ whether to vaccinate their children. 
Vaccinations provide a useful comparison to the present issue.  Some countries are beginning to 
impose sanctions accompanying a failure to vaccinate dependent children. 399   This is due to a 
recognition of the overwhelming benefit of vaccinations to both the individual, as well as society more 
broadly, along with the minimal risk associated with them. 
CAM product regulation, in comparison, sits closer to the grey area.  To a certain extent, there is a 
need to protect the public, often from themselves, and inherently this will limit their right to choose.  
In the case of CAM products, it is difficult to argue that this is not warranted when proponents claim 
they can be as effective as, if not better than, medicines, and yet there is little evidence on either their 
safety or efficacy.  One possible solution which balances these seemingly competing interests is a 
limited right to choose, where consumers can choose products which are efficacious and low risk, 
thereby incentivising companies to conduct the necessary research to ascertain the effect and safety 
of their products.
                                                          
399 Erin Walkinshaw “Mandatory vaccinationa: The international landscape” (2011) 183(16) Canadian Medical 
Association Journal 1167.  Australia has restrictions in place for unvaccinated children, with proposals for fines 
where unvaccinated children enter preschool; Adam Baidawi “'No Jab, No Play': How Australia is Handling the 
Vaccination Debate” The New York Times (online ed, New York, 24 July 2017).  France is making vaccination 
mandatory from 2018; Katie Forster “France to make vaccination mandatory from 2018 as it is 'unacceptable 
children are still dying from measles'” The Independent (online ed, London, 5 July 2017).  Germany has fines of 
up to €2,500 if parents fail to seek medical advice about vaccinating their children; BBC News “Germany 
vaccination: Fines plan as measles cases rise” BBC (online ed, Europe, 26 May 2017).  Italy has also introduced 
mandatory vaccination for children, with fines or the risk of losing custody where parents fail to vaccinate; 
Christopher Livesay “Amid Measles Outbreak, Italy makes Childhood Vaccinations Mandatory” NPR (online ed, 
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5.3 A History of CAM Product Regulation since the Dietary Supplements Regulations 1985 
It has been more than thirty years since the enactment of the DSRs, and during that time, there have 
been multiple attempts to update the legislation and regulations around CAM products.400  From 
1999-2014, much of this drive to update NZ’s regulations centred on a joint-Agency approach with 
Australia for the regulation of medical devices and therapeutic products, which included CAM 
products.  However, this was a contentious issue throughout ANZTPA’s lifecycle, and while its support 
ebbed and flowed, three proposals came and went.  Despite their ultimate failure, some elements of 
these four key proposals are present in the NHSPB, and therefore a discussion of the history of these 
failed regulatory initiatives is a valuable place to start in order to understand that Bill.  Figure 5.1 
depicts the complexities and temporal overlap of these developments and the legislation surrounding 
them. 
5.3.1 The Australia-New Zealand Therapeutic Products Agency (1999-2014) 
The ANZTPA was a product of the late 20th century drive for a closer relationship with Australia.   
The genesis of the ANZTPA can be traced to the initial Closer Economic Relations agreement between 
NZ and Australia in 1983.401  Building on this, the TTMRA came into being in 1998, although this notably 
excluded therapeutic products from its ambit.402  What followed was a drive by the fourth National 
Government 403  to establish a separate scheme for the trans-Tasman regulation of therapeutic 
products.  This culminated in a proposal by the Government for a joint-Agency approach in 1999.404  
This proposal took shape in 2003, when the fifth Labour Government405 signed a treaty with Australia 
to pursue a system of joint regulation for therapeutic products.406 
There were four key landmarks on the road to implementation of joint regulation once the 2003 Treaty 
was signed.  In 2004, the Ministerial Advisory Committee on Complementary and Alternative Health 
(MACCAH) issued their report on Complementary and Alternative Health Care in NZ.407  The second 
                                                          
400 von Tigerstrom, above n 31, at IV; von Tigerstrom has described these regulations as being so weak as to be 
tantamount to deregulation. 
401 New Zealand Australia Closer Economic Relations - Trade Agreement, with Exchange of Letters [1983] NZTS 
1 (1 January 1983). 
402 See further on the CER and TTMRA at 2.5.1. 
403 1990-1999, the Bolger-Shipley Government. 
404 (12 December 2006) 636 NZPD 7087. 
405 1999-2008, the Clark Government. 
406 Agreement between the Government of New Zealand and the Government of Australia for the Establishment 
of a Joint Scheme for the Regulation of Therapeutic Products (signed 10 December 2003, not yet in force). 
407 Ministerial Advisory Committee on Complementary and Alternative Health, above n 16; Although formed in 
2001, the MACCAH took account of recent developments in the form of the 2003 Treaty, and tailored its 




landmark was the tabling of the Therapeutic Products and Medicines Bill408 in Parliament in December 
2006 by the Labour Government.  This Bill was the NZ implementing legislation for the joint-Agency, 
however it suffered from a lack of support in the House, and was abandoned in 2007 before its second 
reading.409  Thirdly, in June 2011 the National Government issued a ‘statement of intent’ alongside 
the Australian Government, signalling a restart to implementation of the joint-Agency approach after 
its four year lapse.410  This statement set a five-year timeline for the ANZTPA’s establishment, and 
excluded CAM products from the Agency’s ambit, catalysing work on the NHSPB.411  Finally, in 2014, a 
joint statement was issued by both Governments spelling an end to the ANZTPA, and leaving each 
country to go their separate ways with the regulation of therapeutic goods.412 
5.3.2 The Ministerial Advisory Committee on Complementary and Alternative Health (2001-2004) 
In 2001, the MACCAH was commissioned to conduct a wide-scale review of CAM health care; in 
particular the regulations surrounding practitioners and the safety, efficacy, benefits, and costs 
associated with CAM therapies, in order to facilitate the creation of guidelines for CAM health care.413  
During this process, multiple developments in this area occurred of which the Committee took 
account; including the enactment of the Health Practitioner Competence Assurance Act 2003, and 
signing of joint-Agency Treaty with Australia as previously mentioned.414 
The Committee recommended regulation of practitioners according to the risk associated with their 
modalities, but there were no changes to practitioner regulation following the report. 415   Two of the 
Committee’s recommendations were implemented, with a CAM Database to provide reliable 
information for consumers on the evidence surrounding CAM products and treatments (‘evidence 
summaries’), and the establishment of a NZ unit which could facilitate the evaluation of safety and 
efficacy of CAM products.416  Although initially supported by the Government, over the ensuing years 
neither have been successfully utilised.  The CAM Database was abandoned in 2006 “…because only a 
small number of evidence summaries could be produced with the resources available and a change in 
                                                          
408 Therapeutic Products and Medicines Bill 2006 (103-1). 
409 Annette King “Therapeutics Products and Medicines Bill on hold” (press release, 16 July 2007); see discussion 
on Therapeutic Products and Medicines Bill 2006 at 5.3.3. 
410 John Key “Australia, NZ announce intention on ANZTPA” (press release, 20 June 2011). 
411  Medsafe “Australia New Zealand Therapeutic Products Agency (ANZTPA)” (28 January 2012) 
<www.medsafe.govt.nz>; see discussion on early history of the Natural Health and Supplementary Products Bill 
2011 at 5.5. 
412  Peter Dutton and Jonathan Coleman “Joint Statement regarding ANZTPA” (joint media statement, 20 
November 2014). 
413 Ministerial Advisory Committee on Complementary and Alternative Health, above n 16, at iii. 
414 See discussion above at 5.3.1. 
415 Ministerial Advisory Committee on Complementary and Alternative Health, above n 16, at 5. 




priorities.”417  Similarly the NZ CAM unit418 was moved between tertiary institutions for a couple of 
years, before quietly fading from the radar.419  At the end of the day, few of the recommendations 
from the MACCAH report affected CAM regulation in NZ in a consequential way, and fewer still made 
their way into the Therapeutic Products and Medicines Bill. 
5.3.3 The Therapeutic Products and Medicines Bill 2006 (2006-2007) 
The Labour Government’s Therapeutic Products and Medicines Bill 2006420 was introduced as an 
omnibus Bill which was intended to be divided later in the legislative process into two distinct bills: 
Parts 1-5 comprising the Therapeutic Products Act 2006, and Parts 6-7 to become the MA 2006.421  
The Bill, and the joint-Agency approach sought to address “…2 key problems…” with NZ’s regulation 
of therapeutic products; “…outdated legislation, and a regulatory capacity that is not sustainable even 
in the short to medium term.”422   
The Bill introduced a risk-based approach for the regulation of CAM products,423 although the focus 
was on “…provid[ing] assurance about safety and quality”,424 rather than efficacy.  In order to bring 
NZ legislation into a position where harmonisation with Australia and other countries was possible, 
the Bill introduced the broadest interpretation of CAM products to date, including; “…herbal remedies 
and medicines, traditional treatments, homeopathic remedies, and most dietary supplements.”425 
                                                          
417  New Zealand Health Technology Assessment and New Zealand Guidelines Group “Complementary and 
Alternative Medicine: High quality and effective alternative medicines” (2017) <www.cam.org.nz>. 
418 Annette King “Response to MACCAH report released” (press release, 16 December 2004). 
419 The ‘New Zealand Centre for Evidence-Based Research into Complementary and Alternative Medicine’ was 
established in July 2004 at the University of Otago, but did not last long before being amalgamated into the 
School of Health Sciences at the University of Canterbury in 2005.  Following the move, research outputs from 
the Centre on the safety and efficacy of CAM products have been increasingly few and far between, however on 
paper, the Centre appears to still exist within the College of Education, Health and Human Development at the 
University of Canterbury; University of Canterbury “ENZCAM: College of Education, Health and Human 
Development” (2017) <http://www.education.canterbury.ac.nz/healthsciences/enzcam/>. 
420 Therapeutic Products and Medicines Bill 2006 (103-1). 
421 As previously mentioned, this Bill was the NZ implementation legislation for the ANZTPA; see 5.3.1 for brief 
note on the place of Therapeutic Product and Medicines Bill 2006 in the context of the ANZTPA. 
422 Therapeutic Products and Medicines Bill 2006 (103-1) (explanatory note) at 3. 
423 At 3-4. 
424 At 3. 




Before the Bill’s first reading,426 three issues emerged which would eventually be fatal for the Bill.  The 
first major problem was the cost of the proposed system.427  As with any novel regulatory system, the 
costs of implementing the system were likely to be substantial, although an exact figure was never 
provided.428  Additionally, the long term costs for NZ were estimated at $20m per annum;429 nearly 
three times Medsafe’s annual budget at the time.430  There was concern that these costs would be 
passed on to consumers, or would drive small CAM product players out of the market.431  To address 
this, the Government negotiated a fifty-percent subsidy to the costs of regulation in order to gain the 
support of two minor parties and thus get the Bill passed its first reading.432 
The second and third issues are closely related.  There was substantial concern from the Māori Party 
that rongoā 433  was going to be adversely affected by the Bill. 434   Despite assurances from the 
Government that it was excluded from the legislation’s ambit, as it is under the MA,435 there remained 
doubt as to how long this would endure, with many projecting that this exclusion would only last until 
the Bill received Royal Assent.436  In addition, the Green and Māori parties expressed concern that a 
joint-agency would result in Australia effectively having control of NZ’s therapeutic goods 
regulation.437  The Māori Party believed this Australian influence would erode protection of rongoā.438  
                                                          
426 Even before the Bill’s introduction, issues with the Bill emerged; notably, the provisions on direct to consumer 
advertising.  Early drafts of the Bill banned direct to consumer advertising, but the Government was required to 
compromise on this ban due a lack of support in the House in the lead-up to the first reading.  Consequently, 
the Bill was amended to permit direct to consumer advertising, although assurances were made that the 
standards for true and balanced advertisements would be enforced.  (12 December 2006) 636 NZPD 7073. 
427 At 7070. 
428 While $9 million was mentioned as the cost of the proposed new agency during the first Parliamentary debate 
on the Bill, it is unclear whether this refers to the costs for implementation, or a projection of ongoing costs; at 
7076. 
429 Therapeutic Products and Medicines Bill 2006 (103-1) (explanatory note) at 93; the total cost of the joint-
agency was estimated to be $68 million annually, with a presumption that 30% of the costs would be borne by 
NZ commensurate with the forecasted number of product licence holders. 
430 At 92; Medsafe’s budget was $6.7 million in 2006. 
431 (12 December 2006) 636 NZPD 7070-7071. 
432 At 7076; there is no reconciliation in the Hansard of the $9 million figure quoted therein for regulation, with 
the $20 million figure posited in the Explanatory notes to the Bill.  One possible explanation for this discrepancy 
is that the $9 million per annum reflects initial costs associated with setting up the joint-agency, while the $20 
million per annum is the forecasted operating costs for NZ once the agency is established.  
433 Rongoā or Rongoā Māori is the all-encompassing term for traditional Māori medicine.  Like many forms of 
traditional medicine, it is a holistic type of medicine which focuses broadly on health and wellbeing in a manner 
closely interwoven with Māori culture and practices.  There are three elements which largely comprise rongoā; 
rakau rongoā, which corresponds to herbal medicine; mirimiri, which is massage or broadly manual 
manipulation; and karakia, which is prayer.  This is evidence of indispensable role of practitioners in rongoā.  See 
Ministry of Health, above n 21, for more information on rongoā in New Zealand. 
434 (12 December 2006) 636 NZPD 7079. 
435 At 7085-7086; Medicines Act 1981, s28. 
436 At 7079-7081. 
437 At 7077-7079. 




However, the structure of the ANZTPA was such, that while Australia’s size may result in it strong-
arming NZ, there was in theory an equal balance of power between the two countries, as each was 
allotted an equal status under this system.439  
While the Bill passed its first reading on 12 December 2006, with 61 to 60 votes, 440  the Select 
Committee was unable to reach an agreement to recommend the Bill to Parliament for its second 
reading.  Coupled with the aforementioned problems and widespread public concern about access to 
CAM products,441 the Bill failed to reach its second reading.  In somewhat of a Catch-22 situation, the 
issues of a capacity deficit and outdated legislation are thus magnified by every passing year without 
new legislation. 
It is also important to appreciate that the Australian system for the regulation of CAM products and 
medicines was (and remains) one of the strictest in the world,442 and this affected the public opinion 
with respect to a joint-agency approach.  The Therapeutic Goods Act 1989 (Cth) creates the Australian 
Register of Therapeutic Goods, wherein medicines or CAM products must be classified as either 
registered goods, or listed goods.  Registration of therapeutic goods is the more onerous standard, 
requiring consideration of an extensive list of criteria in s25 Therapeutic Goods Act, and broadly 
comprising all prescription medicines and the majority of non-prescription medicines and other high 
risk goods.443  The listing of therapeutic goods is a lesser regulatory burden for low risk products, 
whereby they are still listed on the Register, but need not prove efficacy when applying for listing,444 
nor are the claims on the label required to be vetted prior to listing, although the sponsor must hold 
evidence in support of the claims.445  Listed goods must also only contain ‘permissible ingredients’ as 
stated on a white-list.446 
5.3.4 The ‘Joint Industry Natural and Traditional Health Products Bill’ Proposal (2009) 
In 2009, a proposal entitled the ‘Natural and Traditional Health Products Bill’ was drafted by a joint 
industry taskforce comprising a number of consumer and industry groups, heavily invested in the CAM 
                                                          
439 von Tigerstrom, above n 31, at IV.  A loss, or at least lessening of sovereignty was not an entirely unfounded 
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equivalent to one Australian state; (12 December 2006) 636 NZPD 7068-7069. 
440 New Zealand Labour, New Zealand First, United Future and Progressive parties in favour, New Zealand 
National, Green, Māori and Act New Zealand parties against. 
441 At 7079-7081, 7083 and 7091. 
442 Ellena, above n 9. 
443 Eloise Archer and others “Regulation of complementary and alternative medicine: interplay of therapeutic 
goods legislation consumer law” (2013) 25(1) Bond Law Review 13, at 15. 
444 Therapeutic Goods Administration “Listed medicines” (2017) Department of Health <www.tga.gov.au>. 
445 Therapeutic Goods Act 1989 (Cth), s26A(2)(fb) and (fc). 




product market.447  With the Therapeutic Products and Medicines Bill abandoned in 2007, the industry 
posited this proposal as a solution to the lack of regulation of CAM products and those involved in 
their import, export and manufacture. 
While the Proposal is clearly biased due to nature of its drafters, it does present some issues 
confronting a novel CAM product regulatory system.  These include the problems with classifying CAM 
products somewhere between food and medicines,448 questions around how to practically implement 
Health Select Committee recommendations from the inquiry into the trans-Tasman agency,449 and the 
omnipresent funding issues.450  In addition, the Proposal suggests a co-regulation model between 
industry and government which is jointly funded by the two.451  It notes that all CAM products should 
come under this form of regulation, with manufacturers operating under an approved risk-
management programme, and “where appropriate, GMP”,452 with a black-list dictating the products 
which are prohibited.453 
Despite the Proposal raising some pertinent issues, it was ultimately unworkable due to an absence 
of legal mechanisms necessary in regulation of this kind.  The Proposal endeavoured to remove any 
oversight; exemplified in the ouster clause which prevents any “…regulations, rules or decisions that 
may assume such products are inherently unsafe.”454  Furthermore, there were limited penalties for a 
breach, with clause 23 outlining “education”455 and “…penalties… [that] encourage compliance (i.e. 
‘name and shame’)”456 as the primary and secondary sanctions respectively.457  Following the initial 
release of the draft proposal in 2009, the joint industry Proposal resurfaced in 2012 as a submission 
on the NHSPB (a Government Bill),458 however aside from an oblique reference to its peremptory 
position in the summary of submissions,459 it has otherwise largely faded away. 
                                                          
447 Natural Health Alliance Joint Industry Natural and Traditional Health Products Bill 2009 (NZ Health Trust, 
online, February 2009). 
448 At 4-5. 
449 At 11-12; Health Select Committee Inquiry into the proposal to establish a trans-Tasman agency to regulate 
therapeutic products (New Zealand Parliament, online, 9 December 2003). 
450 Natural Health Alliance, above n 447, at 15. 
451 At 12. 
452 At 7 and 18-19. 
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457 Natural Health Alliance, above n 447, at 37. 
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5.4 An Overview of the Natural Health and Supplementary Products Bill 2011 
Simply, the Bill aimed to regulate CAM products.   
To appreciate why this is necessary, the entirety of the thesis until this point should be reflected upon, 
in addition to a couple of general points.  Regulation of CAM products is necessary to control a $1.4 
billion industry, 460  and an internal market which may contain around 20,000 individual CAM 
products,461 where both exporters and manufacturers are drawing upon the ‘Pure NZ’ or ‘clean, green 
NZ’ brand in marketing ‘bioactives’. 462   As previously discussed, new legislation has been sorely 
needed for decades, as the DSRs fail to adequately regulate the industry, leaving NZ out of line with 
most other developed countries.463 
The Bill aimed to regulate CAM products via a range of reactive mechanisms, rather than a pure risk-
based approach targeted towards each product’s respective risks.  This includes: product licensing 
requirements,464 regulation of ingredients,465 export and manufacturing controls,466 restrictions on 
the nature of products’ claims,467 labelling468 and advertising,469 and development of penalties in the 
event of a breach of any part.470   
The Bill created a new Authority and committees, who together would have broad power and 
discretion with respect to application of the Bill and decision making therein. 471 
The framework for the Bill is broadly modelled on the Canadian approach in the Natural Health 
Product Regulations 2003,472 which come under the umbrella of the Food and Drugs Act 1985.473  In a 
                                                          
460 Natural Products New Zealand, above n 2, at 1. 
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462 New Zealand Trade & Enterprise “New Zealand Bioactives” (2017); Bioactives is an all-encompassing term 
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468 At cl24. 
469 At cl12A. 
470 At cls36-40C; see 5.6.7. 
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similar way to the NHSPB, as shall be seen below, the Canadian system employs a white list and a black 
list in respectively permitting or prohibiting CAM products.474  The product licencing requirements in 
Canada are more stringent than those proposed under the NHSPB, with a clear pre-approval process 
requiring extensive details on the product’s ingredients, source, dose, potency, recommended uses, 
safety and efficacy, and labelling.475  
5.5 The legislative history of the Natural Health and Supplementary Products Bill 2011 
The NHSPB endured more than six years in the legislative process, however, it was withdrawn by the 
Labour-NZ First coalition Government at the beginning of the 52nd Parliament.476  This section looks to 
briefly recount the history and changes to the Bill over that time. 
5.5.1 The Bill’s drafting (2008-2011) 
Taking power in 2008, the National Party signed a memorandum of understanding with the Green 
Party.477  One of the key elements of this was the development of a new Natural Health Products Bill.  
On 19 March 2010, a Consultation Paper was released to the public: ‘The Development of a Natural 
Health Products Bill’.478 The Paper set out the background479 to the proposal and options for the 
regulation of CAM products.480  The consultation period elicited about 1500 responses, of which two-
thirds generally agreed with the proposal, while highlighting some changes to be included.481   
The Bill was subsequently drafted, and a regulatory impact statement for the new legislation was 
released in June 2011.482  Perhaps most telling in this statement is the acknowledged widespread 
uncertainty surrounding empirical data on CAM products,483 the CAM product marketplace,484 CAM 
product usage, and safety; 485 ultimately demonstrating the broader problem of an information deficit 
                                                          
474 Natural Health Products Regulations (SOR/2003-196) (Canada), at Schedules 1 and 2. 
475 At reg5.  For further information on the Canadian regulation of CAM products, see Volpe, above n 373; Ellena, 
above n 9; Health Canada “About Natural Health Product Regulations in Canada” (8 December 2016) Health 
Canada <http://www.hc-sc.gc.ca>; and Health Canada “Compendium of Monographs - Natural Health Products” 
(08 December 2016) Health Canada <http://www.hc-sc.gc.ca>. 
476 The 52nd Parliament began on 7 November 2017, and the NHSPB was not reinstated, consequently being 
taken as withdrawn on 8 November 2017; New Zealand Parliament “Natural Health and Supplementary Products 
Bill” (8 November 2017) <www.parliament.nz>. 
477  “Memorandum of Understanding Between The New Zealand National Party and The Green Party of Aotearoa 
New Zealand” (8 April 2009) at 1-2. 
478 Ministry of Health The Development of a Natural Health Products Bill: Consultation paper (19 March 2010). 
479 At 1. 
480 At 5. 
481 At 2-3. 
482 Ministry of Health, above n 3. 
483 At 2-3. 
484 At 2. 




around CAM products in NZ.  This uncertainty was frequently highlighted by public submissions on the 
Bill during the Select Committee stage,486 which questioned the veracity of assumptions upon which 
the Bill was premised, when there was little to no data in support of them.487 
5.5.2 The first and second readings (2011-2013) 
The Bill was introduced to Parliament on 7 September 2011, and had its first reading on 15 
September.488  The Labour opposition affirmed the Bill at its first reading, resulting in general cross-
floor support for the Bill.  At this time, the Bill was heralded as a cost-effective solution which reflected 
the allegedly low-risk status of CAM products, 489  and promoted consumer protection through 
regulation of labelling, health claims, and control of the ingredients in these products.490  Inklings of 
concern were raised by a couple of members on issues like the ongoing Wai 262 claims, 491 
international trade and best-practice,492 and whether the costs would truly be as low as forecast.493  
Nevertheless, the Bill was still widely supported and progressed to the Health Select Committee. 
The Select Committee considered 739 submissions on the Bill before returning it to Parliament on 31 
October 2012.494  The submissions were fairly polarised, from the readily anticipated submissions of 
CAM product manufacturers and industry groups decrying the costs and control placed on the 
industry, through to scientific, medical and healthcare professionals who questioned whether the Bill 
went far enough, suggesting that it relied on unsubstantiated assumptions about the safety of CAM 
products and the good-will of the industry to follow loose regulations.495 
In a minority opinion published alongside the Select Committee report,496 the Green Party raised some 
concerns.497  These concerns addressed the restrictiveness of allowable claims,498 the absence of a 
                                                          
486 See below at 5.5.2. 
487 For example, the dearth of data on the safety of CAM products, and therefore how they can be considered 
low-risk when there is no evidence of this.  See further at 5.6. 
488 Natural Health and Supplementary Products Bill 2011 (324-2). 
489 (15 September 2011) 675 NZPD 21385. 
490 At 21385. 
491 See 8.3 on the WAI262 claims; (15 September 2011) 675 NZPD 21388, Dr Paul Hutchison MP, and at 21391, 
Te Ururoa Flavell MP. 
492 At 21388-21389, Kris Faafoi MP. 
493 At 21392, Hon Steve Chadwick MP. 
494 Natural Health and Supplementary Products Bill 2011 (324-2) (select committee report) at 15. 
495 See further discussion of submission at 5.6. 
496 Natural Health and Supplementary Products Bill 2011 (324-2) (select committee report) at 11-14. 
497 It is unclear from the Commentary on the Bill whether this minority opinion was raised by the Green Party 
members of the Select Committee; namely Kevin Hague and Mojo Mathers, or whether the Green Party was 
given the opportunity to comment on the Select Committee report in recognition of the Memorandum of 
Understanding, which allows greater input by the Green Party into such matters on a case by case basis. 




completed permitted substances list,499 and the lack of inclusion of the Treaty of Waitangi.500  The 
majority of the Select Committee recommendations were uncontroversial minor amendments, 
although five bear noting.  Firstly, the title was amended to include ‘supplementary products’ to reflect 
the broad range of products in the Bill.501  Additional emphasis was placed on the scientific and 
traditional underpinnings of the Bill in cl4(d),502 while greater limitations were added to the definition 
of ‘Natural Health and Supplementary Product’ in cl6, with the definition of ‘food’ including anything 
presented as a food,503 and that of medicine excluding related products and medical devices.504  The 
fourth recommendation was increasing the amount of detail around allowable claims and health 
benefit claims (HBCs), with the addition of cls12A, 505  12B, 506  12C, 507  and 13(2A). 508   Finally, the 
recommendations suggested a broader scope of products excluded from notification, and thus 
regulation under the Act.509  The exclusion was to include homeopathic products, as the Committee 
noted “…there is no accepted scientific evidence for the effectiveness of homeopathy and therefore 
that health benefit claims should not be made for homeopathic products on this basis.”510 
The second reading was held on the 20 March 2013, during which a number of questions arose on 
pertinent matters like the pre-market notification process,511  the black or white list approach to 
products, 512  the definition of a natural health and supplementary product (NHSP), 513  and the 
importance of scientific evidence in the health claims made on products.514  These matters form the 
basis for the discussion on the content of the Bill at 5.6, for they provide a hint of some of the problems 
which may have arisen from the Bill.  Nevertheless, the Bill was widely supported, the amendments 
                                                          
499 See discussion on permitted ingredients at 5.6.4. 
500 See discussion on the absence of the Treaty of Waitangi from the NHSPB at 5.6.2 and Chapter 8. 
501 Natural Health and Supplementary Products Bill 2011 (324-2) (select committee report) at 2-3; see further at 
5.6.1. 
502 At 3. 
503 At cl6(1)(c) and cl6(3). 
504 At cl6(2)(b) and (c). 
505 At cl12A, “Health benefit claims relating to named conditions”. 
506 At cl12B, “Authority may determine allowable claims”. 
507 At cl12C, “Named conditions”. 
508 At cl13(2A), “Before completing the product notification, the product notifier must make available on an 
Internet site, in respect of each health benefit claim made for the product, a summary of the evidence that the 
product notifier relies on to support the claim.” 
509 At 8 and cl13A(d). 
510 At 8. 
511 (20 March 2013) 688 NZPD 8809-8810, per Hon Simon Bridges MP. 
512 At 8809. 
513 At 8810, per Hon Maryan Street MP. 




made by the Health Select Committee majority were agreed to, and the Bill passed its second reading 
with 120-1 votes in favour.515 
5.5.3 Subsequent process (2013-2017) 
More than two years passed before any further developments took place around the NHSPB.  While 
the 2014 general election undoubtedly slowed the process somewhat, the National Government who 
had introduced the Bill remained in power, and no official explanation was offered for this delay, 
although perhaps the Government was waiting to ascertain developments with the ANZTPA before 
proceeding.516  In 2015, substantial work began on guidance documents and codes by the MoH for the 
practical implementation of the Bill.517  In addition to the consultation on these documents, extensive 
stakeholder discussions were underway on the draft permitted substances list for the Bill.  This process 
sparked concern from many within the industry and related fields given the nature of the list and its 
evolution towards a white-list.   
In August 2017, when Parliament dissolved before the 2017 General Election, the Bill was very much 
on the back-burner of the Government’s priorities, despite waiting more than four years for its third 
reading.  Deadlines had constantly been extended for the making of the permitted substances lists 
and consultation on similar matters.  With a change of Government following the 2017 election from 
a National-led Government to a Labour-NZ First Government, the Bill was withdrawn with little 
explanation, leaving a void for a new proposal for the regulation of CAM products in NZ.518 
5.6 A Detailed Consideration of the Natural Health and Supplementary Products Bill 2011 
This section takes a detailed look at the NHSPB, with a focus on key elements of the Bill, many of which 
proved contentious during its history.  The section narrows in on definitions or omissions in the Bill, 
before turning to the administrative structure and bodies created by the NHSPB.  Finally, four novel 
parts of the Bill are considered; permitted ingredients, allowable claims, product notification, and the 
costs and penalties. 
                                                          
515 At 8817-8818; ACT New Zealand were the only Party to vote against the Bill at its second reading. 
516 As mentioned at 5.3.1, ANZTPA arrangements were finally ended in November 2014. 
517 Ministry of Health Draft Code of Manufacturing Practice (Ministry of Health, Natural Health Products Draft 
Papers, November 2015); Ministry of Health Draft Code of Manufacturing Practice Guidelines (Ministry of Health, 
Natural Health Products Draft Papers, November 2015); Ministry of Health Draft Guidelines for Natural Health 
Products Evidence Requirements (Ministry of Health, Natural Health Products Draft Papers, November 2015); 
Ministry of Health Proposed list of conditions about which claims can be made (Ministry of Health, Natural Health 
Product Draft List, November 2015); Ministry of Health The Regulation of Natural Health Products (Ministry of 
Health, Natural Health Products Consultation document, November 2015). 





Definition of ‘dietary supplement’ 
One of the first definitions seen in the NHSPB is that of ‘dietary supplement’.  The wording of the 
definition is nearly identical to that in reg2A(4)-(6) DSRs,519 and therefore would appear to be included 
to ensure a smooth transition from ‘DSs’ to ‘natural health and supplementary products’ as the 
legislation comes into force. 
Definition of ‘natural health and supplementary product’ 
The term ‘supplementary’ was added to the definition and name of the Bill by the Select Committee, 
to broaden its scope and the products which were included in its regulation.  As such, cl6 defined 
‘natural health and supplementary product’.520  There are a plethora of important aspects to this 
definition.  Firstly, it is interesting to note that NHSPs are defined first by their purpose at cl6(1)(a), 
and then by exactly what they are at cl6(1)(b).  Clauses 6(1)(c) and 6(2) then go one to define NHSPs 
                                                          
519 Natural Health and Supplementary Products Bill 2011 (324-2), cl5 ‘dietary supplement’: “dietary supplement 
means a product that is – 
(a) sold in a controlled dosage form as a liquid, powder, or tablet (which might be described on the label 
as a cachet, capsule, lozenge, or pastille instead of as a tablet); and  
(b) intended to be ingested orally; and  
(c) intended to supplement the amount of the amino acid, edible substance, herb, mineral, synthetic 
nutrient, or vitamin normally derived from food” 
520 At cl6 “Definition of natural health and supplementary product 
(1) Natural health and supplementary product means, subject to subsection (2), any product that –  
(a) is, or appears to be, manufactured –  
(i) for human use; and 
(ii) for the primary purpose of bringing about a health benefit to the person who uses 
the product; and 
(b) contains only permitted ingredients unless –  
(i) section 22(2)(b)(i) applies; or 
(ii) the product is a dietary supplement; and 
(c) is not, or is not presented as, a food. 
(2) Natural health and supplementary product does not include –  
(a) any medicine that –  
(i) the Minister has, under section 20 or 23 of the Medicines Act 1981, given consent to 
its distribution; or 
(ii) the Minister is, under section 20(7) of that Act, deemed to have given consent to its 
distribution; or 
(iii) the Director-General, has under section 24 of that Act, given consent to its 
distribution: 
(b) any related product that the Minister has, under section 20 and 96 of the Medicines Act 1981, 
given consent to its distribution: 
(c) any medical device that is the subject of a declaration under regulation 6 of the Medicines 
(Database of Medical Devices) Regulations 2003. 
(3) In subsection (1), food means anything that is ordinarily used or represented for use as food or drink 




by what they are not; namely that they are neither foods nor medicines.  It is worth noting the NZ Law 
Society’s submission on the Bill, which raised a question on the overlap between the definition of 
‘natural health product’ and ‘food’ in the Bill, which would cause many NHSPs to be “…unintentionally 
excluded from the Bill.”521  The Select Committee saw the same issues, and substantially changed it to 
what is seen in the final version of the Bill.522  The Select Committee recommended that the definitions 
of food in cl6, and in the Food Bill (now FA 2014) be consistent to reflect the relationship between the 
two pieces of legislation.523   
In addition to defining the products it covered by their purpose and ‘permitted ingredients’, this 
definition of NHSP represents a monumental change from the DSRs, in that this definition clearly 
states that these products are neither foods, nor medicines.  This issue was directly addressed by the 
Select Committee, where it noted the difficulty between distinguishing foods, medicines and NHSPs, 
but also their desire to have a clear divide between them; for example, herbal tea as a food, and honey 
as a NHSP, if that were its purpose.524  The emphasis on the purpose of the product as a defining 
characteristic to its classification substantially improves the coherence and workability of the 
                                                          
521 New Zealand Law Society “Submission to the Health Committee on the Natural Health Products Bill 2011” 
(2012) at [5]. 
522 Formerly, cl6 read: “Definition of natural health product 
(1) In this Act, unless the context otherwise requires, a natural health product means a product— 
(a) that is intended by the sponsor of the product— 
(i) to be administered to a human being; and 
(ii) to bring about a health benefit to the person to whom the product is administered; 
and 
(iii) to be administered by any of the methods specified in subsection (2); and 
(iv) not to be administered by any of the methods specified in subsection (3); and 
(b) that, subject to section 22(2)(b)(i), contains only natural health product ingredients; and 
(c) that does not contain any prohibited ingredient; and 
(d) that is not— 
(i) a food; or 
(ii) a prescription medicine or pharmacy-only medicine as those terms are defined in 
the Medicines Act 1981; or 
(iii) a controlled drug within the meaning of the Misuse of Drugs Act 1975. 
(2) The methods of administration referred to in subsection (1)(a)(iii) are the following: 
(a) oral ingestion: 
(b) application to the skin, scalp, or nails: 
(c) application to the teeth, throat, anal canal, or vagina: 
(d) application to the mucosa of the mouth or nose. 
(3) The methods of administration referred to in subsection (1)(a)(iv) are the following: 
(a) injection or parenteral infusion: 
(b) application to the eye: 
(c) application in the ear.” 
Now cl6 reads as at footnote 520.  The amendments to prevent overlap between food, medicines and NHSPs 
can be seen in subs(2) and (3) in the new version at footnote 520. 
523 Natural Health and Supplementary Products Bill 2011 (324-2) (select committee report), at 4. 




legislative framework around CAM products, and would have alleviated much of the confusion 
discussed at 4.4 above. 
Lack of definition of ‘natural’ 
Despite the added clarity to the definition of NHSPB, the unrestrained and undefined use of the 
polyseme ‘natural’ in the Bill remained a problem.  The term was neither defined in the Bill, nor in the 
Health Committee Commentary preceding it.  However, a number of professional submissions 
addressed the problems with the use of this term.  This is best summarised by the Chief Science 
Advisor to the Prime Minister, Professor Sir Peter Gluckman, who noted in his submission that; “The 
use of ‘natural’ draws on the naturalistic fallacy that what is found in nature is somehow better – even 
though many ‘natural products’ are highly toxic.” 525   Both the Royal Australasian College of 
Physicians526 and the NZ Medical Association put forward a similar position, with the latter noting that 
‘natural’ indicated to consumers that the product would do no harm when this was not the case, and 
called for the Bill to acknowledge that natural products were not, by nature, low risk.527 
5.6.2 The scope of the Bill and omissions 
Two further definitional matters require addressing.  Firstly, it is important to note that homeopathic 
products were not mentioned by name in the Bill, but were excluded from its scope by cl13A, which 
noted that product notification “…does not apply to… (d) any natural health and supplementary 
product in which the active ingredient to be administered is in a concentration not more than 20 parts 
per million.”.528  This reflects a deliberate decision not to regulate these products under this system 
due to the quantities of active ingredient being too small to measure, coupled with a lack of scientific 
evidence such that HBCs should not be allowed to be made for homeopathic products.529 
The other matter to briefly touch upon is that of traditional medicine.  Like homeopathy, traditional 
medicine was barely mentioned in the NHSPB, although in contradistinction to homeopathy’s 
exclusion, it is likely that the inclusion of TM is largely implicit in the undefined term ‘natural’.  What 
is important is that dispensing of CAM products via a practitioner is not regulated under the Bill, so 
the practise of rongoā will not be affected by the Bill.  However, were a supplier to commercially 
                                                          
525 Professor Sir Peter Gluckman, above n 6, at 1. 
526 The Royal Australasian College of Physicians “Submission to the Health Committee on the Natural Health 
Products Bill 2011” (February 2012) at 1. 
527 New Zealand Medical Association “Submission to the Health Committee on the Natural Health Products Bill 
2011” (2012) at 3. 
528 Natural Health and Supplementary Products Bill 2011 (324-2), cl13A(d). 




produce traditional medicines, they would be subject to the same requirements as any other producer 
of NHSP under the Bill.  While the Green Party sought to have recognition for the principles of the 
Treaty of Waitangi included in the Act, this view was not supported by the majority of the Select 
Committee, although no justification is offered for this.530 
5.6.3 The Authority, its subordinates and its ambit 
The power given to the Authority and Advisory Committee would have been broad under the Bill, 
ranging from administrative,531 to oversight and regulation.532  
The NHSP Regulatory Authority was first noted under cl5,533 and officially established under cl8534 
under the control of the Director-General of Health, who is answerable to the Minister of Health.  Also 
established is the NHSP Advisory Committee, which would have comprised no more than eight 
members, functioning under terms of reference drafted by the Authority,535 and offering expert advice 
to the Authority.536  It did not appear that the Authority was required to accept this advice.  The only 
body which had been appointed to carry out work on the NHSP regulations was the Permitted 
Substances List subcommittee, which had a concerning composition.  The subcommittee comprised 
18 people, 11 of whom currently work, or have worked in the CAM product industry.  Of these 11, 
eight own CAM product companies or CAM practices, while another two work for some of the biggest 
CAM product manufacturers in NZ.  The remaining seven members consisted of a lawyer, four 
                                                          
530 At 14; the Green Party minority opinion is presented without comment from the majority of the Select 
Committee.  As such, there is no justification or comment on why the Committee chose not to include any 
reference in the Bill to the Treaty of Waitangi.  The Green Party opinion on the Treaty is as follows: 
“Recognition of Te Tiriti 
The Green Party is committed to legislation that honours Te Tiriti and ensures Māori participation in decision-
making processes that affect them. Any system that will potentially regulate Māori taonga (such as the 
traditional use of plants) needs to be administered in a way that is consistent with the Treaty. While the bill 
exempts products made on a 1-1 basis, such as occurs with Rongoā, from notification, it still has the potential to 
affect the use of traditional plants. Our desired addition to the bill is to insert a clause that states, ‘In achieving 
the purpose of this Act, all persons exercising functions and powers under it shall honour the articles of Te Tiriti 
o Waitangi.’” 
531 Natural Health and Supplementary Products Bill 2011 (324-2), cls12B, 20, 21 and 11; largely permitting claims 
on products and keeping a variety of lists updated, from the permitted to prohibited substances lists and a list 
of NHSPs. 
532 At cls15, 31, 35, 34, and 44; this includes auditing product notifications and manufacturers, prescribing fees 
and if necessary, taking remediating measures like revoking licences or issuing a recall of products. 
533 At cl5, ‘Authority’ means the Natural Health and Supplementary Products Regulatory Authority established 
under section 8. 
534 At cl8; “Natural Health and Supplementary Products Regulatory Authority 
(1) This section establishes the Natural Health and Supplementary Products Regulatory Authority. 
(2) The Authority is the Director-General of Health. 
(3) The office of the Authority must be administered by the Ministry of Health.” 
535 At cl10(5). 




scientists of varying disciplines, and two medical professionals (both of whom are also actively 
involved in the CAM product industry).  This extremely close relationship to the industry in a 
committee charged with determining what substances were to be permitted under the new Act raised 
substantial concerns for the perceived impartiality of the committee. 
5.6.4 Permitted & prohibited ingredients 
The Bill was quiet around permitted ingredients and the list, aside from regularly mentioning it as one 
of the defining features of NHSPs.  Clause 20 sets out the criteria for inclusion on the permitted 
ingredients list, which must be published online,537 with any restrictions on product use included in 
this listing.538  The Authority may designate any product in Schedule 1539 as a permitted ingredient,540 
and may also perform safety testing on any such product.541  There were three criteria for listing 
permitted ingredients which the Authority must consider:542 other authorities’ use or restrictions on 
the product,543 recognition of the substance in TM or pharmacopoeiae,544 and any other matters they 
deem relevant.545  Alongside these permitted ingredients at cl20, is a prohibited ingredients clause.546  
This was nearly identical to that specified for permitted ingredients, but instead used the procedure 
for banning certain harmful products.   
What was concerning about the permitted substances list was the presence of chemicals which are 
well-recognised as being harmful.547  Two examples illustrate this point.  The first is the colourant 
‘Brilliant Black’;548 widely banned, most notably in the USA.549  Brilliant Black was included on the 
                                                          
537 At cls20(4)-(5). 
538 At cls20(2) and (4). 
539 At Schedule 1; Schedule 1 NHSPB provides a very general list on ‘Suitable substances’, which in addition to 
many of those specifically contained in the DSRs, adds a number of more general classes or substances, including, 
strangely enough, ‘synthetic equivalents’ of many of the ‘natural’ products. 
540 At cl20(1). 
541 At cl20(3)(a). 
542 At cl20(3)(b). 
543 At cl20(3)(b)(i). 
544 At cl20(3)(b)(ii). 
545 At cl20(3)(b)(iii). 
546 At cl21. 
547 In addition to the two examples which follow, other colourants, fragrances and artificial sweeteners present 
on the permitted substances list include a number of cyclohexanol compounds, which are toxic at high doses, 
and sweeteners aspartame, alitame and neotame.  Guy Hatchard “Suspected Toxic Additives to be permitted by 
Medsafe under the NHP Bill” (online, The New Zealand Journal of Natural Medicine, 3 October 2016); while the 
veracity of comments under ‘Toxicity’ in this document has not been corroborated and is not relied upon, the 
list of compounds which are included on the permitted substances list and show at least some evidence of 
toxicity is accurate. 
548 Brilliant Black, Black BN, E151. 
549  The Feingold Association of the United States “List of Colorants” (2017) online 




permitted substances list, 550  despite evidence of allergic reactions and exacerbation of some 
conditions.551  Similarly, the colouring agent Tartrazine552 was set to be included on the permitted 
substances list. 553   A Southampton study showed Tartrazine to affect hyperactivity and cause 
impulsive behaviour in children.554  These two examples pose serious questions about the permitted 
substances list, when products whose only purpose was to colour CAM products are included on the 
list, despite strong evidence of their risk, and when international authorities put restrictions on their 
use.555 
Due to concern during and after the Select Committee stage that there was no permitted ingredients 
list, and thus no certainty as to the scope of the Bill, the MoH appointed the aforementioned 
subcommittee to consider product applications following the second reading.  As of March 2017, the 
permitted substances list contained nearly 6,200 substances which have received approval, while the 
corresponding prohibited substances list has only 155 products on it.556  While the list was voluminous, 
stakeholders claimed that in practice, it should contain more than twice that number of products, and 
this was cited as one of the major problems of the legislative scheme.557  As of April 2017, the period 
for free submissions was closed, with a user-pays process to be implemented if the NHSPB had passed 
into law. 
The permitted and prohibited substances lists are examples of white and black-lists respectively.  
Canada is the only other major country which operates black and white lists simultaneously, and while 
this appears to have functioned relatively smoothly there, it is difficult to predict its success in the 
distinct proposal of the NHSPB.  It is likely that this system will be costly, and have a high administrative 
burden due to continual updates and reviews of these lists.  While this approach appears to have been 
                                                          
550  Ministry of Health “Permitted Substance Search” (May 2017) 
<http://www.medsafe.govt.nz/regulatory/PILSearch.asp>, ‘Brilliant black BN’. 
551 Panel on Food Additives and Nutrient Sources added to Food “Scientific Opinion on the re-evaluation of 
Brilliant Black BN (E 151) as a food additive” (2010) 8(4) European Food Safety Authority Journal 1540; while this 
paper notes the fact that sensitivity to food additives in asthma and other patients is uncommon, the point this 
seeks to illustrate is that there is an ascertainable risk associated with Brilliant Black, which when balanced 
against the non-existent benefit, is unacceptable. 
552 Tartrazine, E102. 
553 Ministry of Health, above n 550, ‘tartrazine’. 
554 Donna McCann and others “Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children 
in the community: a randomised, double-blinded, placebo-controlled trial” (2007) 370(9598) The Lancet 1560. 
555 The Authority, and for the purposes of cl20, the Committee, must have regard for “whether a recognised 
authority permits the use of the substance in a similar product and, if so, whether it imposes any restrictions on 
the use of the substance” Natural Health and Supplementary Products Bill 2011 (324-2) cl20(3)(b)(i).  The 
Feingold Association of the United States, above n 549. 
556 274 products were pending as of 30 March 2017; Ministry of Health, above n 550. 
557 Natural Health Alliance “Natural Health Products Bill and Regulations: Frequently Asked Questions” (2017) 




incorporated for the dual purposes of simplifying the approval process and adopting some vestige of 
a risk-based system, it lacks stakeholder support, and already appears unwieldy, costly and ineffective, 
where other options could viably achieve the same or greater benefits with a much lower financial 
and administrative burden.558 
5.6.5 Permitted Conditions and Allowable Claims 
There are two levels to the new HBCs under the NHSPB; the claims themselves, and the subset of 
allowable claims.  Before highlighting the distinction, it is worth briefly considering how HBCs differ 
from TCs. 
HBCs are first alluded to in the principles of the Bill as one of the defining features of the new 
legislation.559  This is because one of the key goals of the Bill was to address the plethora of TCs which 
were not permitted under the old legislation, and make room for trusted and beneficial claims on the 
packaging which would aid consumer decision making, while not misleading consumers.  As such, the 
idea of HBCs which were supported by scientific or traditional evidence was borne.  While medical and 
scientific professionals were dismayed by the presence of ‘traditional evidence’ alongside scientific 
evidence as sufficient to support a claim,560 this was included largely for practical reasons, for without 
such a provision, it is unlikely the Bill would have support of a large portion of the CAM product 
industry. 
The Bill went on to define a ‘health benefit’ as being one or more of five distinct benefits.561  Whether 
it is intentional or not, it is interesting to see that the various health benefits contain no mention of 
prophylactic effect, which is commonly regarded as the purview of CAM products.  While it is possible 
to read this into the wording of some of the benefits, the fact that there is no direct allowance for 
preventing contraction of a disease, infection or condition may be indicative of a more restrictive 
approach to the claims on CAM products.  Broadly, HBCs are distinct from the TCs prohibited by reg11 
DSRs, except for sub-cl(d), and to some extent sub-cl(e).  Nevertheless, in general, HBCs are envisioned 
                                                          
558 See the black-list approach proposed in Chapter 12. 
559 Natural Health and Supplementary Products Bill 2011 (324-2) cl4(d); “that health benefit claims made for 
natural health and supplementary products should be supported by scientific or traditional evidence.” 
560 For example, Professor Sir Peter Gluckman, above n 6, at 2. 
561 Natural Health and Supplementary Products Bill 2011 (324-2), at cl5 ‘health benefit’: “health benefit means 
any 1 of the following benefits: 
(a) the maintenance or promotion of health or wellness: 
(b) nutritional support: 
(c) vitamin or mineral supplementation: 
(d) affecting or maintaining the structure or function of the body: 




to sit beneath TCs on a spectrum, be supported by evidence of a scientific or traditional kind, and at 
the end of the day, remain fairly general in nature.  The potential for overlap of HBCs with TCs in the 
MA is recognised to some extent in the Select Committee’s report, which notes the fact that high level 
HBCs will require the product to be listed as a medicine.562   
The sub-group of allowable claims comes under HBCs, but concerns claims that a NHSP will treat a 
named condition.  They are defined as such in cl5 NHSPB, with direction to cl12B which elucidates the 
authority’s role in making such claims ‘allowable’.563  Clause 12A details the operation of HBCs which 
relate to named conditions and cl12C defines ‘named conditions’ in the context of allowable claims.  
Simply, allowable claims are HBCs which have been vetted through the notification process, and relate 
either to a pre-established condition about which a claim may be made,564 or else are made on 
application by a person to the Authority with the support of evidence.565  A named condition is 
specified by cl12C to be a “…disease, disorder, condition, ailment, or defect that is listed or described 
in the International Statistical Classification of Diseases and Related Health Problems”, as published 
by the World Health Organisation.566  Since the Select Committee stage of the Bill, preliminary work 
has been underway to develop a proposed list of condition about which claims can be made.567  
Alarmingly, this list contains a range of unexpected conditions for which claims will be allowed to be 
made, including a considerable number for which there are no successful medical cures currently, like 
Alzheimer’s disease and arthritis, or more concerningly, for diseases for which there are very simple 
medical treatments, like diabetes.  The concern around this is two-fold.  For diseases with simple 
medical cures or treatments, the issue is that people will not seek competent medical attention, and 
consequently infect others or become seriously unwell without proper care.  Conversely, where there 
are no medical cures for diseases like those listed above, people may take false hope in NHSPs which 
claim to be akin to ‘miracle cures’, at best, merely  misleading patients, but at worst, causing them to 
neglect treatments which would otherwise alleviate symptoms and enhance quality of life for a 
substantial period.568  While the consequences of HBCs for named conditions will be seen in due 
                                                          
562 At (select committee report), at 7. 
563 At cl5 ‘allowable claim’: “allowable claim means any health benefit claim that the authority has, under section 
12B(1), determined may related to a named condition” 
564 At cl12A(1). 
565 At cl12B. 
566 At cl12C. 
567 Ministry of Health, above n 517. 
568 Type 2 diabetes is an example of this, where there are tried and treated medicines which work for keeping 
the condition in check, which work extremely well.  The concern is that people instead take a CAM product, 




course, it is hoped that the Authority will monitor their use, and not allow wide-scale misappropriation 
of allowable claims. 
5.6.6 Product Notification 
In the first reading of the Bill, there was no doubt that what was being discussed was a self-notification 
scheme, whereby the sponsor (or product notifier as the Bill now calls them) would provide all the 
pertinent information to the Authority, and could then go on and sell their product.  However, at the 
time of the second reading there was an inkling of change in the air, which became apparent at the 
end of the Hon Simon Bridges MP’s speech on the Bill.569  In his speech, he noted that there had been 
concern of a change from a self-notification scheme to a pre-approval scheme; concern which he 
summarily dismissed.570 
Nevertheless, this issue is worth considering.  Following the Select Committee amendments to the Bill, 
there was certainly an altered hue to the Bill.  On the face of it, the Bill still operates on a self-
notification scheme, as seen in cl13, where the product notifier must merely submit the information 
before beginning to sell their product.  However, at the same time, cl15 gives the Authority the power 
to audit these product notifications in any manner which is appropriate with the principles of the Act, 
a section which certainly opens scope for the authority to delay the marketing of this product if it 
deemed the product were not notified correctly.571  Similarly, the Health Committee rewrote cl16, and 
added 16A and 16B, which deal more extensively with grounds for suspension, the effect of 
suspension, and cancellation of product notification respectively.  Finally, the prohibition on HBCs 
relating to named conditions as previously discussed under cl12A and cl12B could also be seen to be 
a check on the self-notification process. 
While the scheme remained largely a self-notification system, substantial uncertainty existed as to its 
practical implementation, which could have erred towards a pre-approval scheme if the Authority 
were to exercise its power in this manner.  Although a minor point, this issues was indicative of the 
uncertainty around the functioning of the NHSPB. 
5.6.7 The Costs and Penalties 
There was little information available on the costs of the proposed system prior to the Bill’s 
withdrawal, although the intention appeared to be that the scheme was jointly funded by industry 
and government.  While it is not particularly beneficial to say much on the enforcement measures in 
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the Bill without context for their use, it is worth noting that the Bill increased penalties and offences 
substantially from the DSRs, with imprisonment available for offences involving deception or 
endangerment of human health, and fines for an array of offences of up to $250,000 for a body 
corporate, or $50,000 for an individual.572 
5.7 Positive Developments & Pitfalls of Natural Health and Supplementary Products Bill 
Finally, this section briefly considers two noteworthy developments in the NHSPB, as well as two major 
problems which the Bill does not address. 
The first development was the publicly accessible register of CAM products.573  This would provide 
consumers with basic information on a product and enables consumer and industry buy-in to ensure 
unregistered products are not on the market.  Furthermore, this register would have made 
Government-mandated recall a simple procedure, in contrast to the Pan Pharmaceuticals situation, 
thus resolving one of the problems, as discussed at 4.5.1. 
Another positive development in the NHSPB was the scheme which has been present in medicines 
regulations for years: that of adverse event reporting.  Given how little work is involved in such a 
system, it is surprising that a reporting mechanism has not yet been implemented by government or 
industry.  In addition, there is no good argument for the industry to not buy into such a scheme, given 
that according to their assertions, it should show nothing if the products are as safe as they claim.  
Nevertheless, the inclusion of cl17 on ‘adverse reaction notification’ feels like something of a pyrrhic 
victory, given the reaction must be ‘serious’.  A serious adverse reaction is defined at cl17(2), which 
lists criteria of hospitalisation, death, disability congenital abnormality or allergic reaction as the 
standard for requiring reporting.574  While the inclusion of any adverse event reporting was a step in 
the right direction, this is a pitifully small step, given the high standard of adverse reaction required 
before the product notifier must alert the authority.  By comparison, adverse event reporting for 
medicines is a much more thorough affair with a lower standard required for reporting than proposed 
in the NHSPB, with health professionals being required to report adverse reactions to medicines, 
alongside a mechanism for public reporting as well.  This is orchestrated through the dedicated Centre 
                                                          
572 At cls36(3), 40(4) and (5). 
573 At cl11. 
574 At cl17(2): “In this section, serious adverse reaction means any reaction that –  
(a) results in hospitalisation, or prolongs any existing hospitalisation: 
(b) is life-threatening or fatal: 
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for Adverse Reactions Monitoring (CARM) wherein a substantial amount of information on the 
adverse event and additional medical information on the affected individual is collected and compiled 
in the CARM database. 
Sadly, multiple problems still plagued the NHSPB.  One such problem was the absence of any efficacy 
considerations.  The Bill carefully avoided dealing with the issue of efficacy when considering the 
claims which could have been made on the products.  While they require scientific evidence for the 
claims, the parallel allowance for traditional evidence effectively renders the scientific requirement 
moot, for if no scientific evidence exists, it should not prove difficult for a product notifier to find some 
claim of traditional usage from one of the 11 currently approved pharmacopoeiae at Schedule 2 
NSHPB.  This is out of step with international practice, where there is an increasing drive to considering 
integrative health and looking at ways to merge CAM products and modalities into more traditional 
Western healthcare models. 
In this vein, the NHSPB missed the mark on a key reason for changing and updating the legislation: the 
issue of capacity.  The largest benefit of a trans-Tasman regulation, despite its problems was the fact 
that together, Australia and NZ could handle the regulation of these products, where individually, 
neither had this capacity.  While this was clear to both legislators and commentators in the early 2000s 
when this proposal was on the table, this new legislation makes little provision for handling the huge 
capacity issue when NZ attempts to regulate alone.575 
5.8 Conclusion 
Beginning with a principled consideration of some of the key issues in CAM product regulation, this 
Chapter reviewed the previous 30-years of CAM product regulation in NZ since the DSRs, and then 
focused on the most recent proposal before Parliament; the NHSPB.  An overview of the Bill, coupled 
with its lengthy passage through Parliament emphasised some of the problems with a new regulatory 
scheme.  While the ensuing detailed consideration of the Bill highlighted some of the positive 
developments arising from the Bill, there are still a significant number of issues with some of the 
mechanisms which the Bill intended to employ in the regulation of CAM products in NZ. 
The NHSPB was far from perfect.  While there is no doubt it was an improvement on the status quo, 
the milestones in the Bill are tempered by the number of aforementioned matters it either does not 
consider, or insufficiently addresses.  With the Bill withdrawn from Parliament, perhaps due in part to 
                                                          




public murmurings of discontent from the new Labour Government’s coalition partner,576 it will be 
necessary to look ahead, and consider new proposals for regulation of CAM products in NZ.577  
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6 Case Study: Miracle Mineral Solution 
6.1 Introduction 
The previous four chapters have considered specific legislation and the complex issues relating to the 
classification and regulation of CAM products.  Before turning to more general legislative approaches 
to CAM product regulation, 578  it is worth briefly considering a case study which analyses the 
application of the food, medicine and CAM product regulations to a contentious product sold in NZ: 
Miracle Mineral Solution (MMS).579   This Chapter will consider the product itself, as well as the 
marketing material associated with the product, before turning to an application of the earlier 
chapters’ material to determine whether MMS is best considered a food, medicine or CAM product.  
Finally, the case study will turn to the remedies or enforcement which may be available under the 
applicable legislation, at the same time using relevant cases to theorise about possible penalties. 
6.2 Background 
6.2.1 A brief history of MMS 
MMS was developed by former gold prospector, Jim Humble, after spending time in South America in 
the 1990s.580  While neither a doctor nor a scientist, Humble created a solution from water and sodium 
chlorite, which he proclaimed to be an effective treatment for malaria.581  In order to disseminate this 
product and associated ideology, Humble established the ‘Genesis II Church of Health and Healing’ 
based in the Dominican Republic.582 
In the late 2000s, MMS sprang to global attention, largely due to the combination of diverse medical 
claims, coupled with the very real risk posed by the product.  MMS does not limit itself to claims of 
curing malaria,583 but has publicised its efficacy at remedying problems like toothache,584 heavy metal 
                                                          
578 See Part II: General Legislation & New Approaches. 
579 Also known as Miracle Mineral Supplement or Master Mineral Solution. 
580 Laura Donnelly and Justin Stoneman “The fake cancer cure conference the 'healers' tried to keep secret” The 
Telegraph (online ed, United Kingdom, 25 May 2015). 
581 Katherine Smith “Jim Humble MMS seminar in NZ” (9 September 2014) The New Zealand Journal of Natural 
Medicine, online ed. <http://www.naturalmedicine.net.nz/infections/jim-humble-mms-seminar-in-nz/>. 
582  This served the additional purpose of avoiding interference by what he labels ‘Illuminati-controlled’ 
governments; Jim V. Humble The Master Mineral Solution of the Third Millennium (Jim Humble, Nevada, 2011), 
at 238; Martin Robbins “The man who encourages the sick and dying to drink industrial bleach” The Guardian 
(online ed, United Kingdom, 15 September 2010). 
583 Humble, above n 582, at 28. 




poisoning,585 HIV,586 all kinds of cancer,587 and autism,588 to name only a few.  Such claims, coupled 
with numerous instances of adverse event reporting have caused the USA,589 Canada,590 the United 
Kingdom (UK),591  Australia, 592  and NZ, 593  amongst other countries, to issue statements deterring 
consumers from purchasing and using MMS.  Many of these countries have also taken steps to warn,594 
or take legal action,595 against manufacturers or suppliers of the product because of the TCs and 
unsubstantiated medical representations made by MMS.  Nevertheless, MMS is still widely available 
online in many countries, with a NZ based supplier being one key distributor of the products. 
6.2.2 What is MMS? 
The name ‘miracle mineral solution’ is itself indicative of the controversy which accompanies MMS.  
Sold as ‘Water Purification Solution 1’ (WPS1) in NZ,596 this product contains 28% sodium chlorite,597 
and is sold with a 5% hydrochloric acid activator.  In addition to the MMS product, there are newer 
products; MMS2 and CDS, which slightly alter the dosage or constituents. 
                                                          
585 At 23. 
586 At 27. 
587 At 27. 
588 Guy Lynn and Ed Davey “'Miracle autism cure' seller exposed by BBC investigation” BBC News (online ed, 
London, 11 June 2015); Todd Drezner “The Curious Case of Autism and MMS” Huffington Post (online ed, United 
States, 14 June 2012). 
589  Food and Drug Administration “Consumer Updates > 'Miracle' Treatment Turns into Potent Bleach” (1 
October 2010) <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm228052.htm>. 
590 Health Canada “Miracle Mineral Solution: Ingesting bleach-like chemical dangerous to health” (26 March 
2015) <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/52719a-eng.php>; Lisa Ellenwood 
and Lisa Mayor “Diluted bleach mixture touted as 'miracle cure' despite Health Canada warnings, the fifth estate 
finds” CBC News (online ed, Canada, 4 March 2016). 
591 Letter from Liz McNulty, (Head of Incident Response, Food Standards Agency) to Heads of Environmental 
Health Services (England) Miracle Mineral Solution (MMS) (24 September 2010); David Connett “Autism: 
Potentially lethal bleach 'cure' feared to have spread to Britain” The Independent (online ed, United Kingdom, 
22 November 2015). 
592  Therapeutic Goods Administration “Miracle Mineral Solution (MMS)” (13 November 2014) 
<https://www.tga.gov.au/alert/miracle-mineral-solution-mms>. 
593 Medsafe “Medsafe warns consumers not to take Miracle Mineral Solution” (press release, 8 October 2010). 
594 At 1; Tom Minear “Genesis II Church of Health and Healing's 'Miracle Mineral Solution' slammed by AMA as 
'snake oil'” Herald Sun (online ed, Melbourne, 3 November 2014); Erik Jensen “Deadly chemical being sold as 
miracle cure” The Sydney Morning Herald (online ed, Sydney, 9 January 2010). 
595  United States Department of Justice “May 28, 2015: Seller of 'Miracle Mineral Solution' Convicted for 
Marketing Toxic Chemical as a Miracle Cure” (press release, 28 May 2015); United States Department of Justice 
“October 28, 2015: Seller of 'Miracle Mineral Solution' Sentenced to Prison for Marketing Toxic Chemical as 
Miracle Cure” (press release, 28 October 2015); Health Canada “Health Canada seizes dangerous health products 
from online retailer” (18 October 2014) <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-
sc/2014/41859a-eng.php> 
596 MMS products are sold through the New Zealand based website; NZ Water Purifier Ltd “NZ Water Purifier 





5𝑁𝑎𝐶𝑙𝑂2 + 4𝐻𝐶𝑙 → 4𝐶𝑙𝑂2 + 5𝑁𝑎𝐶𝑙 + 2𝐻2𝑂  
Equation 6.1: Balanced Chemical Equation for the reaction of sodium chlorite with hydrochloric acid to make chlorine 
dioxide (chlorite), salt and water 
The activated sodium chlorite, or chlorine dioxide, as it is commonly referred to in MMS material, is 
extremely soluble in water, where it forms chlorite ions,598 as seen in Equation 6.1.  Chlorine dioxide, 
or chlorite, is commonly used as a bleach and disinfectant in water treatment due to its reactivity and 
toxicity.  In the same way that it effectively kills bacteria and viruses, it can be extremely harmful to 
humans, resulting in most health authorities setting restrictions on the allowable levels in water.  NZ’s 
maximum acceptable value for chlorite is 0.8 mg/L.599  For comparison, the WPS1 MMS product sold 
in NZ contains 280,000 mg/L sodium chlorite,600 which corresponds to 208,840 mg/L chlorite. 601  The 
MMS website contains various dilutions of the WPS1 product depending on the ailment to be treated, 
which reduces the concentration.  Taking one of the lowest doses of six drops per day for 
‘maintenance’602 will still give a dose of 280 mg/L sodium chlorite,603 or 208 mg/L chlorite;604 certainly 
enough to cause serious toxicity. 
Sodium chlorite, or chlorine dioxide, is acutely toxic to humans.  Side effects include nausea, vomiting, 
diarrhoea, and in some cases, kidney failure or methemoglobinemia605 some of which can result in 
death.606  MMS information notes these symptoms as being indicative of the product working, albeit 
                                                          
598 ClO2- 
599 Ministry for the Environment Draft users' guide: National Environmental Standard for Sources of Human 
Drinking Water (online ed, Wellington, May 2009), Appendix 6, Table 2.2. 
600  NZ Water Purifier Ltd “NZ Water Purifier Ltd: Products” (2017) 
<https://nzwaterpurifier.com/index.cfm?fact=product>; WPS1 is 28% NaClO2 ∴  28g/100mL, or 
28,000mg/100mL, or 280,000mg/L. 
601 Molar mass of NaClO2 = 90.5g/mol and molar mass of –ClO2 = 67.5g/mol ∴ 280,000mg/L × 67.5/90.5 = 
208,840mg/L –ClO2. 
602 Mark Grenon “MMS Instructions” (2017) <https://miraclemineral.co.nz/index.cfm?fact=instructions>. 
603 One drop of water is 0.05mL, and if the WPS1 is presumed to be diluted in a glass of water, that is 300mL.  
Consequently, 0.05mL × 6 drops = 0.3mL. 
280,000mg/L × 0.3mL/1000 = 84mg. 
84mg/300mL = 0.28mg/mL ≡ 280mg/L NaClO2. 
604 280mg/L NaClO2 × 67.5/90.5 = 208mg/L –ClO2. 
605 Methemoglobinemia is a condition characterised by abnormally high amounts of methemoglobin in the blood 
which causes problems with the oxygen-binding of haemoglobin. 
606  Medsafe, above n 593; G Amy and others Disinfectants and Disinfectant By-Products (World Health 




faster than the subject’s body can handle, advising continued usage at a lower dose.607  However, this 
type of information has already resulted in death from MMS, and could feasibly lead to many more.608  
6.2.3 The sale and marketing of MMS in NZ 
Following the trend of the USA, Canada, and the UK, Medsafe issued a statement late in 2010 warning 
the public of the risks posed by MMS.609  This followed a 2009 warning from Medsafe to the NZ 
distributor that the online advertising was in breach of the MA due to high-level TCs, without MMS 
having approval for sale as a medicine.610  Despite this, MMS has continued to be available in NZ, 
although under a unique arrangement which uses different websites to separate advice and 
instructions on the use of the products from their sale.  The NZ website ‘Miracle Mineral’ provides 
extensive information on MMS,611 including numerous disclaimers noting; “MMS products are not 
medicines or drugs”612  or variants on that theme.  Presumably, the TCs which caused the 2009 
Medsafe letter have been removed from the website;613 however, there remain several factors which 
indicate attempts to circumvent this prohibition.  While the website does not contain direct TCs and 
includes disclaimers, it appears designed to send a different message by directing consumers to 
external websites which make the claims, or by attempting to discredit research and government 
publications which cast doubt on MMS products.614 
 Three specific elements suggest the seller’s attempts at coming as close as possible to making a TC, 
without overstepping the line.  First, in a supposed letter to customers on the homepage, the website 
notes that;615  
… regardless of the many thousands of success stories worldwide, and recommendations that 
you may have heard from family and friends; this website cannot and will not make any public 
claims that MMS ‘treats’ or ‘cures’ serious diseases or conditions … 
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608 Mark Russell “'Miracle' elixir linked to death, illness” The Sydney Morning Herald (online ed, Sydney, 22 
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Vanuatu Daily Post (online ed, Vanuatu, 11 November 2014). 
609 Medsafe, above n 593. 
610  Letter from Carole Firth, (Advisor, Medsafe) to Anon. (www.miraclemineral.co.nz) Compliance with the 
Medicines Act 1981 (13 February 2009). 
611 Mark Grenon “Miracle Mineral” (2017) <https://miraclemineral.co.nz/index.cfm?fact=purchaseproduct>. 
612 At 1. 
613 Firth, above n 610. 
614 Grenon, above n 611; further to this point, the website makes use of logical fallacies, which attempt to 
conflate the food sterilisation and water purification uses of chlorine dioxide with the purported medicinal uses 
of MMS by way of the statement on the homepage: “MMS is used to make chlorine dioxide, a proven pathogen 
killing mineral used extensively in the hygiene and water treatment industries… The human body is 60-70% 
water.” 




wherein the letter explicitly lists 35 conditions which MMS elsewhere claims to treat.  The use of 
‘cannot … make any public claims’ followed by a long list of claims is perhaps designed to send the 
opposite message – that the product can do what it claims, but Government regulations do not permit 
the company to make such statements.   The second factor is frequent reference to Humble’s book, 
which the website sells.616  Therein, frequent TCs are made, with instructions on how to formulate 
MMS for treatment of specific medical conditions, including the 35 mentioned above.617  Finally, the 
website contains a page dedicated to ‘success stories’.618  This page contains over 150 ‘testimonies’, 
organised by condition, from people who have used MMS.  The website displays multiple high-level 
TCs relating to many imaginable conditions, and yet avoids making these claims directly.  The overall 
impression of this website is that it indicates a large number of therapeutic purposes for MMS, yet 
ostensibly does not make claims to this effect itself, instead pointing consumers to other sources 
which make the claims; all of which are published directly or indirectly on their website. 
The final aspect to NZ MMS marketplace is the separation between the site providing information, 
and the seller.  Every page on the MMS website displays a disclaimer avoiding any responsibility for 
products or links to material on ‘third-party’ sites.  When attempting to purchase MMS products from 
this website, the prospective customer is sent to a page, which carefully explains how to concoct the 
various preparations from the concentrate, and is then sent to a site which purports to specialise in 
water purification – NZ Water Purifier Ltd.619  Under the auspices of a shop specialising in water 
purification for agricultural, travel, or home water treatment needs, NZ Water Purifier sells a niche 
range of products in inexplicably small volumes, alongside similarly small spray and dropper bottles, 
and gelatine capsules.620  Furthermore, the Miracle Mineral website notes that none of the products 
distributed from the NZ Water Purifier site come with instructions of any kind. 
Through these convoluted mechanisms, MMS and its NZ sellers have avoided any further altercations 
with Medsafe.  This raises questions on whether MMS now fits in the NZ regulatory matrix, and 
whether its attempts to circumvent restrictions on TCs are sufficient to evade regulation as a medicine. 
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6.3 Food, Medicine or CAM Product? 
Having established the background to MMS and an outline of its marketing and sale in NZ, it is possible 
to consider how it may be classified in light of the regulatory regimes considered in Chapters 2-5. 
6.3.1 MMS as a food 
There are some factors that indicate MMS could be a food. 
MMS is a water-based product, with the addition of sodium chlorite.  This could fall within the 
definition of food at s9 FA in that sodium chlorite is added to a drink.621  In addition, water-based 
products are specifically included as being subject to food control plans in Schedule 1 FA.  Similarly, a 
chlorite solution is used to sanitise chicken, to prevent campylobacter contamination, which also 
brings it well within the scope of the FA.  A further argument that MMS is ‘food’ can be found in the 
fact that derivatives of sodium chlorite are included in the Health (Drinking-Water) Amendment Act622 
which modifies the Health Act 1956; and acceptable levels of chlorite in water are also set out in the 
NZ Drinking Water Standards.623  This suggests that MMS falls within the purview of drinking water, 
and therefore arguably food.  
On the other hand, it could be argued that the concentration of the product sold through NZ Water 
Purifier is more akin to bleach than drinking water, and that there is a complete lack of any of the 
marketing material or sale information indicating that this product could be a ‘food’ or similar 
product.624  Consequently, it appears that the argument that MMS is a food would be difficult to 
establish. 
                                                          
621 Food Act 2014, s9(1)(b)(iv)-(v); “9 Meaning of food 
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623 Drinking-water Standards for New Zealand 2005 (Revised 2008), at 8. 
624 This would tend to indicate that the intention is not for the product to be consumed internally by humans, 
especially when the NZ Water Purifier website is considered in isolation from the MMS website.  Intention is 




6.3.2 MMS as a medicine 
There is a stronger argument that MMS is a medicine, or at least a related product under the MA.625  
This was the approach taken by Medsafe in 2009 when the letter was sent to MMS requiring them to 
bring their website in line with the MA.626  Before delving into the possibility of MMS as a medicine, it 
is beneficial to consider the similar case of New Health New Zealand Inc. v Attorney-General,627 which 
considered whether fluoride added to the water supply was a medicine. 
New Health is an interest group, which has taken multiple cases in the past decade against local and 
national government on the fluoridation of water.  In the case at hand, the plaintiff’s argument sought 
declarations that fluoride was a medicine, and consequently subject to the MA and Medicines 
Regulations, in reliance on an earlier case they took against South Taranaki District Council.628  While 
Collins J acknowledged that fluoride was added to the water supply for a therapeutic purpose, and 
administered to the public through the water,629 he ultimately held that the phrase “unless the context 
otherwise requires” in s3 MA when determining what amounts to a medicine allowed a contextual 
approach to be taken,630 resulting in fluoride at such low concentrations as present in water to be 
outside the scope of a medicine in the MA.631  This decision was made even though fluoride is present 
in Schedule 1 MRs as a prescription, restricted and pharmacy-only medicine, as well as listed online as 
a general sale medicine.632  Despite handling a similar conceptual issue between New Health and 
MMS, of a chemical being added to water, the relevance of New Health to MMS is best limited to a 
general indication of the flexibility afforded to the courts to determine what constitutes a medicine or 
related product, notwithstanding apparently strict definitions of both in the MA. 
Returning to MMS, it has been discussed above how the website comes exceedingly close to claiming 
therapeutic benefits from consumption of MMS.  This is seen through a combination of negatively 
worded TCs where more than 35 conditions are listed, the links to external websites, and the 
publication of ‘testimonies’ for named, and often high-level conditions.  The difficulty with establishing 
MMS as a medicine under the definition in s3 of the MA is that scientific evidence suggests it will not 
have a pharmacological, immunological or metabolic mechanism for achieving its claimed therapeutic 
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626 Firth, above n 610. 
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630 See footnote 633, below. 
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purpose.633  Unless a court adopted a relaxed approach to the definition of medicine under s3, any 
action under the MA would have to proceed under s94, claiming that MMS is a ‘related product’. 
To be a related product under s94(1) MA, two criteria must be satisfied.  The product must be a 
cosmetic, dentifrice, or food, and there must be a claim that the product is effective for a therapeutic 
purpose.634  For the purposes of this section, MMS could be considered a food, as discussed at 6.3.1, 
and as seen in the discussion in the preceding paragraph, it is likely that the MMS website contains 
sufficient material to amount to a TC, thus meeting both criteria.  While MMS does not naturally come 
within the definition of food, it is likely that a court would be willing to stretch the definition of food 
or related product, if it held that MMS could not be classified as a medicine.  If MMS were held to be 
either a medicine, or a related product (namely a food making TCs),635 it would amount to a breach of 
s20 MA which prohibits sale, supply or advertisement of availability of a new medicine or related 
product.636 
On the other hand, it would be possible to counter such a case on the grounds that these products are 
chemicals, as sold through NZ Water Purifier, primarily intended for water purification, and not 
intended for human consumption.637  Further, due to the dearth of any evidence of efficacy in support 
of its health claims, it is unlikely that MMS could feasibly be registered as a medicine, so if the option 
of MMS as a related product was unavailable, the MA would not be applicable.  However, the apparent 
close association between the MMS website, and that of NZ Water Purifier is very likely to bring such 
a case within the ambit of ss94 and 20 MA with MMS being a related product or a new medicine.638 
                                                          
633 Medicines Act 1981, s3(1)(a); “3 Meaning of medicine, new medicine, prescription medicine, and restricted 
medicine 
(1) In this Act, unless the context otherwise requires, medicine— 
(a) means any substance or article that— 
(i) is manufactured, imported, sold, or supplied wholly or principally for administering to 1 
or more human beings for a therapeutic purpose; and 
(ii) achieves, or is likely to achieve, its principal intended action in or on the human body by 
pharmacological, immunological, or metabolic means;” 
634 At s94(1); see footnote 625.  There are also three categories of which the product may not be a part, including 
‘any medicine’, but this is not relevant for the present discussion. 
635 At s94(1); and At s96(1); “96 Certain provisions to apply to related products as if medicines 
(1) Sections 20 to 22, and 35, with all necessary modifications, shall apply to new related products in the 
same manner and to the same extent as they apply to new medicines.” 
636 Section 96 MA notes the application of s20 (amongst other sections) to related products in the same way 
they apply to new medicines.  This effectively means s20 can be read “Restrictions on the sale or supply of 
related products” instead of “Restrictions on the sale or supply of new medicines”. 
637 This would imply that it is not a food, and therefore cannot amount to a related product. 
638 As previously noted, the MMS NZ website (www.miraclemineral.co.nz) directs consumers to the NZ Water 
Purifier website on multiple occasions for the purpose of purchasing MMS products, clearly describing which of 




6.3.3 MMS as a CAM product 
Finally, it is possible that there could be an argument that MMS is a CAM product, or more pertinently, 
a DS within the purview of the DSRs, or a ‘natural health and supplementary product’ within the 
NHSPB. 
As a remedy which has little scientific evidence behind it in respect of its efficacy or safety, and yet 
allegedly attracts vast numbers of proponents, MMS certainly falls within the wide ambit of CAM 
products.  However, insofar as the DSRs are concerned, establishing a breach is slightly more difficult.  
Contrary to the claims of proponents online,639 MMS is not a mineral per s2A DSRs, and due to its 
toxicity and lack of evidential basis, is also unlikely to be considered a synthetic nutrient within the 
meaning of s2A.  Furthermore, since legal action in the USA, MMS is no longer called ‘Miracle Mineral 
Supplement’, but rather goes by the name ‘Miracle Mineral Solution’, likely annulling any argument 
that MMS comes within the remit of the DSRs for stating ‘supplement’ in its name. 
While it could be considered a CAM product in a general sense, it is unlikely that MMS is a DS.  
Similarly, it would be difficult to argue that it is a ‘natural health and supplementary product’ within 
the definition provided in cl6 NHSPB.  That clause required that the product bring about a health 
benefit, which MMS will almost certainly not do, as well as requiring the product to only contain 
permitted ingredients.  Currently, chlorite or sodium chlorite are not permitted ingredients,640 and 
therefore it is very unlikely that MMS could have been a natural health and supplementary product 
under the NHSPB. 
6.4 Conclusion 
MMS is a fairly extreme example of a CAM product which defies classification.  It does not come under 
the DSRs, nor does it readily fit within the FA due to difficulties reconciling a liquid more akin to bleach 
than water with the Act, and the absence of an objective intent for chlorite to be consumed as a food.  
There is certainly an argument that MMS is a related product or a new medicine under the MA, and 
while there would be a reasonable chance of success with such an argument, it remains an unnatural 
                                                          
sells nothing else which could be considered to come within the normal business of a water purification company 
(e.g. pumps, filters, pool cleaning or purifying supplies), except for the MMS products and associated 
paraphernalia.  Finally, the physical address for the NZ Water Purifier website is the same as that of the MMS 
conference held in 2014, attended by the leading members of the Church of Health and Healing.  Smith, above 
n 581. 
639 Grenon, above n 611. 
640 As at the time of writing, hypochlorus acid (HClO) and sodium hypochlorite (NaClO) were proposed to be 
permitted ingredients on the list, but these both have distinct chemical composition to chlorite or sodium 




fit.  In order to classify MMS as a related product, it must be established that it is a food, requiring the 
definitions of either food or related product to be stretched to bring MMS within this ambit.  While 
the recommended dose of MMS is significantly diluted, any toxicity is unacceptable in line with a risk 
management framework like the FA, given the non-existent benefit of MMS beyond the placebo 
effect. 
In short, there is no obvious or logical classification for MMS.  This poses problems in a practical sense, 
as enforcement against products such as this can be extremely difficult when they make 
unsubstantiated TCs, or actively mislead and deceive consumers as to their purpose or efficacy.  
Consequently, consumer protection legislation steps in where primary legislation is unable to police 
these types of products, and as seen in Chapter 7, it provides some scope to address unsafe, false, or 





Part II: General Legislation & A Broader Perspective 
7 The Fair Trading Act 1986 & the Consumer Guarantees Act 1993 
7.1 Introduction 
Part I considered specific legislation surrounding CAM products, with a review of food legislation, as 
well as medicines legislation.  That Part finished with a brief look at the case study of MMS and the 
application of the FA, MA, DSRs, and NHSPB to that case.  It concluded that while the FA, DSRs, and 
NHSPB are unlikely to be applicable, it may be arguable that MMS is covered under the MA, although 
this is far from certain.  If these specific Acts are not able to regulate CAM products, an alternative 
option is to consider the applicability of general legislation.  Even if specific legislation is available, 
general legislation may currently be seen as preferable, if it contains remedies that are more 
appropriate than those available through the primary legislation. 
This Chapter will consider the use of the FTA and CGA as alternative means of regulation.  It will also 
revisit the case study of MMS and consider whether the FTA or CGA would provide a more appropriate 
remedy. 
7.2 The Fair Trading Act 1986 
The FTA was designed to be a general piece of consumer protection legislation that could not only 
respond to a constantly changing commercial environment, but also act as a complementary piece of 
legislation to the Commerce Act 1986, which aimed to ensure a well-regulated competitive 
marketplace in NZ.641  This purpose is embodied in s1A FTA,642 which notes at subs(2) that the Act aims 
to achieve this by, amongst other things, prohibiting unfair conduct and practices in trade,643 and 
promoting safety in relation to goods.644  Of the six parts to the Act, Part I, which deals with unfair 
conduct, and Part V, concerning enforcement and remedies, are relevant to the following discussion. 
                                                          
641  Lindsay Trotman and Debbie Wilson Fair Trading: Misleading or Deceptive Conduct (1st ed, LexisNexis, 
Wellington, 2006), at 1-2. 
642 As inserted by the Fair Trading Amendment Act 2013, s5.  Prior to this, the long title stated: “An Act to prohibit 
certain conduct and practices in trade, to provide for the disclosure of consumer information relating to the 
supply of goods and services and to promote product safety and also to repeal the Consumer Information Act 
1969 and certain other enactments”. 
643 Fair Trading Act 1986, s1A(2)(a). 




7.3 Section 9 FTA 
7.3.1 Overview 
In contrast to the other sections of Part I FTA, s9 is unique in its breadth, as demonstrated by the title 
‘misleading and deceptive conduct generally’.645  This section states “No person shall, in trade, engage 
in conduct that is misleading or deceptive or is likely to mislead or deceive.”646  In line with the broad 
scope of this section and its consumer focus, an objective standard is applied, requiring consideration 
of whether a reasonable person was likely to be misled by the conduct.  Furthermore, there is no 
requirement for the defendant to have intended to mislead.647 
A breach of s9 results in the availability of civil remedies in the form of injunctions,648 orders for 
disclosure or corrective advertising,649 and remedial orders between affected parties,650 including 
refunds or damages for loss. 
7.3.2 Tests 
A reading of s9 suggests that three criteria must be met: that the person is in trade, that the person 
engages in conduct, and that the conduct is misleading or deceptive.651  The discussion in this Chapter 
will focus on the third element; whether conduct that is misleading or deceptive can be established in 
relation to CAM products.  It will be assumed that someone advertising or selling CAM products will 
satisfy the first and second criteria in the majority of cases.652 
The initial test for breach of s9 was a three-stage formulation by the Court of Appeal in AMP Finance 
NZ Ltd v Heaven.653  It stipulated that the question of whether there was a breach of s9 should first 
consider whether the conduct was capable of being misleading, secondly whether the plaintiff was 
actually misled, or that other people were likely to be misled,654 and thirdly, the objective test of 
whether a reasonable person would have been misled by the same conduct.655 
                                                          
645 At s9. 
646 At s9. 
647 Trotman and Wilson, above n 641, at 3-4. 
648 Fair Trading Act 1986, s41. 
649 At s42. 
650 At s43. 
651 Red Eagle Corporation Ltd v Ellis [2010] NZSC 20, [2010] 2 NZLR 492, at [26]-[28]. 
652 Glorie v WA Chip & Pulp Co Pty Ltd (1981) 55 FLR 310, 39 ALR 67 (FCA); Pharmaceutical Management Agency 
Ltd v Researched Medicines Industry Association New Zealand Inc. [1996] 1 NZLR 472 (HC). 
653 AMP Finance NZ Ltd v Heaven (1997) 8 TCLR 144 (CA). 
654 Trotman and Wilson, above n 641, at 4. 




In 2010, the Supreme Court revisited the test, in Red Eagle Corporation v Ellis, 656  and took an 
alternative approach.  This did not overrule AMP v Heaven, but rather provided an analysis which 
might be more appropriate in the particular circumstances of a case.657  Blanchard J delivered the 
Court’s decision, outlining the new test:658 
The question to be answered in relation to s9 in a case of this kind is accordingly whether a 
reasonable person in the claimant’s situation – that is, with the characteristics known to the 
defendant or of which the defendant ought to have been aware – would likely have been misled 
or deceived. 
The test then turns to whether a remedy can be awarded under s43; questioning first whether the 
plaintiff was actually misled or deceived by the defendant’s conduct, and if so, whether said conduct 
was an operating659 cause of the plaintiff’s loss.660 
It should be noted that while the test in Red Eagle is commendable for its simplicity and more 
accurately reflects the language of s9, its application usually involves a party who has directly suffered 
loss, rather than a consumer protection body like the CC.  This is demonstrated by almost all the cases 
which apply this precedent.661  If there is no direct loss, for example in situations where the CC is taking 
action against misleading or deceptive conduct to protect consumers, then AMP v Heaven might be 
the most appropriate formulation. 
Under both tests, there is one particular element which has been utilised in establishing whether 
conduct actually misleads or deceives the public that is worth considering.  That is the use of surveys, 
primarily, to provide evidence of broad public confusion.662  In general, survey evidence under the FTA 
has been deemed admissible in NZ, although as one of the leading cases noted, the sample should be 
representative of a cross-section of NZ society.663  Where this has not been the case, or in the event 
of substantial problems with the survey design, the courts have held that survey evidence may still be 
                                                          
656 Red Eagle Corporation Ltd v Ellis, above n 651. 
657 Thomas Gault (ed) Gault on Commercial Law (online looseleaf ed, Thomson Reuters), at [FT9.06(4)]. 
658 Red Eagle Corporation Ltd v Ellis, above n 651, at [28]. 
659  At [29]; Blanchard J goes on to clarify the term ‘operating cause’, noting; “Put another way, was the 
defendant’s breach the effective cause or an effective cause?” 
660 Red Eagle Corporation Ltd v Ellis, above n 651, at [29]. 
661 E-Trans International Finance Ltd v Kiwibank Ltd [2016] NZHC 1031, [2016] 3 NZLR 241; Aldrie Holdings Ltd v 
Clover Bay Park Ltd [2016] NZHC 250, (2016) 17 NZCPR 127; Interclean Industrial Ltd v Camp [2015] NZHC 3177; 
Batchelar Centre Ltd v Westpac New Zealand Ltd [2015] NZHC 272, (2015) 15 NZCPR 726 etc. 
662 Trotman and Wilson, above n 641, at 148-151. 




admissible, but will have lower probative value.664  The importance of surveys in establishing evidence 
of misleading or deceptive conduct will be returned to in Part III. 
7.3.3 Cases 
There are almost no NZ cases which use s9 FTA to handle misleading or deceptive conduct in respect 
of a CAM product.  There are a number of possible reasons for this; including the fact that only civil 
remedies are available under s9, the CC’s apparent preference for settlement or negotiation over 
litigation,665 and s10 having a lower burden of proof than s9.666  One relevant NZ case is CC v New 
Zealand Nutritionals, 667  which concerned the sale of goats’ milk tablets and powder that was 
incorrectly labelled as ‘100% NZ made’.  Action was taken by the CC under s9, s10 and s13(j) FTA, and 
the Court found in their favour on all three counts, on the basis that the labelling led the type of 
consumer who would buy goat’s milk DSs to believe that the product was made in NZ, and this would 
likely be material in their purchasing decision.668  The value of declarations by the HC of the breaches 
under ss9, 10 and 13(j), was deemed appropriate for deterring similar conduct from other 
companies.669 
Two Australian cases provide a more relevant consideration of the application of the Australian 
equivalent to s9 FTA; the former s52 Trade Practices Act 1974 (Cth),670 and the near identically worded 
Victorian state statute, s9 Fair Trading Act 1999 (Vic).671  Decided a mere month apart, these two cases 
demonstrate contrasting approaches to the application of the prohibition on misleading or deceptive 
                                                          
664 Cookie Time Ltd v Griffins Foods Ltd HC Auckland, M1756/SW00, 11 December 2000; Anheuser-Busch Inc v 
Budweiser Budvar National Corp [2003] 1 NZLR 472 (CA). 
665 See Baa Baa Beads case, discussed at 7.7.3.  This is an example of the CC using its s12A powers to avoid 
litigation due to the expense and potential for failure.  With the introduction of enforceable undertakings in Part 
V FTA by way of the Fair Trading Amendment Act 2013, it is likely that more cases will be settled out of court. 
666 See discussion at 7.4.2 on the difference between s9’s ‘likely to mislead or deceive’, and s10’s ‘liable to 
mislead’. 
667 Commerce Commission v New Zealand Nutritionals (2004) Ltd [2016] NZHC 832. 
668 At [36]-[39]. 
669 At [66]. 
670 Trade Practices Act 1974 (Cth); “52 Misleading or deceptive conduct 
(1) A corporation shall not, in trade or commerce, engage in conduct that is misleading or deceptive or is 
likely to mislead or deceive. 
(2) Nothing in the succeeding provisions of this Division shall be taken as limiting by implication the 
generality of subsection (1).” 
671 Fair Trading Act 1999 (VIC); “9 Misleading or deceptive conduct 
(1) A person must not, in trade or commerce, engage in conduct that is misleading or deceptive or is likely 
to mislead or deceive. 
(2) Nothing in the succeeding provisions of this Part is to be taken as limiting by implication the generality 




conduct; one where opinions were held to trump scientific evidence, and the other where expert 
testimony ultimately demonstrate the misleading nature of the claims. 
In Director of Consumer Affairs v Operation Smile,672 a range of claims were made on the defendant’s 
website; from definite statements of fact, like claims around treatment of cancer,673 to more oblique 
claims concerning extension and improvement of life.674  The Supreme Court of Victoria held that 
freedom of expression must be balanced against the requirements of s9 Fair Trading Act 1999 (Vic),675 
and these claims were a matter of opinion.  Despite the fact they directly contradicted established 
scientific evidence and conventional medicine, they were nevertheless outside the scope of 
misleading or deceptive conduct.  The Court reasoned that the combination of a disclaimer, and 
arguable presentation of the statements as opinions excluded them from action under the Fair Trading 
Act 1999 (Vic).676 
The second case is ACCC v Willesee Healthcare. 677   In this case, the defendant was selling and 
advertising CAM products, therapies and resources which claimed to treat, test or cure allergies; 
especially in children.678   While the Court in Operation Smile did not see its role as interpreting 
questions of fact, the Federal Court in Willesee held, on the basis of evidence from expert witnesses, 
that the products could not possibly achieve those representations, and therefore they were 
misleading and deceptive679 under the Trade Practices Act 1974 (Cth).680 
7.3.4 Remedies 
As previously noted, the remedies available under s9 are civil remedies.681  In CC v New Zealand 
Nutritionals, a declaration was issued by the Court.  In Operation Smile, the case was dismissed,682 but 
                                                          
672 Director of Consumer Affairs (Vic) v Operation Smile (Australia) Inc (No 2) [2011] VSC 153. 
673 At [59]; “SUCCESSFULLY TREATED DISEASES … Cancers including Gastrointestinal, Thyroid, Pancreas, Breast 
Cancer with brain metastases, Cervical cancers, Lymphoma, Leukaemia and many others …” 
674 At [65]; “In the majority of cases these treatments lead to an extension of life and an improvement in the 
quality of life.” 
675 At [3]-[4]. 
676 At [76]-[77].  The NZ position with respect to opinions is generally a ‘wider view’, whereby the most important 
aspect is that there is a genuine basis for the opinion that is reasonably based on available information, if it is 
not to be misleading or deceptive; Phillips v King Pie New Zealand Ltd HC Auckland CP165/98, 17 September 
1999; Mok v Bolderson (2011) 13 TCLR 209 (HC).  Even in spite of NZ’s ‘wider view’ it is possible that a different 
decision would be reached in this particular case if it were to come before a NZ court, on the basis of other cases 
on opinion in NZ; at ; Hamid v England (2011) 13 TCLR 376 (HC). 
677 Australian Competition and Consumer Commission v Willesee Healthcare Pty Ltd (No 2) [2011] FCA 752. 
678 At (declaration) 1-2; The representations were that the products could; “cure or eliminate all or virtually all 
allergies, or allergic reactions…” and “successfully treat a person’s allergies or allergic reactions…” 
679 At (declaration) 1-2 and [17]-[21]. 
680 Trade Practices Act 1974 (Cth), ss52, 53(a), 53(aa), 53(c), 55 and 55A. 
681 See 7.3.1. 




in Willesee the Court accepted civil measures in the form of enforceable undertakings made between 
the parties,683 which required, inter alia, corrective advertising.684 
There are a variety of remedies available under Part 5 FTA.  Section 41 allows the courts to grant 
injunctions for breaches of Parts 1-4 of the Act.  Insofar as s41 applies to s9, the most important part 
is the ability for the CC to apply for interim injunctions before taking the case to a full trial.  Section 42 
has a more practical application, allowing for the court to make an order, on application by the CC, 
either for disclosure of information, or publication of corrective advertising.  This is a versatile remedy 
which could be used either in isolation for minor breaches, or in combination with other penalties 
where strong deterrence and public awareness of the misleading or deceptive conduct are sought. 
Section 43 has more limited application, with it only applying where a person has suffered loss or 
damage, or where they are likely to suffer loss or damage.  In the event of a contract between parties, 
there are various remedies under s43(3) around voiding or varying the contract.  Subsection (3) also 
allows the court to make orders for refund,685 repair,686 or compensation for loss or damage by the 
offending party to the misled or deceived person.687  For these remedies to be available, loss, damage, 
or expenditure will have to be shown by the misled or deceived individual, as these are not punitive 
penalties. 
Finally, under ss46A and 46B FTA (and as seen in Willesee), the CC may make accept undertakings from 
a party in breach of the Act which are enforceable by the courts in the event of a breach.  This allows 
the CC some flexibility and promotes cooperation where misleading or deceptive conduct may have 
been unintentional. 
7.3.5 Application to MMS688 
In order for an action against MMS to succeed under s9, the case must meet the test in either Heaven 
or Red Eagle.  Heaven is probably the more appropriate test in this instance, as the case of MMS is not 
the ‘straightforward’ type of scenario for which the Supreme Court in Red Eagle designed its 
alternative test.  Consequently, this application will consider whether MMS meets the requirements 
                                                          
683 Australian Competition and Consumer Commission v Willesee Healthcare Pty Ltd (No 2), above n 677, at 
Annexure 1-6, and [73]; some defendants were required to pay pecuniary penalties as part of the enforceable 
undertakings, but given the limitation of s9 FTA to civil remedies, it is unlikely that this would be possible in NZ. 
684 At Annexure 1-6, and [73]. 
685 Fair Trading Act 1986, s43(3)(e). 
686 At s43(3)(g). 
687 At s43(3)(f). 




of being in trade, engaging in conduct, and involving conduct that is misleading or deceptive in 
accordance with the test in Heaven. 
The fact that the MMS website is engaged in the promotion and advertising of the MMS products sold 
through NZ Water Purifier is sufficient to fall within the wide ambit of ‘in trade’ for the purposes of 
the FTA.  Similarly, the promotion and advertising also amounts to conduct, meeting the second step 
for establishing liability under s9 in the case of MMS.  Furthermore, as conduct includes omitting to 
do an act, any information which is left out of an advertisement would also meet the conduct criteria 
for s9. 
The totality of the material on the MMS website is likely to be capable of being misleading or deceptive 
in line with the first step of the test in Heaven.  Given elements on the website like the testimonies for 
specific diseases, and the appearance of scientific backing, it is plausible that the second step of the 
test may be met in that people are likely to be misled or deceived.  This becomes more certain when 
the third stage is considered; whether it is reasonable for the plaintiff to have been misled.  This is an 
objective test, which requires identification of a relevant section of the public, 689  and then a 
consideration of whether members of this group would be likely to be misled by the conduct.  In this 
instance, the relevant section of the public is plausibly those who will have a preconception as to the 
efficacy of CAM.  As it is likely that they would be misled by the conduct, the requirement under s9 for 
misleading or deceptive conduct would appear to be met in the case of MMS. 
It is in an instance such as this where survey evidence may be extremely valuable to establishing the 
first and second stages of the test in Heaven.  Were a survey to be conducted of a broad cross-section 
of NZers on their perceptions of the outcomes and efficacy of MMS based upon the information 
available on the website, it may provide evidence of misleading conduct.  If a significant proportion of 
participants demonstrated that they were misled or deceived by the MMS website, then this would 
certainly provide evidence for the first step of Heaven, as well as having strong probative value, if not 
being determinative, for the second step, that people are likely to be misled or deceived, and the third 
step, whether it was reasonable for the people to have been misled. 
In summary, it is highly probable that misleading and deceptive conduct can be established for MMS 
under s9 FTA on the grounds that consumers are likely to be misled.  As a result, the civil remedies of 
injunctions, declarations, corrective advertising and enforceable undertakings would likely be 
available, on an application by the CC, on the basis that MMS is likely to mislead consumers under s9.  
                                                          




If in specific cases, actual loss can be demonstrated, then the remedies under s43 would also be 
available. 
7.4 Section 10 FTA 
7.4.1 Overview 
Section 10 FTA is largely similar in terms of scope to s9, except that it narrows its breadth through 
application to goods alone, and only requires that the conduct be ‘liable’ to mislead; a lesser standard 
than ‘likely to’ mislead.  The section states “No person shall, in trade, engage in conduct that is liable 
to mislead the public as to the nature, manufacturing process, characteristics, suitability for a purpose, 
or quantity of goods.”690 
Breach of s10 may result in criminal liability under s40 FTA if relevant charges can be established 
beyond reasonable doubt.  The penalties under s40 involve a maximum fine of $200,000 for an 
individual and $600,000 for a body corporate.691  A breach may also result in civil liability, as discussed 
in relation to s9. 
7.4.2 Tests 
The concept of ‘misleading conduct’ applies to s10 in a similar way as ‘misleading and deceptive 
conduct’ applies in s9,692 as the omission of ‘deceptive’ has no effect on the interpretation.  What is 
pertinent to s10 is the distinction between ‘liable to mislead’ compared to s9’s ‘likely to mislead’. 
Sound Plus v CC693 established that ‘liable to mislead’ imputes a lower burden than ‘likely to mislead’.  
The standard for ‘liable to mislead’ was held to be one of “…a potential less than likelihood or 
probability…”694  This has built upon similar cases,695 which argued that the standard is nearer to 
‘possible’, or as Sound Plus states “subject to the possibility of”.696  Consequently, while s10 limits its 
application, especially in comparison with s9, to goods and misleading conduct relating to their nature 
and characteristics, it is nevertheless a slightly easier threshold of proof to establish that the conduct 
has been misleading when it falls within the ambit of s10 in relation to goods. 
                                                          
690 Fair Trading Act 1986, s10. 
691 At s40(1). 
692 See 7.3.2 for analysis of misleading or deceptive conduct. 
693 Sound Plus Ltd v Commerce Commission [1991] 3 NZLR 329 (HC). 
694 At 332. 
695 Air New Zealand Ltd v Commerce Commission [1985] 2 NZLR 338 (HC). 





Zenith Corporation v CC697 was an appeal from earlier proceedings in the DC.698  The case concerned 
49 offences, which largely centred on advertisements and claims associated with Zenith’s product 
‘Body Enhancer’.  These claims ranged from weight-loss advertisements to healing and improvement 
of cartilage and bones.699  The CC brought the initial action under s10 on the basis that the advertising 
and promotional material was “liable to mislead the public as to the nature or suitability for the 
purpose of the product”, with charges in the alternative under s13.700  Liability was established under 
s13, and therefore s10 was not required to be considered.701 
CC v Erdic also concerned charges brought under both ss10 and 13(a),702 relating to multiple claims 
made on brochures and websites relating to ‘Erdic’ – a plant-based food supplement breast 
beautifying programme.703  This product claimed to “…make female breasts firmer, fuller and more 
beautiful”,704 despite containing neither estrogenic compounds, nor any other hormone which would 
have this effect.  As a result, Judge Kerr held that this conduct was proven to be false and misleading, 
as the product was not doing what it claimed,705 and thus held that the s10 charges were proven 
beyond reasonable doubt.706 
While not directly relevant to CAM products, one recent case does provide a valuable illustration of 
s10’s utility in respect to medicines.707  In the widely publicised case of CC v Reckitt Benckiser,708 Reckitt 
Benckiser, the NZ distributor of the NSAID ‘Nurofen’, pleaded guilty to 10 charges under s10 relating 
to claims on their products that they provided targeted pain relief for specific types of pain.  As it 
eventuated, all the products were identical, and contained no distinct ingredients.  The only element 
                                                          
697 Zenith Corporation Limited and Anor v Commerce Commission, above n 308. 
698 Commerce Commission v Zenith Corporation Ltd, above n 307. 
699 Zenith Corporation Limited and Anor v Commerce Commission, above n 308, at [7]. 
700 At [1]. 
701 At [61]-[64]. 
702 Commerce Commission v Erdic (NZ) Limited DC Tauranga CRI-2006-070-006303, 15 August 2008. 
703 At [8] and [3]. 
704 At [4]. 
705 At [12]. 
706 At [46].  See discussion at 7.5.2 on how representations may, on some occasions, amount to conduct.  This 
appears to have been the position taken in Erdic. 
707 Most cases involving CAM products have not addressed the question of efficacy as CC v Reckitt Benckiser did.  
The Commerce Commission has been quoted on occasion stating: “It is not the Commission’s role to decide on 
the efficacy of alternative health practices…” Commerce Commission “Bird flu remedy is quackery” (press 
release, 15 January 2009).  Consequently, s10 has arguably been underutilised in cases of this kind, see 
Commerce Commission v John Graham Godwin and Anor, above n 161, Zenith Corporation Limited and Anor v 
Commerce Commission, above n 308, and Honey New Zealand (International) Limited v Director General of the 
Ministry for Primary Industries, above n 160, for example, with the Commission instead being more likely to take 
action on the basis of representations under one of the subsections of s13. 




of difference was the labelling, which purported to claim efficacy for one of the four type of pain for 
which the products was marketed.709  The Court considered this to be a straightforward application of 
s10, stating that the defendant’s claims ‘grossly misled’ the public with respect to the characteristics 
and suitability for purpose of the goods.710 
7.4.4 Remedies 
In all three of these cases, criminal liability was established, and the defendants were fined under s40 
FTA. 
In addition to the criminal sanctions under s40, and the civil sanctions, as discussed at 7.3.4, there is 
one other remedy which may be applicable for offences under s10; management banning orders.711  
Where an individual has breached s40 FTA at least twice in a 10-year period, the court may ban the 
person from being a director, or managing a company in any way for up to 10-years.712  Subject to 
certain conditions, this allows the court to protect the public from individual directors who have a 
history of breaching s40 FTA,713 and through either course of action, strongly disincentivise such 
conduct by directors of a company. 
7.4.5 Application to MMS 
Applying s10 FTA to the example of MMS is largely similar to the application of s9, barring a couple of 
key differences.  MMS and NZ Water Purifier are clearly in trade, and engaging in conduct; the main 
question is whether this conduct is liable to mislead the public in relation to the goods.  Erdic clearly 
established that while a website may not have been created by the defendants, their use of the 
website for advertising and the proximity of the website was sufficient there for the purposes of s10, 
as it almost certainly would be in the case of MMS.714  There is no question here that the conduct in 
the MMS example relates to goods, and given the argument at 7.3.5 that the conduct was ‘likely to 
mislead or deceive’ pursuant to s9, it will almost certainly reach the lower standard of ‘liable to 
mislead’.  Finally, three of the specific conducts stipulated in s10 could apply to MMS; misleading 
conduct as to either the nature, characteristics, or suitability for a purpose of the goods.715  
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Once again, survey evidence would be valuable here, as it could not only establish the conduct as 
misleading, but aid in surmounting the burden of proof for criminal liability. 
Thus, in theory, s10 would provide a suitable platform from which to bring charges against a product 
like MMS, either alone, or as an alternative to actions under ss9 or 13; additionally enabling sizeable 
fines as seen in CC v Reckitt Benckiser, which would certainly have a deterrent effect.716  However, in 
practice the CC has shown an inclination to avoid s10 insofar as CAM products are concerned, and 
instead focus on s13 and the broad number of false or misleading representations which may 
encompass a particular case.  This would be the first of three strikes towards a management banning 
order under s46C.   
7.5 Section 13 FTA 
7.5.1 Overview 
Section 13 is somewhat distinct from the previous sections considered, primarily in that it deals with 
false or misleading ‘representations’ as opposed to ‘conduct’ as found in ss9 and 10.  The distinction 
between s9 and s13 was highlighted by Tipping J in Marcol Manufacturers Ltd v CC when he stated, 
“…a representation…is of course a narrower concept than conduct generally”.717 
There are 10 types of false or misleading representations under s13, and while a variety of these 
subsections are employed throughout the cases concerning CAM products,718 the most relevant is 
s13(a), which addresses false or misleading representations; “…that goods are of a particular kind, 
standard, quality, grade, quantity, composition, style, or model, or have had a particular history or 
particular use…”719 
The penalties for a breach of s13 are identical to those for a breach of s10, as discussed at 7.4.1 and 
7.4.5. 
7.5.2 Tests 
A breach of s13 requires that there be a representation, which is made in trade, in connection with 
the supply or possible supply of the goods or services or with the promotion of the supply or use of 
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goods or services, and that the representation be false or misleading and accord with one of the 10 
subsections.720 
While the language of most of these elements is straightforward, ‘representation’ merits some 
discussion.  The interpretation of ‘representation’ in NZ is well established, having been borrowed 
from the Australian case of Given v Pryor,721 which looked at what entailed a representation under the 
equivalent section of the Australian Trade Practices Act.722  In this case, Franki J established a broad 
ambit for representations, encompassing oral and written statements (even when associated with 
images), and in particular cases, may even include conduct.723 
Tipping J adopted this position in Marcol, further explicating via a two stage test; the first question 
being one of law, whether the material can amount to a representation, and the second being one of 
fact, whether the material in question does amount to that representation.724 
These interpretations have been followed since, although the two stage test in Marcol is seldom seen 
as necessary given the relative ease with which representations can be identified.  Tipping J did take 
the opportunity in Mega Vitamin Laboratories v CC on appeal to note that there is not an unreasonable 
need for specificity or proximity of the representation to the product, with the pamphlet in question 
to that case clearly referring to the multi-vitamin tablets and thus the statements made on the 
pamphlet were capable of amounting to a representation.725 
7.5.3 Cases 
CC v Mega Vitamin Laboratories (NZ) Ltd726 was an exceptionally important case which was arguably 
a perfect example of when the FTA should be used over primary legislation; namely for investigations 
which have the ultimate goal of otherwise unachievable consumer protection.  In this case, the CC 
brought an action against Mega Vitamin under s13(a) FTA on the grounds that the label and brochures 
of the defendants’ products ‘falsely represented the composition of the goods’,727 which in practical 
terms meant that the quantity of vitamins listed on the labels was incorrect.  The CC conducted 
analyses of the vitamin contents present in the defendants’ multivitamins, and found the actual 
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content to be between 54.4-87% of the stated amounts.728  While Judge Green noted a willingness to 
adopt a de minimis principle in line with the Food Regulations 1984 such that a variability of 10% would 
be acceptable, the discrepancies were well outside this range, and ultimately the defendants’ were 
found to be culpable.729  This case is notable for the fact that the CC carried out an investigation and 
testing, which demonstrated misleading or deceptive representations not otherwise addressed in 
primary legislation.  Furthermore, the Judge looked to the DSRs, but determined there was nothing in 
the Regulations which handled quantities of vitamins in DSs.730  This case demonstrates an instance 
where the FTA is utilised not only as the best method for addressing misleading and deceptive conduct 
in relation to CAM products, but also as a valuable corollary to investigations of CAM products. 
R v Muscle Marketing USA Ltd concerned a very similar situation, wherein the defendant’s product, 
ATP Advantage Creatine Serum, made misleading statements as to its composition in breach of s13(a) 
FTA.731  Judge Everitt took the opportunity to note the susceptibility of the people to whom this kind 
of product is marketed,732 going on to state that this case falls squarely within the ambit of FTA 
legislation which aims to protect consumers from “…unwholesome claims, snake oil people and the 
like…”733  No mention was made of the applicability of food legislation. 
The charges under subs13(a) and (e) were successful in Zenith, (as discussed at 7.4.3) when argued in 
the alternative with charges under s10.  The three charges under s13(a) were on the basis that the 
labelling on the ‘Neo Nutrients Body Enhancer’ made false representations as to the quality or 
composition of the goods.734  The remaining 23 under s13(e) concerned “false representations as to 
the performance characteristics or benefit of the product.”735  The Court noted the four elements 
which had to be proved for liability under s13(e); namely that Zenith was a person, in trade, had made 
a representation in connection with the supply of the goods, and that representation was false or 
misleading.736  Regarding evidence for this last requirement, the DC Judge accepted evidence from an 
expert witness, which established that the components of ‘Body Enhancer’ could not have the effect 
claimed, and thus the representations were misleading or deceptive.737 
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CC v Godwin is something of an outlier to these cases in that it deals primarily with CAM practitioners 
rather than CAM products, but nevertheless demonstrates the applicability of s13.738  The charges in 
this case were under subs(e) and (f), and amongst other things, represented their products as 
remedies for bird flu, herpes, SARS, and for use in an ‘anti-terrorist kit’.739  Despite these arguably 
being high-level claims, which at least indirectly indicated that they purport to cure otherwise 
incurable maladies, the Judge took a lenient approach; finding the defendants to be only careless, and 
not deliberately misleading, while also making obiter suggestions with respect to a scale for lessened 
penalties in cases such as these.740  The relevance of intention in the decision in Godwin went to the 
sentencing, rather than a question of liability, with the defendants facing criminal liability under s40, 
albeit with reduced fines on the basis of their carelessness. 
In 2010, the CC investigated a number of companies producing Royal Jelly products.  Throughout these 
cases, there are two general themes upon which the various companies were prosecuted.  The most 
prolific was the country of origin labelling issue, with all four cases facing charges under subs13(a) or 
(j) FTA.741  More importantly, two cases faced charges regarding the alleged potency of their royal jelly 
products being much lower than claimed on the label.  CC v NZ Korea Health Ltd742 pled guilty to nine 
charges of misleading claims with respect to both the 10HDA743 content of their products, which 
analysis showed to be approximately 7.83% of what was on the packaging, as well as to the country 
of origin labelling.744  CC v Honey New Zealand (International) Ltd745 was not so straightforward, and 
resulted in a defended hearing.  While initial analysis of Honey New Zealand’s royal jelly products 
showed them to have about 4.27% of the labelled quantity of 10HDA, 746  a combination of 
misinformation and subsequent testing showed this to be erroneous, and due to systemic problems 
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with the testing, the CC dropped the charge under s13(a) with respect to the quantity of 10HDA,747 
and instead proceeded with the charge under s13(j) on country of origin labelling.748  These cases 
demonstrate the rather burdensome logistical operation which must take place in order for the CC to 
prosecute for anomalous levels of the advertised product, and the fact that even once this has 
occurred, prosecution on this basis is neither a sure-thing, nor is it likely to have substantial effect on 
the industry as a whole.  These problems are endemic to a technical, effectively unregulated industry, 
and there is little sign of relief on the horizon.749 
Much like the Honey cases discussed above, NZ Nutritionals was prosecuted under s13(j) for its 
misleading representation of its place of origin on both the powder and the tablets, as previously 
discussed.  NZ Nutritionals defended the case, arguing that due to the combing the imported 
ingredients, and packaging occurring in NZ, the phrase ‘New Zealand made’ was not misleading; an 
argument which ultimately failed in the HC.750 
One final case which bears mention in relation to s13, and specifically to its application to MMS, is CC 
v Ecoworld New Zealand Ltd.751  In this case, Ecoworld sold a variety of water treatment products, 
including the unit in question in this case which is described as follows: “…water is treated in a secret 
process which permanently energises the water by using vibrational frequencies… this treated water 
possesses unique and beneficial qualities...”.752  The material then represents that the water creates 
aerobic conditions in which pathogens and parasites cannot survive, it gives health benefits due to 
resonance with the cosmos, and helps the body detoxify, improving circulation and blood pressure 
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and reducing allergies. 753   Action was taken solely under s13(e) FTA, and criminal liability was 
established. 
7.5.4 Remedies 
Once again, all the cases discussed above resulted in findings of criminal liability under s40, with the 
CC establishing the misleading and deceptive conduct beyond reasonable doubt.  A more detailed 
analysis of the decisions is ultimately irrelevant, as the penalties are entirely fact dependent, and it 
offers little by way of further analysis or analogy to the example of MMS. 
7.5.5 Application to MMS 
There is no doubt that two subsections of s13 are applicable to MMS and would almost certainly yield 
a decision against the company.  Subsection (a) on the composition of the goods, and subs(e) on the 
performance, characteristics, uses or benefits of the goods would both apply to MMS. 
All the requirements of an action under s13 would be present in such a case, with NZ Water Purifier 
Ltd being in the trade of supplying goods, while the MMS website is engaged in the promotion, and 
arguably supply through the associated NZ Water Purifier website.  The representations do appear to 
be misleading, especially when the audience to whom they are targeting is considered; vulnerable, 
desperate people often with serious, terminal or incurable medical conditions.  Finally, MMS would 
likely fall within the scope of subs(a) for the misleading representations that the goods “…have a 
particular history or particular previous use” or subs(e) for the misleading representations that the 
goods have “…performance characteristics… uses, or benefits”.754  There would be no doubt in a case 
like this that the statements on the MMS website are representations, leaving the logical course of 
action to present charges under both s10 and s13 on the basis of both conduct and representations, 
as was done in Zenith and Erdic. 
7.6 Defences for MMS 
There are three factors which might potentially affect the liability of MMS under the FTA.  Those are 
the presence of the disclaimer on the MMS website, the fact the testimonies on the MMS website are 
purportedly from third parties, and the proximity, or lack thereof, between MMS and the NZ retailer 
of the MMS products, NZ Water Purifier. 
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Every page on the MMS website contains the same disclaimer, at the very bottom of the page in small 
font and an indistinct colour.755  While this disclaimer does not seek to contract out of the FTA, it does 
endeavour to avoid all liability for therapeutic statements on the website by breaking the chain of 
causation between any misleading or deceptive statements and the loss suffered.  It does this by 
making it clear that the reader should not be relying on these statements, but instead should be 
forming their own opinion as to therapeutic benefits. 
Ultimately, the use of such a disclaimer is unlikely to be sufficient to avoid responsibility for misleading 
representations and conduct for two reasons.  Firstly, Medical Benefits Fund of Australia Ltd v 
Cassidy756 established that “…to be effective, the qualifying material must not only be sufficiently 
prominent, but also sufficiently instructive to nullify the risk that the primary claim might mislead or 
deceive.”757  The disclaimer on the MMS website is unlikely to meet either of these criteria, firstly, 
because it is not prominent, being displayed at the bottom of the webpages, often far removed from 
the therapeutic statements, in a faint, low contrast font.  To be effective, disclaimers must be 
“…reasonably brought to the attention of the purchaser”,758 and small print,759 illegible text,760 or a 
lack of direction to the disclaimer are likely to make a disclaimer ineffective.761  It is also unlikely to 
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meet the ‘sufficiently instructive’ criteria, as it does not actively disavow the therapeutic statements, 
or even claim they are opinion, but rather states that some countries restrict “…the promotion of 
certain products known to demonstrate therapeutic benefits”,762 and its statement about medical 
advice and diagnosis does not address the misleading and deceptive material as to the purported 
curative effect of the MMS products. 
Secondly, the HC of Australia has established the principle that the ‘dominant message’ is an important 
factor in weighing whether the conduct is misleading or deceptive.763  This position has been adopted 
by the NZ CA in application to ss9 and 13(i) FTA in Godfrey Hirst NZ Ltd v Cavalier Bremworth Ltd.764  
In that case, the Court identified five key principles around misleading representations:765 
(a) Overall impression: It is the ‘dominant message’ or ‘general thrust’ of the 
advertisement that is of crucial importance.’ 
(b) Wrong only to analyse separate effect of each representation … 
(c) Qualifying information sufficiently prominent? … 
(d) Glaring disparity … 
(e) Tendency to lure consumers into error ... 
It is very unlikely that the MMS website meets this high standard with their disclaimer, for similar 
reasons to those outlined in the preceding paragraph around the Medical Benefits case.  Additionally, 
the ‘overall impression’ of the MMS website is that the products will help with a variety of therapeutic 
purposes, meaning they will probably be liable for false or misleading conduct or representations. 
7.6.2 Testimonials 
The issue of testimonials which potentially include misleading or deceptive representations has not 
yet come before the NZ courts.  A similar issue has arisen in Australia, with the ACCC taking action 
against a number of companies for misleading reviews posted on websites which purported to be 
from customers when this was not the case.766  The ACCC subsequently released guidelines on online 
reviews for industry, which note that a company may be responsible for posting or publishing 
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misleading reviews.767  Furthermore, some professions like Chiropractors are specifically prevented 
from using testimonials in advertisements by law in Australia.768   
Due to the lack of a legal foundation for handling health testimonials in NZ, it is difficult to determine 
whether the testimonials on the MMS website would amount to misleading or deceptive conduct, 
however it is certainly arguable that the company bears responsibility to ensure reviews which are 
factually inaccurate are not included on the company’s website (or that a link is not given to these 
testimonies on the website) in support of their products. 
7.6.3 Proximity 
The final issue is whether there is sufficient proximity between the MMS website and NZ Water 
Purifier Website such that content on the latter could be transmuted to the former.  Both Mega 
Vitamin and Erdic demonstrate that there would be sufficient proximity in the case of MMS.  In Mega 
Vitamin, a pamphlet which discussed the multi-vitamin was sufficiently proximate, and in Erdic, claims 
on a variety of distantly related websites were sufficient to support the case.  Based on these cases, 
the specific links on the MMS website to the NZ Water Purifier website will likely be sufficient to enable 
a breach of s13 to be proven.  It has already been suggested that the disclaimer which attempts to 
avoid any relationship between linked websites will be unlikely to be successful.  It could also be noted 
that a mere conduit defence under s44 will probably be unavailable on the basis that the MMS website 
actively makes representations about the products in question.769 
7.7 Section 12A FTA 
7.7.1 Overview 
Section 12A FTA is a new addition to the Act770 which focuses on the making of unsubstantiated 
representations.771  Included in the Act in 2014,772 s12A is relatively untested,773 and due to a stark 
difference in application to a similar section in Australia,774 it is not possible to analogise the position 
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NZ will take.  Nevertheless, s12A is likely to be a vital tool in preventing unsubstantiated 
representations, and could form a basis for many actions against CAM products.775  A breach of s12A 
in NZ can be a basis for the CC776 commencing either civil or criminal proceedings.777 
7.7.2 Elements of s12A 
Section 12A requires that a person who is in trade, makes a representation as to goods or services or 
their promotion, and that this representation be unsubstantiated. 778   Section 12A(2) employs a 
relatively standard definition of ‘unsubstantiated’, which simply requires that the person making the 
representation has no reasonable evidential basis for the claims, regardless of its veracity, or false or 
misleading nature.779  It should also be noted that s12A(3) provides a puffery defence to this section, 
which applies where a reasonable person would not expect the representation to be substantiated. 
7.7.3 Cases 
So far, there have been few cases under s12A,780 and none which dealt with CAM products.  One 
relevant example is that of Baa Baa Beads.  In 2015, Baa Baa Beads were issued a warning letter by 
the Commission about a failure to substantiate claims of the healing properties of their amber 
necklaces.781  These claims included statements that “Succinic acid ‘strengthens the body, improves 
immunity’”, and “Succinic acid has been ‘proven’ to be ‘the equal or better of many commercial 
drugs…’” 782   No further action was taken, as the company amended their representations in 
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consultation with the Commission.  The CC did however make an important statement with respect 
to the evidence sufficient to substantiate such representations:783 
Whether the claim is express or implied, businesses should only make claims based upon facts, 
figures and credible sources of information that support their accuracy.  Traders cannot simply 
rely on general information they find in books and online. 
This statement appeared to include ‘traditional’ evidence of healing properties. 
More recently, the heat pump company Fujitsu were fined for unsubstantiated representations under 
s12A in the first case of its kind in NZ.784  A number of unsubstantiated representations were made 
about heat pump performance over an extended period, and the Judge found it material in sentencing 
that “…consumers or potential consumers are unable, through any reasonable means to test the 
accuracy of these claims.”785  This may be significant for the future use of s12A, in cases involving 
unsubstantiated representations on CAM products, were consumers are at a similar disadvantage to 
testing the efficacy of CAM products, or veracity of the claims made thereon. 
7.7.4 Application to MMS 
Section 12A is an invaluable tool for the CC, especially under current regulations where there are a 
multitude of CAM products making TCs, and insufficient resources to investigate all of them.  The CC 
can require the maker of a TC to substantiate the claim under threat of civil or criminal liability.  
Alternatively, through warning letters under s12A as given to Baa Baa Beads, the Commission could 
address a wide number of unsubstantiated health claims, subsequently determining which to take 
further action upon if the warning did not result in substantiation or removal of TCs. 
In application to MMS, s12A is the most appropriate section considered in this Chapter.  It has been 
established that the MMS website makes representations,786 leaving the question of whether these 
are unsubstantiated.  On first glance, it appears that these representations are supported by evidence, 
with a note on the website’s homepage “Chlorine Dioxide is a scientifically proven pathogen 
killer…”,787 followed by a series of links to government papers, journal articles and other materials 
which are claimed to provide scientific proof.  However, upon thorough analysis, none of these sources 
relate to MMS, nor show anything but the general, and well accepted ability of chlorite as a water 
                                                          
783 At 1. 
784 Commerce Commission v Fujitsu General New Zealand Ltd, above n 780; Commerce Commission “Fujitsu fined 
$310,000 in Commerce Commission's first unsubstantiated claims case” (press release, 20 September 2017). 
785 At [62]. 
786 See discussion on MMS and s13 FTA at 7.5.5. 




sterilant.788  This certainly does not meet the Commission’s standard for substantiation of “…claims 
based on facts, figures and credible sources of information that support their accuracy.”789 
The CC could therefore issue a warning letter, accept enforceable undertakings, or alternatively 
commence civil or criminal proceedings. 
7.8 Concluding remarks to the Fair Trading Act 
Sections 9, 10, and 13 FTA provide valuable and well-tested means of enforcement against misleading 
conduct and representations.  Section 12A enables a more preventative approach to unsubstantiated 
representations, with the option of taking action under this section if necessary.   
In application to misleading or deceptive conduct around CAM products, s12A is a good starting point 
if the product is making unsubstantiated representations, but ss10 and 13 will usually be the most 
                                                          
788 At 1; all references on the MMS website were analysed and brief reasons for their dismissal as relevant, 
supporting or sound scientific evidence follow: 
Centre for Disease Control and Prevention “A Guide to Drinking Water Treatment and Sanitation for Backcountry 
and Travel Use” (10 April 2009) 
<https://www.cdc.gov/healthywater/drinking/travel/backcountry_water_treatment.html>; the CDC website 
contains a wealth of information on water sterilisation with chlorine dioxide, but nothing whatsoever on MMS 
or use of chlorine dioxide for therapeutic purposes. 
Judith R. Lubbers, Sudha Chauan and Joseph R. Bianchine “Controlled Clinical Evaluations of Chlorine Dixoide, 
Chlorite and Chlorate in Man” (1982) 46 Environmental Health Perspectives 57; this is frequently cited by MMS 
proponents as the seminal paper corroborating its use, however the paper used a lower dose of chlorite than 
most of the MMS methods, and more importantly, used a vastly different procedure, with multiple days between 
giving patients the dose.  Finally, this was a relatively small clinical trial, which has not been repeated. 
MMS Testimonials LEAKED: Proof the Red Cross Cured 154 Malaria Cases with MMS; this video is obviously 
insufficient evidence for s12A FTA, and furthermore, the International Federation of Red Cross and Red Crescent 
Societies has dissociated themselves from any relation to the video, and purported ‘clinical trials’, see 
International Federation of Red Cross and Red Crescent Societies “IFRC strongly dissociates from the claim of a 
'miracle' solution to defeat malaria” (press release, 15 May 2013). 
Norio Ogata and Takashi Shibata “Protective effect of low-concentration chlorine dioxide gas against influenza 
A virus infection” (2008) 89 Journal of General Virology 60; the study in this article sprayed chlorine dioxide gas 
into the air at the same time as influenza A virus to determine the effects on mice.  This was extremely effective 
at preventing influenza in the mice when sprayed concurrently, but when sprayed 15 minutes later it was 
completely ineffectual, suggesting its mode of action was an aerosol one before ingestion, and thus showing no 
relationship whatsoever to MMS or its purported mode of action. 
Frederich W. Kuhne, Michael McGrath and Edgar G. Engleman Use of a Chemically-stabilized Chlorite Solution 
for Inhibiting an Antigen-specific Immune Response; while this patent appears to show an antigen response for 
use of chlorite solution, the clinical data and dose data is varied, with only one clinical trial in humans with a very 
low number of participants. 
A. Rubinstein, T. Chanh and DB Rubinstein Chlorine dioxide sterilization of red blood cells for transfusion, 
additional studies; not only did these experiments show incomplete activation by chlorine dioxide, they also 
used a process for treating red blood cells which is in no way comparable to the MMS procedures. 
Thomas Lee Hesselink “On the Mechanisms of Toxicity of Chlorine Oxides against Malarial Parasites: An 
Overview” (6 September 2007) <http://bioredox.mysite.com/CLOXhtml/CLOXprnt+refs.htm>; this is a non-peer 
reviewed website article by a proponent of MMS.  




effective.  The majority of case law involving CAM products under the FTA has been taken under these 
two sections, commonly argued together in the alternative.  Section 10 relates specifically to goods, 
involves a lower standard with ‘liable to mislead’, than s9’s ‘likely to mislead’, and like s13, also enables 
criminal sanctions, as well as civil remedies in the event of breach.  Section 13 deals more specifically 
with representations, focusing on particular kinds of representations which may facilitate more 
targeted enforcement. 
Despite the applicability of the FTA, and ready means of action against misleading or deceptive CAM 
products through the consumer protection arm of the CC, this reliance on the FTA has a downside.  
The litigation of almost all cases involving CAM products under the FTA demonstrates the 
unenforceable and toothless nature of primary provisions like the DSRs.  CAM product regulations 
should prevent such misleading and deceptive practices in the first place, and failing that, provide 
enforcement measures when products or suppliers breach those regulations, with the FTA being a 
backstop for consumer protection where all else fails.  However, the DSRs have failed to regulate in 
this way, and the structure of the NHSPB looks set to make a similar mistake. 
7.9 The Consumer Guarantees Act 1993 
The CGA was enacted to provide some protection for consumers from businesses and suppliers to 
address the possible power imbalance.  The Act defines a ‘consumer’ as a person who obtains goods 
or services, ordinarily acquired from a supplier for “…personal, domestic, or household use or 
consumption”,790 providing they do not acquire them for any commercial purpose.791  It provides a 
number of guarantees for ‘consumers’ as to goods and services, with specific remedies in the event 
that these guarantees are not upheld or adhered to by companies.792  Two of these guarantees are 
potentially relevant to the CAM products. 
With respect to goods, the Act provides consumers with guarantees that they are ‘reasonably safe’, 
‘fit for purpose’, and ‘of an acceptable quality’.793  Where there is a breach of these guarantees, the 
consumer broadly has two remedies against the supplier.  They may require the supplier to remedy 
                                                          
790 Consumer Guarantees Act 1993, s2(1), ‘consumer’ (a). 
791 At s2(1), ‘consumer’ (b). 
792 At s1A.  A consumer broadly has two remedies against a supplier.  They may require the supplier to remedy 
the problem within a reasonable time, which usually amounts to a repair, replacement or refund, with the choice 
reverting to the consumer if the fault is not remedied within a reasonable time.  Alternatively if the failure cannot 
be remedied or is of a substantial nature, the consumer may obtain damages from the supplier, which extends 
to damages for reasonably foreseeable loss resulting from the goods’ failure.  Similar remedies apply in certain 
circumstances against the manufacturers of the goods; at ss18, 19, 25 and 27. 




the problem within a reasonable time,794 which usually amounts to a repair, replacement or refund,795 
with the choice reverting to the consumer if the fault is not remedied within a reasonable time.796  
Alternatively, if the failure cannot be remedied or is of a substantial nature, the consumer may obtain 
damages from the supplier,797 which extends to damages for reasonably foreseeable loss resulting 
from the goods’ failure.798  Similar remedies apply in certain circumstances against the manufacturers 
of the goods.799 
7.9.1 Sections 6 & 7: Acceptable quality 
Section 6 CGA provides that goods supplied to consumers come with a guarantee that they are of an 
acceptable quality.  Where this is not the case, consumers have a right of redress against the supplier 
or manufacturer under Part 2 or 3 CGA respectively.800 
Section 7 provides detail on what ‘acceptable quality’ entails, listing five criteria: goods must be fit for 
all purposes for which they are commonly supplied, have an appropriate appearance and finish, be 
free from defects, safe, and durable. 801   In outlining the meaning of ‘acceptable quality’ for the 
purposes of s6, s7(1) goes on to note matters to which the reasonable consumer may have regard 
when determining whether the goods are acceptable.  In an echo of the FTA, this includes; “…the 
nature of the goods,”802 any statements on the packaging or label,803 and any representation about 
the goods.804  It is important to note the similar objective standard which applies to ‘acceptable 
quality’ here through the ‘reasonable consumer’. 
There is a lack of reported cases which address CAM products under the CGA, due to the requirement 
that the consumer bring the action in such a case, as well as the associated difficulty incumbent upon 
the plaintiff to demonstrate that the CAM product is not of acceptable quality.  While it is thus difficult 
to demonstrate the application of the CGA to CAM products, one Australian case raises an important 
consideration.  In Carey-Hazell v Getz Bros Co,805 it was held that safe, or ‘free from defect’ was a 
                                                          
794 At s18(2). 
795 At s19(1). 
796 At s18(2)(b). 
797 At s18(3). 
798 At s18(4). 
799 At ss25 and 27. 
800At s6. 
801 At s7(1). 
802 At s7(1)(f). 
803 At s7(1)(h). 
804 At s7(1)(i). 




different standard to free from risk, and did not have the same implications.806  Consequently, the fact 
that the plaintiff’s heart valve encountered issues, as happened to a minority of people who received 
them, did not mean the valves were unsafe.807  In relation to CAM products, this might mean that an 
adverse interaction with another product, or reaction of a CAM product with an underlying medical 
condition would not be the fault of the supplier or manufacturer, providing the CAM product was ‘free 
from defect’. 
7.9.2 Section 8: Fit for purpose 
Section 8 generally provides a guarantee as to the fitness of goods supplied to a consumer for a 
particular purpose.  This encompasses any purpose which the consumer expressly makes known to 
the supplier,808 or any more general purpose for which the supplier represents that the goods are 
fit. 809   Section 8(c) creates exceptions if the consumer is not relying on the supplier’s skill or 
judgement,810 or where it would be unreasonable for the consumer to rely on that skill or judgment.811 
There is an important distinction between s7 and s8.  Section 7 guarantees fitness for a common 
purpose, while s8 guarantees fitness for a particular purpose, which the purchaser makes known to 
the supplier.  Section 8(3)812 applies to both common and particular purpose, but importantly, s7 only 
applies to fitness for a common purpose.813 
The question remains of how fitness for purpose, or s8 more generally relates to CAM products.  More 
relevant in this context is the idea of a common purpose, and therefore s6 and 7 are also pertinent 
here.  While a particular purpose will arise where consumers are taking advice from the retailer of the 
product or practitioner on their particular condition, this is probably a less common occurrence, and 
is outside the scope of this thesis.  On the basis of fitness for common purpose, a supplier will need to 
ensure the CAM product is fit for any reasonable purpose for which the goods may be used.  This will 
certainly extend to any claims of performance like TCs or HBCs displayed on the label or associated 
with the product.  As such, if a container of Olive Leaf, for example, stated on the label ‘relieves cold 
                                                          
806 Gault, above n 657, at [CG7.09(5)].  The case was brought under the Trade Practices Act 1974 (Cth), ss75AD, 
75AC, and 74B. 
807 At [CG7.09(5)]. 
808 Consumer Guarantees Act 1993, s8(1)(a). 
809 At s8(1)(b). 
810 At s8(2)(a). 
811 At s8(2)(b).  
812 At s8(3); “This section applies whether or not the purpose is a purpose for which the goods are commonly 
supplied.” 




symptoms’, it would be likely that the reasonable consumer could expect the product to do just that.814  
In the event it did not do so, the issue would be establishing that fact; an onus which rests on the 
consumer, and is one of the principal problems with using the CGA for these types of products.  
7.9.3 Application to MMS 
As previously noted, the CGA could be used if a ‘consumer’ who had purchased MMS claimed it was 
not of acceptable quality or not fit for purpose. 
First, the purchaser must meet the definition of consumer; namely that they are acquiring goods, 
which are ordinarily acquired for a personal or household use or consumption.  Then, one of the 
guarantees must be breached.  An argument that MMS is not of an acceptable quality could be based 
on the fact that it is not safe to be consuming chlorine dioxide, 815  as the MMS website directs 
consumers. 
Alternatively, the consumer could argue that the product was neither fit for a particular nor common 
purpose.  The MMS website, which directs consumer to the NZ Water Purifier site, contains specific 
information on the manner in which MMS has relieved numerous specific medical conditions in the 
form of testimonies, which is arguably tantamount to advice on the suitability of the product for a 
particular purpose.  However, particular purpose must be made known to the vendor by the 
purchaser, and it is unlikely that a particular purpose will usually work when one is ordering online.  
The stronger argument would be that MMS is not fit for common purpose.  In one fell swoop, this 
annuls any argument from NZ Water Purifier that the goods are not supplied for a therapeutic 
purpose,816 and also facilitates an argument that the goods are not fit for that purpose, as they do not 
have the therapeutic effect outlined on the MMS website. 
Despite the fact that a claim against MMS is plausible under the CGA, there remain problems with 
such a claim.  Firstly, MMS and its website is neither the supplier nor manufacturer, and unless their 
representations can be transmuted to NZ Water Purifier, the basis for a claim of acceptable quality of 
fitness for purpose is tenuous.    Furthermore, not only does a consumer need to bring the action and 
prove the elements, the remedy comes in the form of resolution for that particular consumer, rather 
than broad penalties aimed at disincentivising the kind of conduct MMS exhibits.  The consumer bears 
the onus to substantiate the fact that the goods are not fit for purpose or of acceptable quality, and 
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this poses an onerous burden upon consumers, highlighting the root of the problem with applying the 
CGA to CAM products; namely that it is not worth a consumer’s while to take such an action, especially 
when the price of the goods is considered, but rather they are better protesting with their wallets.817 
7.10 Concluding remarks to the Consumer Guarantees Act 
There is certainly scope for an action against a CAM product within ss6 and 7 CGA on acceptable 
quality, and s8 that goods be fit for purpose, but the problem facing an action against a CAM product 
under the CGA is the practicalities.  Such an action must be brought by a consumer, and they will be 
faced with the logistical difficulty of demonstrating that the goods are either not of an acceptable 
quality, or are not fit for purpose.  Due to the low value of CAM products, coupled with the difficulty 
in determining the actual effect of the product, an action by a consumer under the CGA is relatively 
unlikely, with consumers being more prone to merely protest with their wallet and not purchase a 
particular CAM product again.818 
7.11 Conclusion 
It is evident from the variety of cases discussed in this Chapter that the FTA is potentially effective at 
dealing with misleading or deceptive conduct in relation to CAM products.  Conversely, the CGA does 
not provide the same scope for such action; in large part due to the requirement that consumers bring 
actions under the CGA, in contrast to the CC’s ability to bring FTA actions. 
The question remains whether the FTA’s role in addressing misleading and deceptive practices with 
CAM products is appropriate.  Certainly it is necessary, especially when primary legislation like the FA, 
MA and DSRs are ineffective in addressing these problems, but it would appear that an enforceable 
mechanism in the primary legislation which prevents and penalises the presence of misleading or 
deceptive conduct and representations would be more appropriate. 
This is particularly important in light of the CC’s stance that it does not view its role as the judge on 
the efficacy of CAM.819 
The MMS case study has suggested that while the FA, MA and DSRs will struggle to deal with MMS, 
the FTA could potentially address the problems associated with MMS under a number of different civil 
or criminal provisions.  It is difficult to determine whether a case against MMS could be established 
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beyond reasonable doubt, but it is almost certain that it could be on the balance of probabilities.  
Technical questions as to the effect of the separation between the websites, and whether testimonies 
and the equivocation on the effect of the product are tantamount to TCs or misleading and deceptive 
conduct require further consideration. 
With an appreciation for the role of consumer protection legislation as it currently applies to CAM 
products, the next Chapter now turns to consider an even broader issue affecting the regulation of 
CAM products in NZ; the Treaty of Waitangi and the place of traditional medicine and the Wai 262 




8 The Treaty of Waitangi & the Wai 262 Report 
8.1 Introduction 
A review of existing legislation, and a proposal to design new legislation in NZ, would be incomplete 
without consideration of the Treaty of Waitangi and the principles therein.  This is even more essential 
when the subject matter encompass Māori TM and the possibility of its regulation under CAM product 
legislation. 
As noted in Chapter 1, rongoā Māori is an holistic healthcare system, which includes rakau rongoā; a 
form of herbal medicine.  Like many forms of traditional herbalism, it is likely that many of the 
remedies used as part of rakau rongoā contain active ingredients with a pharmacological basis, 
although there has been insufficient research to conclusively determine either the efficacy or toxicity 
of these remedies to date.820 
In the context of rongoā, this Chapter will consider the prominence, or lack thereof, of the principles 
of the Treaty of Waitangi in existing and proposed CAM product regulation in NZ.  The Chapter will 
then turn to review the Wai 262 Report, and specifically the recommendations around rongoā, with a 
view to the adoption and implementation of these, where possible, in the proposal. 
8.2 The Treaty of Waitangi 
Te Tiriti o Waitangi (The Treaty of Waitangi) has a defining role in NZ’s constitutional history, and any 
discussion on CAM regulation, let alone rongoā Māori, would be incomplete without a consideration 
of the Treaty and its principles.  Importantly for the NHSPB, and any other proposed CAM product 
legislation, it must satisfy the Legislation Design Committee Guidelines,821 as well as Cabinet,822 that 
the Bill is not inconsistent with the principles of the Treaty of Waitangi.823 
The principles of the Treaty are one of the cornerstones of NZ’s unwritten constitution.  In the spirit 
of partnership required by the Treaty, there are seven general guidelines regarding the effect of the 
legislation upon the Treaty which should be considered, where applicable, in the drafting of new 
legislation. 824   Broadly, these require identification of affected Māori interests, consultation, 
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consideration of additional measures in the event of conflict, informed decision making, no 
inconsistency with existing Treaty settlements, and where legislation is intended to be inconsistent 
with the principles of the Treaty, then clear language must be used.825 
To appreciate the principles of the Treaty and the relationship of modern legislation with the Treaty, 
it is necessary to briefly consider the history of the Treaty of Waitangi. 
8.2.1 A history of the Treaty 
The Treaty was drafted and signed by many key stakeholders in 1840.  On the behest of Lieutenant-
Governor William Hobson, James Busby and others drafted the original English version of the Treaty, 
which was subsequently translated into Māori by missionaries Henry and Edward Williams.826  Herein 
lie many of the ensuing problems with the Treaty, stemming from a translation which failed to 
construe the same meaning between the English and Māori versions of the Treaty. 
The two versions of the Treaty were available for signature at Waitangi on February 6 1840, then 
travelled throughout the Country,827 collecting the signatures of 500 chiefs.  The Colonial office later 
declared that the Treaty applied to all Māori, regardless of whether they had signed it or not.828   
8.2.2 Article 2 
The following is a recent translation of the Māori text of Article 2 into English, in order to appreciate 
some of the problems arising from the translation, especially insofar as they affect traditional 
medicine.829 
                                                          
825 Legislation Design and Advisory Committee LAC Guidelines 2014 edition: Checklist for officials (online ed, 
LDAC, 16 February 2015); the seven principles which Ministers must have regard insofar as the Treaty of 
Waitangi is concerned are as follows: 
4.1 Māori interests that will be affected by the proposed legislation should be identified.  
4.2 New legislation must not be inconsistent with an existing Treaty settlement.  
4.3 Any land, bodies of water or other resources potentially subject to customary title (or rights), and that 
might be affected by proposed legislation, should be identified.  
4.4 The Government must make informed decisions where legislation will affect, or have the potential to 
affect, the rights and interests of Māori.  
4.5 Consultation must target Māori whose interests are particularly affected.  
4.6 When legislation has the potential to conflict with the rights or interests of Māori under the Treaty, 
additional measures should be considered to ensure recognition of the principles of the Treaty or the 
particular rights concerned.  
4.7 Clear language is required where legislation is intended to be inconsistent with the principles of the 
Treaty. 
826 Ministry for Culture and Heritage “The Treaty in brief” (17 May 2017) NZ History <www.nzhistory.govt.nz/>. 
827 There were eight further copies of the Treaty upon which a total of 500 chief’s signatures were collected. 
828 Ministry for Culture and Heritage, above n 826. 
829  Waitangi Tribunal “Translation of the te reo Māori text” (19 September 2016) 




The Queen of England agrees to protect the chiefs, the subtribes and all the people of New 
Zealand in the unqualified exercise of their chieftainship over their lands, villages and all their 
treasures. But on the other hand the Chiefs of the Confederation and all the Chiefs will sell land 
to the Queen at a price agreed to by the person owning it and by the person buying it (the latter 
being) appointed by the Queen as her purchase agent. 
Two major problems arose from the translation and the promises made to Māori at Waitangi that are 
relevant to this discussion; namely the principles of sovereignty and full authority over taonga, or 
treasures.830  Where the English version of the Treaty notes cession of sovereignty to the Crown,831 
the Māori version used the term kawanatanga, which is more akin to British governance over their 
land while they could maintain sovereignty.832   Similarly, the original English version833  promised 
Māori ‘full, exclusive and undisturbed possession’ over their lands, forests, fisheries and other goods, 
while the Māori version of the Treaty promised tino rangatiratanga over taonga,834 which is generally 
considered to be full authority over all their treasures, tangible or intangible.835  The level of protection 
guaranteed under the Treaty to rongoā, as taonga, is therefore unclear. 
8.2.3 The Treaty & CAM product legislation 
The use of rongoā in NZ has something of a torrid history.  Many years prior to the DSRs, the Tohunga 
Suppression Act prohibited the practise of rongoā at risk of fine or imprisonment.836  Nine convictions 
occurred under the Act,837 before its repeal in 1962.838 
                                                          
830  Taonga is defined as “property, goods, possession, effects, object” and more specifically, as “treasure, 
anything prized - applied to anything considered to be of value including socially or culturally valuable objects, 
resources, phenomenon, ideas and techniques”; Māori Dictionary “Taonga” (2017) 
<www.maoridictionary.co.nz/>. 
831 Ministry for Culture and Heritage “Read the Treaty” (1 February 2017) <www.nzhistory.govt.nz/>; at Article 
1: 
“The Chiefs of the Confederation of the United Tribes of New Zealand and the separate and independent Chiefs 
who have not become members of the Confederation cede to Her Majesty the Queen of England absolutely and 
without reservation all the rights and powers of Sovereignty which the said Confederation or Individual Chiefs 
respectively exercise or possess, or may be supposed to exercise or to possess over their respective Territories 
as the sole sovereigns thereof.” 
832 Waitangi Treaty Grounds “Explore the Treaty” (2017) <www.waitangi.org.nz/>. 
833 Ministry for Culture and Heritage, above n 831; at Article 2: 
“Her Majesty the Queen of England confirms and guarantees to the Chiefs and Tribes of New Zealand and to the 
respective families and individuals thereof the full exclusive and undisturbed possession of their Lands and 
Estates Forests Fisheries and other properties which they may collectively or individually possess so long as it is 
their wish and desire to retain the same in their possession; but the Chiefs of the United Tribes and the individual 
Chiefs yield to Her Majesty the exclusive right of Preemption over such lands as the proprietors thereof may be 
disposed to alienate at such prices as may be agreed upon between the respective Proprietors and persons 
appointed by Her Majesty to treat with them in that behalf.” 
834 Ministry for Culture and Heritage, above n 826. 
835 Māori Dictionary, above n 830. 
836 Tohunga Suppression Act 1907. 
837 Māmari Stephens “A Return to the Tohunga Suppression Act 1907” (2001) 32(2) VUWLR 437, at 459. 




Despite the DSRs not referencing rongoā, the MoH has increased its support for this practice, with 19 
rongoā practitioners currently funded across NZ,839 and the collaborative development of a set of 
standards for the provision of Rongoā healthcare. 840   If concerns were raised about claims or 
advertising of a rongoā product under the current legislation, it is likely rongoā would be handled as a 
herbal medicine or related product under the MA. 
As mentioned in Chapter 5, the NHSPB avoided mentioning the Treaty, or regulating rongoā; aside 
from its avoidance to regulate any kind of practitioner who dispenses CAM products.841  Consequently, 
it was unlikely that much would have changed with respect to the regulation of rongoā under the 
NHSPB, unless rongoā products were to be manufactured in a commercial capacity, resulting in the 
likely application of the NHSPB as it would have applied to any other CAM product.842 
8.3 Wai 262: The Flora & Fauna Case 
The Waitangi Tribunal was created by the Treaty of Waitangi Act 1975 to investigate breaches of the 
Treaty of Waitangi.  The two hundred and sixty-second claim to the Waitangi Tribunal has been 
described as the most important claim the Tribunal has ever considered,843 as well as one of the most 
complex.844  Brought to the Tribunal in 1991, the claim took 20 years to be completed and the report 
detailing its recommendations was released in 2011.  Despite six years passing since the release of the 
findings of the Waitangi Tribunal in Wai 262, the government has still not made a formal response to 
the report or its recommendations, and at the time of writing, no indication was available that the 
‘whole-of-government’ response will ever be forthcoming.845 
                                                          
839 Ministry of Health, above n 21. 
840 Ministry of Health Tikanga ā-Rongoā (Ministry of Health, online ed, Wellington, 2014). 
841 Natural Health and Supplementary Products Bill 2011 (324-2), s13A(a); “Natural health and supplementary 
products that do not require product notification 
Section 13 does not apply to- 
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exclusion of rongoā Māori from the Bill, going further to agree that were rongoā products to be commercially 
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843 Toby Mills “Wai 262” (Film, 2006) online, New Zealand <www.nzonscreen.com/>, David Williams, at 4:55. 
844  Waitangi Tribunal “Ko Aotearoa Tēnei: Report on the Wai 262 Claim Released” (2 July 2011) 
<www.waitangitribunal.govt.nz/>. 
845 See discussions in Barbara Sullivan and Lynell Tuffery-Huria “New Zealand: Wai 262 report and after” (2014) 
9(5) Journal of Intellectual Property Law & Practice 403, at 407; Radio New Zealand “WAI 262 response 
disappointing - Te Rarawa” Radio New Zealand (online ed, New Zealand, 18 June 2013); Lee Taylor Māori Affairs: 




Ko Aotearoa Tēnei, which translates as ‘This is New Zealand’ is the Wai 262 Report,846 and contains 
wide ranging findings which concern Māori intellectual property rights,847 rights to the conservation 
estate, the place of Rongoā Māori in New Zealand,848 and much in-between.  Following an explanation 
of the Tribunal itself and the background to the Wai 262 claim, this section briefly considers the 
recommendations in chapter 7 of the Report insofar as it pertains to rongoā in NZ. 
8.3.1 The Waitangi Tribunal 
The Waitangi Tribunal was created by the Treaty of Waitangi Act 1975 as a permanent commission of 
inquiry to investigate breaches of the Treaty dating back to 1840.849  The Tribunal comprises 20 
members, the Chairperson at the time of the Wai 262 Report being Chief Judge Williams.850  The 
Tribunal may only make recommendations based upon claims brought before it, and these are not 
binding unless explicitly endorsed by the Courts of New Zealand or implemented by Parliament. 
8.3.2 Background to the Wai 262 claim 
While on paper the initial claim listed seven plant and animal species,851 the catalyst for the Wai 262 
claim is widely seen to be the sale of ancient, native kumara tubers by a Government science 
department to a research institute in Japan in the late 1980s.852  This led to the six original claimants853 
from six iwi854 drafting and bringing the claim to the Waitangi Tribunal on 9 October 1991.  Due to a 
variety of matters, the final report was not released until nearly 20 years later, on 2 July 2011.855 
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850 Waitangi Tribunal “Members of the Waitangi Tribunal” (29 March 2017) <www.waitangitribunal.govt.nz/>. 
851 These were: Kumara, Pohutkawa, Koromiko, Puwananga, Pupu harakeke, Tuatara and Kereru, as well as all 
the indigenous forests of Aotearoa; Oliver Sutherland, Murray Parsons and Moana Jackson “The Background to 
WAI 262” (11, June 2011) online, <www.wai262.weebly.com/>, at 6. 
852 Mills, above n 843; Sutherland, Parsons and Jackson, above n 851. 
853 Sutherland, Parsons and Jackson, above n 851, at 4; the original six claimants were Saana Murray, Del 
Wihongi, Witi McMath, Tama Poata, Kataraina Rimene, and John Hippolite. 
854 At 9; the six original tribes the claimants represented were; Te Rarawa, Ngāti Wai, Ngāti Kurī, Kahungunu, Te-
Whanau-o-Ruataupare/Ngāti Porou, and Ngāti Kōata. 
855  David V. Williams “Ko Aotearoa Tenei: Law and Policy Affecting Maori Culture and Identity” (2013) 20 
International Journal of Cultural Property 311, at 321; Waitangi Tribunal Ko Aotearoa Tēnei - Factsheet 2: 




The claim is widely referred to by its number in the queue of Waitangi Tribunal claims; Wai 262.  
However, it is also known as the Flora and Fauna claim.856 Importantly, two key themes pervade the 
entire report.  The first is the encompassing concept that the report as a whole addresses the place of 
mātauranga Māori in contemporary New Zealand.857   
Mātauranga Māori includes language, science and technology, laws, history, systems of 
property and value exchange, and rituals and ceremonies.  It also includes forms of expression 
and art forms… But, more fundamentally, it incorporates core Māori cultural values… 
For the purposes of this discussion, the most important ‘core Māori cultural value’, and the second 
pervasive concept is that of “…kaitiakitanga, or cultural guardianship – the system of law through which 
iwi and hapū are obliged to nurture and care for taonga.”858 
8.3.3 Chapter 7 Ko Aotearoa Tēnei – Rongoā Māori 
Chapter seven is unique in that it is the only chapter in the Report which not only looks on historical 
matters where the findings generally avoid this, but it is the singular occasion where an historical 
grievance is considered in Ko Aotearoa Tēnei; namely the Tohunga Suppression Act 1907.859 
Three recommendations can be crystallised from the Report in relation to rongoā.860  Firstly, the 
Report recommends recognition of the important role of holism in rongoā, with a view beyond efficacy 
to consider not only the quantifiable medical outcomes, but also its role in mental health and lifestyle 
choices more broadly.861  Secondly, a number of points are raised surrounding funding and support 
for rongoā services within the NZ health sector.862  This includes the development of rongoā policies 
between the MoH and other relevant Government agencies like the Department of Conservation, to 
ensure tohunga have access to rongoā rākau.863  The third recommendation from the Wai 262 Report 
was for the collection of empirical data on usage of services and the extent of demand.864  Cost-benefit 
analyses tend to indicate the cost of funding such healthcare is seriously outweighed by the savings 
                                                          
856 This is despite its eventual scope being much broader than merely flora and fauna, with chapters extending 
to the place of Te Reo Māori in New Zealand, and the need to comply with the Treaty principles when agreeing 
to international treaties; Waitangi Tribunal, above n 847, at Chapters 5 & 7. 
857 Waitangi Tribunal Ko Aotearoa Tēnei - Factsheet 1: Key Themes (Wai 262, online, 2011), at 1. 
858 At 1. 
859 Williams, above n 855, at 321. 
860 Waitangi Tribunal, above n 847, at 226-228. 
861 It is generally well recognised that Māori health is at a crisis point.  The Report notes the significantly higher 
rates in Māori than non-Māori of: heart disease, strokes, lung cancer, diabetes, asthma, infant mortality, 
meningococcal disease, schizophrenia, suicide, motor vehicle accident deaths, interpersonal violence, obesity 
and many other illnesses; at 221-222. 
862 At 226-228. 
863 At 228. 




made through freeing critical health services and increases in productivity, and this recommendation 
recognises the need for such data to both justify investment in rongoā, as well as determine 
appropriate levels for such expenditure.865 
While it is difficult to ascertain a shift in perspective by a government agency like the MoH towards a 
system of care like rongoā, the lack of any novel progress since the Report would tend to indicate that 
little attention has been paid to this recommendation.  Progress on updating and supporting rongoā 
services has been ongoing, however when this is viewed in light of the fact that these have been 
underway well prior to the Report, it is unlikely that any of the recommendations around this matter 
have been effected.  In 2006, the MoH released a development plan to “…provide a framework for 
strengthening the provision of quality rongoā services throughout Aotearoa.”866  Following this, a 
national body for the provision of rongoā – Te Paepae Matua was launched in 2008,867 and in 2011, 
Te Kāhui Rongoā trust for the ‘protection, nurture and promotion’ of rongoā was created.868  In 2014, 
new standards were released for the first time in 15 years governing the provision of rongoā.869  None 
of these developments appear to have been effected by Wai 262, and in 2011 Ko Aotearoa Tēnei was 
critical of these efforts, noting:870 
…there is no sense of abiding energy or purpose about the Crown’s actions.  Its support for 
rongoā has been consistently punctuated by delays…  It cannot exert any influence over the 
[district health boards] to contract more services.  In 2004, it even took the regressive step of 
curtailing the funding of rākau rongoā.  In the meantime, of course, Maori health problems 
have festered.  The Ministry of Health seems to have lacked the imagination or conviction to 
engineer a genuine breakthrough or the ability to see the contradiction in its priorities. 
Finally, there is no evidence for increased empirical research into the provision or use of rongoā Māori.  
While there appears to have been preliminary research carried in the wake of the development plan, 
this too appears to have faltered, and there appears to be no substantive progress on this 
recommendation. 
8.3.4 Other recommendations 
One of the other major recommendations of the Report was for the establishment of a Māori advisory 
committee to provide binding advice to the Commissioner of Patents871 in a similar manner to the pre-
                                                          
865 At 225-226. 
866 Ministry of Health Taonga Tuku Iho - Treasures of our Heritage: Ronogā Development Plan (Ministry of Health, 
Wellington, June 2006), at 1. 
867 Mita Ririnui “Te Paepae Matua mo te Rongoa, Rongoa National Body launced today” (press release, 16 June 
2008). 
868 Ministry of Health, above n 21. 
869 Tariana Turia “New national tikanga standards for rongoā released” (press release, 23 May 2014). 
870 Waitangi Tribunal, above n 847, at 225. 




existing ‘Māori Trade Mark Advisory Committee’ established under the Trade Marks Act 2002. 872 
While the Patents Act 2013 does implement a Māori advisory committee akin to the trade marks 
committee, it has considerably more limited scope than recommended in the Report, and does not 
appear to be a product of the Wai 262 Report.873  Nevertheless, in principle, the operation of a Māori 
advisory committee provides a valuable check on decisions where they involve taonga, highlighting 
the possibility of using the same, or a similar system for CAM products, to protect rongoā and avoid 
its exploitation or unwanted commercialisation, thus upholding the principles of the Treaty. 
8.4 Conclusion 
Given the constitutional importance of the Treaty of Waitangi in NZ, as well as the unique opportunity 
to acknowledge and support rongoā as NZ’s traditional medicine, it is surprising that the NHSPB has 
broadly ignored both of these.  This is perhaps best exemplified in the MoH’s creation of the Te Kāhui 
Rongoā Trust for the protection and development of rongoā in 2011, only for this Trust to be avoided 
in the consultation process for the NHSPB, and for no public regard for their subsequent submission 
on the Bill in 2015.874   
In its brief outline of the Treaty and the Wai 262 Report as it affects rongoā, this Chapter sought to 
acknowledge the fundamental importance of these issues in the development of a novel regulatory 
scheme for the regulation of CAM products.  Consequently, three elements are carried through to the 
ultimate proposal of this thesis in Chapter 12; protection for rongoā, support for rongoā, and the 
promotion of a collaborative approach which regulates CAM products, while maintaining a constant, 
peripheral awareness of the Treaty.  
                                                          
872 Trade Marks Act 2002, s177. 
873 Patents Act 2013, at ss225-228; Sullivan and Tuffery-Huria, above n 845, at 409; “…these amendments [to 
the Patents Act] were proposed before the tribunal’s report, and were purposely delayed to provide the 
government with an opportunity to incorporate any additional points raised by the tribunal.” 





Part III: Addressing the Information Deficit  & Resultant Problems 
9 Public Perceptions on Dietary Supplements: A Pilot Study 
Science begins with counting.  To understand a phenomenon, a scientist must first describe it; 
to describe it objectively, [she or] he must first measure it.875 
9.1 Introduction 
The regulatory impact statement for the NHSPB readily acknowledges that there is little information 
within the government on the scale and nature of the CAM product industry in NZ.  There is also 
minimal recent statistical information on the prevalence of use of CAM products in NZ, or a 
comprehensive picture of the extent of potentially illegal practices within the industry.  The only 
indications of such practices within the regulatory impact statement show a significant issue, with 
“…78 percent of the 263 company websites reviewed [being] non-compliant with the Medicines 
Act…”876 
Needless to say, it seems somewhat counter-intuitive to introduce a Bill to uncover the extent of an 
industry and the associated problems, rather than to invest the resources to address the information 
deficit and legislate in response to identified issues. 
This Chapter will first consider the currently available information on usage and marketing of CAM 
products in NZ, and then discuss and reflect on original empirical work carried out in the course of this 
research.  It will suggest that the prevalence of CAM is much greater than previously thought, and that 
elements of the packaging and labelling are artfully used to either mislead consumers, or at least 
confuse them as to the identity and efficacy of CAM products. 
9.1.1 Background 
From a scientific or statistical perspective, there has been a fair amount of research on international 
usage of CAM products or modalities.877  This research indicates a prevalence from 9.8% to 76% of the 
                                                          
875 Siddhartha Mukherjee The Emperor of All Maladies: A Biography of Cancer (Simon & Schuster, New York, 
2010), at 19. 
876 Ministry of Health, above n 3, at 5.  A review of CAM product websites was conducted in March 2007 which 
yielded this data.  This non-compliance is largely due to CAM products displaying therapeutic claims.  At 6; “In a 
subsequent compliance awareness programme, the websites reviewed contained advertisements for over 
12,000 products with just over half of these advertisements including therapeutic claims.  Out of 355 websites 
reviewed as part of this programme, 107 were found to be making high-level claims.” 
877 P. Harris and R. Rees “The prevalence of complementary and alternative medicine use among the general 
population: a systematic review of the literature” (2000)(8) Complementary Therapies in Medicine 88, and 




public using CAM products depending on the country,878 and trends of similar or slightly increasing 
uptake of CAM products where data exists from periodic surveys.879   However, despite systematic 
reviews of this data,880 they bear little direct relevance to NZ given a dearth of comparable usage data 
and varying demographics used in those studies.881 
The research conducted in NZ around CAM products is limited.  There are two sources of reputable 
data worth considering; a peer reviewed article on DS prevalence in NZ, and representative research 
conducted by UMR Research – a market research company. 
The only NZ article on prevalence of DS use collates material from two national studies which used 
personal interviews to collect information; 882  the 1997 National Nutrition Survey, and the 2002 
Children’s Nutrition Survey.883  The 1997 survey is most important here, as it is the only data which 
provides a benchmark for the current prevalence research, however, the 1997 survey considered all 
‘adults’ aged 15 years and older, which makes it difficult to directly compare those results with the 
present research.  In that survey, participants were questioned on DS consumption in the last 24-hours 
                                                          
Bulletin of the World Health Organization 252; these two systematic reviews summarise the majority of the 
prevalence studies prior to 2000.  Since then notable research includes an Australian study in 2005, Charlie Xue 
and others “Complementary and Alternative Medicine Use in Australia: A national population-based survey” 
(2007) 13(6) Journal of Alternative and Complementary Medicine 643, and an update to the earlier paper by 
Harris et al. in 2012; P. Harris and others “Prevalence of complementary and alternative medicine (CAM) use by 
the general population: a systematic review and update” (2012) 66(10) International Journal of Clinical Practice 
924. 
878 Harris and others, above n 877, at 930. 
879 At 930. 
880 Harris and others, above n 877; Ernst, above n 877. 
881 In the meta-analysis in Harris and Rees, above n 877, there are a wide variety of studies used with age ranges 
from all ages, to ≥15, 15-64, ≥18, or 45-75.  There is more control on age ranges in the second systematic analysis 
by Harris et al, Harris and others, above n 877, with the majority being 18 or older.  More problematic is the 
definition of ‘CAM’ and its scope in these surveys.  Most studies considered in Ernst, above n 877, and Harris 
and others, above n 877, specify anywhere between one and 36 CAM products or therapies considered in the 
study.  Consequently, it is difficult to contrast these with the NZ study which has focused solely on dietary 
supplements in children aged 5-14 and adults aged 15+, Winsome R. Parnell, Noela C. Wilson and Claire Smith 
“Dietary supplements: Prevalence of use in the New Zealand population” (2006)(63) Nutrition & Dietetics 199, 
or the current study, which considers adults aged 18+ and refrains from a limited list of CAM products, instead 
opting for the all-encompassing terms ‘dietary supplement’ or ‘complementary and alternative medicine 
products’. 
882 Parnell, Wilson and Smith, above n 881; this study involved secondary analysis of two earlier surveys; the 
1997 National Nutrition Survey which was a “voluntary cross-sectional survey of New Zealanders aged 15 years 
and above” (at 200) and contained 4636 participants, while the 2002 Children’s Nutrition Survey was the same 
style survey, but instead, of children aged 5-14 years with 3275 participants.  The 1997 survey data quoted herein 
was performed at a 95% confidence interval with a P-value <0.0001. 




and the last year.884  The results from the survey showed 59% of adults (from a sample of 4626 people) 
had consumed at least one DS in the previous year.885 
In 2011, UMR Research conducted a representative study of 1000 NZers entitled ‘What do New 
Zealanders believe?’886  Two questions touched on CAM, with both asking participants to rank how 
strongly they believed in a statement on an eight point scale from ‘absolutely certain it’s true’ to 
‘absolutely certain it’s not true’.887  The first statement was ‘That arnica reduces bruising’, which 72% 
of people believed,888 correlating to the top four categories on the eight-point scale; “absolutely 
certain it’s true”, “fairly certain it’s true”, “believe it but not too certain”, and “believe it but not at all 
certain”.  The second statement was that ‘homeopathic remedies are scientifically proven to work’, 
with 51% believing this statement, correlating with the same four categories as for the first 
statement.889   Their second study in 2015 looked at NZ science beliefs, 890  asking people to rank 
statements on a five point scale;891 with 52% of people agreeing vitamin supplements are a proven 
way of making people healthier,892 and 51% agreeing that natural, alternative, holistic health care 
therapies should have an equal place with conventional western medicine.893  Agreement in this study 
                                                          
884 At 200; In that survey, ‘dietary supplements were defined as including “vitamin and mineral supplements … 
and non-vitamin and mineral supplements, including herbal supplements, sports preparations and garlic 
powders.” 
885 At 200. 
886 UMR Research Part 2: December 2011 (alternative remedies) (December 2011); this survey was Part 2 of a 
multi-part series considering New Zealanders beliefs.  This part exclusively considered alternative remedies 
while Part 1 looked at New Zealanders’ religious beliefs and their beliefs in paranormal events, and future parts 
were set to look at beliefs around Māori culture and climate change. 
887 At 5-6. 
888  At 5; Arnica is almost exclusively used as a homeopathic preparation derived from the flowers of the 
herbaceous plant Arnica montana.  While in theory an undiluted form of the plant could be used, this is very 
rare, in part due to its toxicity from the presence of Helenalin which causes skin irritation and can cause 
gastrointestinal discomfort and bleeding if taken internally.  Consequently, the form of Arnica widely available 
in pharmacies, health stores and online is the homeopathic variety, which double-blind, placebo-controlled, 
randomised clinical studies and systematic reviews have demonstrated to be no more effective than a placebo; 
C. Stevinson and others “Homeopathic arnica for prevention of pain and bruising: randomized placebo-
controlled trial in hand surgery” (2003) 96 Journal of the Royal Society of Medicine 60, E. Ernst and MH. Pittler 
“Efficacy of Homeopathic Arnica: A Systematic Review of Placebo-Controlled Clinical Trials” (1998) 133(11) 
Archives of Surgery 1187. 
889 At 6. 
890 UMR Research Science Beliefs (September 2015); this study was part of a broader ‘New Zealand Insight’ study, 
of which one part focused on New Zealanders’ science beliefs.  The questions in this part were generally broad, 
ranging from climate change, immunisation, fluoride in water, evolution and more. 
891 The five points on the scale were; ‘strongly agree’, ‘somewhat agree’, ‘unsure’, ‘somewhat disagree’ and 
‘strongly disagree’. 
892 At ‘Alternative Health’. 
893 At ‘Alternative Health’; these answers are the UMR totals from the two ‘agree’ points on the five point scale 




included “strongly agree”, and “somewhat agree”, while those who were “unsure” were not included 
in the total ‘agreeing’ or ‘disagreeing’ with the statements. 
9.1.2 The purpose of the pilot study 
This research attempts to collect empirical information to provide a foundation for the design of 
legislation which takes account of current and potential problems.  Any effort to attain the necessary 
data to uncover the problems in need of attention would require a multi-disciplinary sciento-legal 
approach which considers matters ranging from usage, efficacy, and safety through to the marketing 
of CAM products and whether they directly or implicitly exhibit misleading or deceptive conduct with 
respect to their efficacy, safety or other matters.  As such, this study begins the process of gathering 
data on the prevalence of use of CAM products, as well as conducting a survey to assess the effect of 
TCs, DS labels, packaging, environment of sale and other matters associated with CAM products, as 
well as ascertaining which factors are most influential upon consumers.  
There is little information on the legal effect of the marketing of CAM products or factors affecting 
consumer perceptions and decision making.  As noted at 7.3.2, there is a history of FTA surveys, which 
have generally been used to aid in determining whether conduct is misleading or deceptive.894  More 
specifically, the survey in Aneheuser-Busch v Budweiser Budvar895 showed participants product images 
for 30-seconds, followed by a series of questions on the products they had just seen in order to assess 
consumer perceptions; a strategy of substantial value in collecting generalised data on consumer 
perceptions.896 
                                                          
894 See Levi Strauss & Co v Kimbyr Investments Ltd, above n 663, Commerce Commission v Griffins Foods Ltd 
[1997] DCR 797 (DC), and Cookie Time Ltd v Griffins Foods Ltd, above n 664. 
895 Anheuser-Busch Inc v Budweiser Budvar National Corp, above n 664. 
896 In the survey referred to in this case, 511 participants were shown three bottles of beer for 30 seconds, one 
being Budvar.  The survey questions went on, in a somewhat leading fashion, if they had recalled something 
similar to ‘Budweiser’ to ask whether the expected an association with Budweiser due to the name.  In this case, 
Doogue J had two problems with the survey.  Firstly, he saw that the questioning was leading, and secondly, that 
“the survey was as far removed from a practical purchasing situation as the presence of a number of bottles 
before me in the courtroom.”  This second issue was largely due to participants being shown a single bottle, 
rather than the 4-pack or 6-pack that Budvar or Budweiser respectively were packaged with in a supermarket.  
These problems are not endemic to this kind of study (a limited-time exposure study), but rather were foibles 
of the Budweiser case, and as such, the value of this type of study in the presence instance is not diminished.  As 
an aside, the survey in Budweiser was still admissible, however its probative value was somewhat lessened due 
to the quality of the survey – an assessment the court makes on the evidence.  Trotman and Wilson, above n 




9.2 The Pilot Study: Methods 
9.2.1 Sample & study design 
This study consisted of an empirical legal questionnaire of NZ university students 897  on their 
perceptions of CAM products, alongside those of food and medicines.898  The study utilised both 
qualitative and quantitative questions coupled with time-limited exposure to CAM products on sale in 
NZ to test the effect of the marketing, and specifically TCs upon consumers.  
9.2.2 Data collection899 
The questionnaire was distributed entirely through the online survey platform Qualtrics. 900  
Respondents were provided with the web address for the survey and subsequently anonymously 
completed the survey online. 
The survey went live on 5 September 2016 and remained open for three weeks.  Participants were 
recruited through social media, e-mails and short presentations in lectures at the University of 
Canterbury.  In total, 535 partial or fully completed responses were returned by the end of the survey 
period, however, when the responses were limited to students, there were 426 useable surveys, with 
the other 109 comprising non-students or submissions where no questions had been answered.  This 
student demographic was selected as it comprised the largest commonality between respondents, 
and made the survey slightly more representative of a subset of society. 
Given the selection of respondents to those who identified as ‘students’ when asked about their 
primary occupation,901 it is unsurprising that 84% of respondents were aged 18-24, while 10.3% were 
25-34 years old.  The female to male response rate was slightly skewed at 66.1% to 31.1% respectively, 
but this may be indicative of both the marketing of the survey, and a gender-linked interest to the 
subject matter.  The ethnicity of respondents followed expected trends, with 69.7% NZ 
                                                          
897 While this study was primarily conducted at the University of Canterbury, there was no identification of the 
tertiary institution with which participants were associated if they selected ‘student’ as their occupation. 
898 Empirical legal research or empirical legal studies (ELS) is a relatively novel field of legal research which 
employs both quantitative and qualitative data either instead of, or in association with traditional legal analyses 
in order to more readily inform decision making and to determine the effects of legal and regulatory 
undertakings.  See Peter Cane and Herbert M. Kritzer (eds) The Oxford Handbook of Empirical Legal Research 
(Oxford University Press, Oxford, 2010) for the authoritative exposition on ELS, and see Marie M. Bismark 
“Learning from claims and complaints: an epidemiological approach to medical regulation” (Doctor of Medicine 
collection of works, University of Otago, 2015) for the application of ELS in a medico-legal context. 
899 This study received approval from the University of Canterbury Human Ethics Committee on 5 August 2016 
(approval reference HEC 2016/37/LR), see Appendix 1. 
900 Qualtrics “Qualtrics Software” (Computer Software, 2005) online <www.qualtrics.com>, used under licence 
to the University of Canterbury. 




European/Pākehā, 12.2% Asian, and 4.5% Māori respondents.  Both education history and income 
aligned with the student demographic, with the majority having a high-school education (69.1%), and 
earning less than $10,000 annually (68.6%). 
9.2.3 Questionnaire design902 
In designing the questionnaire, several factors were brought together from other cases, surveys and 
reports on the best strategy for conducting a study of this nature.903  Given the multidisciplinary nature 
of the subject area, international studies on similar issues come from a variety of backgrounds, ranging 
from epidemiological and public health backgrounds, through to private research companies 
conducting such studies under contract to governments.  The element of difference here is the focus 
on a sciento-legal study which endeavours to amalgamate sound empirical data collection with an FTA 
style study, which tests marketing or sub-conscious influences on the reasonable consumer. 
In order to combine these disparate elements, parts of the study were purely quantitative, in order to 
assess CAM or evidenced-based medicine usage in the style of international studies on these 
questions.  In contrast, other parts merged quantitative and qualitative questions in the FTA-style 
test,904 where three of six products were randomly shown to a participant for 30 seconds, followed by 
a series of questions.  This sought to determine the factors which influence consumer decision making, 
with a focus on four key elements: TCs, packaging, DS label, and name recognition. 
The remainder of the questionnaire employed a mix of questions to either expand upon, or provide a 
check to previous questions.  This also allowed inclusion of further questions on tangential issues like 
the environment of sale, and people’s behavioural responses to minor illness, or a desire for better 
health; all issues where the results indicate scope for further study. 
9.2.4 Data analysis 
The responses from 109 participants who did not identify as ‘students’ were discarded.  Both 
completed and partially-completed questionnaires were utilised, insofar as the questions they 
answered. 
Analysis of the data and statistical parameters905  was aided by consultation with health-sciences 
statistician, Pat Coope.  The majority of the data was analysed using Qualtrics, although qualitative 
                                                          
902 See full survey at Appendix 2. 
903 See material previously discussed on Empirical Legal Research at fn 898, the FTA style survey in Anheuser-
Busch Inc v Budweiser Budvar National Corp, above n 664, as discussed at fn 896, and the three systematic 
reviews of CAM prevalence studies at fn 877. 
904 See 9.2.1. 




data were processed using NVivo 11.906  There was no weighting applied to the reported data as 
precise demographic information for the student cohort was difficult to obtain, and it is recognised 
that the data were also not representative of the student population.907 
9.2.5 Statistics 
A normal distribution is used throughout the analysis to determine the probability of a particular 
response in the general population, and importantly to calculate the margin of error on the reported 
results. 
As such, the margin of error is reported on the data as presented throughout the results,908 based on 
a normal distribution at a 95% confidence level.  The overall standard error of the survey is ±4.75%.  
Unless otherwise noted, all the figures in these results have been rounded to one decimal place. 
9.2.6 Study limitations 
Despite the lack of representativeness, the data merely provides a snapshot of a subset of society and 
their behaviour with respect to CAM products, which is further built upon in the second questionnaire 
study in Chapter 10.   
There were also a couple of other issues which arose throughout the survey, which may have resulted 
in lower accuracy than initially desired.  These issues include the overall length of the survey, 
occasional confusion regarding the expectations of questions or implied definitions, and one particular 
logical inconsistency. 
These issues were minor, and few anomalies were evident from their presence, except for a higher 
than anticipated level of atrophy due to the survey length.  Consequently, only one issue was expressly 
corrected for.909  
                                                          
906 QSR International “NVivo 11 Qualitative Data Analysis” (Computer Software, 2015) online, used under licence 
to the University of Canterbury. 
907  There were a number of indicators that the data were not representative.  John Gerritsen “Female 
enrolments fall at Canterbury University” Radio New Zealand (New Zealand, 18 August 2016) demonstrated that 
female enrolments comprised 49.6% FTE students at the University of Canterbury in 2015; a proportion not 
reflected in the Pilot Study.  An additional complicating matter was somewhat targeted recruitment, which 
favoured students who were likely to take an interest in the research being conducted.  Recruitment was 
directed most heavily towards Law subjects, followed by Psychology, and Chemistry/Biochemistry, which in 
contrast to typical STEM subjects, generally show a higher proportion of women. 
908 See 9.3.  
909 Questions 26 and 29 were removed from analysis due to a logical inconsistency.  These two questions 
implicitly expected participants to put themselves in the shoes of someone looking to purchase the product they 
had just viewed.  This presumption was not immediately apparent to participants, yielding answers which 




9.3 Results & Discussion 
The results in the following section are presented alongside the discussion on their implications.  There 
are three parts to this section; the first on general perceptions and the usage of medicines and CAM 
products, followed by the analysis of the six products and people’s perceptions around them, and 
finally, a brief consideration of the impact of the environment of sale.  
9.3.1 General perceptions and prevalence 
When participants were questioned on their practical response to a minor illness or a desire to 
increase immunity at questions 7 and 8, their answers showed a similar approach to both matters, as 
seen in Table 9.1.  However, when seeking to increase immunity, respondents were more likely to 
take another action entirely, as evidenced by a heightened selection of  ‘Something else/other’, with 
common responses including changing eating or exercise habits. 
 
 
Minor Illness (%) 
Question 7 
Increase Immunity (%) 
Question 8 
Self-medicate 51.9±4.8 46.4±4.8 
Do nothing 28.9±4.4 17.3±3.6 
See a doctor 16.4±3.6 17.8±3.7 
Something else/other 1.9±1.3 11.8±3.1 
See a natural health practitioner 1.0±0.9 6.3±2.4 
Table 9.1: Survey 1 - Results to Questions 7 & 8 - Responses to minor illness or desire to increase general immunity 






Non-Prescribed Medicines (%) 
Question 9 
CAM Products (%) 
Question 10 
Daily 6.3±2.3 26.3±4.2 
Weekly 13.0±3.2 14.5±3.4 
2-3 times per month 12.7±3.2 8.0±2.6 
1-2 times per month 16.1±3.5 5.1±2.1 
1-2 times per 6 months 14.7±3.4 5.8±2.3 
1-2 times per year 11.3±3.0 6.3±2.3 
Less frequently 12.0±3.1 10.6±3.0 
Never 13.9±3.3 23.6±4.1 
Table 9.2: Survey 1 - Results to Questions 9 & 10 - Responses on frequency of consumption of non-prescribed medicines 
and CAM products 




Questions 9 and 10 studied how frequently respondents consumed either medicines or CAM products, 
with the ensuing results in Table 9.2 being one of the primary reasons for conducting this research.  
There was no comprehensive data on NZers usage of CAM products, and while the information below 
only informs about usage in the surveyed student demograph, it provides an enlightening illustration 
of how a generally low-income,910 well-educated911 sector of society use general sale medicines and 
CAM products.  
The general trends in Figure 9.3 show that while a greater number of people have consumed non-
prescribed medicines in the past (86.1±3.3%) than CAM products (76.4±4.1%), the frequency at which 
people consume CAM products is significantly higher than that for medicines.  This would tend to 
support the hypothesis that people take CAM products more readily for prophylaxis, whereas 
medicines tend to be consumed as a treatment in the event of illness.  
                                                          
910 68.5% of respondents earned less than $10,000, while 18.7% earned $10,000-$19,999. 
911  69.1% of respondents listed ‘High School’ as their highest level of education, with 15.6% holding an 



































Questions 9 & 10 - How often do you take (a) non-prescribed 
medicines, (b) CAM products?
Medicine usage CAM product usage




Questions 11-14 turned from quantitative to qualitative, and asked participants to define food, 
medicines and DSs, and then how they distinguished between the three.  The responses to these 
questions only offer basic themes as depicted in the word clouds (Figure 9.5-Figure 9.8), but 
nevertheless provide an insight into respondents’ views of these products.  It is important to note that 
while the larger words appear to dominate the word-clouds, they only account for a maximum of 
approximately 9% weighted frequency.  




Unsurprisingly, food was generally viewed as ‘something which you eat that gives you energy’.  When 
people delved deeper into this definition, the purpose of eating or justifications for doing so became 
important, with prominent terms like ‘energy’, ‘nutrients’, ‘sustenance’ and ‘hunger’. 
A similar approach was taken for medicine, with people divided into two groups; either those that 
defined it for its curative properties in treating illness, or those who saw it as a means to return to 
normality or improved health.  This was exemplified in the heightened frequency of words like ‘illness’, 
‘help’, ‘better’, ‘cure’ and ‘health’. 
Figure 9.5: Word cloud for Question 11 - definition of food 




In defining DSs, there was much less cohesion between answers; however, the common theme which 
arose was an inclination to disambiguate ‘dietary supplements’ by separating the words into its 
morphemes and defining it as such: for example ‘things which supplement your diet’.  A number of 
people also took the opportunity to define DSs by some of the products under this umbrella, like 
‘vitamins’ and ‘minerals’, with a surprising prominence of ‘food’ in this word cloud too. 
When considering the differences between the previous three categories in question 14, the word 
cloud becomes less informative.  However, a review of the responses to this question shows 
something of a pattern.  While the question asked respondents how they differentiated between 
these products in practice, responses instead focused on the relative necessity of these products; 
Figure 9.7: Word cloud for Question 13 - definition of dietary supplement 




namely that food was a necessity for survival, medicines were only needed when a person was sick, 
and DSs were either unnecessary or a means of correcting a deficiency.   







Dietary Supplement (%) 
Question 17 
Labelling or Packaging 65.4±5.0 83.4±3.9 89.5±3.2 
Place of purchase or 
location within shop 
49.1±5.3 50.9±5.3 42.4±5.2 
Familiarity/brand 
recognition 
57.3±5.2 43.3±5.2 36.1±5.1 
Appearance 59.6±5.2 28.2±4.8 20.4±4.3 
Other 8.1±2.9 9.0±3.0 4.7±2.2 
Table 9.3: Survey 1 - Results to Questions 15-17 - Factors used in identification of food, medicines and dietary 
supplements 
Questions 15-17 were a quantitative corollary to questions 11-14; asking participants to select up to 
five factors which they used in identifying food, medicines or DSs.  The trends in their responses can 
be immediately seen in Table 9.3, with the four main factors being comparable in the case of food, 
but increasingly distinct for medicine and DS identification.  This suggests that the labelling and 
packaging become increasingly important as consumers become less certain of the identity of the 
product.  When the goods cannot be immediately recognised as a food from their appearance or a 
familiarity with the goods, then consumers look instead at how it is packaged, and what is displayed 
on the packaging to identify the goods, and in all likelihood the effect of medicine or DS. 






As mentioned earlier, identifying people’s perceptions in relation to six products was one of the 
primary goals of this study. 912   This section focuses on the results from those questions and a 
preliminary discussion, before delving more deeply into a theory on the public’s classification of CAM 
and medicinal products based upon these results at 9.3.3.  
 
 
Three questions warrant discussion here; questions 27, 28 and 30.913  Question 27 takes a qualitative 
approach, asking participants what they think the benefits of taking the product will be, while 
questions 28 and 30 are quantitative, and ask respondents to identify the product and rate how 
effective it will be at therapeutic purposes respectively.   
Six products were shown to participants; Probiotics IBS Support, Advil, Olive Leaf, Arnica, Folic Acid, 
and Ultivite.  Probiotics IBS Support is a listed therapeutic good in Australia and likely a DS in NZ despite 
not being correctly labelled.  It allegedly comprises billions of ‘good’ bacteria, and claims to offer relief 
from the symptoms of Irritable Bowel Syndrome.914  Advil is an NSAID containing ibuprofen and thus  
                                                          
912 See 9.2.1 and 9.2.3. 
913 See 9.2.6 on why questions 26 and 29 will not be discussed. 
914 See Figure 9.12: Probiotics IBS Support. 
Figure 9.10: Survey 1 - Questions 27 & 28 








Figure 9.12: Probiotics IBS 
Support 
Figure 9.13: Advil 
Figure 9.15: Arnica 6x 
Drops 
Figure 9.14: Olive Leaf 
3500 




a medicine, and is included as a control to the CAM products.915  Olive leaf is a herbal remedy, and 
thus a DS, which claims to be effective a relieving cold symptoms and fighting common viral 
infections.916  Arnica is a homeopathic remedy which offers speedy recovery from sports or injury, and 
while strictly a food, could reasonably be considered a DS under current regulations.917    Folic Acid is 
also known as vitamin B9, and while a DS, it has positive effects at reducing likelihood of birth defects 
like spina bifida when taken during pregnancy.918  Finally, Ultivite is a multivitamin aimed at men, 
which falls squarely within the realm of DS, and is intended to supplement mineral, vitamin, and 
antioxidant consumption, or correct deficiencies.919 
Qualitative analysis of the results from question 27 shows one particular trend.    When questioned 
on the benefits of the product, people consistently used the words on the label or derivatives.  While 
the frequency of these words varies significantly from Advil’s ‘pain’  at 26.6%, to  Ultivite’s most 
popular word ‘vitamins’ at 7.8%, a similar pattern is seen across all six products.  Probiotics and Advil 
have eight of the top ten words on the label,920 Folic Acid has six of ten,921 and Olive Leaf has five of 
ten,922 while Arnica and Ultivite show four words on their labels from the top ten used by respondents 
in answering question 27.923 
Question 28 asked participants whether the product they had just viewed was a food, medicine or DS.  
As can be seen from the histogram in Figure 9.18, people identified the majority of these products 
correctly.  Nevertheless, Probiotics, Olive Leaf, and Arnica all display unexpected results; however, 
some background is required to appreciate the potential anomaly.   
                                                          
915 See Figure 9.13: Advil. 
916 See Figure 9.14: Olive Leaf 3500. 
917 See Figure 9.15: Arnica 6x Drops. 
918 See Figure 9.16: Folic Acid. 
919 See Figure 9.17: Men's Ultivite. 
920 Probiotics IBS Support (in descending order of frequency): ‘bowel’, ‘irritable’, ‘syndrome’, ‘IBS’, ‘symptoms’, 
‘relief’, ‘good’ and ‘bacteria’.  Advil (in descending order of frequency): ‘pain’, ‘headaches’, ‘relieves’, ‘fast’, 
‘muscle’, ‘period’, ‘back’, and ‘aches’. 
921 Folic Acid (in descending order of frequency): ‘brain’, ‘development’, ‘nerve’, ‘healthy’, ‘acid’, and ‘folic’. 
922 Olive Leaf (in descending order of frequency): ‘cold’, ‘symptoms’, ‘help’, ‘relieve’, and ‘fight’. 
923 Arnica (in descending order of frequency): ‘injury’, ‘sports’, ‘recovery’, and ‘speedy’.  Ultivite (in descending 





























Question 28 - Identification of Products
Probiotics IBS Advil Olive Leaf Arnica Folic Acid Ultivite




One of the hypotheses which this study sought to test was that TCs, which are required for medicines 
but prohibited for DSs, would consequently cause people to be more inclined to view a product with 
a TC as a medicine.  Given the TC on Olive Leaf, it was expected that there would at least be some 
uncertainty, if not an outright classification of the product as a medicine due to this claim.  However, 
Figure 9.18 clearly shows this is not the case, with the more questionable claims on Probiotics IBS and 
Arnica having a greater effect upon participants’ identification of these products, compared with Olive 
Leaf’s unambiguous identification as a DS.924  The results for Arnica illustrate this particularly well, with 
60.8±7.4% incorrectly identifying it as a medicine, instead of a DS.  While it is probable that Arnica 
does display a weak TC, this demonstrates that TCs are certainly not the only factor which is 
influencing consumer decision making and identification of these products, but rather is likely one of 
a number of factors, as discussed further at 9.3.3. 
Question 30 was also quantitative, but asked people how effective they thought the products would 
be in achieving one of the four therapeutic purposes posited by reg11 DSRs.  Participants were asked 
to select an option for each of the four purposes from a scale of; extremely effective, very effective, 
moderately effective, slightly effective or not effective at all.  The results of one of the four ‘effective’ 
categories are displayed in Figure 9.19, with the remainder comprising the ‘not effective at all’ 
category.  The purpose of this question was generally to assess the impact of TCs on consumers, but 
more specifically, to see whether people noticed the claims, and in the event they did, whether this 
led to them believing that the product would be more effective than if it did not display such a claim.   
                                                          












Curing or alleviating a disease
or ailment
Altering the shape, size or
weight of your body
Interfering with your body's
normal processes















Question 30 - Efficacy of Products at Therapeutic Purposes
Probiotics IBS Advil Olive Leaf Arnica Folic Acid Ultivite





The results in Figure 9.19 provides an interesting comparative picture, but those of Advil, Olive Leaf 
and Ultivite best demonstrate the effects of this question.  Taking the medicine Advil as the first 
example, it can be seen that there is a high level of certainty that the product will cure or alleviate a 
disease or ailment and interfere with the body’s normal processes.  This correlates with the TC on 
Advil which begins “relieves pain fast…”  Advil is seen to be ineffective at the other two purposes, as 
indicated by the substantially lower perceived efficacy.  In a similar vein, Olive Leaf shows a relatively 
high level of perceived efficacy in all categories except for altering the shape of one’s body.    Again, 
this tends to align with the broad TC stated on the packet; “Relieves cold symptoms, Helps fight 
common viral infections”.  On the basis of these two examples, the results appear to indicate that 
people are noticing the TCs, and as a result believe the products will be effective at achieving these 
stated purposes. 
However, it is a different picture when the results from Ultivite are considered.  There is nothing close 
to a TC on the Ultivite packaging, but merely a description of the constituents of the multivitamin and 
the target audience.  Nonetheless, participants have responded to question 30 that Ultivite will be at 
least somewhat effective at all four of the therapeutic purposes.  This immediately dispels the theory 
that people are convinced about the efficacy of a CAM product solely by a TC, but rather poses another 
rationale, which explains the results seen in Figure 9.19.  The trend seen for Advil and Arnica above 
certainly exists, and people are clearly noticing TCs, however the question remains of how people are 
responding to them, given the Ultivite results.  In light of the similar trends with both Ultivite and Folic 
Acid in Figure 9.19, it would appear that people are using TCs to pinpoint the product’s effect.   
Taking this one step further, it would appear that the strength of the TC also plays a role in how certain 
participants were, about the effect of the product.  Generally, Advil showed the greatest margin 
between the peaks and troughs of its four bars, while Probiotics IBS Support was below average, and 
Folic Acid and Ultivite displayed the least margin.  It can thus be surmised that the stronger the TC, 
the more certain consumers are about the particular effect of the product.   
Despite both question 28 and 30 disproving the hypothesis that a TC displayed on a CAM product 
either leads to that product more readily being identified as a medicine, or informs consumers about 
the efficacy of that CAM product, they have nevertheless shown that TCs play some role in consumer 





9.3.3 A theory on the public’s classification of CAM and medicinal products 
The hypothesis that the unlawful presence of TCs on CAM products could cause consumers to confuse 
these products with medicines has been at least partially disproved by the results in 9.3.2.  
Nevertheless, it is worth considering the TCs on the products used in this survey, and the extent to 
which the statements on these products are misleading or deceptive, in line with either the DSRs or 
FTA. 
Therapeutic Claims and Misleading Statements 
This section momentarily moves away from the results of the survey, to discuss whether the 
statements on the labels of the six products used in the study are either TCs within the meaning or 
reg11 DSRs,925 or are misleading and deceptive statements in the vein of reg10 DSRs926 and the FTA.927  
Consequently, this analysis of the claims is an exercise in statutory interpretation. 
For the most part, the analysis in Table 9.4 is uncomplicated.  It is important to bear in mind that while 
alternative arguments are possible, especially for products like Arnica and Probiotics IBS Support, 
participants only had 30 seconds to consider the products in an attempt to replicate the shopping 
environment where people tend to make quick decisions, rather than analysing statements in depth.  
The analysis in Table 9.4 considers whether the ‘nature’ of the CAM products was misleading by way 
of TCs,928 applying the objective standard of the reasonable person to this statutory interpretation.
                                                          
925 Dietary Supplements Regulations 1985, reg11: “Except as permitted by the Medicines Act 1981 and any 
regulations made under the Act, no dietary supplement shall be advertised or labelled with a statement relating 
to any of the following matters:  
(a) treating or preventing disease:  
(b) diagnosing disease or ascertaining the existence, degree, or extent of a physiological condition:  
(c) altering the shape, structure, size, or weight of the human body:  
(d) otherwise preventing or interfering with the normal operation of a physiological function, whether 
permanently or temporarily, and whether by way of terminating or reducing or postponing, or 
increasing or accelerating the operation of that function, or in any other way.” 
926 At reg10: “…(2) No printed, pictorial, or other descriptive matter supplied or displayed with any dietary 
supplement shall include any false or misleading statement, word, brand, picture, or mark purporting to indicate 
the nature, suitability, quantity, quality, strength, purity, composition, weight, origin, age, effects, or proportion 
of the dietary supplement or of any ingredients of the dietary supplement.” 
927 See Chapter 7. 









Therapeutic Claim Rationale 




Misleading Statement Rationale 
(Regulation 10 DSRs & s10 FTA) 
Advil 
Relieves pain fast 
•Headache •Back Pain 
•Muscle Pain •Period Pain 
Yes 
Not subs(a), (b) or (c), but comes under (d).  Pain is a 
normal ‘physiological function’ and this TC states 
that it ‘relieves pain’, which amounts to a reduction 
or termination of that function. 
Unlikely 
This statement does make Advil out to be a medicine, 
but it is obviously not misleading, as Advil is in fact a 
medicine, as distinct from the other five products 
which are DSs. 
Arnica 
Speedy recovery after sports 
or injury 
Probably 
Two possibilities for TC under subs(d).  ‘Injury’ may 
be a physiological condition, and thus ‘speedy 
recovery’ from this would be interference.  
Alternatively, healing is probably a physiological 
function, and it is likely that ‘speedy recovery’ is 
tantamount to ‘increasing or accelerating’ healing 
function. 
Unlikely 
Quite broad, lacks any identification of specific 
problem that this will solve.  Statement could equally 
be applied to water for example. Increasing 
something that is already occurring (recovery) but no 
certainty as to how it will achieve this.  The claim 
alone is unlikely to mislead people into thinking it is a 
medicine. 
Folic Acid 
Supports healthy brain and 
nerve development 
No 
Certainly not subs(a), (b) or (c).  Question is whether 
‘support’ implies ‘interference’ within meaning of 
subs(d).  Very unlikely, given broad nature of claim 
which could similarly apply to any food or beverage. 
Unlikely 
Breadth of the statement, coupled with the term 
‘support’ implies that the product is generally helping 
what is already occurring.  Akin to many DSs, and 
quite distinct to medicine labelling. 
Olive Leaf 
Relieves cold symptoms 
Helps fight common viral 
infections 
Yes 
A cold is a disease, so relief of cold symptoms is 
treatment of the disease under subs(a).  
Furthermore, fighting viral infections is certainly an 
attempt at preventing disease under subs(a). 
Also see similarity to TC for Advil. 
Probably 
Names specific medical condition (cold), addresses 
the root of the problem (symptoms), and tries to 
prevent succumbing to disease. Shares specificity and 





For the symptomatic relief 
of medically diagnosed 
irritable bowel syndrome 
Probably not 
Certainly not subs(b) or (c), nor probably (d), as IBS 
is not physiological function.  Questionable whether 
IBS is a disease for purposes of subs(a).  If so, then 
‘symptomatic relief’ will probably amount to 
treatment or prevention. 
Probably 
Addresses a medical condition, directly references the 
medical input (diagnosis), and proposes relief from 
symptoms.  Almost certainly fits within s4 MA 
definition of therapeutic purpose, and very likely 
medicine label. 
Ultivite 
Multivitamin mineral & 
antioxidant with herbs  
Formula 1 
In Natural Health 40+ Years 
No 
No attempt at TC.  Merely a statement as to the 
contents, with nothing in regards to effect or mode 
of action of the product. 
Unlikely 
Uses terminology commonly associated with DSs.  
Also nothing medicinal whatsoever in the nature of 
the statement. 




Having established the presence or absence of TCs and misleading statements on the products tested 
in this experiment, it is now possible to place them into the bigger picture, and consider how multiple 
factors are likely at play in effecting consumer decision making with regards to the CAM products 
which they purchase. 
Multiple Factors in Decision Making 
 Once it became evident that the TCs were by no means the only, nor perhaps even the most 
important, factor in people’s decision making, it became necessary to take a broader approach to the 
initial thesis, that TCs substantially affect consumer identification of CAM products.  Four factors 
crystallised from the results in section 9.3.2; the ‘dietary supplement’ label, the packaging, TCs and 
name recognition.  Table 9.5 highlights the presence or absence of these characteristics, grouping this 
with how the majority of participants identified each of these products at question 28.  An explanation 
and justification for each of the four heads follows. 
Where ‘Dietary Supplement’, or some iteration thereof,929 appeared on the labels of these products, 
they were unequivocally identified by participants as DSs.  While this statement is required to appear 
on the label, not all DS accord with such requirements.930  Given the effect of a ‘dietary supplement’ 
note on the label, this has been categorised as the primary consideration, although it is by no means 
the only factor, used by participants in identifying the products. 
The secondary factor which has been identified from the results is that of the nature of the packaging.  
From the results, one trend leapt out, which was that people readily associated medicines with boxes, 
and DSs with jars or bottles.  Advil and Arnica were displayed in boxes as the packaging which was 
presented to the consumer, while the other four products came in plastic bottles or jars.  There has 
                                                          
929 See Folic Acid, which merely stated ‘dietary’ on the label. 
930 Dietary Supplements Regulations 1985, reg5(1)(e). 











Advil  Box   Medicine 
Folic Acid  Bottle   
Dietary 
Supplement 
Olive Leaf  Bottle  ? 
Ultivite  Bottle   
Arnica  Box  ? Probably Med 
Probiotics IBS   Bottle ?  Probably DS 




been a substantial amount of research around the effect of pharmaceutical pill size and colour,931 with 
recent research showing the packaging of medicines as an indicator to consumers, of the product’s 
efficacy or potency; 932  adding credence to the theory that the packaging plays a large role in 
influencing consumer identification of their therapeutic or natural health products.  There is a 
recognised “…scarcity of empirical research on pharmaceutical packaging and its growing importance 
in global drug companies’ communication…”933 which also extends to the packaging of CAM products.  
A meta-analysis of the packaging of both medicines and DSs in one of the biggest online pharmacies 
in NZ, showed approximately 84% of medicines were packaged in boxes, while nearly 80% of DSs were 
packaged in bottles.934  These figures would appear to be consistent with research which shows 
Europe and the majority of the developed world package 85% of solid medicines in boxes;935 the 
notable exception to this rule being the USA, where less than 20% of medicines come in boxes.936  This 
supports the theory that consciously or subconsciously, patients are taking account of the packaging 
when selecting their medicines or DSs; a concerning realisation when considering that high-end DSs 
appear to favour being packaged and marketed in boxes.937 
Therapeutic claims have already been discussed in detail,938 and while the initial theory of these being 
the leading determinative factor in identification of products has been set aside, they retain an 
important, yet not exclusive, role in influencing consumer decision making. 
Finally, name recognition was added to this chart as the fourth consideration in order of importance.  
While this may be minimising the effect of name recognition upon people’s identification and 
consequent willingness to buy these products, the survey was not designed to test for this influence, 
and therefore the only evidence in support of this is largely anecdotal.  Name recognition was 
                                                          
931 See the studies mentioned in Bernard Roullet and Olivier Droulers “Pharmaceutical Packaging Color and Drug 
Expectancy” (2005) 32 Advances in Consumer Research 164, at 165 and 169-171. 
932 At 168-169. 
933 At 168. 
934 This data came from a thorough analysis of New Zealand Online Pharmacy Pharmacy Direct “Online Pharmacy 
| NZ's Leading Online Chemist - Pharmacy Direct” (2016) <www.pharmacydirect.co.nz/>.  The analysis was 
carried out on both the medicines supplied on their website, as well as the large range of CAM products. 
935 Ron Pilchik “Pharmaceutical Blister Packaging, Part I” [2000] Pharmaceutical Technology 68, at 70. 
936 At 70; These studies generally focus on the primary form of packaging for medicines; namely blister packages.  
Of interest in the present research is the outward appearance of the medicines given that this is what impacts 
consumers’ perspective.  Where medicines are packaged in blister packaging, they are then usually always 
packaged in boxes as the secondary form of packaging to protect the integrity of the blister pack.  Roullet and 
Droulers, above n 931, focuses more on the secondary packaging, although the emphasis in this paper is on 
colour and its effect on drug expectancy. 
937 See high-end products in ranges like Clinicians, Blis and Blackmores, where more expensive product with 
fewer tablets or capsules are packaged in bottles which are then put in boxes as a secondary form of packaging 
for presentation to consumers. 




considered a factor for Advil, for despite the brand not being very prevalent in NZ, the active ingredient 
‘ibuprofen’ was identified by a number of respondents when answering question 27, and its effects 
discussed.  Similarly, Folic Acid elicited lengthy responses from a significant number of participants, 
although this is likely due to a relatively large number of the students coming from science 
backgrounds.  Finally, Probiotics IBS support is likely accompanied by a modicum of name recognition 
due to the ‘trendy’ nature of the term ‘probiotic’ in recent years, resulting in its appearance on a range 
of food and DS products ranging from yoghurt to cheese to probiotic pickles. 
A theory from behavioural economics offers a potential justification for why a combination of these 
factors may influence consumers to decide a product is something which it is not.  Nudge theory stems 
largely from the exceedingly simplified premise that by nudging people in a particular direction with 
semi-conscious or subconscious suggestions, you can direct them to behave in a desired manner.939  A 
common example of this is placing realistic depictions of flies on men’s urinals to improve aim.  
Application of the theory to the present issue could suggest that through the use of non-verbal 
marketing, like altering the packaging of DSs such that they come in boxes, and using words more 
commonly associated with medicines like relief, recovery and pain for example, this may nudge people 
in the direction of identifying the product as a medicine, or at least believing it to have medicinal 
properties and consequently be more effective.  If further research showed consumers were being 
‘nudged’ towards particular CAM products under the false premises that they were either more 
effective, or more akin to medicines, then issues may arise on whether this amounts to misleading or 
deceptive conduct or representations.940 
The theory discussed above provides a basis for further research, for while it may hold limited 
evidential or persuasive value on its own merits given the lack of a representative sample and limited 
number of products studied, it provides scope for more targeted research.  These ideas and theories 
will be will be discussed in more detail at Chapter 10 in the context of a representative study 
specifically focusing on the packaging and labelling of CAM products. 
9.3.4 Environment of sale 
The final section questioned participants on the environment of sale and further factors which 
influenced their decision making.  However, the results are broad, and do not deliver any 
                                                          
939 Richard Thaler and Cass Sunstein Nudge: Improving Decisions About Health, Wealth, and Happiness (Yale 
University Press, New Haven, 2008) 




consequential findings, and therefore in the interests of brevity will largely be set aside, barring two 
questions: questions 32 and 37. 
 
 
Question 32 provides an interesting corollary to questions 9 and 10 on product usage, instead asking 
here whether participants had ever purchased DSs.  Bearing in mind the relatively weak financial 
position of the majority of respondents, it is rather surprising that 70.7±5.1% of respondents had in 
fact purchased DSs in the past.941 
Four themes emerged from the open-ended question 37, in decreasing level of importance; side-
effects, readily available scientific evidence, efficacy, and safety.  While on first pass, it appears 
concerning that people are not overly interested in seeing information on efficacy and safety on the 
label of their products, detailed analysis of the responses indicates that there is a strong desire for 
reputable scientific information associated with these products to enable consumers to perform their 
own calculi on whether the efficacy versus safety makes purchasing and consuming the product a 
worthwhile endeavour.  Whether this would actually occur in practice is uncertain.  While it is difficult 
to draw any steadfast conclusions from this question, it does indicate a strong desire from consumers 
for a greater amount of information associated with their CAM products to allow them to at least have 
the option of being more informed in their decision making; a laudable desire. 
9.4 Conclusion 
There is scope for a huge array of studies which build upon the work begun in this survey.  However, 
for the purposes of the present investigation into DS and the effect of their marketing on consumer 
decision making, there was one natural path to take.  On the basis of the results at 9.3.2, and to test 
the updated hypothesis introduced at 9.3.3, the logical course of action was to conduct a second study 
which not only sought to answer these questions, but also collected representative data on usage of 
CAM products in NZ to enable comparison with the rest of the world.  This survey and its results will 
be discussed in Chapter 10.  
                                                          
941 Comparisons with international data and the results from Survey 2 will be carried out in the following chapter. 
Figure 9.20: Survey 1 - Question 32 
 




10 Packaging of Complementary & Alternative Medicines in New Zealand: A 
representative study 
10.1 Introduction 
The previous survey concluded that there were multiple relevant factors informing consumer decision 
making with respect to their identification of CAM products or medicines.  In order of priority, these 
were listed as; the ‘dietary supplement’ label, the packaging, TCs, and name recognition.  While the 
‘dietary supplement’ label is fairly self-explanatory in terms of its effect, the influence of the packaging 
and TCs are not as inherently evident.  As a result, a new survey was designed which sought to take 
those two elements and test their effect on consumers’ identification of otherwise plainly packaged 
products.  Ultimately, this information will help determine the relative importance of these two 
factors, as well as provide a springboard from which to assess any FTA implications of misleading or 
deceptive packaging or statements associated with CAM products at Chapter 11. 
Furthermore, this survey provided an opportunity to broaden the scope of its predecessor and take a 
representative approach; recruiting an array of participants from across the country.  Not only did this 
generate balanced and persuasive results on the perceptions of a cross-section of NZers, it also 
enabled their usage of CAM products to be studied.  The resulting data is unique in that no other 
recent information exists on NZers purchasing or consumption of CAM products, and consequently, 
this facilitates a novel comparison with international studies on CAM product usage, whilst 
demonstrating the prevalence of these products and resultant need for reform. 
This Chapter will discuss the findings of this survey, and will suggest that the results reveal a very high 
level of prevalence of CAM products, and the interwoven nature of TCs and the packaging of CAM 
products in affecting consumers’ perceptions. 
10.1.1 Background 
The background to the product packaging part942 of this Representative Study was established through 
the Pilot Study and its results as discussed above.943  Consequently, this section considers national and 
international data on the CAM product usage, in order to put the responses to questions on 
prevalence in this study,944 in perspective. 
                                                          
942 See Questions 9-15, Appendix 4. 
943 See Chapter 9. 




In 1997, a National Nutrition Survey was carried out in NZ on people aged 15 years and older, looking 
at their diet over the past 24-hours, as well as aspects of their diet over the last year.945  As part of 
this, information was collected on DS usage, and this was further considered in a secondary analysis 
some years later.946  There are issues in comparing this data to the present research given the distinct 
age range of participants, but nevertheless, it affords a glimpse into consumption habits in 1997, 
providing a valuable foundation for the present survey to build upon.  Of the 4626 respondents, 59% 
reported using supplements in the past year,947  while 24.1% of participants noted daily use.948 
A significant amount of research has been carried out in Australia with respect to the prevalence of 
CAM usage.  While much of this has focused on particular modalities949 or included CAM practices with 
CAM products,950 the South Australian studies951 have proved a seminal resource in both international 
study design, and showing the prevalence of these products.  In a survey of people 15 years and older, 
the first South Australian study in 1993 showed a 48.5% incidence of over-the-counter use of CAM 
products in the previous 12 months.952  More recent studies suggest that the prevalence has increased 
to nearer 70% in 2005,953 although care should be taken in comparing studies whose ambit, with 
respect to CAM products and modalities, may vary. 
In the USA, systematic reviews indicate a high degree of fluctuation between different studies, but 
nevertheless place CAM usage at an average of 40.5%.954  Meanwhile the UK shows a greater level of 
consistency in systematic analyses, with the most recent data indicating 26.3% usage of CAM among 
the adults surveyed.955 
                                                          
945 David Russell, Winsome Parnell and Noela Wilson NZ Food: NZ People. Key results of the 1997 National 
Nutrition Survey (Ministry of Health, Wellington, New Zealand, August 1999). 
946 Parnell, Wilson and Smith, above n 881. 
947 At 201. 
948 At 201. 
949 This includes modalities of acupuncture, chiropractic, homeopathy, osteopathy reflexology, massage, or 
generalised practitioner visits; Harris and others, above n 877, at 93-94; Xue and others, above n 877, at 646-
648. 
950 Xue and others, above n 877. 
951 Alastair MacLennan, David Wilson and Anne Taylor “Prevalence and cost of alternative medicine in Australia” 
(1996) 347(9001) The Lancet 569; Alastair MacLennan, David Wilson and Anne Taylor “The escalating cost and 
prevalence of alternative medicine” (2002)(35) Preventitive Medicine 166; Alastair MacLennan, Stephen Myers 
and Anne Taylor “The continuing use of complementary and alternative medicine in South Australia: Costs and 
beliefs in 2004” (2006) 184(1) Medical Journal of Australia 27. 
952 Harris and Rees, above n 877, at 93. 
953 Xue and others, above n 877, at 643; Roger Byard and others “What risks do herbal products pose to the 
Australian community?” (2017) 206(2) Medical Journal of Australia 86, at 86. 
954 Harris and others, above n 877, at 930; Data extrapolated from Table 3. 




A number of systematic reviews of international CAM surveys have been conducted in the past two 
decades,956 and all have struggled with the variety of methodologies, not to mention the plethora of 
modalities which may or may not be included under the umbrella of CAM when surveying members 
of the public.   
10.2 The Representative Study: Methods 
10.2.1 Sample & study design 
This study is an empirical legal questionnaire study of a cross section of NZers on their usage, and 
perceptions around the packaging and claims of CAM products.  Through primarily quantitative 
questions which rely on a high degree of subjectivity, this survey reduces products to their most basic 
level, wherein only the packaging and therapeutic or non-TCs remain, in order to obtain raw data on 
the effect of these two characteristics upon consumers. 
10.2.2 Data collection957 
This survey was distributed to 2500 NZers who were randomly selected958 from the NZ Electoral 
Roll.959 
Participants were provided with a printed survey and return post envelope, as well as a personalised 
link to the online survey.  Responses were tracked to ensure participants did not respond twice 
through online and postal formats.  The survey was opened on 28 December 2016, and participants 
were informed they had until 31 January 2017 to respond.  Following this, a follow-up letter with the 
same survey included was sent to 500 people who were randomly selected from those in the initial 
cohort who had not responded to the first survey.  The follow-up letter noted a final closure date of 
31 March 2017.  To ensure the representativeness of the survey was not affected, no recruitment 
outside of the postal distribution to the selected 2500 person cohort was conducted. 
In total, 573 responses were received.  In addition, 44 letters were returned due to failed delivery or 
incorrect information, and these were removed from consideration of the total distributed.  On this 
basis, the response rate was 23.3%.  While this is lower than initially anticipated, it should be viewed 
in light of a significant period since the last NZ Census in 2013, or general election in 2014 when the 
                                                          
956 Harris and Rees, above n 877; Ernst, above n 877; Harris and others, above n 877. 
957 This study received approval from the University of Canterbury Human Ethics Committee on 9 December 
2016 (approval reference HEC 2016/68/LR); see Appendix 3. 
958 Randomisation was performed using the random number generator in Microsoft Excel 2013, used under 
licence to the University of Canterbury. 
959 Permission to use the Electoral Roll was granted under s112 Electoral Act 1993 for the purposes of human 




information on the electoral roll tends to be the most accurate.  Furthermore, the topic may appear 
abstract due to the nature of questioning on plain packaging, likely leading to a lower response rate. 
Nevertheless, on the whole, the demographics of respondents provides a fairly accurate picture of 
NZers, demonstrating the representative nature of this study.  While there is slight variance between 
the demographic data collected in the survey and data from the 2013 NZ Census,960 the survey data 
has not been weighted, as these variations are minor, and selecting a characteristic or characteristics 
to apply weighting is more likely to add discrepancies to the data considered at 10.3. 
Respondents’ ages are distributed along the lines of a normal distribution, with a slight shift towards 
the older age ranges.  Nearly 60% of people were aged between 45 and 74, while 34.9% of people 
were above retirement age.  This corresponds with 29.4% of respondents being retired, and generally 
indicates a trend towards retired, older people having both a greater desire to complete surveys and 
generally having more time to do so.961  The female-male divide is slightly exaggerated in the survey 
compared to Census data, with the survey showing 54.7% females to 45.3% males, while 2013 data is 
51.3% females to 48.7% males.962  Ethnicity data also trended towards an inflated number of NZ 
Europeans, with 84.3% selecting this option.  People who identified their employment status as retired 
were second only to those who were employed full time (50.6% of respondents).  Finally, education 
level and income levels were both somewhat higher than the NZ average, with 7.1% responding to the 
survey as having less than a high school education, compared to the NZ level of 20.9% without a formal 
qualification.963  Similarly, 17.4% of respondents earned less than $20,000, whereas 38.2% NZers fell 
into this category, and 5.9% NZers earned more than $100,000 in contrast to the 13.1% who selected 
this option in the survey.964 
Despite the survey data not directly correlating to NZ Census data, it is important to recall that this 
census data is from 2013, and represents all NZers, as opposed to this survey which just sought to 
survey adults over the age of 18.  It should also be noted that this particular topic is unavoidably going 
to interest respondents who are predisposed to CAM products and modalities, and international 
                                                          
960  Statistics New Zealand “2013 Census QuickStats about national highlights” (December 2013) 
<www.stats.govt.nz>. 
961 At 12; Census data would indicate that 14.3% of the population is aged over 65, although this is noted to be 
on the rise. 
962 At 12. 
963 At 18. 




studies also show some leaning towards female respondents, often on high incomes, who are well 
educated.965 
10.2.3 Questionnaire design 
Given the simplified format of the questionnaire966 compared to the earlier survey, designing this 
survey was a much more straightforward undertaking.967  While the material around the packaging 
and TCs was of somewhat novel design, the questions around prevalence were written in such a way 
as to make them comparable to international studies so that the incidence of CAM usage in NZ can be 
juxtaposed with countries like Australia, the USA and the UK.968 
In order to generate comparable usage data, a number of strategies were implemented from two 
systematic reviews on CAM usage. 969   Prior to questions on prevalence, the survey provided 
definitions for both medicine970 and DS.971  While ideally, the term ‘complementary and alternative 
medicine’ would have been used in this setting, this conflicted with the desire to make the survey 
relatable for NZers who are accustomed to the term ‘dietary supplements’ when dealing with the 
majority of their CAM products.  The other primary strategy employed to enable comparison was to 
question both purchasing as well as consumption of DSs, and in response to a positive answer to the 
question on consumption, ask about frequency of consumption.  Short of considering modalities, this 
covered all the bases of previously conducted international studies.972 
To study the packaging and TCs together, a strategy was devised to remove all other features from 
the products, and to display pictures of packages with and without statements to participants.  In an 
effort to obtain a broad picture of participants’ perceptions, two slight variations were developed, 
                                                          
965 Ernst, above n 877, at 253 and 255; Parnell, Wilson and Smith, above n 881, at 200; Harris and others, above 
n 877, at 924-925. 
966 See Appendix 4: Packaging of Complementary and Alternative Medicines in New Zealand. 
967 See 9.2.3. 
968 Three systematic reviews previously mentioned contain all the international studies considered in this thesis, 
as they ensured consistency with select review criteria and integrity of data analysis in the included studies; 
Harris and Rees, above n 877, Ernst, above n 877, Harris and others, above n 877.  The only other study not 
included in these reports was Parnell, Wilson and Smith, above n 881.  The only systematic review which could 
have considered this was the 2012 review, and while its failure to be included would indicate it did not meet the 
standards for inclusion, it is the only NZ study on prevalence prior to the present work, and therefore requires 
consideration herein. 
969 Harris and Rees, above n 877; Ernst, above n 877. 
970 Appendix 4, Definition of Medicine: “For the purposes of this survey, a medicine is defined as a drug or other 
preparation for the treatment or prevention of disease.” 
971 Appendix 4, Definition of Dietary Supplement: “For the purposes of this survey, a dietary supplement is a 
product which contains herbs, minerals, vitamins, natural or supplementary nutritional oils or any other product 
generally considered a complementary or alternative medicine product or a natural health product.  Such a 
product is not a medicine.” 




with half the participants being shown version one,973 while the remainder saw version two (see all 12 
images at pages 178-179).974  In total, there were two different boxes and two different bottles, which 
were displayed with and without statements.  There were two claims which were deemed to be TCs, 
and two which were deemed to be non-TCs.  By showing six different permutations in both variation 
one and two, all possible combinations of claim and packaging were achieved, removing the possibility 
of bias or internal errors.975  With the image of the product before them, participants were asked to 
identify the six images as either a medicine, a DS, or ‘other’ wherein they were offered the option to 
comment. 
The survey culminated in an open ended option for comment. 
10.2.4 Data analysis 
All responses to the survey were used for the purposes of analysis at 10.3.  While some responses 
were only partially completed, these were still recorded for the information which they gave. 
Statistical guidelines for the analysis of these results was provided by a health-sciences statistician for 
the earlier survey,976 and the same parameters were employed in analysis of this survey.977  The 
majority of the data in this survey was quantitative, and consequently was analysed using Qualtrics.978  
NVivo complemented manual analysis of responses to the few open-ended qualitative questions in 
the survey.979 
10.2.5 Statistics 
A normal distribution is used in this analysis to determine the probability of a particular response in 
the general population, and also to calculate the margin of error on the reported results.   
As such, the margin of error is reported on the data as it is presented throughout the results section,980 
based on a normal distribution at a 95% confidence level.  The overall standard error of this survey is 
±4.09%.  As with the Pilot Study, all results are reported to one decimal place unless otherwise noted. 
                                                          
973 See Table 10.3 and Figure 10.6: Box1, TC1, Figure 10.8: Bottle1, NTC1, Figure 10.12: Box2, NTC2, Figure 10.14: 
Bottle2, TC2, Figure 10.10: Box1, Blank, and Figure 10.11: Bottle1, Blank. 
974 See Table 10.3 and Figure 10.7: Box1, NTC1, Figure 10.9: Bottle1, TC1, Figure 10.13: Box2, TC2, Figure 10.15: 
Bottle2, NTC2, Figure 10.16: Box2, Blank, and Figure 10.17: Bottle2, Blank. 
975 See survey at Appendix 2. 
976 See 9.2.4. 
977 See further at 10.2.5 
978 Qualtrics, above n 900, used under licence to the University of Canterbury. 
979 QSR International, above n 906, used under licence to the University of Canterbury. 




10.2.6 Study limitations 
The limitations seen in the survey at Chapter 9 were identified and corrected prior to conducting the 
present study.  Consequently, outside of participants’ difficulty grappling with the actual material they 
were being questioned upon, the questionnaire study itself otherwise ran smoothly. 
The only real limitations present in the survey relate to the representativeness of the survey, as 
discussed earlier.981  While weighting the survey according to NZ Census data would alleviate this 
issue, it is minor in the context of the data being analysed and consequently, such steps were not 
taken.  Were a further study to be carried out along these lines, researchers should increase the size 
of the initial cohort.  This would raise the number of respondents and reduce the impact from a lack 
of representativeness. 
10.3 Results & Discussion 
The results which follow are presented alongside comparisons with other studies and discussion on 
their ramifications.  There are two parts to this section; the first on the prevalence of CAM products, 
and the second on the effects of packaging and TCs on consumer identification of CAM products. 
10.3.1 The prevalence of CAM products 
As previously stated, participants were first provided with a definition of DS and medicine to facilitate 
informed and accurate responses to the questions on prevalence.   
                                                          
981 See 10.2.2. 





 Purchased a DS (%) 
Question 7 
Taken a DS (%) 
Question 8 
Yes 79.0±3.3 80.8±3.2 
No 21.0±3.3 19.2±3.2 
Table 10.1: Survey 2 - Results to Questions 7 & 8 - Responses on purchasing & consumption of CAM products 























Questions 7 & 8 - Purchasing & Consumption of CAM Products
Purchased a DS Taken a DS




Participants were asked both whether they had ever bought a DS, and whether they had ever taken a 
DS.  While this was done partially to ensure maximum comparability with international studies, it also 
allowed for a comparison between purchasing and consumption trends.  
The first point about these results which leaps out is the incredibly high incidence of both purchasing 
and consuming DSs.  NZ usage was estimated to be around 70% prior to conducting this survey from 
a mix of international studies and the popularity of such products in NZ.982  As previously mentioned,983 
international studies showed prevalence up to 76%,984 while closer to home, Australia’s prevalence 
reached a peak of 52.2% in the South Australian studies,985 or a national total of 68.9%.986  More than 
10 years has elapsed since those studies, and when considered in light of the more relaxed regulatory 
system in NZ than Australia, and the effect of ‘brand NZ’ with buzzwords like ‘clean, green’ and ‘100% 
Pure NZ’, the basis for this estimation becomes apparent. 
 Nevertheless, the fact that over 80% of NZers have taken CAM products demonstrates the scale, and 
consequent importance of this issue in NZ.  Figure 10.3 illustrates that the difference between the 
slightly higher numbers of people who take DSs compared to those who purchase is in fact negligible, 
especially in light of approximately ±3.3% margin of error in these results. 
The second part of the questioning on usage was to study how often those who consume CAM 
products do so.987  As such, respondents who answered affirmatively to question 8 were directed to 
answer question 8a, which asked how frequently they took DSs. 
Table 10.2: Survey 2 - Results to Question 8a - Responses on frequency of consumption of CAM products 
                                                          
982 See also the one New Zealand study, Parnell, Wilson and Smith, above n 881.  While the results are nearly 
two decades old, they indicated a 59% prevalence of DS use amongst NZ adults aged 15+ years. 
983 See 9.1.1. 
984 Harris and others, above n 877, at 930; see Singapore and Japan. 
985 MacLennan, Myers and Taylor, above n 951; prevalence was 52.2% in the third South Australian Health 
Omnibus Survey. 
986 Xue and others, above n 877, at 644; Conducted in 2005, this trial showed a peak CAM usage of 68.9% in 
subjects aged 18+ years. 
987 Question 8a; see Figure 10.2: Survey 2 - Questions 7-8a. 




2-3 times per month 5.5±2.1 
1-2 times per month 5.3±2.1 
1-2 times per 6 months 6.2±2.2 
1-2 times per year 5.3±2.1 




Importantly, the results showed a high number of people consuming these products daily.  In viewing 
the results in Table 10.2 and Figure 10.4, it is important to appreciate that the results will be slightly 
skewed by those selecting ‘less frequently’, as this encompasses those respondents who have taken a 
CAM product once in the past, or previously used to do so, but have since ceased.  When the results 
from questions 7, 8 and 8a are viewed holistically, they suggest that approximately 43% of NZers 
consume CAM products on a daily basis.988  This is an unprecedented level of consumption of CAM 
products, which while suspected for some time, has until now lacked evidence.989 
Despite these figures, it is important to bear in mind that there may be a procedural issue with respect 
to the responses to the questionnaire in that those with an interest in CAM are more likely to respond, 
and also more likely to consume these products.  Nevertheless, the representative nature of the 
survey attempted to remove the incidence of this error, and the fact that this data largely follows 
international trends, as discussed above,990 suggests that it is largely an accurate representation of 
prevalence in NZ. 
                                                          
988 This figure of ‘43% NZers consuming CAM products daily’ is extrapolated from the responses to Question 11 
which showed 53.2% of the 80.8% of respondents who answered affirmatively to Question 10 were taking CAM 
products daily. 
989 The highest levels of reported CAM usage in international studies was 76% in Singapore and Japan; Harris and 
others, above n 877. 






























Question 8a - Frequency of CAM product consumption




In light of the only other NZ research,991 which showed a 59% usage in the previous year and 24.1% 
usage in the previous 24 hours, it would appear reasonable that 20 years later, prevalence shows 
80.8% of respondents have taken CAM products in the past, while 53.2% imbibe daily. 
As an aside, it is interesting to note the similar trend between the histograms in Figure 9.3 and Figure 
10.4.992  In both, there are peaks for CAM product consumption at ‘daily’ and ‘less frequently’.  While 
the frequency of students’ consumption at Figure 9.3 is considerably lower for the ‘daily’ consumption, 
the results from the two surveys show a similar proportion of people who have previously taken CAM 
products; with 76.4±4.1% students, and 80.8±3.2% NZers. 
10.3.2 Product packaging & therapeutic claims 
Background993 
To study the packaging and the claims thereon, two TCs and two non-TCs, and two boxes and two 
bottles were selected and combined.994  The claims were printed on plain labels and affixed to the 
packaging.  The finished products are displayed in Figure 10.6 to Figure 10.17.   
                                                          
991 See outline of the NZ Nutrition Survey of 1997 as published in Parnell, Wilson and Smith, above n 881 
992 See List of Figures at page x.  
993 Note: The numbering of these questions was inconsistent between version one and version two.  The same 
questions were numbered 9-14 in version one, and 13-18 in version two due to formatting problems with the 
online survey software.  The set of questions will be referred to as 13-18 throughout the results section. 
994 What follows is the wording of the TCs and Non-TCs, and a brief justification for their classification as such: 
TC1: “Relieves cold symptoms | Helps fight common viral infections”.  For the purposes of comparison and 
congruence, this was the wording taken from the Olive Leaf product used in the Pilot Study; see Table 9.4 for 
justification of classification as a therapeutic claim. 
TC2: “Speedy Recovery after sports or injury”.  For the purposes of comparison and congruence, this was the 
wording taken from the Arnica product used in the Pilot Study; see Table 9.4 for justification of classification as 
a therapeutic claim. 
NTC1: “Supports healthy brain and nerve development”.  For the purposes of comparison and congruence, this 
was the wording taken from the Folic Acid product used in the Pilot Study; see Table 9.4 for justification of 
classification as a non-therapeutic claim. 
NTC2: “• Soothes & cools the throat | • Moisturises dry throat | • Pleasant taste”.  This was the only novel claim 
used in this study which had not been analysed in the Pilot Study.  It was used due to a lack of other suitable 
claims from the Pilot Study.  With respect to its classification as a non-therapeutic claim, the totality of the 
statement was considered; namely the bullet point format, which tended to indicate a less formal or therapeutic 
nature.  More importantly though, it did not mention a specific problem, disease, medical condition, or explicitly 
state that it offered relief from any physiological condition as per reg11 DSRs.  Furthermore, it does not appear 
to be hastening healing, but rather is akin to NTC1 wherein it could equally likely be a label on a beverage as on 
a CAM product. 




In order to a variety of packaging and claim combinations, two alternative versions were created, as 
seen at Table 10.3.  This enables two distinct comparisons; one which studies the effect of different 
claims when displayed on identical packaging, and the other which studies the effect of different 




Figure 10.6: Box1, TC1 
Figure 10.9: Bottle1, TC1 






Figure 10.7: Box1, NTC1 
 
Figure 10.8: Bottle1, NTC1Figure 10.7: Box1, NTC1 
Figure 10.8: Bottle1, NTC1 







Figure 10.12: Box2, NTC2 Figure 10.13: Box2, TC2 
Figure 10.14: Bottle2, TC2 Figure 10.15: Bottle2, NTC2 




Effect of different claims on identical packaging 
As can be seen in Table 10.3, the same packaging was used between both versions of the survey, but 
the claim was switched around.  For example, Box1 was part of the question 13 in both versions, but 
in version 1, it displayed a TC, and in version 2, a non-TC. 
 Version 1 Version 2 











































Table 10.3: Survey 2 - Results from Questions 13-18 
For both questions 13 and 14, the results were unsurprising.  Respondents identified the products 
with the TC ‘relieves cold symptoms, helps fight common viral infections’ as being a medicine, 
irrespective of the packaging.  Conversely, they identified the packets with the non-TC ‘supports 
healthy brain and nerve development’ correctly as DSs, regardless of the packaging.   
However, when the results from questions 15 and 16 are considered, the matter becomes less clear-
cut.  Instead of identifying the two packages with the TC ‘speedy recovery after sports or injury’ as 
medicines, participants clearly viewed this as a DS, while they did the opposite with the non-TC; 
identifying ‘• soothes & cools the throat • moisturises dry throat • pleasant taste’ as indicative of a 




Finally, questions 17 and 18 gave fairly consistent results. The two boxes, when devoid of packaging, 
both gave consumers the impression of a medicine, while the bottles leave them uncertain, although 
slightly leaning towards DSs as opposed to medicines.995 
There are two key findings from the results in Table 10.3.  Firstly, the hypothesis that the packaging of 
the products is determinative as to the contents is clearly incorrect, as seen from the polarised 
perspectives between versions when the packaging was identical but the claim was different.  
Nevertheless, this is not to say that the packaging is not having some effect, even if it is not conclusive 
on its own, as shall be seen below.  The second point is that despite a strict legal interpretation 
identifying ‘TC2’ as a TC, and ‘NTC2’ as a non-TC, this is evidently not how the public view these 
claims.996  This poses a problem in that the line between TCs and non-TCs is so fine that a legal 
interpretation of these claims is insufficient in determining how the public view them.  Therefore, 
when health-benefit claims are added into the mix, supposedly coming in between TCs, as allowed on 
medicines,997 and non-TCs, as allowed on CAM products,998 this already thin line is set to be broken 
into pieces, making the situation only more confusing for consumers. 
Effect of different packaging on identical claims 
Where Table 10.3 considered parallels between TCs and non-TCs on the same packaging, Figure 10.18 
and Figure 10.19 turn to look at what effect that packaging is having upon consumer perceptions. 
                                                          
995 Q18, Bottle1, Blank; Other (41.2±5.8%), Dietary Supplement (30.1±5.4%), and Medicine (28.7±5.3%). 
Q18, Bottle2, Blank; Other (41.7±6.1%), Dietary Supplement (32.3±5.8%), and Medicine (26.0±5.4%). 
996 See analysis of TC2 at Table 9.4: Therapeutic Claims and Misleading Statements, under ‘Arnica’, and fn 994. 
997 Medicines Regulations 1984, reg8; and Medicines Act 1981, s4; see discussion on therapeutic purpose and 
the requirement that this be displayed at Chapter 3. 





When viewed in pairs, the trend in these results is instantly apparent.  The two packets which display 
TC1 show that while the majority of participants view both the box and bottle as a medicine, there is 
a much higher level of certainty among respondents in the case of the boxed product.  The same trend 
is seen in the reverse for the product displaying NTC1, with the bottled product showing a greater 






















Questions 13 & 14 - Packaging Comparison
Medicine Dietary Supplement Other























Questions 15 & 16 - Packaging Comparison
Medicine Dietary Supplement Other





while difference in the results for NTC2 is not statistically significant due to being within the margin of 
error,999 it nevertheless does not buck the trend. 
Despite not altering the outcome in any of these cases, the packaging is still a vital component in 
consumers’ decision making in identifying their medicines and CAM products.  It follows, that in 
instances like those in the first survey, where there was widespread uncertainty as to the identity of 
some of the products, participants could well be tipped over into a particular identification by such a 
prominent characteristic as the packaging. 
Finally, it is important to look at participants’ identification of the plain packaging in questions 17 and 
18.  What is immediately apparent is the certainty that the box does not represent a DS, but probably 
contains a medicine in both cases.  In both versions, these questions rendered very high ‘other’ results, 
which are largely attributable to participants failing to grasp the intent of the question, namely what 
was more likely to be inside the package, and consequently answering with some variant of 
‘unknown’, ‘empty container’ or ‘no label’.  In turn, this skewed the results for the two bottles in 
question 18.  Nevertheless, the confusion regarding the identity of the bottled product remains 
informative, as it demonstrates that while people will generally instantly conflate a box with a 
medicine, the same reasoning is not applied to bottles wherein people are probably more likely to 
take into account additional factors when determining the product’s identity. 
                                                          























Questions 17 & 18 - Packaging Comparison
Medicine Dietary Supplement Other




An holistic overview 
Finally, the responses to the open-ended question 19, while not particularly informative, demonstrate 
the direction of most people’s thinking.  There were a number of general themes in response to this 
question.  Some people took the opportunity to recount personal information like why they take 
supplements or medicines, or the kinds and amounts which they consume.  Others used the 
opportunity to comment on the previous questions, with some identifying a theme in terms of 
packaging, while others talked of the TCs.  The final type of responses to this question was those who 
focused on the problems in terms of regulation or merely what was required on the label.  Although 
some of these people considered this from a perspective of wanting less regulation, the majority of 
these respondents desired greater information or more stringent regulation to ensure the medicines 
and CAM products they were consuming were safe and effective. 
The totality of this survey’s findings on packaging and TCs brings the results of these two surveys full 
circle.  Initially, the TCs were seen to be a determinative factor in the public’s identification of CAM 
products; an hypothesis disproved by the first survey.  The second survey subsequently set out to test 
whether packaging was perhaps solely responsible for incongruous responses in the first survey, and 
as it eventuates, it does not act alone, but rather in concert with associated elements like the TCs.  
This dichotomy is best illustrated by considering some comparable results from the two surveys, with 




Box & Claim 
(Survey 2) 























Table 10.4: Comparison between Survey 1 & Survey 2 Products 
                                                          
1000 These products were three of the six products used in the Pilot Study.  As noted at fn 994, the claims from 
these three products were reused in the present survey to enable the comparison which follows.  Table 9.4: 
Therapeutic Claims and Misleading Statements sets out justifications for classification of the statements as 
therapeutic claims or non-therapeutic claims, but in summary: 
Folic Acid: “Supports healthy brain and nerve development” – a non-therapeutic claim; NTC1. 
Olive Leaf: “Relieves cold symptoms | Helps fight common viral infections” – a therapeutic claim; TC1. 
Arnica: “Speedy Recovery after sports or injury” – a therapeutic claim; TC2. 




Despite differences in survey construction and execution, a comparison of these two surveys 
immediately illustrates the importance of multiple factors for the public’s identification of CAM 
products.  In the case of Folic Acid, a blatant non-TC is barely impacted by removal of other labelling 
elements, and shows only a slight drop in certainty when packaged in a box.  The same cannot be said 
for Olive Leaf, whose TC overshadows everything else when the ‘dietary supplement’ tag and other 
material is removed from the label, with Survey Two unequivocally identifying it as a medicine on the 
basis of this claim.  The opposite is true for Arnica.  When the relatively plain logo and product name 
are removed from the box in survey two, the weak TC is instead considered a DS by a majority in both 
the box and bottle.  This suggests that the public do not view ‘speedy recovery after sports or injury’ 
as indicative of a medicine.  Instead, in Survey One, the name ‘Arnica’ or brand name ‘Weleda’ causes 
the majority to identify it as a medicine. 
10.4 Conclusion 
The present research provides a valuable starting point for understanding current NZ CAM product 
prevalence.  Furthermore, the results follow expected trends in light of other countries,  with this 
research showing NZ’s usage of CAM products to be higher than most other countries.  This is 
potentially due to nearly a decade between this research and the cited international studies, and also 
NZ’s strong CAM product manufacturing industry; which is likely due to relaxed legislation, and the 
‘100% Pure NZ’ or ‘clean, green’ image. 
In many ways, this second survey has confirmed the conclusions of the first survey in a more rigorous 
and representative manner.  Chapter 9 concluded that multiple factors effect consumer decision 
making, loosely ranking them in order from most important as; the DS label, the packaging, TCs, and 
name recognition.  This study took two of those elements and studied them in isolation, with a variety 
of results.  It demonstrated the interlinked importance of the packaging and TCs, but also the trouble 
with identifying one as more important than the other.  In some cases, the packaging effected more 
than 20% of respondents in their answers, but TCs and non-TCs tipped the balance of majoritarian 
identification; just not always in the anticipated direction.  At the same time, through comparison to 
the results of the earlier survey, the importance of aspects like the DS label was further corroborated, 
as seen in the case of Olive Leaf. 
In summary, it is evident from the interplay seen in participants’ responses that both the packaging, 
and the statements displayed on the label are taken into account in identifying the contents.  The 
histograms in this Chapter clearly show the importance of packaging in facilitating this identification, 




confirms that in the absence of other material, they are an indispensable aid to consumer 
identification. 
There remains a wealth of further material to study along these lines.  The way in which the public 
interpret TCs, and how they distinguish between TCs and non-TCs remains unclear in light of the 
results of this survey.  Alongside this, there is scope for a consideration of how the public’s 
interpretation of TCs corresponds to a legal interpretation of TCs.  What this survey does demonstrate, 
however, is that both TCs and packaging have an effect on how members of the public identify CAM 





11 Misleading or Deceptive Packaging & the Fair Trading Act 1986 
11.1 Introduction 
Chapter 7 initiated a discussion of misleading and deceptive conduct and representations in the 
context of the advertising and sale of CAM products.  It considered the various sections of the FTA and 
CGA and suggested that while sections in both Acts were potentially applicable to CAM products, the 
FTA posed the most likely course of action in terms of the appropriateness of its remedies. 
Chapter 11 considers the applicability of the FTA in the context of the packaging of CAM products.  
This discussion is a consequence of the results of the surveys, as discussed in Chapters 9 and 10, which 
indicated that packaging may have a material effect upon consumers’ identification of CAM products, 
and their consequent perceptions of those products. 
This Chapter discusses whether the packaging of CAM products can in fact be misleading under ss9, 
10 and 13 FTA, through an application of the law, as previously considered, to the evidence obtained 
in the previous two chapters.1001 
11.2 Liability under sections 9, 10 & 13 Fair Trading Act 
Before delving into the central issue of whether packaging can be misleading, it is necessary to briefly 
establish that the other criteria for ss9, 10 and 13 FTA are met, before proceeding with a discussion 
on misleading and deceptive (or misleading, or false or misleading) packaging.1002 
11.2.1 Section 9 
Section 9 FTA requires three elements to be proven: the person must be in trade, there must be 
conduct, and that conduct must be likely to mislead or deceive.1003 
As discussed at 7.3, ‘in trade’ has a wide ambit, and therefore the advertising, promotion or sale of 
CAM products in the packaging in question, as a business activity, or in preparation for a business 
activity will meet this criteria.  Likewise, the advertising, selection of how CAM products will appear 
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relevant, as misleading packaging is likely to be distinct from more ‘normal’ representations, as evidenced by 
the discussions in this Chapter.  See 7.7 for more on s12A and unsubstantiated representations. 




to the consumer, or sale of the CAM products will amount to ‘conduct’, while the ‘misleading or 
deceptive’ requirement will be discussed in more detail below at 11.3 and 11.4. 
11.2.2 Section 10 
Section 10 FTA also requires three elements to be proven: the person must be in trade, there must be 
conduct, and that conduct must be liable to mislead as to the nature, manufacturing process, 
characteristics, suitability for a purpose, or quantity of the goods.1004 
As for s9, the requirements of s10 around being ‘in trade’ and engaging in ‘conduct’ will also be met.  
Furthermore, there is little question that if misleading conduct is established by the packaging as 
considered below, it will relate to the ‘nature’, ‘characteristics’, or ‘suitability for a purpose’ of the 
goods.  Finally, it is important to reiterate that the standard in s10 of ‘liable to mislead’ is lower than 
that of s9, being ‘likely to mislead’.1005 
11.2.3 Section 13 
Section 13 FTA requires three slightly different elements: the person must again be in trade, there 
must be a representation of the kind listed in subs(a)-(j) that is false or misleading, and that 
representation must be in connection with the supply or promotion of goods or services.1006 
The term ‘representations’ in s13 is narrower than ‘conduct’ as in ss9 and 10,1007 but in this instance, 
the packaging and the language displayed on this is almost certainly a representation as to the goods 
contained inside, bringing it well within the scope of s13(a), and perhaps even subs(e).  Once again, 
the ‘in trade’ requirement will be met in this instance, and the mere display of the packaging certainly 
amounts to the ‘promotion’ or ‘possible supply’ of the goods for the purposes of this section.  As with 
s10, the individual requirements of s13(a) and (e) that the goods be misleading as to the ‘kind’, 
‘performance characteristics’, or ‘uses’ will be satisfied if the packaging can be found to be misleading 
as to the identity or efficacy of the goods. 
11.3 Can aspects of the packaging be misleading? 
Having established that the other requirements of ss9, 10 and 13 FTA are met, the question turns 
towards whether the packaging itself can be misleading and deceptive.  There are two cases in NZ 
which have considered whether the packaging, or aspects of the packaging can be misleading or 
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deceptive; CC v Reckitt Benckiser (New Zealand) Ltd concerning the colour of the packaging, and CC v 
Sweetline Distributors Ltd on misleading packaging in the case of slack-fill. 
11.3.1 Colour 
In CC v Reckitt Benckiser (New Zealand) Ltd,1008 four Nurofen products were labelled as ‘Nurofen 
Migraine Pain’, ‘Nurofen Tension Headache’, ‘Nurofen Period Pain’, and ‘Nurofen Back Pain’,1009 and 
these all contained statements indicating particular pain relief from the named problems.  
Additionally, “[t]he specific pain products had different coloured packaging and were frequently sold 
side by side on stall shelves.”1010  Although Reckitt Benckiser pleaded guilty in this case, the Judge 
acknowledged the importance of “…the overall impression created by the packaging…”,1011 which 
suggests that the totality of the packaging, colour, and labelling would be relevant if a similar case 
were to be decided by the courts. 
Reckitt Benckiser pleaded guilty to the charges under s10 FTA relating to misleading representations 
with respect to their packaging and website,1012 with the case noting: “RBNZ responsibly accepts the 
overall impression created by packaging a product that specifically nominated a type of pain was liable 
to mislead consumers.”1013  Although this case is not decided on the packaging alone, nor does the 
Judge consider whether the packaging itself is misleading, the acknowledgement of the packaging as 
a factor in the ‘overall impression’ that ‘was liable to mislead consumers’ shows a clear path for the 
courts’ acceptance of misleading packaging in the appropriate case. 
11.3.2 Slack-fill 
Slack-fill is a form of misleading or deceptive packaging, usually achieved by using a container to make 
it appear that there are more, or bigger, contents than is actually true.1014  Slack-fill can still occur 
when the weight on the product’s package is correct, if the information on weight is insufficient to 
address the overall impression of the size or number of products. 
While the issue of slack-fill has not been widely addressed in NZ, it has been raised in a couple of cases, 
the most pertinent being CC v Sweetline Distributors Ltd,1015 as discussed in detail below.  Similar 
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1009 At [5]. 
1010 At [6]-[7]. 
1011 At [22]-[24]. 
1012 At [1]. 
1013 At [22]. 
1014 Eric C. Wall “A Comprehensive Look at the Fair Packaging and Labeling Act of 1966 and the FDA Regulation 
of Deceptive Labeling and Packaging Practices: 1906 to Today” (Harvard University, 2002), at 5. 




examples arise occasionally, like the recent situation involving Inghams Enterprises and Tegal Foods, 
where the CC issued a warning over the size of their chickens, which despite containing the correct 
net weight on the package, was overinflated due to the chickens including marinade and stuffing, 
rather than just the chicken.1016 
Slack-fill has been more widely addressed in the USA, which not only has legislation to protect against 
it,1017 but also has seen a number of cases around the issue of slack-fill.  The majority of these cases 
relate to food products or consumer toiletries.1018 
Sweetline is the only case in NZ which not only establishes misleading packaging as an actionable 
offence under the FTA, but effectively does so on the basis of slack-fill.1019  Here, the defendant 
imported and sold Easter eggs in containers similar to that in which poultry eggs are packaged.  
However, the packages did not contain normal, egg-shaped marshmallow eggs, but instead contained 
half-eggs, which were flat on one side.  While the net weight of the product was correct on the label, 
there was 67.98% free space inside the packaging.1020  The CC brought that action under s10 FTA, or 
s13(a) in the alternative, with the Judge sentencing under s10.  In convicting the defendant, the Judge 
noted that the case relied entirely on the representation made by the packaging, and confirmed that 
s10 covers virtually the same conduct as s13:1021  
In this case it is not suggested that the defendant, or any person on its behalf, made any 
representation beyond the presentation to its customers of a sample package. That is 
essentially the same conduct that I have already held amounts to misleading conduct in terms 
of s10. 
The key point from Sweetline is that the packaging, in and of itself, was misleading and deceptive 
under s10 FTA. 
11.4 Can the type of packaging be misleading? 
Having established that all but the misleading and deceptive elements of ss9, 10 and 13 are met, and 
following a discussion of the two NZ cases which raise misleading or deceptive packaging, it is now 
                                                          
1016 Commerce Commission “Commission issues warning over chicken size representations” (press release, 7 
March 2017). 
1017 Federal Food and Drugs Act § 8, 34 Stat. 768 (1906) (USA); Food, Drug, and Cosmetic Act 1938 (USA). 
1018 See Wall, above n 1014, at 7-9 for a discussion on some of these cases, although there have been more 
recent cases and settlements involving, for example, lip balm (Ebner v Fresh Inc. No. SACV 13-477 JVS, 2013 WL 
9760035 (CD Cal 2013)), tuna (Hendricks v StarKist Co. 13-CV-729 YGR; 2014 WL 1245880 (CA 2014)) and the 
cases surrounding false bottoms or sides to the container involving Johnson & Johnson and others. 
1019 While the whole case effectively centres around slack-fill, as can be seen from the facts which follow, the 
exact issue was never named as such in this case. 
1020 Commerce Commission v Sweetline Distributors Ltd, above n 1015, at 1. 




necessary to turn to the most important question; whether the packaging alone can be misleading or 
deceptive.  This consideration will involve a review of the criteria for misleading and deceptive conduct 
in line with the Red Eagle and Heaven tests, followed by an holistic discussion which utilises the survey 
evidence and the preceding material around the FTA to ascertain whether misleading packaging is a 
viable course of action. 
11.4.1  Misleading packaging in light of Red Eagle & Heaven 
In Chapter 7, the two tests for determining misleading or deceptive conduct were outlined; the three-
stage test in AMP Finance NZ Ltd v Heaven, and the alternative and simpler approach of Red Eagle 
Corporation v Ellis.1022  Were a misled individual to take action against a CAM product company on the 
basis of misleading packaging, the most appropriate test for determining misleading or deceptive 
conduct would be Red Eagle, as it is readily applicable to situations involving a party who has directly 
suffered loss.  However, as with the application of Heaven to MMS,1023 this matter of misleading or 
deceptive packaging is not the kind of ‘straightforward’ case that Red Eagle is designed for, and 
consequently, Heaven is a more appropriate test in this instance. 
As in section 7.3.2 and 7.3.5 where the test in Heaven was applied to the case study of MMS, there 
are three criteria to meet: whether the conduct is capable of being misleading, whether people are 
likely to be misled, and whether a reasonable person will be misled by the same conduct. 
In applying this test to the abstract packaging issue, it is helpful to use applicable results from the two 
surveys to ascertain whether the criteria are met.  The results in Survey 1 show participants 
conclusively identifying boxed products as medicines (Figure 9.18).1024  While Survey 2 shows less of a 
disparity between participants’ identification of boxed and bottled products, there is an undeniable 
trend for boxes to be more commonly associated with medicines, as demonstrated by the results in 
Figure 10.20, and more participants identifying boxed products as medicines, than identifying the 
corresponding bottled product as a medicine (Figure 10.18-Figure 10.19).1025  This indicates that the 
conduct of packaging CAM products in boxes may be capable of being misleading. 
In addition to substantiating the first criteria, these survey results also show that people are likely to 
be misled by the packaging of CAM products in boxes. 
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The third criteria of the test in Heaven is an objective consideration.  As noted when this test was used 
to apply s9 FTA to the MMS case study, the test requires identification of the relevant section of the 
public and then a consideration of whether members of this group would be misled.1026  Without an 
actual case at hand, it is difficult to isolate a section of society.  Nevertheless, the surveys provided 
two particular groups.  The Pilot Study showed that a reasonable student could be misled by the 
packaging, while the Representative Study provided strong evidence for general public being misled 
by the packaging of products in boxes.  On the basis of the evidence in the surveys, there is an arguable 
case for the packaging being likely to mislead or deceive the reasonable consumer. 
11.4.2 A discussion on misleading packaging 
Although there is an arguable case for misleading packaging, it is unclear on the currently available 
evidence whether such a case would succeed. 
While misleading CAM product packaging arguably meets the test in Heaven and may be likely to 
mislead consumers, such case would have a greater chance of success by taking an action under s10 
FTA due to the lower threshold for ‘liable to mislead’ under s10, than ‘likely to mislead’ in s9.  If the 
conduct could be shown to be liable to mislead, there is no doubt that it would be established ‘as to 
the nature of the goods’.  Section 13 could be argued in the alternative, although CC v Reckitt Benckiser 
established that misleading conduct in terms of s10 encompassed misleading representations.1027  
Furthermore, both CC v Reckitt Benckiser and Sweetline were decided under s10, demonstrating the 
applicability of that section to misleading packaging. 
Although both studies would likely be admissible in such a case, their probative value may not be high, 
as their purpose was for general information gathering with a broad ambit.  The two surveys in this 
thesis would help identify potential misleading and deceptive elements in the advertising and sale of 
CAM products, and would provide useful evidence in a case, but in seeking a remedy, a directed survey 
will be more persuasive.  For greater applicability to an individual case relating to packaging, a survey 
would need to be commissioned specifically for that case, to achieve the necessary focus and 
representativeness. 
Considering the bigger picture for a moment, if the CC were to bring an action around CAM product 
packaging, it is highly unlikely that such an action would be brought in isolation from other elements 
of the packaging and labelling, which have a combined effect to be misleading and deceptive.1028  
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These were discussed at Chapter 9, and include elements like the ‘dietary supplement’ label, and TCs 
on CAM products.  To take the example of Arnica from the Pilot Study, the combination of a boxed 
CAM product that is liable to mislead consumers, evidence in the form of the survey which showed 
consumers being misled into identifying the product as a medicine, and a possible TC on the label, are 
highly likely to result in an action by the CC under ss10 and 13 FTA being successful. 
Although a potential action against misleading packaging under the FTA is a positive enforcement 
measure, ideally the government would assess the problems like this which permeate CAM product 
regulation, and ensure new legislation or regulations adequately addresses them such that general 
legislation does not need to step in where specific legislation is not considered sufficient.  This thesis 
proposes a new regulatory scheme in Chapter 12, and the issue of packaging is included in this 
proposal. 
11.5 Conclusion 
This Chapter suggests that the choice of packaging itself may be misleading or deceptive, or at 
minimum liable to mislead or deceive in contravention of ss10 and 13 FTA.  Misleading and deceptive 
packaging is able to be established through the language of the section, with the aid of the recognised 
tests for misleading and deceptive conduct, and this approach is not inconsistent with the wording or 
purpose of these sections.  Furthermore, the little precedent which exists in NZ around misleading 
packaging supports the argument that given the right case, with evidence of misleading conduct like 
that provided by the two surveys, there may be a good argument for misleading packaging in NZ. 
There are not many cases on misleading packaging, but the prevalence of CAM product use as 
demonstrated in the surveys by the number of people using the products, coupled with their 
frequency of use suggests that it is only a matter of time before such an issue appears before the NZ 
courts.  Nevertheless, rather than leaving the FTA to pick up the pieces of lacking CAM product 
legislation, it is recommended that new legislation is considered, which acknowledges the problems 




Part IV: A New Hope 
12 A Proposal for a New CAM Product Regulatory System 
This proposal is the pièce de résistance of the entire thesis.  It utilises discussion from the preceding 
chapters in order to design draft legislation which seeks to regulate CAM products now, and into the 
future.  However, this proposal goes beyond merely attempting to regulate in the heavy-handed, over 
prescriptive manner of previous iterations of CAM legislation like the NHSPB, but aims to put forward 
a mechanism by which, over time, scientific evidence can be obtained that establishes the efficacy of 
particular CAM products; ultimately creating a safer, more effective, more transparent marketplace 
for the benefit of all stakeholders.  
This Chapter follows a legislative structure.  It begins with a brief commentary justifying the need for 
a new regulatory regime, then gives an overview of the proposed Bill.  There are four parts to this Bill; 
preliminary matters, a risk-based approach to the regulation of CAM products, the administration of 
the Bill, and enforcement of the proposed legislation.  The Chapter concludes with a brief look at the 
key provisions to be included in regulations to the Bill, as well as practicalities associated with the 
enactment of such a system. 
For ease of reference, the proposed legislation appears in full in Appendix 5. 
12.1 Introduction 
12.1.1 Why a new proposal is necessary 
There is no question amongst stakeholders that some new form of regulation is necessary; the issue 
being what form such regulation should take.  The current DSRs are so lacking they have been 
described as tantamount to deregulation.1029  Even the MoH acknowledges the numerous problems 
with the existing framework; including the unchecked TCs and misleading information on CAM 
products, 1030  a systemic lack of information on the safety of CAM products, 1031  a widespread 
classification issue resulting in a lack of clear delineation between food, medicines and CAM 
products,1032 and a regulatory system for CAM products which lags behind most countries.1033 
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Various options for reform have been proposed, including a joint trans-Tasman approach to regulation 
of therapeutic goods,1034 a permissive approach which effectively allows industry to self-regulate,1035 
continued regulation of CAM products under food legislation,1036 or regulation of CAM products under 
medicines’ legislation.1037  The latter two options were considered in the regulatory impact statement 
for the NHSPB, with this regulatory impact statement ultimately favouring a new option: regulation of 
CAM products through specific individual legislation.1038     
It is submitted that specific legislation, as recommended in the regulatory impact statement, is the 
most appropriate way forward, however this does not mean that the NHSPB should be considered an 
appropriate model for legislation.  The NHSPB attempts to regulate in a reactive manner, imposing 
strict and uncompromising regulations which leave no room for flexibility to either relax the approach 
in response to well-researched and effective products, or to draw a line in the sand banning unsafe 
products with no benefit.   
This Chapter will argue that what is needed is an approach that drafts specific legislation for CAM 
products, and which is proactive in encouraging research into the safety and efficacy of CAM products.  
This approach regulates on the basis of sound risk assessments and scientific evidence, and 
incorporates a principle of flexibility to ensure the ongoing relevance and reactiveness of the proposed 
legislation. 
12.1.2 New Zealand’s international treaty obligations 
It is essential in the design of new legislation for NZ that this is consistent with obligations surrounding 
existing legislation and international agreements with other countries.  This thesis has already 
considered the primary pieces of legislation which this proposed Bill will affect,1039 and addresses 
those interactions where they arise throughout this Chapter.  However, it is important to acknowledge 
key international agreements which may be affected by this proposed Bill,1040 as well as the defining 
treaty of NZ’s constitutional foundation; the Treaty of Waitangi. 
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The Agreement on Closer Economic Relations1041 between Australia and NZ is noted to be one of the 
most comprehensive in the world.1042  Alongside the Closer Economic Relations is the TTMRA codified 
in the 1997 Act,1043 which removes restrictions on the free movement of most goods and persons 
between Australia and NZ.1044  However, s79 and Schedule 2 TTMRA Act prevent the free movement 
of therapeutic goods between the two countries,1045 so unless the scheme this Bill develops is explicitly 
accepted as commensurate with the Australian regulation of CAM products1046 and changes are made 
to the TTMRA Act to reflect this, there will be no substantial effect by this legislation upon NZ’s trade 
agreements with Australia. 
The application of the 2008 Free Trade Agreement between NZ and China to CAM products is 
unclear,1047 as there is no specific information on these products in the trade deal or associated 
material.1048  When considered in light of the strict policy already operated by NZ Customs with 
regards to the entrance of plant, animal, or food matter into NZ without a licence, it is apparent that 
this Bill is unlikely to affect the NZ-China free trade agreement in any way. 1049   
The Comprehensive and Progressive Agreement for Trans-Pacific Partnership1050 (formerly the Trans-
Pacific Partnership Agreement1051) is a free trade agreement between 11 countries1052 designed to 
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signature); as at the time of writing, drafting of the new agreement was underway, with minor adaptations to 
the earlier iteration, the Trans-Pacific Partnership Agreement, in recognition of the new nature of the agreement 
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“Trans-Pacific Partnership Agreement (TPP)” (2017) <www.mfat.govt.nz/>. 
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relieve trade tariffs, draw the economies of the countries together, and amongst other matters, 
harmonise intellectual property regulation between countries to streamline protection of goods.1053  
While the Agreement does not directly address CAM products, issues around pharmaceuticals and 
intellectual property rights can have flow-on effects for the regulation of CAM products.  However, 
this Bill will not alter intellectual property rights around CAM products; instead leaving any changes in 
this area to more specialist intellectual property legislation like the Patents Act 2013, 1054  and 
consequently, this Bill will not affect any of NZ’s obligations under this Agreement.1055 
This Bill recognises the unassailable role that the Treaty of Waitangi plays in NZ’s constitutional 
framework.  Although this Bill is focussed on CAM products, and will not regulate the practice of 
rongoā, or other CAM practices, it is foreseeable that an issue like the commercial production of 
rongoā products could arise.  Therefore, it ensures, through a couple of mechanisms,1056 that Māori 
interests and the principles of the Treaty underlie the Bill, and that the recommendations of the Wai 
262 report are incorporated, insofar as relevant.1057 
12.1.3 An overview of the proposed Bill 
This proposal recommends regulation of CAM products through an evidential, risk-based approach 
similar to the FA 2014 and MA, incorporating three tiers for CAM products commensurate with their 
risk, and the evidence available as to their effects and benefits.  Alongside these tiers will be a black-
list, which will prohibit ingredients or products known to be dangerous, that also have a risk profile 
such that they do not merit being in CAM products.  To oversee this regime, a regulator would be 
created, which would oversee pre-approval screening, classification and reclassification of products, 
and post-market surveillance.  The system would be partly government funded and partly industry 
funded, with a sliding fee scale which promotes safety and efficacy in CAM products through lessened 
costs depending on the tier classification.  The proposal adopts a number of specific policies which 
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aim for a more harmonised approach with international regulators in recognition of NZ’s size and 
limited capacity, as well as upholding and respecting the principles of the Treaty of Waitangi and rights 
of Māori as tangata whenua.  Some of the significant provisions of the proposal will be discussed 
below, while the full draft Bill is included in Appendix 5: The Complementary and Alternative Medicinal 
Products Bill.  Where appropriate, clauses of the Bill footnote or explain comparisons with other 
legislative provisions which were used in the design and drafting of the particular clause. 
12.2 The Complementary and Alternative Medicinal Products Bill: Part 1 – Preliminary provisions 
12.2.1 Title 
1 Title 
This Act is the Complementary and Alternative Medicinal Products Act 2017. 
Throughout this Chapter, the proposed Bill will be abbreviated as the CAM Products Bill. 
12.2.2 Overview 
2 Overview 
The CAM Products Bill will adopt an overview clause akin to that in the FA 2014.  This will provide an 
overview on the direction of the legislation, which will potentially be more complicated than the 
NHSPB due to its thorough, reactive and scientific risk-based approach.1058   
The Bill will contain four parts.  Part one will comprise preliminary provisions around the purpose, 
principles and definitions of terms in the Bill.  Part two will detail the crux of the proposal; the risk-
based approach to the regulation of CAM products.  Part three will concern the administration of the 
Bill, outlining the authorities and their functions around the Bill’s operation.  Finally, Part four will 
broadly contain enforcement provisions, including offences, defences, and other remedies available 
under the Bill.  There may be additional Parts added relating to export, audit, licensing and other 
matters, but these will not be discussed here.  The Bill will include three schedules; the black-list,1059 
approved international regulators,1060 and approved published materials.1061 
12.2.3 Purpose1062 
3 Purpose 
The purpose of this Act is to— 
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1059 Schedule 1, Complementary and Alternative Medicinal Products Bill 2017. 
1060 Schedule 2, Complementary and Alternative Medicinal Products Bill 2017. 
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(a) restate and reform the law relating to the sale, marketing, advertising, and trade of 
complementary and alternative medicinal products; and 
(b) achieve safety and quality in complementary and alternative medicinal products; and 
(c) regulate complementary and alternative medicinal products in a manner commensurate 
with the risk of these products, by providing for a risk-based approach that— 
(i) minimises and manages the risks to public health; and 
(ii) ensures any claims of efficacy are supported by sound scientific evidence; and 
(iii) require persons who trade in complementary and alternative medicinal 
products to take responsibility for the safety and suitability of those 
products. 
Both the FA and the NHSPB include a purpose clause which sets out the direction of the legislation.  
Rather than adopt a similar succinct statement of purpose to the NHSPB,1063 the CAM Products Bill has 
followed the FA 2014, with a relatively detailed purpose clause which focuses on the key 
characteristics of the Bill which are developed in this Chapter.1064 
12.2.4 Principles 
4 Principles 
This Act is based on the following principles: 
(a) that the regulation of complementary and alternative medicinal products is managed by 
a risk-based approach; and 
(b) that the regulation, classification, sale, trade, marketing, advertising, decision making 
and any other matters under this Act are all supported by sound scientific evidence, unless 
otherwise stipulated in the risk-based approach; and 
(c) that the regulation of complementary and alternative medicinal products under this Act 
favour a flexible approach, where products are reasonably judged on their own merits. 
While this Bill will include a principles clause like the NHSPB, it is otherwise quite distinct in its 
execution.  Where the NHSPB principles clause puts forward specific aims of the legislation; for 
example the information to be included on the label of CAM products and the basis for HBCs,1065 cl4 
                                                          
1063 Natural Health and Supplementary Products Bill 2011 (324-2), cl3; “Purpose 
The purpose of this Act is to establish a system for the regulation of natural health and supplementary products 
in New Zealand.” 
1064 Compare: Food Act 2014, s4; Natural Health and Supplementary Products Bill 2011 (324-2), cl3. 
1065 At cl4; “Principles 
This Act is based on the following principles: 
(a) that natural health and supplementary products should be fit for human use: 
(b) that the regulation of natural health and supplementary products should be proportionate to the risks 
associated with their use: 
(c) that natural health and supplementary products should be accompanied by information that— 
(i) is accurate; and 




CAM Products Bill will simply posit three foundational propositions intended to underpin the entire 
legislation. 
Firstly, this Bill reiterates the principle of a risk-based approach.  While the NHSPB also notes that 
“…regulation… should be proportionate to the risks…”,1066 its mechanism of achieving such regulation 
by permitted and prohibited ingredient lists is unlikely to be sufficient.1067  In contrast, the CAM 
products Bill develops a detailed and effective plan for managing CAM products in line with their risks.  
Similar risk-based measures have been demonstrated to be both workable and effective in the FA 
2014 and MA. 
The second principle of this proposal is its basis in science.  A risk-based approach cannot exist without 
a firm foundation of scientific knowledge upon which to analyse the hazard and exposure and thus 
determine the risk.  Where the NHSPB only looks to make HBCs scientifically supported,1068  this 
proposal goes further, requiring scientific evidence to underpin all aspects of the regulation of CAM 
products under this Bill.  It does, however, allow room for traditional evidence to be used in support 
of tier 3 products. 
Thirdly, the principle of flexibility aims to encourage and foster research into CAM products, generally 
and specifically.  Ideally, as a result of this flexibility in the risk-based approach outlined at cl9,1069 the 
problems of a lack of information on the CAM product marketplace identified in the regulatory impact 
statement for the NHSPB can be addressed with additional data and evidence around all aspects of 
CAM products.  A flexible piece of legislation would be perfectly positioned to then respond to these 
developments, through conventional means of regulations where necessary, but ideally through the 
decisions and application of the law by the regulatory authority, if the legislation strikes a suitable 
balance of prescriptiveness such that decisions are fair, while maintaining some flexibility and 
discretion in its application. 
12.2.5 Interpretation 
5 Interpretation 
In this Act, unless the context otherwise requires, — 
                                                          
(d) the health benefit claims made for natural health and supplementary products should be supported by 
scientific or traditional evidence.” 
1066 At cl4(b). 
1067 See discussion on the permitted and prohibited ingredients lists at 5.6. 
1068 Natural Health and Supplementary Products Bill 2011 (324-2), cl4(d). 




black-list means the register of prohibited products or ingredients, listed in Schedule 1 and 
declared by the Regulatory Authority under section 10 to be a prohibited substance on the basis 
of a risk assessment 
The black-list will be discussed in more detail at 12.3.9. 
complementary and alternative medicinal product has the meaning given to it by section 6 
dietary supplement is a sub-group of complementary and alternative medicinal products that— 
(a) is intended to be ingested orally; and 
(b) is intended to supplement the amount of amino acid, edible substance, herb, mineral, 
synthetic nutrient, or vitamin normally derived from food products 
This definition of ‘dietary supplement’ is a paired down version of that in both the DSRs and the 
NHSPB.  It clarifies that these products come under the general umbrella of CAM products, but also 
specifies the products which may be part of this sub-group.  This will be discussed further in cl6 under 
the definition of CAM products.1070 
efficacy claims are statements on the positive benefits or effects of complementary and 
alternative medicinal products that— 
(a) are prohibited for tier 3 products; but 
(b) are permitted for tier 2 products where they— 
(i) are supported by scientific evidence; and 
(ii) are on prophylactic uses for complementary and alternative medicinal products, 
including, but not limited to dietary supplementation and nutritional support; and 
(c) are permitted for tier 1 products where they— 
(i) are supported by scientific evidence; and 
(ii) are on prophylactic uses for complementary and alternative medicinal products, 
including, but not limited to dietary supplementation and nutritional support; or 
(iii) are for relief of mild, or low-grade medical conditions; or 
(iv) are for symptomatic relief from the effects of mild, or low-grade medical 
conditions; but 
(d) do not include statements that— 
(i) claim to cure any medical condition; or 
(ii) claim to treat any medical condition; or 
(iii) make any reference to acute illness, chronic illness, severe illness, cancer, or any 
other serious curable, manageable, or treatable medical condition; or 
(iv) relate to children, or childhood illnesses in any way 
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The term ‘efficacy claims’ was selected as an alternative to ‘therapeutic claims’, ‘therapeutic 
purposes’, and ‘health benefit claims’ and the confusion the use of these terms has generated.  This 
definition is very detailed, forming one of the key components of the risk-based approach outlined at 
cl9 below.  The ability for products to make efficacy claims as outlined in this definition will be 
discussed in more detail there, but it is important to briefly highlight sub-cl(d).   
By excluding statements of treatment or cure, the definition leaves these as the domain of the MA, 
where the level of testing and regulation is necessarily higher to reflect medicines’ added risks and 
benefits.  Furthermore, products are prevented from making efficacy claims which provide false hope 
for serious conditions which can be medically handled in any way; requiring any evidence-based 
treatment for such ailments to go through the process of becoming a medicine, and thus having 
regulation commensurate with its risks and benefits.  Finally, efficacy claims are prevented on 
targeting their products towards children, due to the potential for increased susceptibility from 
harmful side-effects, children’s lack of autonomy, and the need for parents to seek proper medical 
attention for their children rather than relying on CAM products. 
food products— 
(a) means any product which has the appearance of food products or drink as they are 
ordinarily understood; and 
(b) either— 
(i) is primarily intended for human consumption as food products or drink; or 
(ii) is primarily used as an ingredient in food products or drink for human 
consumption; and 
(c) includes— 
(i) formulated supplementary sports food as defined by standard 2.9.4 Australia New 
Zealand Food Standards Code 2002; and 
(ii) supplemented food as defined by the New Zealand Food (Supplemented Food) 
Standard 2016 
This definition avoids importing the definition of food from s9 FA due to its broad nature, which would 
encompass a number of CAM products and their ingredients.  Instead, this definition will use the 
slightly different term of ‘food product’, while also having a narrower scope than ‘food’ in the FA.  




Although cl6(3) NHSPB employs the concept of defining food by its ‘ordinary use’, 1071  the CAM 
Products Bill definition will emphasise, to a greater extent, the importance of the intended purpose 
or use of the goods, based on the ‘ordinary use’ template used in the CGA when defining ‘consumer’ 
at s2.1072  This is critical where examples like turmeric or garlic are considered; if they are presented 
as, or intended for use in, a food or drink, then they should be regulated as a food and not a CAM 
product.1073 
healthcare advisory statement is a statement which notes— 
(a) if side effects occur, please consult your doctor or pharmacist, and remember to always 
check with your healthcare professional before mixing medicines and CAM products 
This healthcare advisory statement is similar to the warning statements required for medicines under 
reg13 MRs, albeit less detailed.1074  This Bill proposes a single, simple statement to appear on every 
CAM product to ensure people are presented with the same information across the board, and are 
under no illusions that natural products are ipso facto safe.1075 
herbal medicine or herbal remedy is a sub-group of complementary and alternative medicinal 
products that— 
(a) includes— 
(i) any substance produced by subjecting a plant to drying crushing , or any other 
similar process; or 
(ii) a mixture comprising 2 or more such substances only; or 
(iii) a mixture comprising 1 or more such substances with water or ethyl alcohol or 
any inert substance; and 
(b) is not a medicine 
                                                          
1071 Natural Health and Supplementary Products Bill 2011 (324-2), cl6(3); “In subsection (1), food means anything 
that is ordinarily used or represented for use as food or drink for human beings.” 
1072 Consumer Guarantees Act 1993, s2; “consumer means a person who— 
(a) acquires from a supplier goods or services of a kind ordinarily acquired for personal, domestic, or 
household use or consumption; and 
(b) does not acquire the goods or services, or hold himself or herself out as acquiring the goods or services, 
for the purpose of— 
(i) resupplying them in trade; or 
(ii) consuming them in the course of a process of production or manufacture; or 
(iii) in the case of goods, repairing or treating in trade other goods or fixtures on land” 
1073  Compare: Food Act 2014, s9; Consumer Guarantees Act 1993, s2; Natural Health and Supplementary 
Products Bill 2011 (324-2), cl6(3). 
1074 The requirement in reg13(1)(i) MRs for warning statements is a general requirement, which is then specified 
by Medsafe’s label statements database; Medsafe “Label Statements Database” (July 2017) 
<www.medsafe.govt.nz/>. 




This definition will bring herbal medicine or herbal remedy under the present Bill as a CAM product, 
while also envisaging the definition of herbal remedy being removed from the MA.  This definition is 
largely taken from the MA, however, there remains scope within s3 MA for a herbal remedy to be a 
medicine where it meets the MA’s requirements.1076 
homeopathy is a sub-group of complementary and alternative medicinal products in which the 
active ingredient to be administered is in a concentration of not more than 10 parts per million. 
This Bill will regulate homeopathy as any other CAM product, although there will be added restrictions 
on its classification, as discussed at 12.3.  The level of 10 parts per million or more dilute was selected 
as incorporating the majority of homeopathic products, although if new scientific evidence suggested 
that products more dilute than this level could be effective, then it could be adjusted to reflect this. 
Minister means the Minister of the Crown who, under the authority of the Prime Minister, is 
responsible for the administration of the Act 
medicine 
(a) is a product that— 
(i) is used for a therapeutic purpose within the meaning of section 4 of the Medicines 
Act 1981; and 
(ii) the Minister has, under section 20 or 23 of that Act, given consent to its 
distribution; or 
(iii) the Minister is, under section 20(7) of that Act, deemed to have given consent to 
its distribution; or 
(iv) the Director-General, has under section 24 of that Act, given consent to its 
distribution; 
(b) includes— 
(i) any related product that the Minister has, under section 20 and 96 of the Medicines 
Act 1981, given consent to its distribution; or 
(ii) any medical device that is the subject of a declaration under regulation 6 of the 
Medicines (Database of Medical Devices) Regulations 2003 
This definition is largely taken from the NHSPB definition of medicine at cl6(2), as it adequately covers 
all the potential categories of medicines.  Additionally, the requirement that a medicine be used for a 
therapeutic purpose further differentiates it from CAM products, as defined at 12.2.6, which will not 
be required to have a health benefit.  As with the definition of food products above, this definition of 
medicine aims to avoid cross-over or confusion between food, medicines, and CAM products insofar 
as practical.1077 
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primary display means the part of a label that is most likely to be displayed, presented, 
shown, or examined, under ordinary or customary conditions of display for retail sale; and, in 
the case of cylindrical packaging or labelling, the width of the primary display shall not 
exceed one-third of the circumference of the package 
rongoā Māori means the practice of Māori traditional medicine and is not regulated by this Act 
where it comes within the scope of complementary and alternative medicine practices at section 
6(2); but where traditional Māori remedies are produced on a commercial scale for sale or supply 




(i) randomised, blind, placebo controlled studies; or 
(ii) meta-analyses or systematic reviews; or 
(iii) reputable scientific texts; or 
(iv) sound, peer reviewed research; or 
(v) material in reputable peer-reviewed scientific journals; or 
(vi) monographs or similar materials from approved international regulators, as listed 
in Schedules 2 and 3; or 
(vii) repeatable experiments; or  
(viii) chemical or biological structure modelling; or 
(ix) chemical structure-activity modelling; or 
(x) verifiable quantitative research; or 
(xi) any combination of the above requirements; or 
(xii) other material deemed to be sound scientific evidence by the regulatory authority 
It is difficult defining what amounts to scientific evidence when it is widely accepted that even the 
process for obtaining scientific evidence for medicines is systemically flawed.  Nevertheless, this list 
attempts to collate widely accepted sources of scientific information, adding qualifiers in some cases 
which require a higher standard, but also allow the regulatory agency some discretion in accepting 
the evidence.  Additionally, sub-cl(xii) envisages that early in its establishment, the regulatory 
authority would establish a set of guidelines relating to the scientific evidence necessary to support 
classification as a CAM product.1078  
traditional evidence is evidence of a longstanding history of use of traditional medicine 
products, commonly sourced from approved published materials listed in Schedule 3 
                                                          




This definition aims to provide flexibility beyond a strict list of pharmacopoeiae, where sufficient 
evidence is demonstrated by an applicant.  It also allows the regulator to exercise some discretion in 
determining what amounts to a ‘longstanding history of use’, and how persuasive this information is 
for the purposes of a product’s classification.  It is intended that Schedule 3 contain the list of 11 
pharmacopoeiae currently in the NHSPB, although a number of these are not available for public 
access, so the final list of approved sources in Schedule 3 should be reviewed by the regulatory 
authority.1079 
traditional medicine products is a sub-group of complementary and alternative medicinal 
products that— 
(a) includes— 
(i) any traditional or indigenous medicine which has a longstanding history of use; 
but 
(b) does not include— 
(i) rongoā Māori 
This definition aims to avoid any debate around traditional versus indigenous medicine by regulating 
both in the same way as any other CAM product providing they have a history of safe use, which will 
be employed in the lower tiers, as discussed at cl9.  Rongoā Māori is defined separated in this Bill. 
12.2.6 Meaning of CAM product 
6 Meaning of complementary and alternative medicinal product 
(1) In this Act, subject to any specific definition provided for use in another section, 
complementary and alternative medicinal product— 
(a) is any product that— 
(i) is intended for human use; and 
(ii) shows scientific evidence or traditional evidence for its safety; and 
(iii) has a risk commensurate with the benefit of the product; and 
(iv) is approved for sale and classified by the complementary and alternative products 
regulatory authority; and 
(b) includes— 
(i) dietary supplements; and 
(ii) herbal medicine or herbal remedies; and 
(iii) homeopathy; and 
(iv) traditional medicine products products; but 
                                                          




(c) does not include— 
(i) any product or ingredient included on the black-list; and 
(ii) complementary and alternative medicine practices, or specialist products 
formulated for an individual patient and dispensed in the course of the practice; 
and 
(iii) any food products, or product presented as a food product; and 
(iv) any medicine, or product presented as a medicine; and 
(v) any product administered by injection, parenteral infusion, application to the eye, 
or application to the ear of any human. 
(2) In this section, complementary and alternative medicine practices means any practice which 
is not a part of standard medical healthcare in New Zealand. 
This definition of CAM product seeks to set defined boundaries for inclusion, while maintaining 
flexibility.  It explicitly excludes foods and medicines in order to clarify the scope of the regulations.  
While it prohibits certain methods of application on the basis of the risks associated with them, it 
intentionally does not specify approved methods of application; leaving wide scope for the legislation 
to encompass a variety of products.  With respect to the delineation with food, it is important to note 
that the phrase ‘must not be presented as a food’ is taken directly from the NHSPB, and was a specific 
recommendation from the Health Select Committee.1080  It enables a line to be clearly drawn between 
food and CAM products, where the boundaries have often been murky.  Finally, this clause 
incorporates a broad definition for CAM practices; using this to exclude any products created by the 
practitioner especially for their customer, on the basis of their practice, from regulation as a CAM 
product within the meaning of this Bill.  Most importantly, as seen in the definition of rongoā Māori 
at 12.2.5, this will exclude Māori traditional medicine in its usual sense from regulation under this Bill. 
12.2.7 The Treaty of Waitangi1081 
7 Treaty of Waitangi (Te Tiriti o Waitangi) 
In achieving the purpose of this Act, all persons exercising functions and powers under it shall 
take into account the principles of the Treaty of Waitangi. 
12.3 The Complementary and Alternative Medicinal Products Bill: Part 2 – Risk-based approach 
8 Overview of this Part 
As with the ‘Overviews of Parts’ in the FA, those in the CAM Products Bill will give an indication of the 
direction of the following Part.  This Part establishes the risk-based approach to CAM product 
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regulation, utilising a table within the legislation in a similar way to the flowcharts in the Income Tax 
Act 2007,1082 before going on to set up a framework for the system in the following clauses.  There 
may also be scope for the examples seen in Table 13.1 to be used in the legislation, in a similar way to 
the Companies Act 1993 or Patents Act 2013.1083 
12.3.1 A Risk-based approach 
Table 13.1 provides an outline of the three tiers, along with a precis of the labelling requirements and 
evidence requirements for each tier.  The examples provided at the end of the table form the basis for 
a more detailed discussion on the practical application and implementation of the scheme in 12.3.6-
12.3.8.  This risk-based approach is a pre-approval scheme requiring products to be classified in one 
of the three tiers prior to being marketed in NZ, and adopts similar tenets to the risk-based measures 
of the FA 2014 and the MA, in the classification of food sectors1084 or medicines1085 respectively, 
according to their risk. 
Table 13.1 is intended to provide a comparative guideline for all stakeholders on the risk-based 
classification of CAM products.  To this end, it could either be included in the legislation or regulations, 
or alternatively could be published by the regulator as an overview of the system. 
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1083 Compare: Food Act 2014, s20.  See Companies Act 1993, ss199 and 207I; Patents Act 2013, ss11, 15 and 282. 
1084 See 2.4. 











High benefit, low risk 
High benefit, Moderate risk 
Moderate benefit, low risk 
Low benefit, very low risk  
No benefit, very low risk 
Can make strong efficacy 
claims 
Can make weak efficacy 
claims 
Cannot make efficacy 
claims 
May be required to specify 
purpose 
May be required to specify 
purpose 
Cannot specify purpose 
No packaging restrictions 
May be limit on amount of 
product per package 
Products cannot be 
packaged in boxes 
Lowest annual licencing 
fees 
Moderate annual licencing 
fees 
High annual licencing fees 
Labelling 
Requirements 
Labelled with a • (green 
dot) and 
‘Tier 1 CAM product’  
on primary display 
Labelled with a • (orange 
dot) and 
‘Tier 2 CAM product’  
on primary display 
Labelled with a • (red 
dot) and 
‘Tier 3 CAM product’ or 
‘Tier 3 Homeopathic 
product’ on primary display 
Must make healthcare 
advisory statement 
Must make healthcare 
advisory statement.  Must 
list side-effects 
Must make healthcare 
advisory statement 





Must supply a copy of the 
label 
Must supply a copy of the 
label 
Must supply a copy of the 
label 
Must have scientific 
evidence on safety.  
Biochemical basis for mode 
of action and toxicological 
safety assessments likely 
required - traditional 
evidence is insufficient. 
Must show sound evidence 
of safety – traditional 
evidence unlikely to be 
enough alone 
Must show some evidence 
of safety – traditional 
evidence will suffice 
Must show biochemical 
mode of action, and provide 
sound scientific evidence 
for efficacy claims, e.g. 
monographs, peer reviewed 
research of clinical studies 
Must hold scientific 
evidence for any efficacy 
claims.  Monographs, peer 
reviewed research, or 
clinical studies all accepted.  
Theoretical basis may be 
acceptable. 
No proof of efficacy 
required 
Must provide evidence of 
GMP, Quality Control and 
product testing 
Must provide evidence of 
GMP & Quality Control 
plans 
Must provide evidence of 
GMP & Quality Control 
plans 
Must provide evidence of 
structural similarity 
assessments 
Must provide evidence of 
structural similarity 
assessments 
No structural similarity 
assessment necessary 
Examples Iron products Olive Leaf 
- Arnica 6X Drops 
(Homeopathic) 
-  Men’s Multivitamins 




9 Classification of complementary and alternative medicinal product tiers for purpose of 
assigning applicable risk-based approaches 
(1) The classification of complementary and alternative medicinal product tiers under this Part— 
(a) is based on, among other things, the level of risk that their activities pose to public health 
in terms of the safety and suitability of complementary and alternative medicinal 
products; and 
(b) is for the purpose of ensuring that the information presented to the public on the labelling, 
packaging and advertising of complementary and alternative medicinal products accords 
with the risk posed by the particular product; and 
(c) is for the purpose of ensuring certainty amongst all stakeholders on the evidential 
requirements and effect of the classification of complementary and alternative medicinal 
products on the 3 risk-based tiers. 
(2) Accordingly, the regulatory authority is responsible for the classification of individual products 
into 1 of the 3 risk-based tiers upon application by the manufacturer, importer, or other interested 
party, in accordance with the measures set out in subsection (3). 
(3)  The measures referred to in subsection (2) are as follows: 
(a) complementary and alternative medicinal products that generally pose a high benefit and 
commensurately low risk are classified as Tier 1 products; and— 
(i) must supply scientific evidence in support of the safety of the product and its 
effect; and 
(ii) are subject to labelling and advertising regulations as appropriate to the individual 
product; and 
(iii) must supply any other material reasonably required by the regulatory authority as 
stipulated in the regulations to this Act: 
(b) complementary and alternative medicinal products that generally pose either a high 
benefit and commensurately moderate risk, or a moderate benefit and commensurately 
low risk are classified as Tier 2 products and— 
(i) must supply scientific evidence, and where relevant, traditional evidence, in 
support of the safety of the product and its effect; and 
(ii) are subject to labelling, packaging, and advertising regulations as appropriate to 
the individual product; and 
(iii) must supply any other material reasonably required by the regulatory authority as 
stipulated in the regulations to this Act: 
(c) complementary and alternative medicinal products that generally pose either a low 
benefit and commensurately very low risk, or no benefit and commensurately very low 
risk are classified as Tier 3 products and— 
(i) must supply either scientific evidence, or traditional evidence, in support of the 
safety of the product; and 
(ii) are subject to labelling, packaging, and advertising regulations as appropriate to 
the individual product; and 
(iii) must supply any other material reasonably required by the regulatory authority as 




Before applying the risk-based approach to three examples which demonstrate the practical 
application of the system, it is necessary to briefly consider a few parts to the administration of this 
scheme.  The CAM Products Regulatory Authority, as established in cl13, will be responsible for the 
operation and functioning of this approach, as detailed in cl14.1086  This will include matters discussed 
below of the pre-approval scheme, reclassification reviews, post-market surveillance, and 
management of fees, as well as handling policy-based matters and designing guidelines around 
product classification, the levels and nature of scientific evidence required for different tiers, and the 
respective stringency around labelling, packaging and advertising regulations for the different tiers.1087 
12.3.2 Pre-market approval 
The risk-based approach proposed in this Bill will be a pre-approval scheme, where products are 
required to be classified before being sold or advertised.  The NHSPB claimed to be a notification 
scheme where manufacturers were required to notify the Authority of the products before they were 
sold.  However, with the advent of black- and white-lists in the NHSPB, and limited HBCs for select 
conditions, this became tantamount to a pre-approval scheme due to the level of restrictions.  In 
contrast, the CAM Products Bill aims to introduce a pre-approval scheme which is considerably more 
flexible than Australia’s system, while upholding the principles of a risk-based approach to ensure safe, 
high quality CAM products for NZ consumers. 
12.3.3 Reclassification reviews 
There are two matters to touch upon with respect to reclassification reviews, as included in the 
Authority’s ambit at 12.4.2.  Classifications, for which the Authority is responsible, 1088  will last 
indefinitely providing the licence fee is paid.  Instances where reclassification may be necessary will 
be where there has been a substantial lapse in the licence fee, but the applicant wishes to sell the 
product again, or where new information or further research has become available, and the applicant 
wishes to reclassify to a higher or lower tier on this basis.   
The second point to note is that licence holders should be aware that each payment of the licence fee 
constitutes a representation that the information submitted with their initial product classification 
remains correct.  There will be a process stipulated in the regulations for minor changes, like new 
labelling or other matters which do not require reclassification, but in the event new evidence shows 
a licence holder’s product is not as effective, not as safe, or not of the requisite quality, then such 
                                                          
1086 See 12.4. 
1087 Compare: Food Act 2014, s21. 




matters must be brought to the attention of the Authority, and will likely require reclassification of 
the product.  Failure to do so will amount to an offence. 
12.3.4 Post-market surveillance 
After its role in classification of CAM products, this proposal envisages post-market surveillance to be 
one of the biggest responsibilities of the Authority. 
Post-market surveillance involves a large number of activities; monitoring the packaging, labelling, and 
sale of CAM products in a physical setting and in an online setting, ensuring licence holders comply 
with the terms of their tier, ensuring new research does not contradict the basis upon which licences 
were granted, ensuring there is no misleading or deceptive conduct or misleading or deceptive 
representations surrounding the products, and monitoring adverse event reporting. 
This Bill will use a similar system to medicines for reporting adverse events; either running the process 
through the regulator, or outsourcing to a pre-existing agency.  For medicines, Medsafe operates an 
adverse event reporting service,1089 as does the NZ Pharmacovigilance Centre, which operates the 
Centre for Adverse Reactions Monitoring out of the University of Otago.1090  Manufacturers, licence 
holders, and medical professionals should be obliged to report any adverse effects, no matter how 
trivial, and consumers should be made aware of the process, and be directed to online forms through 
which they can submit comprehensive adverse event information. 
12.3.5 Costs of the proposal 
On costs, this thesis did not set out to provide an economic analysis of existing, proposed, or future 
CAM product legislation.  Earlier versions of CAM product legislation yielded substantial debate in 
Parliament on the costs of the system,1091 but as one commentator has observed, NZ has a capacity 
problem with respect to regulating CAM, and for that matter medicinal products on their own, and as 
a result any workable system for the regulation of CAM products, will naturally involve significant 
investment and elevated ongoing costs compared to the status quo.1092   
This proposal links licencing fees and product classification costs with the risk tier of a product; using 
costs as an incentivising tool to encourage stakeholders to invest in scientific research into CAM 
products in order to reduce product licencing costs. 
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1091 See 5.3.3. 




Although the exact fees will be imposed by regulation, this proposal envisages that the classification 
fees will be a one-off payment for classification (or reclassification), which recognises the work 
required to review the products and associated material: a high volume of work to review and classify 
tier 1 products is matched by a higher classification fee, while a lower classification fee would be set 
for tier 3 products which are comparatively simple to classify. 
In contrast, the annual licencing fees will fund post-marketing surveillance and registration activities 
by the Authority.  These are again commensurate with the work required for products in particular 
tiers, while achieving a corollary purpose of encouraging product classification in better tiers.  Tier 3 
products inherently have less benefit, with consequent potential for greater risk and thus require a 
higher degree of post-marketing surveillance, and thus higher licencing fees in response.  Meanwhile, 
Tier 1 products will have undergone rigorous classification reviews, and with a greater acceptable risk 
due to their higher benefit, they require less monitoring, and justify lower licencing fees.  Ideally, the 
Authority will set these fees at such a level as to encourage and reward licence holders who undertake 
work to demonstrate the safety, efficacy, and scientific evidence for their products in order to have 
their products classified in a better tier.1093 
12.3.6 An example of Tier 3 products 
This clause provides examples of how products meet the requirements for Tier 3 classification under 
cl9(3)(c)(i), and the consequent obligations to which they are subject under cl9(3)(c)(ii).  It concludes 
by summarising how the products are likely to meet the general classification in cl9(3)(c) as a Tier 3 
product.  Two products illustrate the dual branches to Tier 3: the homeopathic ‘Arnica 6X’ as seen in 
the Pilot Study,1094 and the Men’s Ultivite Multivitamin from the same study.1095 
For ‘Arnica 6X’ it is envisaged that a low level of scientific or traditional evidence will be required to 
demonstrate the safety of the product, in addition to the existence of GMP and quality control plans.  
In this instance, the applicant would likely be required to show that there was virtually no arnica 
remaining in the homeopathic mixture,1096 as well as the fact that the excipients are safe. 
                                                          
1093 This is similar to the more relaxed packaging and labelling standards which will mirror the licencing fee 
incentivisation.  Higher tiers will have more permissive packaging and labelling regulations, due to the evidence 
and more acceptable risk profile, in comparison to the more strict regulations envisaged around the packaging 
and labelling of Tier 3 products.  See 12.6 for more on the regulations, and the packaging and labelling 
suggestions. 
1094 Figure 9.15. 
1095 Figure 9.17. 
1096 A 6X dilution will generally contain one part per million of the active ingredient, which in a volume of 30mL, 




The obligations on the product will likely involve strict labelling and packaging restrictions which 
clearly show that ‘Arnica 6X’ is a homeopathic product, no statement of purpose or efficacy claims, no 
packaging in boxes, and a healthcare advisory statement and list of ingredients displayed on the label.  
These obligations will be established in the regulations, discussed at 12.4.6 and 12.6. 
As ‘Arnica 6X’ is a homeopathic product, its only option for classification is Tier 3 due to the fact that 
there is no scientific evidence for the efficacy of homeopathic products, and thus there is no benefit 
from them beyond the placebo effect. 
For Tier 3 classification, Men’s Ultivite Multivitamin would need to show low level scientific evidence 
of the safety of the constituents, negligible risk from the individual products or their combinative 
effect, and the presence of GMP and quality control processes. 
The labelling and packaging obligations would be akin to that for Arnica, except Ultivite would instead 
state ‘Tier 3 CAM Product’ instead of ‘Tier 3 Homeopathic Product’ on the label. 
While there is a possibility of a multivitamin like Ultivite achieving Tier 2 classification if the 
requirements were met,1097 recent evidence suggests multivitamin supplements provide little benefit 
in tablet form, as the body is unable to absorb them,1098 and without this efficacy or benefit from these 
products, they are unlikely to meet the standard for classification as a Tier 2 product. 
12.3.7 An example of a Tier 2 product 
As with 12.3.6, this clause also considers the requirements for a Tier 2 product under cl9(3)(b)(i), and 
the obligations for that product in cl9(3)(b)(ii), before substantiating its proposed classification as a 
Tier 2 product within cl9(3)(b).  This section uses the Pilot Study example of Olive Leaf.1099 
In addition to requiring scientific and traditional evidence for safety, the requirements in cl9(3)(b)(i) 
are distinct from that for Tier 3 in that they also require evidence of its effect.  The scientific evidence 
required to classify Olive Leaf as a Tier 2 product will be more substantial than that required for Tier 
3 classification.1100  The applicant for Olive Leaf will be required to hold scientific evidence for all 
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1098 Coco Ballantyne “Fact or Fiction?: Vitamin Supplements Improve Your Health” Scientific American (online 
ed, USA, 17 May 2007). 
1099 Figure 9.14. 
1100 If approved by the Authority under cls20 or 21, the applicant may be able to rely, in full or in part, upon the 
monographs prepared by the European Medicines Authority and Health Canada; European Medicines Agency 
Community herbal monograph on Olea europaea L., folium (EMA, online, 22 November 2011); Health Canada 




efficacy claims that the product makes, as well as supplying evidence of structural similarity 
assessments alongside the evidence for the safety of the product. 
In turn, the obligations of the Tier 2 Olive Leaf will be slightly more relaxed than for a Tier 3 product, 
with weak efficacy claims being permissible where supported by evidence.1101  The product may be 
obliged to display a statement to the purpose of the product on the label, and will be required to 
outline the ingredients, a healthcare advisory statement, and a list of side-effects thereon.1102  The 
Authority may also restrict the amount of product permitted in the package if this will lower the risk 
by reducing an individual’s exposure;1103 limiting the amount of active ingredient per tablet or capsule, 
limiting the number of tablets or capsules in the container, or limiting both. 
Olive Leaf is an excellent example of a Tier 2 product, as it shows some evidence of efficacy as an 
antioxidant or diuretic,1104 but there is also evidence of adverse effects associated with its use.1105  This 
balance of benefits and risks will likely result in Olive Leaf’s categorisation as a product with moderate 
benefit and low risk, making it suitable for Tier 2 classification. 
12.3.8 An example of a Tier 1 product 
The requirements and obligations for Tier 1 products again builds upon those for Tier 2,1106 with the 
risk-based scheme envisaging that the regulator will require relatively strong scientific evidence at 
cl9(3)(a)(i), and adopt a permissive approach to labelling and advertising obligations at cl9(3)(a)(ii).  In 
this example, the classification of an iron supplement is considered. 
The requirements for the iron supplement to attain Tier 1 classification should be onerous, to ensure 
that the product is definitely safe and effective.  For this reason, scientific evidence alone must 
demonstrate the safety, mode of action, and efficacy of the product, supported by toxicological and 
structural similarity assessments.  As with the lower tiers, GMP and quality control processes must be 
demonstrated, as well as the existence of ongoing batch testing to ensure consistently high quality 
products.  The quality and nature of this scientific evidence will be required to be of a higher level than 
for Tier 2, with the other major difference between the requirements of these two tiers being that the 
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1103 See Equation 2.1. 
1104 Health Canada, above n 1100, at 2. 
1105 Ian C Shaw “Possible toxicity of olive leaf extract in a dietary supplement” (2016) 129(1432) New Zealand 
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applicant must provide the evidence of efficacy for classification in Tier 1, in contrast to merely 
possessing such evidence in Tier 2. 
With a more stringent pre-approval process, Tier 1 products gain less arduous ongoing obligations.  As 
the iron supplement will have demonstrated efficacy through the scientific evidence and pre-vetting 
of efficacy claims, these claims may be stronger than would be permissible for Tier 2 products.  Aside 
from this, the only other obligations are those of including the green dot symbol and ‘Tier 1 CAM 
Product’ on the label, along with the ingredients and a healthcare advisory statement.  In some 
instances, the Authority may require the purpose of the product to be displayed where efficacy claims 
are not present or the purpose is unclear from the claims. 
Iron supplements have a high benefit due to their efficacy in addressing iron deficiency and anaemia.  
They have a relatively low risk, and coupled with the substantial volume of evidence around their 
efficacy and safety, the process for Tier 1 classification for these products would be relatively 
straightforward. 
As a brief postscript, this Bill will view food, CAM products, and medicines on a spectrum, where 
isolated constituents of foods can be CAM products, and the very best CAM products, backed by sound 
scientific research (like iron supplements) can be mainstream medicines.  The three tiers in the CAM 
Products Bill are a part of this spectrum; an identical product may be classified in different tiers if the 
applicant either wishes to make different claims for the products,1107 or merely does not want to 
provide as much evidence or be subject to as rigorous a review as a higher Tier would demand. 
12.3.9 The black-list 
10 Prohibited products or ingredients 
(1) The Regulatory Authority may, on the recommendation of the Expert Advisory Committee, 
declare an ingredient or complementary and alternative medicinal product to be a prohibited 
ingredient or complementary and alternative medicine product, and require that product to be 
listed in Schedule 1. 
(2) … 
(3) A declaration made by the Minister under this section must be published on an Internet site 
maintained by or on behalf of the Authority. 
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The purpose of the black-list is to prohibit substances whose risk is too high when balanced with the 
benefit.  The list will not ban many of the products that fail to attain Tier 3 status, but will primarily be 
used to ban dangerous ingredients or excipients like colouring agents which have next-to-no benefit, 
and fairly strong evidence of risk.  Insofar as the process around black-listing of products, this clause 
provides only a basic framework, which would be expanded upon in the terms of reference for the 
Authority. 
Two examples of products likely to be black-listed are Brilliant black and Tartrazine, which are both on 
the permitted substances list in the NHSPB, despite their only purpose being as colouring agents, and 
having substantial evidence for their toxicological effect.  While there is evidence that colour plays a 
role in the placebo effect in pharmaceuticals, this is insufficient a basis to allow colouring agents with 
a definite risk to be used in CAM products. 
The distinction between the black-list here, and the prohibited and permitted substances lists in the 
NHSPB is that this Bill does not prescribe a white-list, as such a prescriptive approach would 
contravene the principle of flexibility, unnecessarily restrict CAM products while increasing the 
regulatory burden, and not achieve any benefit in terms of a risk-based approach.1108 
12.4 The Complementary and Alternative Medicinal Products Bill: Part 3 – Administration 
11 Overview of this Part 
This proposal does not intend on putting a rigorous structure in place for the Authority, but to note 
some key tenets and responsibilities envisaged for the authority under this Bill. 1109 
12.4.1 Transitional provisions 
12 Overview of transitional provisions 
This proposal then envisages a five year ‘grandfathering period’, whereby any CAM products which 
have been registered could be nominally granted tier 3 status for up to five years while they collected 
the necessary material, and applied for reclassification.  After that period expired, any product which 
had not applied for classification would be struck off, and would have to apply as a new CAM product.  
During this period, the manufacturers would have to pay the Tier 3 licencing fees, incentivising the 
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quick collection of information and application for reclassification into one of the higher tiers where 
appropriate.1110 
12.4.2 Structure and roles of the Authority and its subsidiaries 
13 Complementary and Alternative Medicinal Products Regulatory Authority 
(1) This section establishes the Complementary and Alternative Medicinal Products Regulatory 
Authority (the Authority). 
(2) The Authority is the Director-General of Health. 
(3) The office of the Authority must be administered by the Ministry of Health. 
14 Role of the Regulatory Authority 
(1) The Regulatory Authority has the functions, duties, and powers given to it under this Act. 
(2) The Regulatory Authority has a role in the complementary and alternative medicinal product 
regime that includes, without limitation,— 
(a) engaging in post-market surveillance of any complementary and alternative medicinal 
product, including: 
(i) monitoring compliance with the applicable requirements of this Act; and 
(ii) conducting any testing on complementary and alternative medicinal products to 
verify their contents, safety, efficacy or veracity of their claims, as appropriate. 
(b) co-ordinating the response to emergencies that may undermine the purpose of this Act; 
and 
(c) implementing, managing, monitoring, and auditing the risk-based measures for the 
safety, suitability, and where appropriate, efficacy, of complementary and alternative 
medicinal products; and 
(d) providing information to the complementary and alternative medicinal product industry 
and the public on matters relating to the safety, suitability, and where appropriate, 
efficacy, of complementary and alternative medicinal products; and 
(e) establishing and maintaining the public registers; and 
… 
(l) carrying out any functions that are incidental and related to, or consequential upon, the 
roles set out in paragraphs (a) to (k). 
15 Complementary and Alternative Medicinal Products Expert Advisory Committee must be 
established 
(1) The Authority must establish an expert advisory committee known as the Expert Advisory 
Committee on Complementary and Alternative Medicinal Products (Expert Advisory 
Committee). 
16 Structure of the Expert Advisory Committee 
                                                          




This legislation establishes an Expert Advisory Committee of between 8-12 members with a diverse 
range of backgrounds which represent the majority of stakeholders, including industry, CAM product, 
government, consumer, medical, and scientific representatives.1111 
17 Functions of the Expert Advisory Committee 
(1) The Expert Advisory Committee has the following functions: 
(a) to collaborate and refer decisions to the Māori Advisory Committee, and take the advice 
of the Māori Advisory Committee where appropriate on matters involving; 
(i) Māori traditional knowledge; or 
(ii) Māori traditional medicine; or 
(iii) rongoā Māori; or 
(iv) any indigenous plant or animal materials. 
(b) to issue guidelines and give advice where requested by the Regulatory Authority as to;  
(i) the classification of complementary and alternative medicinal products; or 
(ii) the requirements of the individual tiers of the risk-based approach; or 
(iii) traditional or scientific evidence. 
(c) to provide advice to the Authority on; 
(i) products or ingredients to be included in the black-list at Schedule 1; or 
(ii) international regulators to be approved under section 20; or 
(iii) published materials to be approved under section 21. 
(d) any other function that the Minister assigns to the Expert Advisory Committee by written 
notice. 
18 Designation of Māori Advisory Committee 
A Māori Advisory Committee with expertise in Māori interests, especially insofar as they relate to 
traditional knowledge, flora, and fauna will be adopted from a pre-established Māori Advisory 
Committee set up under other legislation.1112 
19 Functions of the Māori Advisory Committee 
The Māori Advisory Committee will provide advice to the Expert Advisory Committee on any matters 
relating to rongoā Māori, Māori traditional knowledge, and indigenous flora and fauna. 
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Clauses 13-19 establish the basic structure for the administration of the Bill, selecting appropriate 
elements from a range of other legislation.1113  There are two other branches to the administration of 
the Bill which bear mentioning.  Firstly, the Authority will comprise a substantial body of administrative 
staff to carry out the day-to-day workings of the Bill.  Secondly, there will be an internal appeals board 
which can handle basic administrative matters which arise from the functioning of the legislation.  This 
will generally be appeals against denied classifications, or other matters related to the ongoing 
regulation of CAM products.1114 
12.4.3 Publicly available materials 
Alongside its other responsibilities as noted in cl14, the Authority will be required to publish material 
online for consumers and applicants.  In addition to the material in the Schedules to the Bill, there are 
three key categories which the regulator will need to make available on the internet. 
Firstly, there will need to be a searchable database of licenced CAM products, which includes the 
details relied upon in their classification application, and any of the safety, quality and efficacy 
information as applicable.  Licence holders for Tier 2 products will not have to show their efficacy 
information here, but if it is not on the packaging or labelling, they will be required to link to evidence 
of this information on their own internet resources.  The second database the regulator is responsible 
for is one of the scientific and traditional evidence materials relied upon by applicants.  While some 
of this may be available in the database of CAM products, the idea with a source of evidence on CAM 
products is that this has been reviewed and approved by the authority, and provides a valuable future 
resource for the public and potential applicants.  Furthermore, if there are sufficient resources, the 
regulator may be able to conduct research on important compounds, the evidence for which can also 
populate this database.  Finally, the regulator will be required to publish all enforcement decisions 
online.  This will take a similar form to the way the CC publishes decisions, and helps to demonstrate 
enforcement and emphasise the deterrent effect of penalties. 
12.4.4 Approved international regulators 
20 Authority may declare approved international regulators 
This clause allows the Authority to approve similar international CAM product or medicines regulators 
for particular purposes.  It is envisaged that regulators like the Australian TGA, the Natural and Non-
prescription Health Products Directorate in Canada, and the European Medicines Agency will be 
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approved regulators.  The extent to which the decisions and materials produced by approved 
regulators are accepted as evidence towards the safety and efficacy of a product will be a case-by-
case decision for the Authority with respect to each regulator they approve.  Any conditions or limits 
to approved regulators will be listed alongside their approval status in Schedule 2.1115 
12.4.5 Approved published materials 
21 Authority may declare approved published materials 
Much like 12.4.4, this clause allows the Authority to exercise its discretion when allowing published 
materials to be used as evidence in classification applications or other matters.  While materials will 
not need to be permitted to be used as evidence, this system will provide more certainty for applicants 
as to the materials which are already approved, and will make the application and classification 
process easier for both applicant and Authority.  Resources like the monographs of the European 
Medicines Agency, and the pharmacopoeia listed in Schedule 2 NHSPB will likely constitute approved 
sources, although these will need to be reviewed by the Authority to ensure compliance with the 
principles of this Bill.1116 
12.4.6 Regulations 
22 Regulations 
(1) The Governor-General may, by Order in Council made on the recommendation of the Minister, 
make regulations— 
(a) adding a complementary and alternative medicinal product or ingredient to the black-list 
in Schedule 1 if the Minister is satisfied that the product or ingredient does not meet the 
standard for safety under the risk-based approach: 
(b) amend Schedule 2 by— 
(i) adding an approved international regulator to, or removing an approved 
international regulator from, the schedule; or 
(ii) amending a condition or limit on an approved international regulator in the 
schedule. 
(c) amending Schedule 3 by— 
(i) adding an approved published material to, or removing an approved published 
material from, the schedule; or 
(ii) amending a condition or limit on an approved published material in the schedule. 
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(d) prescribing requirements for the labelling or packaging of complementary and alternative 
medicinal products; or 
(e) prescribing requirements for the advertising of complementary and alternative medicinal 
products; or 
(f) prescribing standards or guidelines for scientific evidence or traditional evidence; or 
(g) prescribing standards or guidelines for efficacy claims; or 
(h) prescribing standards or guidelines for the classification or reclassification of 
complementary and alternative medicinal products; or 
(i) prescribing the manner in which applications for classification must be made; or 
(j) prescribing guidelines on good manufacturing practices and quality control processes for 
complementary and alternative medicinal products; or 
(k) prescribing the requirements relating to access of all publicly available information; or 
(l) providing for any other matters contemplated by this Act, necessary for its 
administration, or for giving effect to any provision of this Act. 
This overview of what the regulations will cover is similar to that in cl47 NHSPB.  There may be more 
matters to be added to the list upon completion of the Bill, however it is important that in the final 
drafting of this clause and in the ultimate creation of the regulations, no Henry VIII power is bestowed 
by the regulations such that the Minister can override or change the legislation or effect of the 
legislation by way of the regulations.  The material in a couple of these regulations will be discussed 
in more detail at 12.6.1117 
12.5 The Complementary and Alternative Medicinal Products Bill: Part 4 – Enforcement 
This proposal intends to largely import Part 5 FTA into this scheme to provide for civil and criminal 
sanctions, as well as defences, and alternative penalties like management banning order, enforceable 
undertakings, and corrective advertising orders.  Although the FTA will remain applicable, it is hoped 
that this specific regime will take precedence in order to build a clear series of cases to guide 
manufacturers. 
12.5.1 Misleading and deceptive conduct1118 
23 Misleading and deceptive conduct generally 
No person shall, in trade, engage in conduct in relation to complementary and alternative 
medicinal products that is misleading or deceptive or is likely to mislead or deceive. 
24 Misleading conduct in relation to complementary and alternative medicinal products 
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No person shall, in trade, engage in conduct that is liable to mislead the public as to the nature, 
manufacturing process, characteristics, suitability for a purpose, or quantity of complementary 
and alternative medicinal products. 
12.5.2 Unsubstantiated, false or misleading representations 
25 Unsubstantiated representations 
This clause adopts s12A FTA, but focuses the unsubstantiated representations around CAM products 
and the possible supply or promotion of those products.1119 
26 False or misleading representations 
(1) No person shall, in trade, in connection with the supply or possible supply of complementary 
and alternative medicinal products or with the promotion by any means of the use of 
complementary and alternative medicinal products— 
(a) make a false or misleading representation that complementary and alternative medicinal 
products are of a particular kind, standard, quality, grade, quantity, composition, style, 
or model, or have had a particular history or particular previous use; or 
(b) make a false or misleading representation that complementary and alternative medicinal 
products have any sponsorship, approval, endorsement, performance characteristics, 
accessories, uses, or benefits; or 
(c) make a false or misleading representation with respect to the price of any complementary 
and alternative medicinal products; or 
(d) make a false or misleading representation concerning the need for any complementary 
and alternative medicinal products; or 
(e) make a false or misleading representation concerning the place of origin of 
complementary and alternative medicinal products. 
These clauses are similar to ss12A and 13 FTA, and it is intended that they apply in the same way to 
CAM products as they do in the FTA.  Consequently, cl25 on unsubstantiated representations in this 
Bill will impose a strict liability offence for CAM products, which will be especially beneficial in 
requesting further information from licence holders, or penalising licence holders for not holding or 
publishing material in support of their Tier 2 efficacy claims, for example.1120 
12.5.3 Offences1121 
27 Offences 
(1) Every person who contravenes a provision of Part 1, Part 2, or sections 24-26 (except section 
23), commits an offence and is liable on conviction— 
(2) in the case of an individual, to a fine not exceeding $200,000; and 
(a) in the case of a body corporate, to a fine not exceeding $600,000. 
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(1) Subject to this section, it is a defence to a prosecution for an offence against section 27 if the 
defendant proves— 
(a) that the contravention was due to a reasonable mistake; or 
(b) that the contravention was due to reasonable reliance on information supplied by another 
person; or 
The penalties in cl27 will be kept at the same level as in the FTA.  While this is higher than in the 
NHSPB, this is intentional, as any misleading or deceptive conduct with respect to healthcare products 
should be sanctioned to the highest level.  With regards to penalties for the earlier Parts of this Bill, 
the courts are experienced in using discretion to apportion penalties, and there is no indication in this 
area of law that a higher maximum penalty set by legislation results in higher fines on offenders.1122  
Additionally, it is important to note that as with the FTA, intention is not necessary in any of these 
offences, and providing the standard of proof, beyond reasonable doubt, is established, then an 
individual or body corporate is liable for the sanctions under this clause.  Clause 28 also provides for 
defences to the preceding clause in a similar way to s44 FTA. 1123 
12.5.4 Civil proceedings 
29 Injunctions 
In much the same way as s41 FTA, this Bill will include the ability for the court to grant injunctions on 
application of the Authority.1124 
30 Order to disclose information or publish advertisement 
Corrective advertising is a vital tool for addressing misleading and deceptive conduct or 
representations.  This can be extended to specific instances under the present Bill where licence 
holders have made false efficacy claims, for example, and is an additional tool which allows the 
Authority to target the enforcement measures to adequately handle the problem, and prevent similar 
conduct from other manufacturers.1125 
12.5.5 Enforceable undertakings 
31 Enforceable undertakings 
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This Bill would introduce enforceable undertakings for lower level offending.  In a similar way to which 
such provisions work in the FTA, the Authority under this Bill may choose to work with the parties to 
reach a solution as a first resort, rather than immediately turning to prosecution.1126 
12.5.6 Management banning orders 
32 Management banning orders 
While they are unlikely to be regularly employed, the adoption of management banning orders into 
the present legislation is important for its deterrent effect.  When directors or managers face the risk 
of a ban from managing a CAM product company, there is likely to be increased adherence to the 
legislation and a desire to meet the Authority’s standards.1127 
12.6 The Complementary and Alternative Medicinal Products Regulations 
The Authority will be required to design regulations to facilitate the smooth functioning and operation 
of this Bill, as well as establishing further detail around matters like fees, classification of CAM 
products, and the labelling and packaging requirements for CAM products.  This section does not 
propose to put forward extensive regulations, but rather to merely posit a few suggestions around the 
main issues for the CAM Product Regulations. 
12.6.1 Labelling 
There will need to be extensive regulations around the labelling of CAM products to avoid any 
indication by manufactures that they are similar to medicines, or more effective than is actually the 
case.  The two studies in Chapters 9 and 10 demonstrated the importance of the labelling informing 
consumers’ perceptions.  Notably, the ‘dietary supplement’ phrase on the primary display was crucial 
to participants’ correct identification of the products as DSs, and the presence of TCs tended to affect 
consumer identification as to the particular effect of the product.  Consequently, both of these 
elements will be managed in the Bill and regulations.  The primary display statement indicating the 
product’s tier coupled with the coloured dot symbol will endeavour to reproduce the effect of the 
‘dietary supplement’ label, while the Bill will take specific measures to remove TCs, and instead 
introduce the milder, evidence-based efficacy claims to aid consumers with reliable, useful 
information on their CAM products. 
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Additionally, there will be regulations around font, label size, location of writing and pictures, and 
similar matters, in a similar vein to labelling provisions in the Medicines Regulations 1984 and the 
Smoke-free Environments Regulations 2017. 
12.6.2 Packaging 
Similarly to the labelling, it is envisaged that there will be substantial regulations around the packaging 
of CAM products in response to the indications from the quantitative work in Chapters 9 and 10.  Those 
studies demonstrated the previously under-appreciated effect of packaging on the public’s 
identification of CAM products as distinct from medicines.  In conjunction with TCs on CAM product 
labels, boxed CAM products were causing consumers to identify the products as medicines,1128 and 
the mere presence of a box, even in the absence of a TC, caused a proportionally greater percentage 
of the public to identify the product as a medicine, compared to the same product in a bottle.1129  As 
a result, the Bill will take a firm stance on managing the packaging of CAM products.  The risk-based 
approach notes that Tier 3 products should not be packaged in boxes,1130 leaving the regulations to 
implement this.  The other major packaging restrictions proposed in that approach relate to the 
Authority’s ability to restrict packaging size or number of products in a package for Tier 2 products, in 
order to limit consumers’ exposure to the product where necessary.  These, and any other provisions 
that the Expert Advisory Committee recommends around the size, shape, nature and style of the 
packaging will be part of the CAM Products Regulations. 
12.6.3 Good manufacturing practices 
One of the roles of the Expert Advisory Committee would be to establish a set of guidelines on GMP.  
These would likely take a form similar to the CC’s fact sheets, which offer generalised information to 
specific industries or on specific matters.1131 
Alongside these, there will be regulations which stipulate requirements for manufacturers to ensure 
suitable manufacture, packing, storage, handling, safety, and quality control measures are in place; 
similar to those seen in Part 5 MRs. 
12.6.4 Advertising 
Advertisements for CAM products should be restricted to the material which could be published on 
the label of the product, and the regulations should reflect this restriction.  In a similar manner to Part 
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3 MRs applying to medicine advertisements, CAM product advertisements should not be able to refer 
to official endorsement or approval by the Government, but must note their classification status, 
healthcare advisory statement, the presence of side-effects where relevant, and may publicise their 
efficacy claim where permitted by the product’s tier.  Furthermore, the regulations should ensure that 
an advertisement of a CAM product makes it abundantly clear to the viewer that this product is a CAM 
product, and not a medicine. 
It may be advisable to the Expert Advisory Committee to develop advertising guidelines, or at 
minimum work with an advertising body to establish guidelines for CAM product advertising as has 
occurred with the therapeutic and health advertising code by the Advertising Standards Authority.1132 
As further information and research is conducted on CAM products and the effects of their labelling, 
packaging and advertising, the Expert Advisory Committee may decide to put further restrictions in 
place or relax restrictions if necessary.  Furthermore, the Committee should have the ability to 
recommend alternative labelling, packaging, or marketing devices for communicating the relative 
ranking of CAM products according to their classification to consumers, if the coloured circle symbol 
and statement are determined to be ineffective. 
12.7 Conclusion 
This Chapter has recommended the introduction of a new legislative regime, which will bring NZ’s 
CAM product regulations into the 21st Century. 
The scheme implements a risk-based approach to CAM product regulation through the classification 
of CAM products into three tiers, which account for their risks and benefits and regulate accordingly.  
The Bill establishes an Authority, whose decisions must be informed by an Expert Advisory Committee, 
as well as a Māori Advisory Committee in particular instances, with extensive experience in all relevant 
matters involving CAM products, ensuring all stakeholder voices are brought to the table.  The Bill also 
provides for a broad array of enforcement options similar to those in the FTA, to ensure that an 
optimal outcome is reached when a breach of the legislation arises. 
Finally, this Complementary and Alternative Medicinal Products Bill largely addresses the many failings 
of earlier legislative proposals, by prioritising consumers and their safety, while still constructing a 
sustainable and flexible system, which not only encourages and rewards innovation and research, but 
is structured so as to adapt to the ever-changing CAM product marketplace.  
                                                          






This thesis has proposed a new piece of legislation that provides a light-touch risk-based approach to 
the regulation of CAM products in NZ, with the goal of increasing the safety, effectiveness and quality 
of CAM products sold in NZ.  The aim of this research was to analyse and critique current and proposed 
regulations for CAM products in NZ, and on the basis of novel research conducted in the course of this 
thesis, propose the best option for CAM product regulation in NZ. 
This Chapter summarises the preceding 12 chapters, reviewing the history of CAM product legislation, 
restating the problems this thesis set out to address and outlining the findings from this thesis.  It 
finishes by questioning whether the proposed CAM Products Bill is the best method of addressing the 
problems facing CAM product regulation, before noting scope for further legal and scientific research 
in this field.  
13.2 Three Decades of the Dietary Supplements Regulations 
CAM product regulation in NZ truly began with the regulation of ‘herbal remedy’ as a medicine within 
s2 MA 1981.  The MA also regulated ‘related products’,1133 which importantly includes any food about 
which a TC is made.1134  This would later provide an avenue for litigation against CAM products where 
they made TCs.1135  In 1985, the DSRs came about under the FA 1981, with the regulations coming into 
force in 1987.1136  Thirty years later, the DSRs remain in force, under the new FA 2014. 
During this period, multiple proposals for reform of CAM product regulation have come and gone.  
Between 1999-2014, there were various proposals for a joint regulator of CAM products and 
medicines between Australia and NZ, although this ultimately failed. 1137   In 2001, an Advisory 
Committee was established to review complementary and alternative healthcare, with its eventual 
2004 report recommending continuing research and development in the healthcare sector to keep 
pace with the progress in this rapidly changing area.1138  The Therapeutic Products and Medicines Bill 
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was introduced in 2006 as an omnibus bill to facilitate the establishment of the ANZTPA as a joint NZ-
Australian regulator of CAM and medicinal products, but did not have the support to reach its second 
reading.1139  A piece of legislation was proposed by the NZ CAM product Industry in 2009, but this 
failed to gain traction.1140  Finally, in 2011, the NHSPB was introduced to Parliament.1141 
Although the best attempt at CAM product regulation in NZ to date, the NHSPB had a number of 
issues, perhaps foremost being that it languished in the legislative process for more than six years, 
and consequently the pre-existing issues of its lack of relevance, and absence of understanding of the 
CAM marketplace grew more pronounced by the day.  With the Health Select Committee reporting 
back on the Bill towards the end of 2012, the Bill passed its second reading on 20 March 2013.  Close 
to five years have elapsed since that point, until, on 8 November 2017, the Bill was finally withdrawn, 
and consequently the DSRs continue to regulate CAM products in theory.  In practice, these products 
are effectively unregulated in NZ, with widespread breaches of the regulations acknowledged by the 
MoH itself,1142 and the primary means of enforcement being actions by the CC under the FTA.1143 
13.3 The Problems 
As stated in the introduction at Chapter 1, the problems surrounding NZ’s regulation of CAM products 
can be condensed into two broad issues.   
The first is the inability of current or proposed legislation to effectively regulate CAM products such 
that there is clarity around their safety, efficacy, and quality.  This issue is exacerbated by ineffective 
enforcement measures, resulting in the need to use alternative legislation like the FTA. 
The second issue is the information deficit around the CAM product market in NZ, usage of CAM 
products in NZ, public perceptions of CAM products, and the safety and efficacy of CAM products 
generally.  This is closely related to the first issue, as the primary reason for the failure of multiple 
CAM product regulatory proposals over the past 20-years has been due to a lack of information about 
the market to be regulated, no comprehension about how wide-spread CAM product consumption is, 
and little appreciation for the multifarious issues to be encountered when regulating such an area. 
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13.4 A Summary of the Findings 
There were broadly three aims to the present research: to ascertain the scope and scale of the 
problems facing CAM product regulation in NZ, to analyse the efficacy of alternative legislation in 
handling those problems, and ultimately to propose new legislation which would address the 
identified problems and provide the best solution for managing CAM products.  As stated in the 
introduction, there were three findings which effected the proposed legislation, and ultimately 
achieved the aims of the research. 
13.4.1 The advent of risk-based regulation 
Chapters 2 and 3 served a dual purpose.  Firstly, they established the background to CAM product 
regulation by discussing the parallel legislation governing food and medicines.  Arguably more 
importantly, they set the scene for a comparison of any legislation regulating products for human 
consumption, with the gold standard of risk-based approaches to product regulation.  The MA 1981 
led with a remarkably prescient approach, which was followed in a similar manner by the FA 2014.  
These examples of risk-based measures provided a stark contrast to the regulation in the DSRs, and 
although the NHSPB claims to establish a risk-based system,1144 the reality is that the Bill takes little to 
no account of risks and associated benefits of products and ingredients,1145 instead regulating in a 
somewhat haphazard and directionless manner. 
13.4.2 The blind leading the blind: a lack of comprehension or direction in CAM product regulation 
The many shortcomings of the DSRs outlined in Chapter 4 could be forgiven in 1985, when CAM 
products were a niche item, and primarily did comprise DSs.  However, in light of their more 
widespread use, general acceptance, and the plethora of available products encompassed in the term 
‘CAM products’ today, the continued existence of the same regulations in 2017 is a serious problem.  
Throughout all the attempts at replacing the DSRs, as outlined in Chapter 5, the clear problem is a lack 
of direction and no strong vision for the future.  As such, there has been, at best, lacklustre support 
for any of these reforms.  Whether it is the reason for the lack of direction, or a symptom of it, the 
defining problem plaguing reform is the absence of sound empirical data on the safety, efficacy, use, 
quality, and public’s perceptions of CAM products.  Chapter 6 emphasised how the irrelevance of the 
DSRs, coupled with failure of any measures for reform results in products like MMS effectively having 
free reign with respect to product safety, and claims about the product. 
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13.4.3 Analysis of the problems: their scale, scope and the use of alternative legislation 
The example of MMS from Chapter 6 and the broad failure of food, medicine, or CAM product 
legislation to handle this issue was a stark contrast to the FTA’s ability to address the problems of 
misleading and deceptive conduct and false representations.  Chapter 7 clearly demonstrated why the 
FTA has become the only successful enforcement measure against CAM products, and while having 
some means of enforcement is a step in the right direction, the use of consumer protection legislation 
to address a fraction of the misleading conduct associated with CAM products is a far cry from an 
optimal solution.  Chapter 8 addressed a slightly separate problem, but nonetheless one at the 
forefront of a CAM product regulatory scheme for NZ: the place of the Treaty of Waitangi and the 
recommendations of the Wai 262 report on TM.  It is telling of the systemic flaws in the NHSPB that it 
fails to even recognise the Treaty, despite its immediately apparent relevance to this area of law. 
Chapters 9 and 10 set about addressing the second major problem; that of the information deficit.  
These empirical studies focused on the prevalence of CAM product usage among NZers, and consumer 
perceptions of CAM products.  While only the tip of the iceberg around the information necessary to 
effectively regulate, these studies established the raw scale of CAM product consumption among 
NZers, with findings suggesting that 80% consume CAM products, and 50% of those do so on a daily 
basis.  They also highlighted the factors involved in misleading consumers around the identity of CAM 
products and their efficacy, prompting the question in Chapter 11 of whether the packaging of CAM 
products can be misleading or deceptive within the FTA.  This discussion again demonstrated the 
broad application of the FTA to issues involving CAM products, with the result being that the FTA’s 
enforcement measures and provisions around misleading and deceptive conduct and false 
representations were built into the CAM Products Bill in Chapter 12, given their history of use in CAM 
product cases, and efficacy in handling such matters. 
13.4.4 Options for the regulation of CAM products 
With this background and empirical work explained, the thesis considered three options for the 
regulation of CAM products going forward: the status quo of the DSRs, the NHSPB, or the proposed 
CAM Products Bill in Chapter 12.1146 
There is almost unanimous agreement among stakeholders that the status quo is unacceptable and 
change is necessary.  The NHSPB was undoubtedly more appropriate than the DSRs, but was ultimately 
unwieldly, and lacked understanding of the market it was trying to regulate.  It arguably polarised the 
industry, while still failing to adequately protect consumers and ensure the availability of safe, 
                                                          




effective, and quality products.  On the basis of the arguments raised throughout this thesis, the CAM 
Products Bill proposed herein is posited as the best solution currently available for the regulation of 
CAM products in NZ. 
13.5 Does the CAM Products Bill adequately address the problems? 
If the CAM Products Bill is to be recognised as the best option for the future of NZ CAM product 
regulation, then it must, at minimum, address the problems plaguing CAM product regulation that this 
thesis has highlighted. 
By adopting various elements from different pieces of legislation which have proven effective in 
similar situations (for example the risk-based approach in the FA 2014, and the enforcement measures 
in the FTA), the CAM Products Bill endeavours to create one piece of legislation which will regulate 
CAM products without substantial reliance on more general legislation.  At the same time, the risk-
based approach which underpins the Bill prioritises safety, quality, and efficacy in CAM products, with 
scientific evidence being encouraged and rewarded within this scheme.  As such, the CAM Products 
Bill addresses this issue head-on, resulting in a Bill that will provide clarity and relative simplicity to 
consumers, industry, and government alike. 
With the benefit of knowledge gained from two empirical studies providing additional information 
around CAM products, this Bill is already in a better position to address the information deficit than 
other proposals.  The Bill was constructed with an appreciation for the huge market, which currently 
exhibits major problems around misleading consumers as to the nature and efficacy of CAM products.  
Consequently, knowing the market size, this Bill is able to regulate to an appropriate level, while taking 
account of problems like misleading packaging, and implementing measures to prevent this from 
continuing (like prohibiting Tier 3 products from being packaged in boxes).  At the same time, the Bill 
acknowledges the substantial information still to be gathered around CAM products in NZ, and allows 
sufficient flexibility in its regulation to manage unknown current problems, and future problems as 
they arise in the course of ongoing research. 
Finally, the Bill ensures additional issues raised in the course of this thesis are handled, including 
rongoā Māori and the Treaty of Waitangi.  This Bill proposes tried, workable, and readily 
implementable systems derived from a wide assortment of legislation, to enable straightforward 
passage through Parliament so as to begin the process of regulating NZ’s CAM product marketplace 




13.6 Further Research 
This thesis took a broad approach to researching CAM product regulation from both a scientific and 
legal perspective.  It considered a raft of relevant legislation, in addition to conducting empirical work, 
which in turn raised issues of misleading and deceptive practices surrounding CAM products.  
Nevertheless, there remains a significant amount of legal and scientific research to be conducted in 
this area. 
Building upon the research and findings of this thesis, further legal research could be conducted into 
intellectual property considerations around CAM products, with an especial focus on strategies for the 
protection of traditional medicine and associated traditional knowledge.  This thesis also enables 
detailed reviews of CAM product regulations in different countries, with potential starting points being 
comparisons between the USA and NZ’s DSRs, Canada and NZ under the NHSPB, and between 
Australia and NZ; although consideration of China, Hong Kong, the European Union and the UK would 
provide a varied global perspective. 
While further scientific research could be conducted into perceptions of CAM products, and the effect 
of packaging, advertising and labelling upon consumers, this would be best conducted in response to 
a particular case requiring evidence of misleading and deceptive conduct as noted at 11.4.2.  Instead, 
the two directions for scientific research would be to study the active ingredients, mode of action, and 
efficacy of common CAM products, or to conduct a wide scale study in NZ similar to the Newmaster 
research discussed at 4.5.2, that analyses the actual constituents of CAM products in NZ, the accuracy 
of the listed ingredients, and the presence of contaminants, fillers, or other materials within CAM 
products. 
13.7 Concluding Remarks 
To return to the question posed at the very beginning of this thesis; why does the regulation of 
complementary and alternative medicine products matter? 
CAM product regulation matters to the 80% of NZers who have taken CAM products.  NZ is renowned 
for its socialised healthcare, with publicly funded hospital care, accident coverage, and subsidised 
medicines, but it is out of step to have effectively unregulated CAM products readily available to the 
public.  Where those 80% of people trust the government sufficiently to regulate their foods and 
medicines, they should also know that at minimum, the safety and quality of their CAM products is 




CAM product regulation matters to all NZers, because no-one should be misled or deceived by false 
or misleading CAM products.  No-one should blindly be left to rely on representations made on a 
product as to its safety, efficacy, or quality with no way of knowing the veracity of the representations, 
or lack thereof.  CAM product regulation should matter to everyone, as additional research, 
development, and investment into CAM products will only yield positive outcomes; removing 
ineffective or dangerous products from the market, and demonstrating the efficacy, safety, and 
benefits of particular products. 
CAM product regulation matters to an industry that seeks legitimacy and broader mainstream 
acceptance.  Rather than stymieing the progress of legislation for the regulation of CAM products, the 
industry stands to make significant gains from legislation which supports its products through a cost-
effective, risk-based proposal.  If the endless claims of the industry that CAM products are safe, 
effective, and high quality are true, then regulation in line with the proposal in the CAM Products Bill 
will provide a simple and cheap way to gain high-tier approval for their CAM products under a light-
touch risk-based scheme, inspiring consumer confidence, and providing substantial opportunities for 
the global potential of NZ CAM products. 
 
The [Natural Health and Supplementary Products Bill] is regulatory overkill … 
 [and] is a solution looking for a problem.1147  
                                                          





Appendix 1: Survey 1 University of Canterbury Human Ethics Committee 
Approval ‘Human Perceptions on Dietary Supplements’ 
Approval from the University of Canterbury Human Ethics Committee follows for Survey 1; initially 
entitled ‘Human Perceptions on Dietary Supplements’, but known herein as ‘Public Perceptions on 








Appendix 2: Public Perceptions on Dietary Supplements: A Pilot Study 
What follows is Survey 1: ‘Public Perceptions on CAM Products: A Pilot Study’ reproduced in its 
entirety.  As noted in Chapter 9, this survey was conducted entirely online, which meant the format 
and rules associated with skipping questions where a negative answer was given, or selecting three of 
the six possible products to show each participant are not noted on the following version.  
Nevertheless, where these were vital to the study, they are noted in Chapter 9, and otherwise they 
should be presumed immaterial.  As is normal in online surveys, a circular check icon is indicative of 
only one response being able to be selected, whereas a square check icon is indicative of multiple 
responses being able to be selected.  The images reproduced here are used for the purposes of 









































Appendix 3: Survey 2 University of Canterbury Human Ethics Committee 
Approval ‘Packaging of Complementary and Alternative Medicines in New 
Zealand: A Representative Survey’ 
Approval from the University of Canterbury Human Ethics Committee follows for Survey 2; entitled 









Appendix 4: Packaging of Complementary and Alternative Medicines in New 
Zealand: A Representative Survey 
What follows is Survey 2: ‘Packaging of Complementary & Alternative Medicines in New Zealand: A 
representative study’ reproduced in its entirety.  As noted at Chapter 10, this survey was conducted 
through both physical distributions via the post, and online distributions through the Qualtrics 
software.  For the purposes of reproducibility, the postal version follows, as this contains explicit 
directions for questions like 10 & 11, where otherwise participants would not have been privy to the 
rules used which excluded display of the question depending on the answer to the preceding question.  
Both version one and version two of this survey are included in their entirety to demonstrate the 
overall similarity, barring questions 13-18 where the packaging and labelling were altered between 





































































Appendix 5: The Complementary and Alternative Medicinal Products Bill 





This Act is the Complementary and Alternative Medicinal Products Act 2017. 
2 Overview 
(1) This Act replaces the Dietary Supplements Regulations 1985. 
(2) This Part contains preliminary provisions that— 
(a) state the purpose of this Act; and 
(b) state the principles of this Act; and 
(c) define certain terms used in this Act. 
(3) Part 2 relates to the risk-based approach to regulation of complementary and alternative 
medicinal products.  In particular, it includes provisions that— 
(a) provide for the classification of complementary and alternative medicinal 
products into 3 tiers based on, among other things, the level of risk that they pose 
to public health; and 
(b) establish a black-list of compounds or ingredients that are prohibited from being 
complementary and alternative medicinal products, or being components of 
complementary and alternative medicinal products; and 
(c) establish a pathway for dietary supplements regulated under the Dietary 
Supplements Regulations 1985 to come within the 3 risk-based tiers for the 
duration of the introductory period of this Act, or until the manufacturer has 
sought reclassification of the complementary and alternative medicinal product. 
(4) Part 3 contains provisions relating to the administration of the Act.  In particular, it 
includes provisions that— 
(a) provide for the structure and composition of the regulatory authority and 
subcommittees under the Act; and 
(b) outline the duties and functions of the regulatory authority and subcommittees 
under this Act; and 
(c) establish a framework for recognition of international authorities and resources 
in accordance with the principles and risk-based approach in this Act; and 
(d) empowering the regulatory authority to make regulations for the functioning and 




(5) Part 4 contains provisions relating to the enforcement under this Act, and includes 
provisions that— 
(a) establish offences under this Act; and 
(b) set penalties for offences under this Act; and 
(c) provide additional order which the regulator may make for enforcement under 
this Act; and 
(d) deal with the court’s powers to make additional orders for effective enforcement. 
(6) Schedule 1 sets out the black-list of prohibited products or ingredients as required under 
this Act. 
(7) Schedule 2 sets out approved international regulators as approved under this Act. 
(8) Schedule 3 sets out approved published materials as approved under this Act. 
(9) This section is intended as a guide only.1148 
3 Purpose 
The purpose of this Act is to— 
(a) restate and reform the law relating to the sale, marketing, advertising, and trade 
of complementary and alternative medicinal products; and 
(b) achieve safety and quality in complementary and alternative medicinal products; 
and 
(c) regulate complementary and alternative medicinal products in a manner 
commensurate with the risk of these products, by providing for a risk-based 
approach that— 
(i) minimises and manages the risks to public health; and 
(ii) ensures any claims of efficacy are supported by sound scientific evidence; 
and 
(d) require persons who trade in complementary and alternative medicinal products 
to take responsibility for the safety and suitability of those products.1149 
4 Principles 
This Act is based on the following principles: 
(a) that the regulation of complementary and alternative medicinal products is 
managed by a risk-based approach; and 
(b) that the regulation, classification, sale, trade, marketing, advertising, decision 
making and any other matters under this Act are all supported by sound scientific 
evidence, unless otherwise stipulated in the risk-based approach; and 
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(c) that the regulation of complementary and alternative medicinal products under 
this Act favour a flexible approach, where products are reasonably judged on 
their own merits.1150 
5 Interpretation 
In this Act, unless the context otherwise requires, — 
black-list means the register of prohibited products or ingredients, listed in Schedule 1 
and declared by the Regulatory Authority under section 10 to be a prohibited substance 
on the basis of a risk assessment 
complementary and alternative medicinal product has the meaning given to it by 
section 6 
dietary supplement is a sub-group of complementary and alternative medicinal 
products that— 
(a) is intended to be ingested orally; and 
(b) is intended to supplement the amount of amino acid, edible substance, herb, 
mineral, synthetic nutrient, or vitamin normally derived from food products1151 
efficacy claims are statements on the positive benefits or effects of complementary and 
alternative medicinal products that— 
(e) are prohibited for tier 3 products; but 
(f) are permitted for tier 2 products where they— 
(i) are supported by scientific evidence; and 
(ii) are on prophylactic uses for complementary and alternative medicinal 
products, including, but not limited to dietary supplementation and 
nutritional support; and 
(g) are permitted for tier 1 products where they— 
(i) are supported by scientific evidence; and 
(ii) are on prophylactic uses for complementary and alternative medicinal 
products, including, but not limited to dietary supplementation and 
nutritional support; or 
(iii) are for relief of mild, or low-grade medical conditions; or 
(iv) are for symptomatic relief from the effects of mild, or low-grade medical 
conditions; but 
(h) do not include statements that— 
(i) claim to cure any medical condition; or 
                                                          
1150 Compare: Natural Health and Supplementary Products Bill 2011 (324-2), cl4. 
1151 Compare: Dietary Supplements Regulations 1985, reg2A; Natural Health and Supplementary Products Bill 




(ii) claim to treat any medical condition; or 
(iii) make any reference to acute illness, chronic illness, severe illness, cancer, 
or any other serious curable, manageable, or treatable medical condition; 
or 
(iv) relate to children, or childhood illnesses in any way 
food products— 
(c) means any product which has the appearance of food products or drink as they 
are ordinarily understood; and 
(d) either— 
(i) is primarily intended for human consumption as food products or drink; or 
(ii) is primarily used as an ingredient in food products or drink for human 
consumption; and 
(c) includes— 
(i) formulated supplementary sports food as defined by standard 2.9.4 
Australia New Zealand Food Standards Code 2002; and 
(ii) supplemented food as defined by the New Zealand Food (Supplemented 
Food) Standard 20161152 
healthcare advisory statement is a statement which notes— 
(b) if side effects occur, please consult your doctor or pharmacist, and remember to 
always check with your healthcare professional before mixing medicines and 
CAM products1153 
herbal medicine or herbal remedy is a sub-group of complementary and alternative 
medicinal products that— 
(c) includes— 
(i) any substance produced by subjecting a plant to drying crushing , or any 
other similar process; or 
(ii) a mixture comprising 2 or more such substances only; or 
(iii) a mixture comprising 1 or more such substances with water or ethyl 
alcohol or any inert substance; and 
(d) is not a medicine1154 
homeopathy is a sub-group of complementary and alternative medicinal products in 
which the active ingredient to be administered is in a concentration of not more than 10 
parts per million. 
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Minister means the Minister of the Crown who, under the authority of the Prime 
Minister, is responsible for the administration of the Act 
medicine 
(c) is a product that— 
(i) is used for a therapeutic purpose within the meaning of section 4 of the 
Medicines Act 1981; and 
(ii) the Minister has, under section 20 or 23 of that Act, given consent to its 
distribution; or 
(iii) the Minister is, under section 20(7) of that Act, deemed to have given 
consent to its distribution; or 
(iv) the Director-General, has under section 24 of that Act, given consent to its 
distribution; 
(d) includes— 
(i) any related product that the Minister has, under section 20 and 96 of the 
Medicines Act 1981, given consent to its distribution; or 
(ii) any medical device that is the subject of a declaration under regulation 6 
of the Medicines (Database of Medical Devices) Regulations 20031155 
primary display means the part of a label that is most likely to be displayed, 
presented, shown, or examined, under ordinary or customary conditions of display for 
retail sale; and, in the case of cylindrical packaging or labelling, the width of the 
primary display shall not exceed one-third of the circumference of the package1156 
rongoā Māori means the practice of Māori traditional medicine and is not regulated by 
this Act where it comes within the scope of complementary and alternative medicine 
practices at section 6(2); but where traditional Māori remedies are produced on a 
commercial scale for sale or supply outside the practice of rongoā Māori, this Act will 
apply as if they are a traditional medicine products 
scientific evidence 
(b) includes— 
(i) randomised, blind, placebo controlled studies; or 
(ii) meta-analyses or systematic reviews; or 
(iii) reputable scientific texts; or 
(iv) sound, peer reviewed research; or 
(v) material in reputable peer-reviewed scientific journals; or 
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(vi) monographs or similar materials from approved international regulators, 
as listed in Schedules 2 and 3; or 
(vii) repeatable experiments; or  
(viii) chemical or biological structure modelling; or 
(ix) chemical structure-activity modelling; or 
(x) verifiable quantitative research; or 
(xi) any combination of the above requirements; or 
(xii) other material deemed to be sound scientific evidence by the regulatory 
authority1157 
traditional evidence is evidence of a longstanding history of use of traditional 
medicine products, commonly sourced from approved published materials listed in 
Schedule 31158 
traditional medicine products is a sub-group of complementary and alternative 
medicinal products that— 
(c) includes— 
(i) any traditional or indigenous medicine which has a longstanding history 
of use; but 
(d) does not include— 
(i) rongoā Māori 
6 Meaning of complementary and alternative medicinal product 
(1) In this Act, subject to any specific definition provided for use in another section, 
complementary and alternative medicinal product— 
(a) is any product that— 
(i) is intended for human use; and 
(ii) shows scientific evidence or traditional evidence for its safety; and 
(iii) has a risk commensurate with the benefit of the product; and 
(iv) is approved for sale and classified by the complementary and alternative 
products regulatory authority; and 
(b) includes— 
(i) dietary supplements; and 
(ii) herbal medicine or herbal remedies; and 
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(iii) homeopathy; and 
(iv) traditional medicine products products; but 
(c) does not include— 
(i) any product or ingredient included on the black-list; and 
(ii) complementary and alternative medicine practices, or specialist products 
formulated for an individual patient and dispensed in the course of the 
practice; and 
(iii) any food products, or product presented as a food product; and 
(iv) any medicine, or product presented as a medicine; and 
(v) any product administered by injection, parenteral infusion, application to 
the eye, or application to the ear of any human. 
(2) In this section, complementary and alternative medicine practices means any 
practice which is not a part of standard medical healthcare in New Zealand. 
7 Treaty of Waitangi (Te Tiriti o Waitangi) 
In achieving the purpose of this Act, all persons exercising functions and powers under 




8 Overview of this Part 
(1) This Part contains provisions relating to the risk-based approach, which is the main 
means under this Act for ensuring complementary and alternative medicinal products 
are safe, supported by evidence, and where relevant, effective. 
(2) This Part— 
(a) classifies complementary and alternative medicinal products into 3 risk tiers 
based on, among other things, the level of risk that they pose to public health 
when balanced with their benefit; and 
(b) outlines general requirements for complementary and alternative medicinal 
products in each of the 3 tiers under this Act; and 
(c) outlines labelling requirements for complementary and alternative medicinal 
products in each of the 3 tiers under this Act; and 
(d) outlines the required evidence which manufacturers or importers must submit to 
the regulatory authority for the classification of a complementary and alternative 
medicinal product in each of the 3 tiers under this Act. 
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(3) This Part also contains provisions that create the black-list.1160 







High benefit, low risk 
High benefit, Moderate 
risk 
Moderate benefit, low 
risk 
Low benefit, very low 
risk  
No benefit, very low risk 
Can make strong efficacy 
claims 
Can make weak efficacy 
claims 
Cannot make efficacy 
claims 
May be required to 
specify purpose 
May be required to 
specify purpose 
Cannot specify purpose 
No packaging restrictions 
May be limit on amount 
of product per package 
Products cannot be 
packaged in boxes 








Labelled with a • (green 
dot) and 
‘Tier 1 CAM product’  
on primary display 
Labelled with a • 
(orange dot) and 
‘Tier 2 CAM product’  
on primary display 
Labelled with a • (red 
dot) and 
‘Tier 3 CAM product’ or 
‘Tier 3 Homeopathic 
product’ on primary 
display 
Must make healthcare 
advisory statement 
Must make healthcare 
advisory statement.  
Must list side-effects 
Must make healthcare 
advisory statement 





Must supply a copy of 
the label 
Must supply a copy of 
the label 
Must supply a copy of 
the label 
Must have scientific 
evidence on safety.  
Biochemical basis for 
mode of action and 
toxicological safety 
assessments likely 
required - traditional 
evidence is insufficient. 
Must show sound 
evidence of safety – 
traditional evidence 
unlikely to be enough 
alone 
Must show some 
evidence of safety – 
traditional evidence will 
suffice 
Must show biochemical 
mode of action, and 
provide sound scientific 
evidence for efficacy 
claims, e.g. monographs, 
peer reviewed research of 
clinical studies 
Must hold scientific 
evidence for any efficacy 
claims.  Monographs, 
peer reviewed research, 
or clinical studies all 
accepted.  Theoretical 
basis may be acceptable. 
No proof of efficacy 
required 
Must provide evidence of 
GMP, Quality Control 
and product testing 
Must provide evidence of 
GMP & Quality Control 
plans 
Must provide evidence of 
GMP & Quality Control 
plans 
Must provide evidence of 
structural similarity 
assessments 
Must provide evidence of 
structural similarity 
assessments 
No structural similarity 
assessment necessary 
                                                          




Examples Iron products Olive Leaf 
- Arnica 6X Drops 
(Homeopathic) 
-  Men’s Multivitamins 
Table 12.1: A Proposed Risk-based Approach for CAM Product Regulation 
9 Classification of complementary and alternative medicinal product tiers for 
purpose of assigning applicable risk-based approaches 
(1) The classification of complementary and alternative medicinal product tiers under this 
Part— 
(a) is based on, among other things, the level of risk that their activities pose to 
public health in terms of the safety and suitability of complementary and 
alternative medicinal products; and 
(b) is for the purpose of ensuring that the information presented to the public on the 
labelling, packaging and advertising of complementary and alternative medicinal 
products accords with the risk posed by the particular product; and 
(c) is for the purpose of ensuring certainty amongst all stakeholders on the evidential 
requirements and effect of the classification of complementary and alternative 
medicinal products on the 3 risk-based tiers. 
(2) Accordingly, the regulatory authority is responsible for the classification of individual 
products into 1 of the 3 risk-based tiers upon application by the manufacturer, importer, 
or other interested party, in accordance with the measures set out in subsection (3). 
(3)  The measures referred to in subsection (2) are as follows: 
(a) complementary and alternative medicinal products that generally pose a high 
benefit and commensurately low risk are classified as Tier 1 products; and— 
(i) must supply scientific evidence in support of the safety of the product and 
its effect; and 
(ii) are subject to labelling and advertising regulations as appropriate to the 
individual product; and 
(iii) must supply any other material reasonably required by the regulatory 
authority as stipulated in the regulations to this Act: 
(b) complementary and alternative medicinal products that generally pose either a 
high benefit and commensurately moderate risk, or a moderate benefit and 
commensurately low risk are classified as Tier 2 products and— 
(i) must supply scientific evidence, and where relevant, traditional evidence, 
in support of the safety of the product and its effect; and 
(ii) are subject to labelling, packaging, and advertising regulations as 
appropriate to the individual product; and 
(iii) must supply any other material reasonably required by the regulatory 
authority as stipulated in the regulations to this Act: 
(c) complementary and alternative medicinal products that generally pose either a 
low benefit and commensurately very low risk, or no benefit and 




(i) must supply either scientific evidence, or traditional evidence, in support 
of the safety of the product; and 
(ii) are subject to labelling, packaging, and advertising regulations as 
appropriate to the individual product; and 
(iii) must supply any other material reasonably required by the regulatory 
authority as stipulated in the regulations to this Act. 
(4) When applying for classification in 1 of the 3 risk-based tiers, the manufacturer, 
importer, or other interested party must pay a classification fee for the regulator’s 
assessment of the complementary and alternative medicinal product; 
(a) that— 
(i) is a higher than average fee, for a product seeking Tier 1 classification; or 
(ii) is an average fee, for a product seeking Tier 2 classification; or 
(iii) is a lower than average fee, for a product seeking Tier 3 classification. 
(5) Subsection (4) applies in the same way to products seeking reclassification.1161 
10 Prohibited products or ingredients 
(1) The Regulatory Authority may, on the recommendation of the Expert Advisory 
Committee, declare an ingredient or complementary and alternative medicinal product 
to be a prohibited ingredient or complementary and alternative medicine product, and 
require that product to be listed in Schedule 1. 
(2) In tendering advice to the Minister under subsection (1) about an ingredient or 
complementary and alternative medicinal product to be listed in Schedule 1, the 
Regulatory Authority must provide the Minister with a report that sets out the 
following: 
(a) information about the ingredient or product; and 
(b) a risk-assessment of the ingredient or product drawn from scientific evidence; 
and 
(c) advice as to whether, in the Authority’s expert opinion, the known risks to public 
health of the ingredient or product fall within a level of risk that is acceptable in 
New Zealand; and 
(d) any traditional evidence or published history of traditional use; and 
(e) any other matter that the Authority considers relevant in the circumstances. 
(3) A declaration made by the Minister under this section must be published on an Internet 
site maintained by or on behalf of the Authority.1162 
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11 Overview of this Part 
(1) This Part contains provisions relating to the administration of the Act. 
(2) This Part— 
(a) provides a structure for the transition between the previous legislation governing 
complementary and alternative medicinal products and the risk-based approach 
in the current Act; and 
(b) establishes the Complementary and Alternative Medicinal Products Regulatory 
Authority; and 
(c) specifies the roles of the Regulatory Authority; and 
(d) provides for a list of approved international regulatory authorities whose 
regulation of complementary and alternative medicinal products is able to be 
considered or employed in the regulation of complementary and alternative 
medicinal products under this Act; and 
(e) provides for a list of approved materials which may be able to be considered or 
employed in the regulation of complementary and alternative medicinal products 
under this Act.1163 
12 Overview of transitional provisions 
(1) This section describes the general scheme and effect of the transitional provisions 
contained in this subpart.  It is by way of explanation only and does not limit or affect 
the other provisions of this Act. 
(2) The Dietary Supplements Regulations 1985 are repealed in this subpart. 
(3) Sections in this subpart on preliminary registration of all complementary and alternative 
medicinal products come into force on the day after that date on which this Act receives 
the Royal assent. 
(4) All complementary and alternative medicines have 1 year for preliminary registration. 
(5) The transitional provisions in this subpart come into force a year and a day after the 
date on which this Act receives the Royal assent. 
(6) All preliminarily registered complementary and alternative medicinal products will 
have a 5 year authorised period from the date in subsection (5) to make the transition 
from the Dietary Supplements Regulations to the new requirements of this Act. 
(7) During that period, all preliminarily registered complementary and alternative 
medicinal products will be nominally classified as Tier 3 products, and subject to the 
annual licencing fees associated with this classification. 
                                                          




(8) Complementary and alternative medicinal products can apply for classification at any 
time from the day after the date on which this Act receives Royal assent.1164 
13 Complementary and Alternative Medicinal Products Regulatory Authority 
(1) This section establishes the Complementary and Alternative Medicinal Products 
Regulatory Authority (the Authority). 
(2) The Authority is the Director-General of Health. 
(3) The office of the Authority must be administered by the Ministry of Health.1165 
14 Role of the Regulatory Authority 
(1) The Regulatory Authority has the functions, duties, and powers given to it under this 
Act. 
(2) The Regulatory Authority has a role in the complementary and alternative medicinal 
product regime that includes, without limitation,— 
(a) engaging in post-market surveillance of any complementary and alternative 
medicinal product, including: 
(i) monitoring compliance with the applicable requirements of this Act; and 
(ii) conducting any testing on complementary and alternative medicinal 
products to verify their contents, safety, efficacy or veracity of their 
claims, as appropriate. 
(b) co-ordinating the response to emergencies that may undermine the purpose of 
this Act; and 
(c) implementing, managing, monitoring, and auditing the risk-based measures for 
the safety, suitability, and where appropriate, efficacy, of complementary and 
alternative medicinal products; and 
(d) providing information to the complementary and alternative medicinal product 
industry and the public on matters relating to the safety, suitability, and where 
appropriate, efficacy, of complementary and alternative medicinal products; and 
(e) establishing and maintaining the public registers; and 
(f) developing standards and implementing those standards for the safety, 
suitability, and where appropriate, efficacy, or complementary and alternative 
medicinal products; and 
(g) performing the function of a registration authority; and 
(h) conducting, on application, reviews of certain decisions made by persons acting 
under its delegated authority; and 
(i) monitoring and implementing the enforcement system under this Act and 
working collaboratively with other regulatory bodies; and 
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(j) prescribe fees and charges for the purposes of cost recovery, as stipulated in the 
regulations to the Act; and 
(k) exempt persons from the application of this Act generally; and 
(l) carrying out any functions that are incidental and related to, or consequential 
upon, the roles set out in paragraphs (a) to (k).1166 
15 Complementary and Alternative Medicinal Products Expert Advisory Committee 
must be established 
(1) The Authority must establish an expert advisory committee known as the Expert 
Advisory Committee on Complementary and Alternative Medicinal Products (Expert 
Advisory Committee).1167 
16 Structure of the Expert Advisory Committee 
(1) The Expert Advisory Committee— 
(a) consists of not fewer than 8 and not more than 12 members; and  
(b) may, subject to this Act and any directions that the Regulatory Authority gives 
by written notice to the committee, regulate its procedure in any manner that the 
committee thinks fit. 
(2) Each meeting of the Expert Advisory Committee may be attended by the chairperson 
of the Māori Advisory Committee or a member of the Māori Advisory Committee 
nominated by the chairperson of the Expert Advisory Committee, but a person 
attending under this subsection is not a member of the Expert Advisory Committee. 
(3) The Expert Advisory Committee must include— 
(a) 1 or more members with expertise in complementary and alternative medicinal 
products and complementary and alternative medicinal products research; and 
(b) 1 or more registered medical professionals; and 
(c) 1 or more Ministry of Health representatives; and 
(d) 1 or more members with the ability to articulate issues from a consumer 
perspective; and 
(e) 1 or more toxicologist; and 
(f) 1 or more members with expertise in relevant areas of the law; and 
(g) 2 members with the ability to represent the interests of the complementary and 
alternative medicinal products industry, including, but not limited to; 
(i) manufacturers; or 
(ii) importers; or 
(iii) industry bodies; or 
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17 Functions of the Expert Advisory Committee 
(1) The Expert Advisory Committee has the following functions: 
(a) to collaborate and refer decisions to the Māori Advisory Committee, and take the 
advice of the Māori Advisory Committee where appropriate on matters 
involving; 
(i) Māori traditional knowledge; or 
(ii) Māori traditional medicine; or 
(iii) rongoā Māori; or 
(iv) any indigenous plant or animal materials. 
(b) to issue guidelines and give advice where requested by the Regulatory Authority 
as to;  
(i) the classification of complementary and alternative medicinal products; 
or 
(ii) the requirements of the individual tiers of the risk-based approach; or 
(iii) traditional or scientific evidence. 
(c) to provide advice to the Authority on; 
(i) products or ingredients to be included in the black-list at Schedule 1; or 
(ii) international regulators to be approved under section 20; or 
(iii) published materials to be approved under section 21. 
(d) any other function that the Minister assigns to the Expert Advisory Committee 
by written notice.1169 
18 Designation of Māori Advisory Committee 
(1) The Authority may, by written notice given to an applicable committee, designate that 
committee as the Māori Advisory Committee for the purposes of this Part. 
(2) An applicable committee for the purposes of subsection (1) is; 
(a) the Māori Advisory Committee appointed under section 225 Patents Act 2013; 
or 
(b) the Māori Trade Marks Advisory Committee appointed under section 177 Trade 
Marks Act 2002; or 
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(c) Ngā Kaihautū Tikanga Taiao, the Environmental Protection Authority Māori 
Advisory Committee established under section 18 Environmental Protection 
Authority Act 2011; or 
(d) any other Māori advisory committee established under legislation, which reflects 
a balanced view of Māori interests and handles matters related to Māori rights 
over traditional knowledge, flora and fauna. 
(3) Each meeting of the Māori Advisory Committee may be attended by the chairperson of 
the Expert Advisory Committee or a member of the Expert Advisory Committee 
nominated by the chairperson for the meeting, but a person attending under this 
subsection is not a member of the Māori Advisory Committee.1170 
19 Functions of the Māori Advisory Committee 
(1) The Māori Advisory Committee has the following functions: 
(a) to provide guidelines for the use of Māori traditional knowledge in 
complementary and alternative medicinal products: 
(b) to provide guidelines for the use of any indigenous flora or fauna in 
complementary and alternative medicinal products: 
(c) to provide advice to the Expert Advisory Committee on any of the matters at 
section 17(1)(a): 
(d) to provide advice to the Expert Advisory Committee on any commercialisation 
and classification of rongoā Māori: 
(e) any other function that the Expert Advisory Committee assigns to the Māori 
Advisory Committee by written notice.1171 
20 Authority may declare approved international regulators 
(1) The Authority may, by notice in the Gazette, and by listing the regulator in Schedule 
2, declare an international regulator to be an approved international regulator— 
(a) for a specified purpose under this Act or provisions of this Act; and 
(b) for a specified period or not. 
(2) The Authority may only declare an international regulator to be an approved 
international regulator— 
(a) where the international regulator meets or exceeds the relevant principles of 
this Act; and 
(b) where the international regulator makes decisions in respect of similar products 
upon a risk-based scheme, to a similar, or more robust standard than prescribed 
in this Act.1172 
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21 Authority may declare approved published materials 
(1) The Authority may, by notice in the Gazette, and by listing the materials in Schedule 
3, declare published materials to be approved published materials— 
(a) for a specified purpose under this Act or provisions of this Act; and 
(b) for a specified period or not. 
(2) The Authority may only declare published materials to be approved published 
materials— 
(a) where the published materials meet or exceed the relevant principles of the Act; 
and 
(b) where the published materials are based on reasonable scientific evidence; or 
(c) where the published materials document a history of safe use. 
(3) For the purposes of subsections (1) and (2), published materials may include, but are 
not limited to— 
(i) monographs; and 
(ii) national formulary; and 
(iii) pharmacopoeiae; and 
(iv) traditional knowledge databases; and 
(v) traditional medicine databases.1173 
22 Regulations 
(1) The Governor-General may, by Order in Council made on the recommendation of the 
Minister, make regulations— 
(a) adding a complementary and alternative medicinal product or ingredient to the 
black-list in Schedule 1 if the Minister is satisfied that the product or ingredient 
does not meet the standard for safety under the risk-based approach: 
(b) amend Schedule 2 by— 
(i) adding an approved international regulator to, or removing an approved 
international regulator from, the schedule; or 
(ii) amending a condition or limit on an approved international regulator in 
the schedule. 
(c) amending Schedule 3 by— 
(i) adding an approved published material to, or removing an approved 
published material from, the schedule; or 
                                                          




(ii) amending a condition or limit on an approved published material in the 
schedule. 
(d) prescribing requirements for the labelling or packaging of complementary and 
alternative medicinal products; or 
(e) prescribing requirements for the advertising of complementary and alternative 
medicinal products; or 
(f) prescribing standards or guidelines for scientific evidence or traditional 
evidence; or 
(g) prescribing standards or guidelines for efficacy claims; or 
(h) prescribing standards or guidelines for the classification or reclassification of 
complementary and alternative medicinal products; or 
(i) prescribing the manner in which applications for classification must be made; or 
(j) prescribing guidelines on good manufacturing practices and quality control 
processes for complementary and alternative medicinal products; or 
(k) prescribing the requirements relating to access of all publicly available 
information; or 
(l) providing for any other matters contemplated by this Act, necessary for its 




23 Misleading and deceptive conduct generally 
No person shall, in trade, engage in conduct in relation to complementary and 
alternative medicinal products that is misleading or deceptive or is likely to mislead or 
deceive.1175 
24 Misleading conduct in relation to complementary and alternative medicinal 
products 
No person shall, in trade, engage in conduct that is liable to mislead the public as to the 
nature, manufacturing process, characteristics, suitability for a purpose, or quantity of 
complementary and alternative medicinal products.1176 
25 Unsubstantiated representations 
(1) A person must not, in trade, make an unsubstantiated representation. 
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(2) A representation is unsubstantiated if the person making the representation does not, 
when the representation is made, have reasonable grounds for the representation, 
irrespective of whether the representation is false or misleading. 
(3) This section does not apply to a representation that a reasonable person would not 
expect to be substantiated. 
(4) In this section, representation means a representation that is made— 
(a) in respect of complementary and alternative medicinal products; or 
(b) in connection with the supply or possible supply of complementary and 
alternative medicinal products; or 
(c) in connection with the promotion by any means of the use of complementary and 
alternative medicinal products.1177 
26 False or misleading representations 
(1) No person shall, in trade, in connection with the supply or possible supply of 
complementary and alternative medicinal products or with the promotion by any means 
of the use of complementary and alternative medicinal products— 
(a) make a false or misleading representation that complementary and alternative 
medicinal products are of a particular kind, standard, quality, grade, quantity, 
composition, style, or model, or have had a particular history or particular 
previous use; or 
(b) make a false or misleading representation that complementary and alternative 
medicinal products have any sponsorship, approval, endorsement, performance 
characteristics, accessories, uses, or benefits; or 
(c) make a false or misleading representation with respect to the price of any 
complementary and alternative medicinal products; or 
(d) make a false or misleading representation concerning the need for any 
complementary and alternative medicinal products; or 
(e) make a false or misleading representation concerning the place of origin of 
complementary and alternative medicinal products.1178 
27 Offences 
(1) Every person who contravenes a provision of Part 1, Part 2, or sections 24-26 (except 
section 23), commits an offence and is liable on conviction— 
(a) in the case of an individual, to a fine not exceeding $200,000; and 
(b) in the case of a body corporate, to a fine not exceeding $600,000.1179 
28 Defences 
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(1) Subject to this section, it is a defence to a prosecution for an offence against section 27 
if the defendant proves— 
(a) that the contravention was due to a reasonable mistake; or 
(b) that the contravention was due to reasonable reliance on information supplied by 
another person; or 
(c) that— 
(i) the contravention was due to the act of another person, or to an accident 
or to some other cause beyond the defendant’s control; and 
(ii) the defendant took reasonable precautions and exercised due diligence to 
avoid the contravention. 
(2) For the purposes of subsection (1)(b) and (c), the term another person does not 
include— 
(a) a servant or agent of the defendant; or 
(b) where the defendant is a body corporate, a director, servant or agent of the 
defendant. 
(3) A defendant is not, without the leave of the District Court, entitled to rely on the defence 
provided by subsection (1)(b) that the contravention was due to reasonable reliance on 
information supplied by another person, or by subsection (1)(c)(i) that the contravention 
was due to the act of another person, unless the defendant has, not later than 7 days 
before the date on which the hearing of the proceedings commences, served on the 
prosecutor a notice in writing identifying that person. 
(4) It is a defence to a prosecution for an offence against section 27, or to any other 
proceedings under this Part, in relation to a contravention of a provision of this Act 
committed by the publication of an advertisement, if the defendant proves— 
(a) that the defendant’s business is publishing or arranging for the publication of 
advertisements; and 
(b) that the defendant received the advertisement, or the information contained in 
the advertisement, as the case may be, in the ordinary course of that business and 
did not know and had no reason to suspect that the publication of the 
advertisement or the publication of the advertisement containing the information, 
as the case may be, would constitute a contravention of the provision.1180 
29 Injunctions 
(1) The court may, on the application of the Authority or any other person, grant an 
injunction restraining a person from engaging in conduct that constitutes or would 
constitute any of the following— 
(a) a contravention of any of the provisions of Part 1, Part 2, or sections 23-26: 
(b) any attempt to contravene such a provision: 
                                                          




(c) facilitating in any way the contravention of such a provision. 
(2) The court may at any time rescind or vary an injunction granted under this section. 
(3) Where an application is made to the court under this section for the grant of an 
injunction restraining a person from engaging in conduct of a particular kind the court 
may— 
(a) if it is satisfied that the person has engaged in conduct of that kind, grant an 
injunction restraining the person from engaging in conduct of that kind; or 
(b) if in the opinion of the court it is desirable to do so, grant an interim injunction 
restraining the person from engaging in conduct of that kind, whether or not it 
appears to the court that the person intends to engage again, or continue to engage 
in conduct of that kind.1181 
30 Order to disclose information or publish advertisement 
(1) Where, on the application of the Authority, the court is satisfied that a person has 
engaged in conduct constituting a contravention of any of provisions of Part 1, Part 2, 
or sections 23-26, the court may make either or both of the following orders: 
(a) an order requiring that person, or any other person involved in the contravention, 
to disclose, at that person’s own expense, to the public, or to a particular person 
or to persons included in a particular class of persons, in such manner as is 
specified in the order, such information, or information of such a kind, as is so 
specified, being information that is in the possession of the person to whom the 
order is directed or to which that person has access: 
(b) an order requiring that person, or any other person involved in the contravention, 
to publish, at that person’s own expense, in such manner and at such times as are 
specified in the order, corrective statements the terms of which are specified in, 
or are to be determined in accordance with, the order. 
(2) The court may hear and determine an application under subsection (1) in conjunction 
with any other proceedings under either of sections 27 or 29.1182 
31 Enforceable undertakings 
(1) The Authority may accept a written undertaking given by, or on behalf of, a person in 
connection with any matter relating to the enforcement of this Act. 
(2) The person may withdraw or vary the undertaking with the consent of the Authority. 
(3) If the Authority considers that a person who has given an undertaking under subsection 
(1) has breached a term of that undertaking, the Authority may apply to the court for an 
order under subsection (4). 
(4) The court may make any of the following orders if it is satisfied that the person has 
breached a term of the undertaking: 
(a) an order directing the person to comply with the term: 
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(b) an order directing the person to pay to the Crown an amount not exceeding the 
amount of any financial benefit that the person has obtained directly or indirectly 
and that is reasonably attributable to the breach: 
(c) any order that the court thinks appropriate directing the person to compensate 
any other person who has suffered loss or damage as a result of the breach: 
(d) an order for any consequential relief that the court thinks appropriate.1183 
32 Management banning orders 
(1) A District Court may make a management banning order against an individual who— 
(a) has, on at least 2 separate occasions within a 20-year period, committed an 
offence against section 27; or 
(b) is, or was at the time of the commission of the offence, a director of, or concerned 
in the management of, an incorporated or unincorporated body that has, on at 
least 2 separate occasions within a 20-year period, committed an offence against 
section 27. 
(2) The court may make the order only if it is satisfied that the order is necessary to protect 
the public from the risk that the person, or any incorporated or unincorporated body of 
which the person is a director, or the management of which the person is concerned in, 
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